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Abstract	
	 The	 biologically	 and	 medically	 important	 heparan	 sulphate	 and	 heparin	polysaccharides	 have	 previously	 been	 shown	 to	 modulate	 the	 activity	 of	 an	 aspartyl	protease,	β-secretase	(BACE1),	implicated	in	the	aetiology	of	Alzheimer’s	disease.	Research	groups	investigating	the	activity	of	heparin	with	BACE1	have	demonstrated	both	inhibitory	and	 stimulatory	 effects	 of	 this	 glycosaminoglycan,	 and	other	 analogues.	 In	 an	 attempt	 to	understand	 this	 relationship,	a	 review	of	 the	available	 recombinant	BACE1	products	was	conducted	 to	 determine	 if	 protein	 purification	 tag	 had	 an	 effect	 on	 the	 heparin/heparan	sulphate	interaction	with	BACE1.	FLAG-tagged	BACE1	was	identified	as	a	suitable	proxy	for	native,	untagged	BACE1	for	activity	studies.			 In	this	study,	the	common	purification	tag,	IgG	Fc	region,	has	been	shown	to	interact	with	heparin	and	other	glycosaminoglycans	at	acid	pH	(pH	4.0	and	pH	5.0)	with	heparin	affinity	of	>	800	mM.	Further	investigation,	first	of	whole	immunoglobulin	(IgG	&	IgM)	and	then	with	Fab	and	F(ab’)2	antibody	fragments,	identified	heparin	binding	at	acid	pH	in	all	fragments	 tested.	 Thermal	 stability	 studies	 were	 conducted	 to	 identify	 heparin/HS	structural	requirements	for	this	novel	interaction,	which	suggest	sulphate	is	necessary	but	not	sufficient	for	activity.			 Finally,	a	library	of	chemically	sulphated	non-heparin	polysaccharides	were	utilised	to	identify	‘hit’	BACE1	inhibitors	with	beneficial	BACE1	therapeutic	attributes	such	as	low	molecular	weight,	minimal	charge	and	attenuated	off-target	effects,	such	as	anti-coagulant	activity.	 Differential	 scanning	 fluorimetry	 was	 identified	 as	 a	 potential	 high-throughput	screening	 assay	 to	 replace	 fluorescence	 resonant	 energy	 transfer,	 during	 the	 initial	 non-heparin	polysaccharide	library	BACE1	inhibitor	screening.			
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Chapter	1:	Introduction
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1.1	Proteoglycans		 Proteoglycans	(PGs)	are	a	family	of	biomolecules	comprised	of	a	core	protein	with	projecting	 glycosaminoglycan	 (GAG)	 chains	 (Esko	 JD,	 2009;	 Ey,	 Prowse,	&	 Jenkin,	 1978).	GAGs	 are	 a	 structurally	 complex	 class	 of	 carbohydrate	 polymers,	 composed	 of	disaccharides	with	alternating	monosaccharide	residues;	they	are	polyanionic	and	linear	in	structure	(idem).	A	wide	variety	of	different	protein	cores	exist	and	this,	combined	with	the	polydisperse	 nature	 of	 the	 covalently	 bound	 glycosaminoglycans	 (GAGs),	 creates	 a	ubiquitous	group	of	molecules	with	wide	ranging	actions	(idem).			 The	GAG	family	includes	chondroitin	sulphate	(CS),	dermatan	sulphate	(DS),	keratan	sulphate	 (KS),	 hyaluronan	 (HA),	 heparan	 sulphate	 (HS)	 and	 heparin	 (idem).	 The	disaccharide	 building	 blocks	 of	 GAGs	 are	 composed	 of	 a	 (N-acetylated,	 N-sulphated	 or	unsubstituted)	 hexosamine	 and	 a	 uronic	 acid	 residue	 (glucuronic	 acid	 or	 the	 C5	 epimer,	iduronic	 acid)	 (Backstrom	 et	 al.,	 1979;	 Bjorck	 &	 Kronvall,	 1984;	 Hagner-McWhirter,	 Li,	Oscarson,	&	Lindahl,	2004;	Jacobsson	et	al.,	1984).			 A	 high	 level	 of	 structural	 variability	 is	 conferred	 through	 modifications	 to	saccharide	 unit	 position,	 chain	 length,	 and	 the	 arrangement	 of	 sulphated	 modifications,	which	 is	 specific	 to	 the	 biosynthetic	 cell	 origin	 and	 environment	 (Akerstrom	 &	 Bjorck,	1986;	Gallagher	&	Walker,	1985).	This	diversity	enables	the	formation	of	binding	sites	for	a	multitude	 of	 different	 ligands,	 encompassing	 growth,	 development	 and	maintenance	 (e.g	vascular	 endothelial	 growth	 factor	 (VEGF)	 (Ashikari-	 Hada,	 Habuchi,	 Kariya,	 &	 Kimata,	2005;	 Park,	 Keller,	 &	 Ferrara,	 1993),	 hepatocyte	 growth	 factor/scatter	 factor	 (HGF/SF)	(Ashikari,	 Habuchi,	 &	 Kimata,	 1995),	 hepatocyte	 growth	 factor	 receptor	 (HGFR)	(Jonquieres,	 Pizarro-Cerda,	 &	 Cossart,	 2001),	 heparin	 binding-epidermal	 growth	 factor	(HB-EGF)	(Cook,	Ashton,	Karkaria,	Siess,	&	Shipley,	1995),	 fibroblast	growth	 factor	(FGF)	(Yates,	 Guimond,	 &	 Turnbull,	 2004;	 Yayon,	 Klagsbrun,	 Esko,	 Leder,	 &	 Ornitz,	 1991),	
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fibroblast	growth	factor	receptors	(FGFRs)	(Esko	&	Lindahl,	2001),	Wnt	signaling	pathway,	sonic	hedgehog	protein	(SHH)	and	stem	cells),	inflammation	(e.g	chemokines	(Kuschert	et	al.,	1999)),	 inhibition	of	 lectin	and	selectin	(Koenig,	Norgard-Sumnicht,	Linhardt,	&	Varki,	1998),	coagulation	(Damus,	Hicks,	&	Rosenber.Rd,	1973),	 interferon-	ϒ	(INF-ϒ)	(Sasaki	et	al.,	2001)	and	 tumor	necrosis	 factor-α	(TNF-α)	(Kenig,	Gaberc-Porekar,	Fonda,	&	Menart,	2008)),	 neurodegenerative	 disease	 (e.g	 Alzheimer’s	 disease	 (Snow	 &	 Wight,	 1989),	Parkinson’s	 disease	 (Cohlberg,	 Li,	 Uversky,	 &	 Fink,	 2002),	 prion	 disease	 (Bovine	spongiform	 encephalopathy,	 Creutzfeldt-Jakob	 disease	 (Snow	 et	 al.,	 1990)),	 infectious	disease	 (e.g	malaria	 (Barragan	et	al.,	2000),	African	sleeping	sickness	 (Nishimura,	Shima,	Asakura,	Ohnishi,	&	Yamasaki,	2005),	leishmaniasis	(Love,	Esko,	&	Mosser,	1993),	Human	immunodeficiency	virus	(HIV)	(Vives,	Imberty,	Sattentau,	&	Lortat-Jacob,	2005)	and	herpes	simplex	 virus	 (Tiwari	 et	 al.,	 2006))	 and	 other	 disease	 states	 such	 as	 cancer	 (Park	 et	 al.,	1993).			 Members	of	 the	GAG	 family	have	a	varied	phenotype,	with	CD,	DS,	KS,	HS	and	HA	expressed	 in	multiple	 cell	 types	 and	 locations.	 Chondroitin	 sulphate,	 the	most	 abundant	GAG	 in	 the	 body	 (Buddecke,	 2009),	 is	 present	 in	 PGs	 on	 the	 cell	 membranes	 in	 NG2	(nerve/glial	antigen	2)	(Price	et	al.,	2011)	and	phosphacan	(Maurel,	Rauch,	Flad,	Margolis,	&	 Margolis,	 1994),	 secreted	 pericellularly	 in	 type	 XV	 collagen	 along	 with	 HS	 (Rehn,	Hintikka,	 &	 Pihlajaniemi,	 1994),	 extracellularly	 as	 aggrecan	 along	 with	 KS	 (Heinegard,	2009)	and	in	versican	(Shinomura,	Nishida,	Ito,	&	Kimata,	1993;	Zimmermann	&	Ruoslahti,	1989)	(Table	1).			 Heparan	 sulphate	 is	 ubiquitously	 expressed	 on	 the	 cell	 membranes	 in	 syndecan	(Bernfield	 et	 al.,	 1999)	 and	 in	 glycosylphosphatidylinositol–anchored	 proteoglycans,	glypicans	 (Filmus	&	Selleck,	2001).	HS	 can	also	be	 secreted	 in	pericellular	proteoglycans	such	as	agrin,	perlican	and	type	XVIII	collagen	(Table	1)	(Rehn	et	al.,	1994).	
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	 Keratan	 sulphate	 is	 also	 found	 extracellularly,	 in	 small	 leucine-rich	 PG	 (SLRPS)	(Iozzo,	 1997),	 fibromodulin	 (Heinegard	 et	 al.,	 1986)	 and	 lumican	 (Svensson,	 Narlid,	 &	Oldberg,	 2000).	 Dermatan	 sulphate	 is	 found	 in	 the	 SLRPS	 decorin	 (Krumdieck,	 Hook,	Rosenberg,	&	Volanakis,	1992)	and	epiphycan	(H.	J.	Johnson	et	al.,	1997)	as	shown	in	Table	1.	 Prolargin	 (PRELP)	 does	 not	 have	 GAG	 branching	 but	 binds	 HS	 through	 collagen	 and	
Table	 1:	 Four	 families	 of	 proteoglycans	 based	 on	 cellular	 location,	 and	both	 gene	 and	protein	homology,	adapted	from	(Iozzo	&	Schaefer,	2015).		
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perlecan	binding	in	the	basement	membrane.	Similarly,	asporin	does	not	have	the	serine-glycine	repeats	required	for	GAG	modification	but	maintains	structural	homology	with	the	other	CII	canonical	SLRPS	(Table	1)	(Henry	et	al.,	2001).			 Heparin	 is	 expressed	 solely	 in	mast	 cell	 and	 basophil	 secretory	 granules	 through	attachment	to	a	serine-glycine	rich	protein	core	serglycin	(Metcalfe	et	al.,	1979).	Serglycin	utilises	 electrostatic	 forces	 to	 bind	 proteases,	 inflammatory	 mediators,	 chemokines,	cytokines	and	growth	factors	into	granular	storage	(Douaiher	et	al.,	2014).		 Proteoglycans	are	 involved	with	many	physiological	processes,	 including	 skin	and	tendon	 strength,	 viscoelasticity	 of	 blood	 vessels,	 cartilage	 structure	 and	 as	 an	 essential	component	of	the	extracellular	matrix	(Buddecke,	2009),	with	a	GAG	constituents	playing	the	primary	role	in	these	functions.	
1.2	Glycosaminoglycans		 The	disaccharide	chains	of	GAGs	are	composed	of	repeating	residues	comprising	of	a	uronic	acid,	typically	glucuronic	acid	(GlcA),	or	its	C-5	epimer	iduronic	acid	(IdoA),	and	a	hexosamine	(Backstrom	et	al.,	1979;	Hagner-McWhirter	et	al.,	2004;	Jacobsson	et	al.,	1984),	usually	glucosamine	(GlcN)	or	galactosamine	(GalN)	(Turnbull,	Powell,	&	Guimond,	2001)	forming	 a	 linear	 polysaccharide.	 Covalent	 modification	 to	 the	 disaccharide	 chain	 allow	GAGs	specific	to	tissue	and	cell	 type	to	be	manufactured	through	a	process	of	 incomplete	enzymatic	modifications	(Buddecke,	2009).	The	uronic	acid	residues	can	be	2-O-sulphated	(IdoA2S	or	more	rarely	GlcA2S)	(Rong,	Habuchi,	Kimata,	Lindahl,	&	Kusche-Gullberg,	2001)	or	 remain	 unsulphated,	 while	 the	 glucosamine	 residues	 can	 be	 N-sulphated	(GlcNS)(Lindahl,	 Feingold,	 &	 Roden,	 1986)	 and/or	 O-sulphated,	 N-acetylated	 (GlcNAc)	(Habuchi,	Habuchi,	&	Kimata,	1995;	Liu,	Shworak,	Fritze,	Edelberg,	&	Rosenberg,	1996)	or	remain	 unsulphated	 as	 the	 free	 amine	 (GlcN)	 (Born,	 Jann,	 Assmann,	 Lindahl,	 &	 Berden,	1996).	Galactosamine	 (GalNAc)	 containing	GAGs	 (CS,	DS	and	KS)	 can	be	O-sulphated	but	
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not	 N-sulphated	 (idem).	 Hyaluronic	 acid	 contains	 no	 sulphate	 moieties	 and	 it	 is	 not	covalently	 attached	 to	 a	 core	 protein,	 but	 instead	 interacts	with	 proteoglycans	 via	 a	 HA	binding	 motif	 (Laurent	 &	 Fraser,	 1992).	 O-linked	 and	 N-linked	 glycans	 (typically	 10-14	residues)	still	populate	the	core	protein	structure,	but	these	glycans	are	dwarfed	in	size	by	the	significantly	larger	GAG	chains	(40-10,000	kDa)	(Casu,	2005).		 Heparin,	HS,	DS	and	CS	have	a	common	tetrasaccharide	linkage	region	consisting	of	uronic	acid	(β1-3)Gal(β1-3)Gal(β1-3)Xyl(β1-0)-Ser	containing	sulphation	at	both	position	C4	and	C6	in	the	galactose	residues	(Sugahara,	Ohi,	Harada,	Dewaard,	&	Vliegenthart,	1992;	L.	J.	Zhang	&	Esko,	1994)	and	phosphorylation	at	C2	of	the	xylose	(Moses,	Oldberg,	Cheng,	&	Fransson,	1997).	 	Preferential	 synthesis	of	HS	occurs	over	CS	when	 the	 linkage	 region	contains	 three	 closely	 spaced	 Ser-Gly	 repeats	 in	 the	 core	 protein,	 with	 the	 amino	 acid	environment	containing	a	hydrophobic	residue	and	a	group	of	acidic	residues	(L.	J.	Zhang	&	Esko,	1994).	
1.3	Heparin	and	heparan	sulphate	
1.3.1	Structure		 Heparan	 sulphate	 and	 the	 more	 highly	 sulphated	 homogenous	 analogue	 heparin	have	been	shown	to	contain	the	most	structural	diversity	of	any	of	the	molecules	expressed	in	 multicellular	 organisms	 (Casu	 &	 Lindahl,	 2001).	 Both	 heparin	 and	 HS	 have	 β1-4	glycosidic	 linkages	 and	 share	 a	 common	 biosynthetic	 pathway	 (Rabenstein,	 2002)	originating	from	the	unsulphated	precursor	N-acetyl	heparosan	(Casu	&	Lindahl,	2001).		 HS	has	a	domain-like	secondary	structure,	with	regions	of	high	sulphation	levels	(NS	domains),	 intermediate	 domains	 comprising	 of	 sulphated	 and	 non-sulphated	 (N-acetylated)	 disaccharides	 (NA/NS	 domains)	 and	 low/unsulphated	 sulphate	 regions	 (NA	domains)(Figure	1)	(Esko	&	Lindahl,	2001).	
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	 The	monosaccharide	content	 is	much	more	varied	 in	HS	than	heparin.	Uronic	acid	residues,	 β-D-glucuronic	 acid	 and	 α-L-iduronic	 acid	 can	 be	 2-O-sulphated	 (IdoA(2S)	 or	more	rarely	GlcA(2S))	and	found	in	the	NS	domain,	or	unsulphated	in	the	NA/NS	domains	(Casu,	 2005).	 The	 α-D-N-acetylglucosamine	 can	 be	 N-sulphated	 (GlcNS),	 N-acetylated	(GlcNAc),	 6-O-sulphated	 (GlcNS(6S)	 or	 GlcNAc(6S))	 or	 more	 rarely,	 unsubstituted	(GlcN)(Figure	2)	(Esko	&	Lindahl,	2001).	Rarely,	the	GlcNS	and	GlcNS(6S)	can	also	be	3-O-sulphated	(GlcNS(3S)	and	GlcNS(3,6S))	(Rabenstein,	2002).	The	ratio	of	GlcNS	to	GlcNAc	is	approximately	1:1	in	HS,	due	to	GlcNAc	predominantly	in	the	NA	domains	(idem).		
	Figure	 1:	 Schematic	 illustrating	 the	 domain	 organisation	 of	 heparan	 sulphate.	 Tri-sulphated	disaccharide,	 IdoA(2S)-GlcNS(6S)	 most	 predominantly	 in	 the	 NS-domain,	 while	 unsulphated	disaccharide	 GlcA-GlcNAc	 appears	 most	 predominantly	 in	 the	 NA-domain.	 Adapted	 from	(Rabenstein,	2002)	
		Figure	2:	Schematic	of	the	heparan	sulphate	disaccharide	repeat	unit,	demonstrating	the	structural	diversity	of	this	glycopolymer.	Adapted	from	(Patey,	Edwards,	Yates,	&	Turnbull,	2006).	
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	 Heparin	 exists	 as	 a	 linear	 glycopolymer	 comprised	 of	 pyranose	 rings	 adopting	 a	variety	 of	 structures	 dependent	 on	 the	 ring	 substitutions	 and	 neighboring	 ring	modifications,	usually	in	energetically	favorable	conformations	(B.	Mulloy,	Forster,	Jones,	&	Davies,	1993).	Glucuronic	acid	and	glucosamine	adopt	the	4C1	chair	conformation	in	which	all	 functional	 groups	 apart	 from	 the	 anomeric	 hydroxyl	 group	 of	 glucosamine	 are	equatorial	 (Ferro	et	 al.,	 1986).	 	The	more	 flexible	 IdoA	adopts	either	 the	 1C4	 chair	or	 2S0	boat	 conformations,	 with	 unsubstituted	 IdoA	 most	 commonly	 occupying	 the	 1C4	conformation	(Yates	et	al.,	1996).			 Heparin	may	be	 thought	 of	 as	more	highly	 sulphated,	 homogenous	 version	 of	HS,	representing	 the	 NS	 domain;	 although	 it	 does	 include	 regions	 of	 lower	 sulphation	interspersed	throughout	the	molecule	(Rabenstein,	2002).	The	GlcNS	to	GlcNAc	ratio	is	4:1	representing	 the	 absence	 of	 the	 NA	 unsulphated	 region	 present	 in	 HS	 (idem).	 The	most	common	disaccharide	 in	heparin	 is	α-L-iduronic	acid(2S)-(1-4)-α-D-N-sulphoglucosamine	(6S),	accounting	for	≈	90	%	of	bovine	lung	heparin	(BLH)	and	≈	70	%	of	porcine	mucosal	heparin	(PMH)	(idem).	Heparin	is	more	highly	sulphated	than	HS,	largely	due	to	the	more	restricted	enzymatic	action	of	the	endosulphatases,	thereby	reducing	O-sulphate	levels	that	are	 most	 prominent	 at	 position	 6	 of	 the	 glucosamine	 residue	 (Casu,	 2005).	 Dynamic	biosynthesis	of	HS	creates	variable	regions	of	sulphation	depending	on	cell	and	tissue	type	and	 degree	 of	 cell	 differentiation.	 This	 complexity	 is	 thought	 to	 be	 responsible	 for	 the	enormous	variation	in	biological	functions	(Turnbull	et	al.,	2001).		 Since	 1935,	 heparin	 has	 been	 extracted	 and	 purified	 from	 animals	 and	 utilised	pharmaceutically	 as	 an	 anticoagulant.	 This	 is	 due	 to	 the	 ability	 of	 heparin	 to	 bind	 the	plasma	serine	protease	inhibitor,	antithrombin	III	(AT).	The	discovery	of	a	pentasaccharide	AT	binding	 sequence	was	 the	 first	 evidence	 that	 a	 specific	 structural	modification	 in	 the	GAGs	 enabled	 this	 interaction	 (Casu	 et	 al.,	 1981).	 The	 pentasaccharide	 sequence	GlcNAc/NS(6S)-GlcA-GlcNS(3,6S)-IdoA(2S)-GlcNS(6S)	 includes	 a	 rare	 3-O-sulphate	
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modification	on	GlcNS(6S)	(Casu	et	al.,	1981;	Riesenfeld,	Thunberg,	Hook,	&	Lindahl,	1981).	Only	 one	 third	 of	 all	 heparin	 chains	 confer	 anticoagulant	 activity	 in	 this	 AT	 binding	pentasaccharide	(idem).	
1.3.2	Biosynthesis		 Heparin	biosynthesis	begins	from	a	serglycin	protein	core	through	a	tetrasaccharide	linker	comprising	of	xylose,	galactose	(two)	and	glucuronic	acid	residues	in	the	form	of	the	β-GlcA-(1-3)-	 β-Gal-(1-3)-	 β-Gal-(1-4)-	 β-Xyl-	 motif	 attached	 to	 random	 serine	 residues	within	serglycin	(Lindahl,	1989).	Polymerisation	of	the	glycan	chain	occurs	from	this	GlcA	residue	 with	 sequential	 addition	 of	 the	 monosaccharides	 GlcNAc	 and	 GlcA	 [GlcA-(1,4)-GlcNAc]n	(Figure	3)	(idem).		
	Figure	3:	Schematic	of	the	enzymes	responsible	for	heparan	sulphate	polymerisation	of	UDP-GlcNAc	and	UDP-GlcA,	and	the	covalent	modification	of	the	residues.	Figure	modified	from	(Bernfield	et	al.,	1999)		
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	 Enzymes	may	modify	the	polymer	chain	although	this	does	not	necessarily	occur	to	completion.	 N-deacetylase/N-sulphotransferase	 (NDST)	 may	 partially	 convert	 GlcNAc	 to	GlcNS;	 NDST	 proceeds	 along	 the	 heparin	 chain	 until	 reaching	 an	 intractable	 GlcNAc	residue,	 leading	 to	 the	 incomplete	 N-sulphation	 of	 the	 heparin	 chain	 (Kjellen	&	 Lindahl,	1991).	 The	 action	 of	 N-deacetylase/N-sulphotransferase	 restricts	 further	 chain	modification,	 as	 the	 subsequent	 enzymatic	 modifications	 rely	 on	 the	 presence	 of	 GlcNS	residues	 (Rabenstein,	 2002).	 C5-epimerase	 catalyses	GlcA	 to	 IdoA	 and	 is	 specific	 only	 to	GlcA	residues	at	the	reducing	end	of	GlcNS	in	the	GAG	chain	(Hagner-McWhirter,	Lindahl,	&	Li,	 2000).	 IdoA	 can	 be	 modified	 with	 2-O-sulphotransferase,	 but	 if	 attached	 to	 C-1	 of	GlcNS(6S)	is	not	a	viable	substrate	(Rabenstein,	2002).	GlcNS	can	be	modified	with	a	6-O-sulphotransferase,	 however	 the	 disaccharide	 IdoA(2S)-GlcNS(6S)	 is	 abundant	 in	 heparin	indicating	the	2-O-sulphation	occurs	before	the	6-O-sulphation	(idem).			 Less	 frequently,	 modifications	 are	 seen	 that	 require	 2-O-sulphation	 of	 GlcA	(GlcA(2S)),	6-O-sulphation	can	occur	in	the	GlcNAc	adjacent	to	a	disaccharide	containing	a	GlcNS	 and	 GlcNS(6S)	 can	 be	 3-O-suphated	 as	 seen	 in	 the	 AT	 binding	 pentasaccharide	(Lindahl,	Backstrom,	Thunberg,	&	Leder,	1980).		 In	HS,	chain	formation,	polymerisation	and	modification	occur	similarly,	but	with	an	organised	 domain	 structure,	 therefore	 containing	 fewer	 O-sulphate	 modifications	(Rabenstein,	2002).	The	domain	 regions	are	 split	 into	a	 structurally	modified	 region	 (NS	domain),	which	includes	a	higher	proportion	of	epimerised	IdoA,	an	intermediate	region	of	modification	 (NA/NS	 domain)	 and	 a	 region	 of	 low	 enzymatic	modification	 (NA	 domain)	(Sugahara	&	Kitagawa,	2000).		 In	the	final	phase	of	biosynthesis,	desulphation	by	an	endosulphatase	produces	HS	whereas	 depolymerisation	 through	 selective	 cleavage	 of	 GlcA	 by	 an	 endo-β-D-glucuronidase	results	in	a	polydisperse	mixture	of	heparin	chains	(Robinson,	Horner,	Hook,	Ogren,	&	Lindahl,	1978).	
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1.3.3	Bioactivity		 Heparin	 and	 heparan	 sulphate	 interact	 with	 a	multitude	 of	 extracellular	 proteins	that	regulate	and	modulate	bioactivity.	The	more	flexible	pyranose	ring	in	IdoA,	compared	to	GlcA	and	GlcN	monosaccharide	units,	is	thought	to	explain	the	ability	of	heparin	and	HS	in	 binding	 to	 a	 wide	 range	 proteins;	 this	 is	 believed	 to	 be	 due	 to	 the	 anionic	 groups	interacting	with	cationic	amino	groups	present	on	the	target	proteins	(Rabenstein,	2002).	Non-ionic	hydrogen	bonding	and	hydrophobic	interactions	may	also	contribute	to	protein	binding	 (Noti	 &	 Seeberger,	 2005).	 Utilising	 conformationally	 locked	 synthetic	carbohydrates;	 Das	 et	 al.	 were	 able	 to	 show	 that	 the	 2S0	 skew-boat	 IdoA	 conformation	regulates	the	exogenous	anti-thrombotic	activity	of	heparin	(Das	et	al.,	2001).		 Studies	 utilising	 gene	 disruption	 of	 N-deacetylase/N-sulphotransferase-2	 in	transgenic	mice	produced	a	low-sulphated	version	of	heparin	(Humphries	et	al.	1999).	The	mast	cells	located	in	transgenic	murine	skeletal	muscle	lacked	metachromatic	granules	and	failed	 in	 storing	mouse	mast-cell	 proteases	 (mMCP)-4,	 (mMCP)-5	 and	 carboxypeptidase	(mMC-CPA)	(Humphries	et	al.,	1999).	The	study	conducted	by	Humphries	et	al.	illustrated	the	 action	 of	 heparin	 during	 post-translational	 modification	 of	 the	 proteases,	 showing	control	 in	 levels	 of	 specific	 positively	 charged	 proteases	 inside	mast	 cells	 (idem).	 These	proteases	have	a	variety	of	 roles	 in	vivo:	 inflammatory	and	anti-inflammatory,	protective	and	 deleterious,	 in	 allergy,	 tissue	 homeostasis	 and	 innate	 immunity	 (Caughey,	 2011).	Research	done	to	reduce	the	pro-inflammatory	mediator	histamine	in	the	transgenic	mice	indicated	 a	 stabilising	 relationship	 between	 deprotonated	 histamine	 (pH	 5.2-6.0)	(Humphries	 et	 al.,	 1999)	 (R.	 G.	 Johnson,	 Carty,	 Fingerhood,	 &	 Scarpa,	 1980)	 and	 highly	negatively	charged	heparin	through	electrostatic	interactions	(Rabenstein,	2002).		 Heparan	 sulphate	 proteoglycans	 (HSPGs)	 have	many	wide-ranging	 activities	with	modifications	 to	 the	 GAG	 sequence	 and	 protein	 core	 permitting	 a	 plethora	 of	 different	HSPGs.	Examples	of	HSPGs	include:	
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-	HSPGs	in	basement	membrane	such	as	perlecan,	agrin	and	type	XVIII	collagen	(Rehn	et	al.,	1994)	 that	 work	 in	 conjunction	 with	 components	 of	 the	 extracellular	 matrix	 to	 form	basement	membranes		-	 HSPG	 scaffolds	 that	 bind	 cytokines,	 chemokines,	 growth	 factors	 (GF)	 and	morphogens	providing	 a	 region	 for	 accumulation	 and	 interaction	 including	 morphogen	 gradient	formation,	 essential	 for	 cell	 specification	 and	 development.	 One	 example	 includes	morphogen	 gradients	 utilised	 in	 leukocyte	 recruitment	 and	 homing	 during	 an	 immune	response	(D.	Yan	&	Lin,	2009)	-HSPGs	act	as	protease	receptors,	maintaining	spatial	distribution	and	activity	(Casu	et	al.,	1981)	-HSPGs	 in	 cell	 membranes	 act	 to	 facilitate	 extracellular	 matrix-cell	 attachment,	 cell-cell	attachment	and	motility	with	integrins	and	other	factors	-HSPGs	 in	 cell	 membranes	 co-operate	 as	 receptors	 for	 growth	 factors	 such	 as	 tyrosine	kinase	(Cohen	et	al.,	1995)	and	fibroblast	(Yayon	et	al.,	1991)	GF	receptors		-HSPGs	 in	 membranes	 act	 as	 endocytic	 receptors	 for	 clearance	 of	 ligands	 such	 as	lipoprotein	lipase	in	the	liver	(Sarrazin,	Lamanna,	&	Esko,	2011).	
1.3.4	Coagulation		 Heparin	binds	 the	 serpin	AT	at	 residues	Lys114,	 Lys	125,	Arg	129,	Asn45,	Arg46,	Arg47,	 Lys11,	 Arg13	 and	 Glu113	 (Schedin-Weiss,	 Arocas,	 Bock,	 Olson,	 &	 Bjork,	 2002)	(Huntington,	 2005).	 The	 heparin:AT	 pair	 then	 go	 on	 to	 form	 complexes	when	 thrombin	(factor	 IIa),	 factor	 IXa,	Xa,	XIa,	and	XIIa	serine	proteases	(Lever	&	Page,	2002)	attack	 the	Arg	393-Ser394	bond	(Olson	&	Bjork,	1994)	in	the	carboxyl	terminal	region	of	AT,	inducing	a	 conformational	 change	 and	 inhibiting	 the	 serine	 protease	 (Fu,	 Liu,	 Frost,	 &	 Lemere,	2010).	Optimal	levels	of	heparin	accelerate	the	natural	anticoagulant	action	of	AT	by	up	to	2000-fold	(idem).	The	heparin	pentasaccharide	binds	AT	altering	the	conformation	of	the	
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serpin	creating	a	more	effective	binding	site	 for	 the	serine	proteases;	 factors	 IXa,	Xa,	XIa	and	XIIa	(Racke	et	al.,	2005);	AT	acts	as	a	suicide	substrate	(Huntington,	2005).		 Heparin	also	includes	a	polysaccharide	sequence	(≥	18	saccharides	long)	utilised	as	a	 scaffold,	 bringing	 the	 proteinase	 thrombin	 and	 the	 serpin	 AT	 into	 close	 proximity	therefore	 increasing	the	AT	 inhibition	of	 thrombin	(Bjork	&	Lindahl,	1982).	These	 longer	polysaccharides	in	unfractionated	(UF)	heparin	also	stimulate	the	release	of	platelet	factor	4	 (PF-4)	 from	 platelets	 and	 can	 form	 complexes	 that	 become	 auto-reactive	 in	 heparin-induced	thrombocytopenia	type	2	(HIT)	(Deitcher	&	Carman,	2001).	
1.3.5	Clinical	use		 Low	 molecular	 weigh	 heparins	 (LMWHs)	 have	 been	 developed	 by	 chemical	depolymerisation	(cleavage	by	β-elimination	of	benzyl	ester,	nitrous	acid	depolymerisation	and	peroxyl	radical	cleavage)	(Hirsh	et	al.,	1998)	(Quader,	Stump,	&	Sumpio,	1998)	to	form	ardeparin,	 dalteparin,	 enoxoparin	 and	 reviparin,	 through	 enzymatic	 methods	 (β-elimination	 by	 heparinase	 3)	 to	 form	 tinzaparin	 or	 by	 size	 fractionation	 of	 unmodified	heparin	 (Linhardt	 &	 Gunay,	 1999).	 These	 LMWH	 have	 reduced	 content	 of	 the	 18-saccharide	 scaffold	 contained	 in	 full-length	 heparin	 preparations	 and	 therefore	 reduce	thrombin	 interactions,	 leading	 to	 an	 improved	 therapeutic	 index,	 while	 retaining	 the	specific	 AT	 binding	 pentasaccharide	 (Lindhardt	 and	 Sibel-Gunay	 1999).	 The	 factor	IIa:factor	Xa	binding	ratio	of	these	LMWHs	ranges	from	1.6	in	tinzaparin	to	4.2	in	reviparin	(Gray,	Mulloy,	&	Barrowcliffel,	2008).		
1.3.6	Research	into	other	applications	of	heparin	as	a	potential	therapeutic		 Heparin	 has	 been	 researched	 as	 a	 possible	 treatment	 for	 many	 HSPG	 binding	protein	related	diseases	with	success	in	many	varied	pathologies	including	but	not	limited	to	the	following	examples.	
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	 Heparin	has	been	 identified	as	a	molecule	capable	of	blocking	parasite	 invasion	of	host	cells	by	competing	with	exogenous	HS;	in	P.falciparum	malaria,	heparin	is	thought	to	bind	 the	 viral	 TRAP	 (thrombospondin-related	 anonymous	 protein)	 sporozoite	 surface	receptor	 (Akhouri,	 Bhattacharyya,	 Pattnaik,	 Malhotra,	 &	 Sharma,	 2004).	 Heparin	 also	reduces	 cytoadherance	 (Xiao,	 Yang,	 Patterson,	 Udhayakumar,	 &	 Lal,	 1996)	 and	 rosetting	(Carlson	et	al.,	1992)	of	P.	falciparum	infected	erythrocytes	helping	to	reduce	the	burden	of	the	disease	on	the	sufferer.			 Heparin	 can	 also	 block	 viral	 cell	 invasion	 through	 competition	 with	 host	 cell	 HS	surface	receptors.	Diseases	such	as	herpes	(Nahmias	&	Kibrick,	1964),	influenza	(Skidmore	et	al.,	2015),	dengue	fever	(Y.	L.	Lin	et	al.,	2002),	yellow	fever	(Germi	et	al.,	2002),	varicella	zoster	(responsible	for	chicken	pox/shingles),	hepatitis	B	(Schulze,	Gripon,	&	Urban,	2007)	and	C	(Basu	et	al.,	2007),	HIV	(M.	Ito	et	al.,	1987),	coxsackie	virus	(Frizelle,	Schwarz,	Huber,	&	Leslie,	1992)	and	Zika	virus	(Ghezzi	et	al.,	2017)	all	show	heparin	inhibition.			 Aberrant	 protein	 aggregation	 diseases	 such	 as	 type	 II	 diabetes	 (Jaikaran	&	 Clark,	2001),	neurodegenerative	diseases	bovine	spongiform	encephalopathy	(BSE),	Creutzfeldt-Jakob	 disease	 (CJD)	 (Vieira,	 Cordeiro,	 Caughey,	 &	 Silva,	 2014),	 Parkinson’s	 disease	 (PD)	(Cohlberg	et	al.,	2002),	and	Alzheimer’s	disease	(AD)	(Bergamaschini,	Rossi,	Vergani,	&	De	Simoni,	2009)	all	include	HSPGs	in	aggregates.			 Heparan	 sulphate	 proteoglycans	 are	 thought	 to	 act	 as	 a	 nucleation	 point	 for	aberrant	 fibril	 formation,	 rich	 in	 β-sheet	 structure;	 fibrils	 are	 the	 main	 component	 of	amyloid	plaques.	Extracellular	prion-like	conversion	to	fibrillar	protein	progresses	through	the	neurons	via	cell	membrane	HSPG	binding	(B.	B.	Holmes	et	al.,	2013).	Cellular	uptake	of	fibrillar	 protein	 and	 therefore	propagation	of	 seed	 fibril	 proteins	was	halted	by	heparin,	chlorate,	 heparinase	 and	 knockdown	 of	 HSPG	 biosynthetic	 enzyme,	 Ext1	 (exostosin	glycosyltransferase	1)	(idem).		
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	1.4	Dementia		 Dementia	is	commonly	defined	as	a	chronic	or	progressive	syndrome	of	a	diseased	brain,	which	manifests	as	disturbances	in	higher	functioning	including	memory,	language,	comprehension,	 learning	capacity,	and	 judgement	with	no	changes	seen	 in	consciousness	(WHO,	 2012).	 These	 chronic	 disturbances	 are	 usually	 preceded	 by	 changes	 in	 mood,	emotional	control	or	motivation	(idem).	Neurological	changes	can	be	expressed	in	different	behavioural	 and	 psychological	 symptoms	 that	 are	 commonly	 seen	 in	 dementia	 sufferers	including	 aggression,	 anxiety,	 disinhibition,	 euphoria,	 irritability,	 depression,	 and	hallucinations	(Hughes,	2011).			 The	most	common	form	of	dementia	is	AD,	which	represents	approximately	60%	of	all	 dementia	 cases	 (Boltz,	 2011).	 Other	 forms	 of	 dementia	 include	 vascular	 dementia,	dementia	with	Lewy	bodies,	 fronto-temporal	dementia	and	even	more	rarely	Creutzfeldt-Jakob	 disease	 (idem).	 Vascular	 dementia	 is	 caused	 by	 the	 loss	 of	 brain	 tissue	 through	impaired	 cerebral	 blood	 supply,	 strokes,	 sclerotic	 lesions	 in	 cerebral	 vessels,	 high	 blood	pressure,	 high	 cholesterol,	 and	 diabetes	 (idem).	 Dementia	 with	 Lewy	 bodies	 has	characteristics	seen	commonly	in	both	AD	and	PD,	caused	by	α-synuclein	protein	deposits	(Lewy	 bodies)	 in	 neuronal	 cytoplasm,	 found	 throughout	 the	 brain	 (Lee,	 Goedert,	 &	Trojanowski,	 2001).	 Fronto-temporal	 dementias	 are	 a	 range	 of	 conditions	 describing	morphological	 changes	 to	 the	 frontal	 lobe	 and/or	 temporal	 lobes	 of	 the	 brain	 (idem).	Approximately	 half	 of	 these	 cases	 are	 due	 to	 aggregation	 of	 microtubule	 stabilising	 tau	protein	into	tangles	or	‘Pick	bodies’,	while	the	other	half	are	due	to	a	protein	that	stains	for	ubiquitin	called	transactive	response	DNA	binding	protein	(TDP-43)	(Hughes,	2011).			 In	April	2012,	 the	World	Health	Organisation	 (WHO)	announced	via	press	 release	that	 ‘dementia	 cases	 set	 to	 triple	 by	 2050,	 but	 still	 largely	 ignored’	 (WHO,	 2012).	 The	statistics	 released	with	 this	 report	highlight	35.6	million	people	are	currently	 living	with	dementia,	with	 this	 figure	estimated	 to	 rise	 to	115.4	million	people	by	2050	 (idem).	The	
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report	highlights	problems	in	early	diagnosis,	with	progress	in	this	area	allowing	medical	intervention	 to	 control	 symptoms,	 affording	 few	 more	 years	 to	 ailing	 individuals.	 The	report	also	notes	medical	intervention	currently	treats	some	of	the	symptoms	of	dementia,	but	goes	no	way	to	address	the	causes	of	the	condition	(idem).		
1.5	Alzheimer’s	disease		 There	are	2	main	sites	of	anomalous	protein	deposits	in	AD;	plaques	formed	by	β-amyloid	 (Aβ)	 protein	 and	 neurofibrillary	 tangles	 formed	 by	 hyperphosphorylated	 tau	proteins	(microtubule	associated	protein	τ) (Lee	et	al.,	2001).	The	amyloid	hypothesis	of	AD	was	 first	 suggested	by	Dennis	Selkoe	 in	1991	and	has	become	a	central	 theme	 in	 the	aetiology	 of	 AD	 (Selkoe,	 1991).	 Alongside	 this	 protein	 misfolding,	 oxidative	 and	inflammatory	damage	result	in	neuronal	energy	failure,	synaptic	dysfunction	and	cell	death	(Querfurth	&	LaFerla,	2010).			 Tau	is	a	low	molecular	weight	(55	–	70	kDa)	microtubule	associated	protein	(MAP)	expressed	predominantly	in	CNS	axons,	encoded	by	a	single	16	exon	gene	at	chromosome	17q21	 (Neve,	 Harris,	 Kosik,	 Kurnit,	 &	 Donlon,	 1986).	 Tau	 modulates	 the	 assembly	 of	microtubules	 into	 bundled	 forms,	 which	 provide	 strength	 and	 stability	 to	 axons	 during	morphogenesis	 and	 provide	 tracks	 for	 vesicular	 transport	 (Drechsel,	 Hyman,	 Cobb,	 &	Kirschner,	 1992).	 Tau	 isoforms	 differ	 developmentally,	 with	 only	 the	 smallest	 isoform	present	 in	 the	 foetal	 human	brain	 and	6	 isoforms	present	 in	 adults	 (Goedert,	 Spillantini,	Jakes,	Rutherford,	&	Crowther,	1989).				 The	 microtubule	 binding	 motifs	 occur	 at	 the	 carboxy-terminal	 of	 tau,	 with	phosphorylation	 sites	 located	 flanking	 these	binding	 regions;	 increasing	phosphorylation	at	 these	 sites	 negatively	 regulates	 microtubule	 binding	 (Drechsel	 et	 al.,	 1992).	Hyperphosphorylation	of	tau	excludes	microtubule	binding	and	leads	to	self-association	to	form	paired	helical	 filaments	 (PHF)	 of	 tau	 either	 consisting	 of	 a	 pair	 of	 proteins	 twisted	
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round	 a	 third	 (Crowther	 &	 Wischik,	 1985),	 or	 straight	 filaments	 lacking	 this	 helical	structure	 (Crowther,	 1991).	 Aggregates	 of	 PHF	 form	 neuronal	 and	 glial	 cell	 inclusions	called	 neurofibrillary	 tangles	 (NFT),	 which	 are	 thought	 to	 play	 a	 role	 in	 cellular	degeneration	 through	 disruption	 to	 axon	 cytoskeleton,	 vesicle	 transport	 and	 synaptic	dysfunction	(Lee	et	al.,	2001).	The	exact	aetiology	of	tau	in	AD	has	yet	to	be	fully	elucidated,	with	NFT	formation	also	thought	to	have	a	neuroprotective	role	as	a	neuronal	response	to	oxidative	damage	(Medina	&	Avila,	2014).		 For	information	regarding	other	hypotheses	for	AD	pathogenesis,	including	the	role	of	tau	cytoskeletal	microtubule	associated	protein,	the	reader	is	referred	to	the	review	by	Kaj	Blennow	et	al.	(Blennow,	de	Leon,	&	Zetterberg,	2006).		
	 Aβ	 is	 a	 36-43	 residue	 peptide	 produced	 in	 normal	 metabolism	 through	 the	sequential	processing	of	amyloid	precursor	protein	(APP)	(largest	isoform	770	residues	in	length);	a	single	 trans-membrane	protein	expressed	mainly	 in	neuronal	synapses	(Figure	4)	(Ballard	et	al.,	2011).	In	the	amyloidogenic	pathway,	implicated	in	Alzheimer’s	disease,	
	Figure	4:	Schematic	of	non-amyloidogenic	and	amyloidogenic	metabolism	of	 the	770	amino	acid	transmembrane	APP.	Modified	from	(Stanga	et	al.,	2010).			
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APP	 is	 cleaved	 by	 a	 β-secretase	 known	 as	 BACE1	 (β-site	 APP	 cleaving	 enzyme)	 or	memapsin-2;	a	 class	 I	 transmembrane	aspartyl	protease	 (Selkoe,	1991).	APP	cleavage	by	BACE1	 liberates	 soluble	 APP-β	 peptide	 with	 the	 remaining	 C99	 peptide	 membrane	anchored	 (idem).	 BACE1	 processing	 is	 followed	 by	 γ-secretase	 (multi-unit	 enzyme)	cleavage	of	 the	membrane	anchored	C99	peptide.	γ-secretase	 is	a	multi-subunit	protease	consisting	of	a	presenilin	(catalytic	subunit),	nicastrin,	APH-1	and	PEN-2	(Kimberly	et	al.,	2003).	 γ-secretase	 proteolysis	 of	 C99	 results	 in	 the	 formation	 of	 an	 amyloidogenic	 Aβ	fragment,	which	is	released	into	the	cerebral	intracellular	space,	and	the	APP	intracellular	cytoplasmic	domain	(AICD)	(Selkoe,	1991),	targeted	to	the	nucleus	signalling	transcription	activation	(Querfurth	&	LaFerla,	2010).			 In	the	non-amyloidogenic	pathway,	APP	is	first	cleaved	by	α-secretase,	a	disintegrin	and	 metalloproteinase	 domain-containing	 protein	 10	 (ADAM-10)	 consisting	 of	 a	disintegrin	and	a	metalloprotease	domain	that	 liberates	sAPP-α	peptide	and	a	membrane	bound	C83	peptide	(Querfurth	&	LaFerla,	2010).	This	is	then	further	modified	by	the	same	γ-secretase	cleavage	 to	release	p3	 fragment,	 leaving	 the	APP	 intracellular	domain	(AICD)	(idem).		 Following	APP	cleavage	by	BACE1,	Aβ40	is	a	much	more	prevalent	species	than	pro-aggregating	Aβ42	species,	with	90-95%	Aβ40	and	only	5-10%	Aβ42	(Iwatsubo,	Saido,	Mann,	Lee,	 &	 Trojanowski,	 1996).	 One	 explanation	 of	 AD	 pathogenesis	 suggests	 imbalance	between	 production	 and	 clearance	 of	 these	 Aβ42	 peptides	 allowing	 them	 to	 coalesce,	aggregate	and	deposit	(Querfurth	&	LaFerla,	2010).	This	imbalance	was	suggested	from	the	study	 of	 early-onset	 dementia	 that	 occurs	 frequently	 in	 trisomy	 21	 (Down’s	 syndrome)	sufferers,	as	 the	APP	gene	 is	 located	on	 the	 long	arm	of	chromosome	21	at	position	21.3	(Mrak	&	Griffin,	2004).	This	extra	gene	increases	transcription	levels	of	APP	mRNA,	leading	to	an	increase	in	Aβ42	when	compared	to	that	of	healthy	controls;	Mrak	and	Griffin	believe	this	to	be	a	contributing	factor	to	Down’s	early	onset	AD	(Mrak	&	Griffin,	2004).		
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	 Investigations	by	Ehehalt	et	al.	postulate	the	processing	pathway	of	APP	depends	on	the	cholesterol	and	sphingolipid	rich	 lipid	raft	 formations	present	 in	 the	cell	membranes	(Ehehalt,	 Keller,	 Haass,	 Thiele,	 &	 Simons,	 2003).	 The	 apolipoprotein	 E4	 allele	 has	 been	shown	to	be	a	major	risk	factor	for	AD	(Corder	et	al.,	1993),	with	low-density	lipoprotein	(LDL)	 cholesterol	 levels	 in	 mid-life	 correlating	 with	 increased	 AD	 risk	 (Kivipelto	 et	 al.,	2001).	The	removal	of	 lipid	rafts	 inhibited	the	production	of	Aβ	in	mouse	neuroblastoma	N2a	cells	(Ehehalt	et	al.,	2003).	Amyloid	precursor	protein	present	in	raft	formations	was	cleaved	 by	 BACE1,	 while	 APP	 found	 outside	 these	 formations	 was	 processed	 non-amyloidogenically	(idem).			 Aβ	 spontaneously	 coalesces	 into	 multiple	 different	 protein	 conformations,	beginning	 as	 oligomeric	 forms	 consisting	 of	 2	 to	 6	 peptides	 (Kayed	 et	 al.,	 2003).	 These	accretions	 then	collect	 into	 intermediate	 formations	before	 forming	 insoluble	 fibrils	with	complex	β-pleated	sheet	formations	called	senile	plaques	(Kayed	et	al.,	2003).	Neurotoxic	oligomers	and	plaques	disrupt	critical	neuronal	metabolic	processes,	cell-to-cell	transport	and	communications,	 illicit	 immune	response	network	causing	inflammatory	damage	and	oxidative	 damage	 (Lesne	 et	 al.,	 2006).	 In	 both	 transgenic	mouse	models	 and	 human	AD	brains,	 a	mixture	 of	 Aβ	 species	 is	 present,	 from	monomers	 to	mature	 plaques	 (Haass	 &	Selkoe,	 2007).	 The	 hypothesis	 that	 soluble	 oligomers	 of	 Aβ	 cause	 the	 biochemical,	 and	electrophysiological	 effects	 (e.g	 through	 the	 inhibition	 of	 hippocampal	 long	 term	potentiation)	seen	in	the	brain	is	supported	by	other	related	neurodegenerative	diseases,	such	 as	 Parkinson’s	 and	Huntington’s	 (idem).	 It	 is	 hypothesised	 large	 plaque	 formations	represent	reservoirs	in	equilibrium	with	the	soluble	Aβ	species	(idem).		 Synapses	in	the	hippocampus	begin	to	decline	in	the	early	stages	of	AD,	referred	to	as	 mild	 cognitive	 impairment	 (MCI)	 with	 an	 increasing	 loss	 of	 synapses	 (Querfurth	 &	LaFerla,	2010).	Aggregation	of	Aβ	causes	neuronal	dysfunction	at	the	synapses,	a	reduction	
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in	 dendritic	 spines	 (reducing	 communication	 with	 other	 axons)	 and	 reduced	 synaptic	transmission	(Querfurth	&	LaFerla,	2010).			 The	pathway	of	neuronal	degeneration	begins	in	the	entorhinal	cortex,	through	the	hippocampus,	 into	 the	 posterior	 temporal	 and	 parietal	 neocortex	 into	 the	 surrounding	cerebral	cortex	in	late	stage	AD	(Vemuri	&	Jack,	2010).	The	progression	of	AD	causes	initial	generalised	 atrophy	 in	 the	mild	AD	brain	with	 increased	ventricle	 size	moving	 to	 severe	cortical	shrinkage	and	enlarged	ventricles	in	the	severely	affected	patient	(Vemuri	&	Jack,	2010).			 The	 typical	 symptom	of	memory	 loss,	 seen	 in	AD	patients,	 is	 due	 to	 hippocampal	and	 cortical	 acetylcholine	 transferase	 level	 insufficiencies	 and	 loss	 of	 cholinergic	projections	 into	 the	basal	 forebrain	 (Selkoe,	1991).	Neuronal	 loss	 leads	 to	a	 reduction	 in	the	release	of	neurotransmitter	and	the	number	of	receptors	available	in	the	acetylcholine,	dopamine	 and	 N-methyl-D-aspartate	 (NMDA)	 pathways	 (idem).	 Memantine,	 an	 NMDA	receptor	 agonist,	 aids	 regulation	 of	 glutamate	 as	 a	 neuroprotectant	 against	 excesses	associated	 with	 neuron	 loss	 (NICE,	 2011).	 Cholinesterase	 inhibitors	 like	 donepezil,	galantamine	 and	 rivastigmine	 block	 the	 normal	 breakdown	 of	 acetylcholine,	 increasing	intrinsic	efficacy	(idem).	These	treatments	help	remaining	functional	neurons	retain	their	limited	 capacity,	 however	 the	 action	 of	 these	 drugs	 diminishes	 with	 reducing	 neuron	number,	 therefore	 a	 treatment	 plateau	 occurs	 when	 this	 limit	 is	 met;	 the	 currently	available	pharmaceuticals	do	not	treat	the	causes	of	AD,	which	progresses	typically.			 BACE1	catalyses	the	 initial	and	rate	 limiting	cleavage	of	APP	as	a	precursor	to	the	production	of	Aβ42	and	 is	 therefore	 seen	as	a	 superior	drug	 target	 for	 the	 therapy	of	AD	(Sinha	et	al.,	1999).		
	 21	
1.6	β-Site	APP	cleaving	enzyme	1	(BACE1)		 BACE1	(β-site	APP	cleaving	enzyme	1)	is	a	type-1	transmembrane	aspartyl	protease	ubiquitously	 expressed	 in	 the	 brain	 and	 pancreas	 (Sathya	 et	 al.,	 2012).	 High	 enzymatic	activity	 is	only	 found	 in	 the	brain	due	 to	alternative	splice	variants	of	BACE1	(Mowrer	&	Wolfe,	2008).	The	BACE1	gene	 is	 located	on	 the	 long	arm	of	 chromosome	11	at	position	23.2	(Sathya	et	al.,	2012),	spans	approximately	30	kilobases	and	includes	9	exons	(Cole	&	Vassar,	 2007).	 Maturation	 of	 pro-BACE1	 to	 BACE1	 occurs	 after	 endoplasmic	 reticulum	processing	and	involves	the	removal	of	both	the	pro-peptide	domain	region	and	N-terminal	signal	 sequence,	 and	 the	 N-glycosylation	 of	 4	 asparagine	 residues	 (Haniu	 et	 al.,	 2000).	Mature	 BACE1	 is	 sulphated	 at	 N-glycosylated	 moieties	 and	 three	 C-terminal	 cysteine	residues	 are	 palmitoylated	 (Benjannet	 et	 al.,	 2001).	 N-glycosylation	 is	 required	 for	enzymatic	function	while	palmitoylation	is	utilised	for	cellular	trafficking	and	localisation	(idem).		 The	 501	 amino	 acid	 splice	 variant	 with	 β-secretase	 activity	 is	 found	 almost	exclusively	in	the	neuronal	endosome,	Golgi	apparatus	and	the	trans-Golgi	network	(Vassar	et	al.,	1999).	BACE1	present	in	the	human	pancreas	is	expressed	in	high	levels	but	has	low	levels	 of	 β-secretase	 activity;	 this	 splice	 variant	 is	 missing	 a	 large	 majority	 of	 exon	 3	(Ehehalt	et	al.,	2002)		 BACE1	 has	 optimum	 enzymatic	 activity	 at	 pH	 ≈	 4.5,	 due	 to	 the	 primary	 action	 in	acidified	endosomes	(Willem,	Lammich,	&	Haass,	2009).	BACE1	forms	homodimers	when	localised	in	cell	membrane,	but	does	not	when	released	as	a	soluble	form	(Westmeyer	et	al.,	2004).	 The	 dimerisation	 occurs	 before	 pro-BACE1	 processing	 to	 mature	 BACE1	 and	improves	the	affinity	and	turnover	of	APP	processing	(idem).		 BACE1	 is	 transported	 to	 the	 axonal	 membrane	 (predominantly	 the	 pre-synaptic	membrane)	and	can	be	released	from	the	axon	terminal	(Lazarov,	Lee,	Peterson,	&	Sisodia,	2002).	BACE1	and	APP	are	internalised	together	from	the	neuronal	cell	membrane	to	the	
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early	 endosomes;	 this	 is	where	APP	 processing	 occurs,	 ultimately	 generating	Aβ	 (Koo	&	Squazzo,	 1994).	 BACE1	 is	 subsequently	 recycled	 into	 the	 trans-Golgi	 network	 (idem).	BACE1	proteolysis	of	APP	and	the	production	of	Aβ	is	dependant	on	endocytosis,	with	α-secretase	cleavage	showing	no	change	in	activity	when	endocytosis	is	inhibited	(Ehehalt	et	al.,	2003).		 The	production	of	Aβ42	species,	through	cleavage	of	APP	by	BACE1,	is	increased	in	most	familial	AD	(FAD)	mutations	(X.	D.	Cai,	Golde,	&	Younkin,	1993).	Such	modification	in	regions	that	enhance	the	substrate	binding	to	BACE1,	for	example	in	the	Swedish	APP670NL	mutation,	lysine-methionine	is	replaced	with	asparagine-leucine	at	position	670	becoming	an	 improved	 substrate	 of	 BACE1	 therefore	 generating	 greater	 turnover	 of	 all	 products	including	Aβ42	(X.	D.	Cai	et	al.,	1993;	Haass	et	al.,	1995).		
1.6.1	Structure		 BACE1	 peptide	 forms	 a	 compact	 globular	 arrangement	 with	 enzyme	 activity	conferred	 through	 the	 typical	 motif	 for	 eukaryotic	 aspartyl	 protease;	 two	 aspartic	 acid	residues	 at	 positions	 93	 and	 289	 (Hong	 et	 al.,	 2002).	 As	 a	 result	 of	 gene	 duplication,	aspartyl	proteases	have	a	double	domain	structure,	each	presenting	an	aspartyl	residue	in	the	enzyme	active	 site	 (Holm,	Ollo,	Panthier,	&	Rougeon,	1984).	Aspartyl	proteases	were	historically	called	acid	proteinases	due	 to	 their	optimal	activities	at	pH	1.5	–	5.0	 (Polgar,	1987).	When	crystallised,	BACE1	was	found	to	share	30-37%	amino	acid	homology	(Haniu	et	 al.,	 2000)	 with	 other	 mammalian	 and	 fungal	 aspartyl	 proteases,	 for	 example	 renin,	cathepsin	D,	pepsin,	pencillopepsin	and	rhisopus	pepsin	(Venugopal,	Demos,	Rao,	Pappolla,	&	Sambamurti,	2008).			 The	action	of	 aspartyl	proteases	 is	widely	accepted	 to	occur	 through	an	acid-base	mechanism.	The	deprotonated	α-carboxylic	acid	in	the	aspartate	residue	forms	a	hydrogen	bond	with	a	water	molecule,	which	completes	a	nucleophilic	attack	of	the	carbonyl	carbon	
	 23	
in	the	scissile	bond,	creating	a	tetrahedral	oxyanion	intermediate	(Suguna,	Padlan,	Smith,	Carlson,	&	Davies,	1987)	(Brik	&	Wong,	2003).	Protonation	of	the	amide	nitrogen	caused	by	
the	intermediate	rearrangement	leads	to	the	separation	of	the	peptide	(idem).			 Six	ectodomain	cysteine	residues	are	involved	in	the	formation	of	the	enzyme	active	site	 structure	 through	 the	 formation	 of	 three	 disulphide	 bonds	 (Haniu	 et	 al.,	 2000).	 In	comparison	 to	 other	 aspartyl	 proteases,	 BACE1	 contains	 an	 extra	 loop	 region	 forming	 3	subsites	 that	 seem	 to	 increase	 the	 ligand	 recognition	 cleft	 creating	 a	 requirement	 for	 an	increased	 substrate	 size	 (Figure	 5)	 (Turner,	 Hong,	 Koelsch,	 Ghosh,	 &	 Tang,	 2005).	Structural	 studies	by	Hong	et	al.	 (2002)	with	 the	BACE1	 inhibitor	OM00-3	 (Glu-Leu-Asp-Leu-Ala-Val-Glu-Phe,	 K(i)	 =	 0.3	 nM)	 identified	 four	 hydrogen	 bonds	 within	 the	 catalytic	aspartic	 acids	 and	 ten	 other	 hydrogen	 bonds,	 involved	 with	 OM00-3	 inhibitor	 binding	(Hong	 et	 al.,	 2000).	 The	 BACE1	 active	 site	 is	 also	 less	 hydrophobic	 than	 that	 of	 other	
	Figure	5:	Structure	of	BACE1.	A)	Inactive	structure	pH	7.0	dark	blue,	active	structure	pH	4.0,	4.5	&	5.0	 (−)	 Catalytic	 aspartic	 acids	 represented	 in	 (−).	 B)	 Close	 up	 of	 flap	 conformation	 (−):	 active,	inactive:	 (−).	 Immature	 structure:	 (−),	 complexed	 with	 OM99-2	 inhibitor:	 (−).	 C)	 Front	 view.	 D)	Differences	in	residue	conformation	in	active	form	(−)	and	active	form	(−).	Image	reproduced	with	permission	from	the	rights	holder,	American	Society	of	Biology	(Shimizu	et	al.,	2008).	
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aspartyl	 proteases	 (idem).	 The	 two	 domains	 of	 BACE1	 contain	 a	 flexible	 β-hairpin	 loop	forming	a	‘flap’,	which	both	blocks	or	manoeuvres	substrates	depending	on	conditions	and	is	thought	to	aid	removal	of	reaction	products	(Shimizu	et	al.,	2008).			 Shimizu	et	al.	(2008)	crystallised	BACE1	with	a	peptidomimetic	inhibitor	OM99-2	at	different	 pH	 (pH	 4.0,	 4.5,	 5.0	 and	 7.0)	 (Figure	 5)	 and	 found	 the	 main	 structural	modifications	occur	between	the	inactive	and	active	forms	of	the	enzyme	and	not	between	active	 conformations,	 with	 the	 most	 obvious	 change	 occurring	 at	 positions	 67	 to	 77	residues	which	form	the	flap	region	(Shimizu	et	al.,	2008).	This	flap	region	is	created	by	the	hairpin	 loop	 of	 the	 N-terminal	 lobe	 and	 acts	 to	 partially	 cover	 the	 cleft	 region	 formed	between	the	two	lobes	(Hong	&	Tang,	2004).	Various	conformations	of	the	flap	have	been	identified	in	the	quest	for	a	BACE1	inhibitor.	BACE1	in	complex	with	a	peptide	or	peptide-like	 inhibitor,	 showed	 the	 flap	 moving	 closer	 to	 the	 catalytic	 aspartic	 acids,	 whereas	complexing	 with	 non-peptide	 inhibitors	 awards	 much	 greater	 variation	 in	 flap	conformation,	with	modifications	of	 the	Tyr71	residue	 leading	 to	 self-inhibition	 (Gorfe	&	Caflisch,	2005).	To	date,	around	180	structural	elucidations	of	BACE1	are	recorded	in	the	Protein	Data	Bank,	either	crystallised	with	a	 ligand	or	 in	 its	 immature	form	(Cosconati	et	al.,	2012).		
1.6.2	Normal	action		 The	 action	 of	 BACE1	 is	 not	 limited	 to	 the	 proteolytic	 processing	 of	 APP	 (Vassar,	Kovacs,	Yan,	&	Wong,	2009);	BACE1	substrates	include	Golgi-localised	membrane-bound	α-2,6	 sialytransferase	 (ST6Gal1)	 (Kitazume	 et	 al.,	 2001),	 P-selectin	 glycoprotein	 ligand	 1	(PSLG-1)	 (Lichtenthaler	 et	 al.,	 2003),	 APP	 homologs	 APLP-1	 and	 APLP-2	 (Eggert	 et	 al.,	2004),	 low-density	 lipoprotein	 receptor-related	 protein	 (LRP)	 (von	 Arnim	 et	 al.,	 2005),	voltage	gated	sodium	channel		β-subunit	2	(Nav	β2)	(D.	Y.	Kim,	Ingano,	Carey,	Pettingell,	&	
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Kovacs,	2005),	neuregulin-1	(NRG1)	(Willem	et	al.,	2006)	and	neuregulin-3	(NRG3)	(Hu	et	al.,	2006).			 Golgi-localised	 membrane-boundα-2,6	 sialytransferase	 (ST6Gal1)	 catalyses	 sialic	acid	 transfer	 from	 CMP-sialic	 acid	 to	 galactose	 containing	 substrates	 involved	 in	 cell-differentiation	 antigen	 formation	 (Kitazume	 et	 al.,	 2001).	 ST6Gal1	 is	 secreted	 from	 the	Golgi	 following	 BACE1	 cleavage,	 with	 ST6Gal1	 expression	 increased	 with	 BACE1	overexpression	(idem).				 P-selectin	 glycoprotein	 ligand	 1	 (PSLG-1)	 moderates	 leukocyte	 adhesion	 in	inflammation	 as	 a	 counter-receptor	 for	 cell	 adhesion	 molecules	 P-,	 E-	 and	 L-selectin,	expressed	 in	T-lymphocytes	and	myeloid	 cells,	 adhering	 leukocytes	 to	activated	platelets	and	endothelium	(Lichtenthaler	et	al.,	2003).			 Low-density	 lipoprotein	receptor-related	protein	(LRP)	 is	a	 type	I	 transmembrane	receptor	and	is	involved	in	the	endocytosis	of	AD	ligands	such	as	APP,	apolipoprotein	E	and	is	involved	in	trafficking	and	degradation	of	Aβ	(von	Arnim	et	al.,	2005).	  	 Voltage	 gated	 sodium	channel	β-subunit	 2	 (Nav	β2)	 expression	 is	not	 required	 for	channel	 action	 but	 is	 required	 for	 full	 voltage-gated	 sodium	 channel	 functionality	 and	cellular	localisation	(D.	Y.	Kim	et	al.,	2005).	Nav	β2	is	cleaved	by	both	BACE1	and	γ-secretase	with	 the	 resulting	 protein	 fragments	 involved	 in	 a	 feedback	 mechanism	 utilised	 to	moderate	 Na+	current	 and	 alterations	 in	 membrane	 excitability	 (idem).	 Another	physiological	action	of	BACE1	is	with	neuregulin-1	(NRG1).	NRG1	is	a	known	regulator	of	peripheral	 nervous	 system	 myelination,	 halting	 BACE1	 cleavage	 of	 NRG1	 causes	 a	reduction	in	myelin	sheath	thickness	in	both	peripheral,	sciatic,	and	optic	nerves	(Willem	et	al.,	2006).			 The	identification	of	all	the	BACE1	substrates	is	essential	in	evaluating	the	effects	of	toxicity	 associated	 with	 BACE1	 inhibitors	 (Vassar	 et	 al.,	 2009).	 Soluble	 BACE1	 has	 no	
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proteolytic	 activity,	 suggesting	 a	 transmembrane	 site	 for	 proteolytic	 cleavage,	 as	 BACE1	substrates	are	all	present	as	transmembrane	species	(Hu	et	al.,	2006).	
1.6.3	BACE1	homology		 BACE2,	 the	 BACE1	 homolog	 has	 64%	 sequence	 similarity,	 sharing	 common	attributes	 such	 as	 aspartyl	 protease	 and	 C-terminal	 active	 site	 domains;	 however	 the	cellular	 localisation	 of	 BACE2	 in	 astrocytes	 differs	 from	 BACE1	 (neurons	 and	microglia)	(Basi	 et	 al.,	 2003).	 BACE2	 has	 been	 seen	 to	 function	 similarly	 to	 α-secretase,	 acting	antagonistically	with	BACE1,	but	does	not	compensate	for	the	amyloidogenic	action	under	BACE1	inhibition	(Y.	Luo	et	al.,	2001).	The	active	site	binding	residues	in	BACE1	and	BACE2	are	 extremely	 similar	 but	 this	 structural	 homology	does	not	 preclude	 the	 formulation	 of	inhibitors	with	high	specificity	exclusively	for	each	protease	(Turner	et	al.,	2002).	Ghosh	et	
al.	 (2016)	 have	 identified	 a	 BACE2	 inhibitor	with	 >	 170000	 fold	 selectivity	 over	 BACE1	with	a	Ki	of	0.03	nM	(Ghosh	et	al.,	2016).	Ghosh	et	al.	(2012)	identified	multiple	inhibitors	of	 BACE1	 with	 very	 high	 selectivity	 over	 BACE2,	 for	 example,	 Ki	 of	 17.0	 pM	 in	 BACE1	inhibition	 and	 >	 7000	 fold	 selectivity	 over	 BACE2	 (Ghosh	 et	 al.,	 2012).	 Other	physiologically	 relevant	 aspartyl	 proteases	 include	 renin,	 pepsin,	 pepsinogen	 and	cathepsin	D	and	E.	Ghosh	et	al.	(2008)	outline	the	importance	of	off	target	effects	in	these	enzymes	when	identifying	BACE1	inhibitors	(Ghosh	et	al.,	2008).			 Pepsin	 and	 pepsinogen	 are	 present	 only	 in	 their	 zymogen	 form	 until	 exposed	 to	gastric	 juices	 and	denature	upon	 entering	 the	 intestines	 (idem).	 These	proteases	 are	not	adversely	 affected	 by	 off-target	 aspartyl	 protease	 inhibitors	 (idem).	 Renin,	 an	 important	enzyme	 involved	 in	 blood	 pressure	 homeostasis,	 has	 an	 extremely	 high	 specificity,	 with	Ghosh	 et	 al.	 commenting	 it	 is	 unlikely	 to	 be	 inhibited	 by	 a	 off-target	 BACE1	 inhibitor;	however	 this	 test	 is	 relatively	 cheap	 and	 would	 allow	 a	 conclusive	 evidence	 of	 any	interaction	(idem).	Cathepsin	D	is	found	ubiquitously	in	the	cell	 lysosome	and	is	 involved	
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with	protein	degradation	and	precursor	activation.	The	phenotype	of	double	cathepsin	D	knockout	mice	is	seizures	and	blindness	around	post-natal	day	26	(Koike	et	al.,	2000)	and	therefore	must	be	assayed	 for	off-target	effects	of	BACE1	 inhibitors;	 cathepsin	 structural	homology	is	so	high,	only	one	can	be	tested	(idem).		The	off-target	inhibition	of	any	of	the	aforementioned	 aspartyl	 proteases	 could	 cause	 major	 systemic	 damage;	 therefore	 the	BACE1	 inhibitor	 must	 have	 high	 selectivity	 for	 BACE1	 with	 little	 or	 no	 action	 at	 other	related	aspartyl	proteases,	in	order	to	be	a	potential	drug	candidate.		
1.6.4	Consequences	of	BACE1	inhibition		 In	2001,	three	different	teams	furthered	understanding	of	the	action	of	BACE1	(H.	B.	Cai	 et	 al.,	 2001;	 Y.	 Luo	 et	 al.,	 2001;	 Roberds	 et	 al.,	 2001).	 Cai	 et	 al.	 (2001)	 brief	communication	 utilised	 homologous	 recombination	 of	 murine	 embryonic	 stem	 cells	 to	create	a	population	of	BACE1-/-	mice,	removing	cortical	neurons	for	immunoprecipitation-mass	 spectrometry	 analysis	 (H.	 B.	 Cai	 et	 al.,	 2001).	 Double	 knockout	mice	 expressed	 no	APP	 cleavage	 to	 form	 Aβ42	 and	 no	 compensatory	 cleavage	 by	 BACE2;	 suggesting	 this	enzyme	is	not	significantly	involved	in	APP	processing	in	the	neurons	(idem).	Experiments	with	human	APP	 cDNA	designed	with	 the	Swedish	APP	mutation	were	 completed	 in	 cell	culture;	 BACE1+/+	cells	 produced	 high	 levels	 of	 both	Aβ40	 and	Aβ42	whereas	 BACE-/-	cells	produced	 no	 detectable	 levels	 (idem).	 Cai	 and	 team	 then	 went	 on	 to	 find	 whether	 APP	processing	 through	 the	 α-secretase	 increases	 if	 the	 BACE1	 pathway	 is	 non-functional	(idem).	 This	 showed	 an	 approximately	 2-fold	 increased	 flux	 across	 the	 α-secretase	pathway	 suggesting	 that	 BACE1	 processing	 is	 in	 direct	 competition	 with	 α-secretase	processing	of	APP;	therefore	when	BACE1	is	inhibited,	APP	is	processed	through	the	non-amyloidogenic	 pathway	 (idem).	 These	 investigations	 revealed	 100%	BACE1	 inhibition	 in	mice	abolishes	 the	production	of	amyloidogenic	Aβ	species,	with	no	alternative	route	 for	Aβ	production;	this	result	was	mirrored	in	human	APP	producing	neuronal	cultures	(wild-
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type	 and	 Swedish	 mutation)	 (idem).	 The	 non-amyloidogenic	 α-secretase	 pathway	increased	 the	 rate	 of	 APP	 processing	 due	 to	 the	 increase	 in	 substrate	 APP,	 displaying	 a	compensatory	mechanism	for	the	processing	of	APP.			 Luo	et	al.	(2001)	investigated	the	effects	of	this	genotype	on	mouse	phenotype	with	anatomy	and	histology,	 fertility,	haematology,	chemistry	and	general	health	screening	(Y.	Luo	 et	 al.,	 2001).	 Compared	 to	wild	 type	 and	 heterozygous	 littermates,	 the	 BACE-/-	mice	showed	no	variations	 in	pathology	under	microscopic	brain	analysis,	no	modifications	 to	clinical	 chemistry	metabolites	 and	no	 alterations	 to	blood	 cells	 (Y.	 Luo	 et	 al.,	 2001).	The	mice	 appeared	 healthy,	 fertile	 and	 behaved	 normally,	 however	 the	 mice	 were	 not	challenged	 by	 any	 conditions	 of	 stress	 therefore	 the	 effects	 this	 may	 have	 on	 the	homozygous	 mice	 is	 unknown	 (Y.	 Luo	 et	 al.,	 2001).	 Stress	 resulting	 in	 increased	hypothalamic-pituitary-adrenal	(HPA)	axis	activation,	endocrine	up-regulation,	 increasing	blood	 brain	 barrier	 (BBB)	 permeability,	 immune	 system	 activation,	 neuroplasticity	 and	decline	in	long-term	potentiation	(Olfe,	Domanska,	Schuett,	&	Kiank,	2010),	along	with	the	BACE-/-	genotype	could	negatively	impact	the	resulting	mouse	phenotype.			 Roberds	 et	 al.	 (2001)	 found	 no	 abnormalities	 between	 genotypes	 according	 to	SHIRPA	 (Smith	 Kline	 Beecham,	 Harwell,	 Imperial	 College,	 Royal	 London	Hospital,	phenotype	assessment)	to	test	phenotypic	abnormalities,	with	no	adverse	effects	on	mouse	behaviour	(Roberds	et	al.,	2001).	Harrison	et	al.	(2003)	used	two	differing	mouse	models	 to	 demonstrate	 BACE1	 modifications	 do	 have	 an	 effect	 on	 mouse	 behaviour,	without	 changing	 typical	 factors	 such	as	morbidity	 and	mortality	 (Harrison	et	 al.,	 2003).	Mice	 designed	 to	 over	 express	 BACE1	 had	 increased	 5-hydroxytryptamine	 (5-HT	 or	serotonin,	a	monoamine	neurotransmitter)	turnover	that	caused	the	mice	to	be	energetic	and	 exploratory	 (SHIRPA	behaviour	 screening);	 this	was	 expected	 as	 low	5-HT	 turnover	leads	to	anxiety	(idem).	BACE1	knockout	mice	in	this	study	exhibited	more	anxious	and	less	
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exploratory	 behaviour,	 possibly	 revealing	 a	 link	 between	 BACE1	 incidence	 and	 the	serotonin	pathway	(idem).		 Positive	 effects	 of	 BACE1	 inhibition,	 following	 a	 measurable	 reduction	 in	amyloidogenic	Aβ	to	recordable	reductions	in	AD-linked	behaviour,	were	not	characterised	until	the	paper	published	by	Ohno	et	al.	(Ohno	et	al.,	2004).	This	study	created	a	BACE1-/-	mouse	 that	 overexpressed	 human	 APP	 (Tg2576+)	 (idem).	 This	 model	 produced	dramatically	reduced	levels	of	Aβ40	and	Aβ42	with	none	of	the	cognitive	and	electrophysical	abnormalities	seen	in	the	single	mutation	Tg2576+	(APP	over-expression)	model	(idem).	In	tests	for	social	recognition	memory,	BACE1-/-/	Tg2576+	mice	outperformed	Tg2576+	mice	and	 were	 equivalent	 to	 wild-type	 littermates	 in	 a	 maze	 task,	 again	 showing	 significant	differences	between	the	two	groups	(idem).	The	study	concludes	that	inhibition	of	BACE1	to	reduce	Aβ	levels	works	to	correct	hippocampal	cholinergic	dysfunctions	in	these	mouse	models	 (idem).	BACE1	null	mice	exhibit	minor	behavioural	 changes	over	wild	 type	mice,	suggesting	 partial	 inhibition	 sought	 through	 BACE1	 therapeutics	 should	 not	 have	detrimental	 effects	 to	 the	 patient,	 however	 human	 studies	 are	 required	 to	 confirm	 this	expectation.			 Investigations	by	Edbauer	et	al.	(Edbauer	et	al.,	2003)	and	Kimberly	et	al.	(Kimberly	&	Wolfe,	 2003),	 into	 the	 effects	 of	 γ-secretase	 knockouts	 was	 undertaken	 to	 determine	whether	 this	 second	 phase	 of	 the	 APP	 processing	 pathway	 could	 be	 targeted	 with	inhibitors,	 to	produce	a	 clinically	 relevant	 reduction	 in	Aβ	 (idem).	Presenilin-1,	nicastrin,	anterior	 pharynx-defective	 1	 (APH-1)	 and	 presenilin	 enhancer	 2	 (PEN-2)	 forming	 the	 γ-secretase	 complex	 were	 assessed	 as	 possible	 AD	 therapeutic	 targets.	 In	 a	 presenilin-1	knockout	mouse,	the	result	is	embryonic	lethal	phenotype	(Shen	et	al.,	1997).	The	resultant	null	mutation	progeny	has	 severe	 deformities	 and	 suffered	 from	 central	 nervous	 system	haemorrhage	 suggesting	a	whole-body	 role	 for	presenillin-1,	highlighting	 the	γ-secretase	complex	as	an	non-viable	target	for	inhibition	to	treat	AD	(idem).	
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	 Willem	 et	 al.	 (2006)	 noted	 the	 highest	 levels	 of	 BACE1	 found	 in	 the	 post-natal	mouse	 brain	 were	 found	 during	 periods	 in	 development	 involving	 peripheral	 nerve	myelination,	 with	 levels	 falling	 until	 adulthood	 where	 expression	 is	 low	 (Willem	 et	 al.,	2006).	Peripheral	nerve	cell	myelination	by	Schwann	cells	is	dependent	on	the	presence	of	(type	III)	epidermal	growth	factor	(EGF)-like	factor	neuregulin-1	(NRG1),	which	is	thought	to	 require	 endoproteolysis	 for	 its	 signalling	 activity	 (idem).	 NRG1	 (type	 III)	 activates	receptor-tyrosine	 kinase	 ErbB2	 and	 ErbB3	 receptors	 on	 the	 surface	 of	 Schwann	 cells	triggering	 activation;	 NRG1	 (type	 III)	 and	 ErbB	 knockouts	 cause	 peripheral	 nerve	hypomyelination,	whereas	 over	 expression	 of	NRG1	 (type	 III)	 leads	 to	 hypermyelination	(Hu	 et	 al.,	 2006)	 (Willem	et	 al.,	 2006).	Garratt	et	al.	 (2000)	 showed	BACE1	may	process	NRG-1	 (type	 III),	 activating	 this	 ligand,	 allowing	 binding	 to	 ErbB2	 and	 ErbB3	 receptors,	leading	 to	 myelination	 and	 peripheral	 bundling	 of	 axons	 by	 activated	 Schwann	 cells	(Garratt,	Britsch,	&	Birchmeier,	2000).	Sankaranarayanan	et	al.	(2008)	tested	the	effects	of	BACE1	inhibition	on	NRG-1	processing	and	showed	inhibition;	although	lowering	Aβ	levels	in	 aged	 mice,	 BACE1	 inhibition	 did	 not	 significantly	 lower	 NRG-1	 processing	(Sankaranarayanan	et	al.,	2008).		 BACE1	null	mice	synthesise	no	Aβ42	amyloidogenic	species,	with	no	compensation	seen	from	BACE2	(H.	B.	Cai	et	al.,	2001).	The	non-amyloidogenic	pathway	processes	APP,	removing	the	possibility	of	APP	cellular	toxicity	(idem).	No	phenotypic	changes	are	seen	in	BACE-1	null	mice,	both	behavioural	(Harrison	et	al.,	2003)	and	biochemical	(Y.	Luo	et	al.,	2001),	 but	 hypomyelination	 is	 observed	 (Willem	et	 al.,	 2006).	As	 this	myelination	phase	occurs	 post-natal,	 the	 effect	 of	 BACE-1	 inhibition	 in	 aged	 patients	 suffering	 with	Alzheimer’s	disease	is	unlikely	to	be	applicable	(Sankaranarayanan	et	al.,	2008).			 Levels	 of	 BACE1	 protein	 and	 proteolytic	 activity	 are	 significantly	 increased	 in	AD	brains,	as	identified	by	Fukumoto	et	al.	(2002)	in	dissections	of	brains	donated	through	the	Massachusetts	 Alzheimer’s	 Disease	 Research	 Centre	 brain	 bank	 (Fukumoto,	 Cheung,	
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Hyman,	&	Irizarry,	2002).	This	research	determined	BACE1	enzyme	activity	was	increased	by	63%	in	the	temporal	neocortex	of	sufferers,	a	13%	increase	in	the	frontal	neocortex	but	no	 increase	 in	 the	 cerebellar	 cortex	 (idem).	 BACE1	 protein	 level	 was	 increased	 in	 the	frontal	 cortex	 by	 14%,	 with	 15%	 increase	 in	 temporal	 cortex	 and	 no	 difference	 in	 the	cerebellar	cortex	(idem).	The	amount	of	BACE1	activity	in	the	temporal	neocortex	was	seen	to	 increase	with	AD	duration,	but	did	not	correlate	with	measures	of	 insoluble	Aβ	 levels;	the	neurotoxic	soluble	Aβ	levels	were	not	tested	(idem).	The	increase	in	BACE1	expression	and	activity	could	be	a	causative	factor	in	the	development	of	AD,	suggesting	the	inhibition	of	this	target	could	improve	disease	outcomes.			 Genetic	analysis	of	the	BACE1	open	reading	frame	in	sporadic	AD	patients	found	no	mutations	 in	 a	 study	 conducted	 by	 Li	 et	al.	suggesting	 the	 increase	 in	 BACE1	 levels	 and	activity	 are	not	 due	 to	 a	 gene	mutation	 in	 this	 group	of	AD	 sufferers	 (R.	 Li	 et	 al.,	 2004).	BACE1	mRNA	expression	was	found	to	be	elevated	in	the	same	regions	of	increased	BACE1	protein	activity;	the	authors	postulate	the	stability	of	BACE1	mRNA	could	be	a	cause	of	the	increased	BACE1	activity,	however	this	had	not	been	explored	further	(idem).	Faghihi	et	al.	(2008)	demonstrated	the	BACE1	noncoding	antisense	transcript	improves	BACE1	stability	
in	vitro	with	levels	increased	alongside	BACE1	in	AD	in	vivo	(Faghihi	et	al.,	2008).			 BACE1	levels	of	translation	also	increase	alongside	amplified	cellular	stressors	such	as	oxidative	damage,	hypoxia,	ischemia,	neighbouring	apoptosis	and	trauma	(Vassar	et	al.,	2009).	A	reduced	capacity	for	efficient	glucose	metabolism	is	characteristic	of	an	AD	brain	and	 is	 thought	 to	 be	 due	 to	 the	 reduction	 or	 loss	 of	 axonal	 transport	 and	 cytoskeletal	function	 caused	 by	 increased	 tau	 and	 Aβ	 levels	 (Braak,	 Braak,	 Bohl,	 &	 Reintjes,	 1996).	Neurons	affected	in	the	early	stages	of	AD,	in	the	medial	temporal	lobe	and	hippocampus,	have	 high	 metabolic	 rates	 and	 therefore	 glucose	 requirements	 (idem).	 The	 reduced	neuronal	activity	and	eventual	neuronal	loss	seen	initially	these	areas,	is	thought	to	be	due	to	 ineffective	 glucose	 metabolism	 (idem).	 Reduced	 glucose	 metabolism	 can	 be	 used	 in	
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diagnostic	 positron	 emission	 tomography	 (PET)	 scanning	 with	 2-fluorodeoxy-D-glucose	(2FDG)	(Velliquette,	O'Connor,	&	Vassar,	2005).			 Mimicking	the	disruption	in	glucose	metabolism	in	mouse	models,	causes	a	two-fold	elevation	in	BACE1	levels,	imitating	the	effects	seen	in	AD	patients	(Fukumoto	et	al.,	2002;	Velliquette	et	al.,	2005).	O’Connor	et	al.	(2008)	determined	this	rise	was	due	to	increased	translation	 of	 BACE1	mRNA,	 attributable	 to	 phosphorylation	 of	 the	 translation	 initiation	factor	eIF2α	(O'Connor	et	al.,	2008).	Mouse	models	given	inhibitors	of	energy	metabolism	produced	an	increased	amount	of	phosphorylated	eIF2α,	BACE1,	Aβ	and	amyloid	plaques;	with	 the	 increase	 in	 phosphorylated	 eIF2α	 positively	 correlated	 with	 Aβ	 levels	 in	 post-mortem	brains	of	people	with	AD	(idem).		
1.7	BACE1	inhibitors	
1.7.1	Early	peptidomimetic	inhibitors		 The	active	site	of	BACE1	poses	problems	with	inhibitor	design	due	to	the	extended	cleft	 region	 along	 with	 the	 flexibility	 of	 the	 enzyme	 structure	 and	 the	 requirements	 for	blood	brain	barrier	access	 (McGaughey	&	Holloway,	2007).	The	design	of	 small	molecule	inhibitors	for	BACE1	was	first	published	in	2000,	through	work	done	by	Arun	Ghosh	et	al.	(Ghosh	et	al.,	2000).	Peptide-based	inhibitors	have	low	toxicity	metabolites	in	vivo,	but	the	intact	delivery	to	the	brain	and	the	low	passive	diffusion	across	the	BBB	create	a	problem	for	their	action	as	potential	therapeutics	(Egleton	&	Davis,	1997).			 Early	 inhibitor	designs	were	based	around	 the	Swedish	mutation	of	APP	 (APPSW),	which	 converted	 APP	 from	 a	 poor	 substrate	 (kcat/Km=	 40s-1	 M-1)	 to	 an	 excellent	 target	(kcat/Km=	2450s-1	M-1)	 	 (SEVKM/DAEFR	 to	 SEVNL/DAEFR)	 (Ghosh	 et	 al.,	 2000).	Aspartic	acid	 (D)	 was	 substituted	 with	 alanine	 (A)	 increasing	 lipophilicity	 and	 reducing	 polarity	(idem);	 both	 modifications	 that	 ultimately	 improve	 blood	 brain	 barrier	 penetration	(Kearney	&	Aweeka,	1999).		
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		 The	 scissile	 bond	 in	APPsw	was	 replaced	with	 a	 hydroxyethylene	 transition-state	isostere	 (Figure	 6)	 that	 acts	 to	 mimic	 the	 intermediate	 state	 of	 the	 APP	 cleavage,	 and	therefore	blocks	the	action	of	the	enzyme	through	competitive	inhibition	(Wangsell	et	al.,	2010).	 OM99-1	 has	 the	 sequence	 Val-Asn-Leu*Ala-Ala-Glu-Phe,	 where	 the	 asterisk	represents	the	position	of	the	transition	state	isostere,	whereas	OM99-2	has	the	sequence	Glu-Val-Asn-Leu*Ala-Ala-Glu-Phe	(Ghosh	et	al.,	2000).		
	 The	 therapeutic	 possibilities	 of	 OM99-1	 and	 OM99-2	 are	 limited,	 due	 to	 the	 high	molecular	 weight	 (1.1	 kDa)	 and	 peptidic	 nature	 if	 these	 inhibitors,	 reducing	 the	 BBB	penetration	 (Hong	 et	 al.,	 2002).	 Improvements	 to	 the	 lipophilicity	 of	 these	 inhibitors,	through	 increasing	 the	 number	 of	 lipophilic	 groups	 or	 reducing	 the	 hydrogen	 binding	potential,	 were	 investigated	 to	 improve	 BBB	 passive	 diffusion	 (Egleton	 &	 Davis,	 1997).	Enhancements	 to	 OM99-2	 have	 lead	 to	 OM00-3,	 consisting	 of	 Glu-Leu-Asp-Leu*Ala-Val-Glu-Phe	with	a	Ki	of	0.3	nM;	the	replacement	of	the	second	alanine	with	valine	stabilises	the	Glu-Phe	 binding	 (Hong	 et	 al.,	 2002).	 Although	 these	 compounds	 have	 excellent	 BACE1	inhibitory	 activity,	 OM99	 and	OM00	 compounds	 have	 low	 brain	 retention	 in	vivo	 due	 to	high	efflux	through	P-glycoprotein	transport	(Hunt	&	Turner,	2009).		
	Figure	 6:	 Examples	 of	 hydroxyethylene,	 statine	 and	hydroxyethylamine	 transition-state	 isostere	structures.	The	peptide	bond	is	replaced	with	a	stable	hydroxyl	group.	Modified	from	(Wangsell	et	al.,	2010).	
	Figure	7:	The	structure	of	pepstatin,	a	hexapeptide	containing	 the	statine	residue.	Adapted	 from	(Rich,	Sun,	&	Ulm,	1980).	
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	 Other	studies	focused	on	pepstatin,	discovered	by	Umezawa	et	al.	(1970),	a	known	aspartic	protease	inhibitor,	which	contains	the	γ	amino	acid	(amine	attached	to	γ-carbon)	statine;	 (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic	 acid	 (Figure	 7)	 (Umezawa	 et	 al.,	1970).	 With	 a	 poor	 Ki	 of	 300	 μM,	 APPSW	 residues	 were	 added	 to	 give	 the	 inhibitor	 a	specificity	 and	 potency	 not	 seen	 in	 the	 generic	 statine	 (X.	 L.	 Lin	 et	 al.,	 2000).	 This	 cell	permeable	P10-P4′	(Schechte.I	&	Berger,	1967)	(Thr662-Phe674),	P1(S)-statine-substituted	amino	acid	inhibited	BACE1	dose	dependently,	with	half	maximal	inhibitory	concentration	(IC50)	 of	 approximately	 40	 μM	 (Sinha	 et	 al.,	 1999).	 Through	 the	 modification	 of	 single	residues,	the	highest	potency	BACE1	inhibitor	was	obtained	through	substitution	of	valine	for	aspartic	acid	at	position	P1′	(P10-P4′StatVal)	(IC50	≈	30	nM)	(idem).	As	these	APP-statine	based	 inhibitors	 are	 highly	 peptidic	 in	 nature,	 they	 have	 little	 or	 no	 capacity	 for	 brain	penetration;	they	will	not	lower	the	neurotoxic	Aβ	found	in	the	CNS	of	AD	sufferers	(Probst	&	Xu,	2012).			 The	 first	 generations	 of	 statine-based	 inhibitors	 were	 replaced	 with	 a	hydroxyethylene	 (HE)	 (Figure	 8)	 pentapeptide,	 with	 the	 example	 in	 Figure	 8	 exhibiting	enhanced	potency	 (IC50	of	20	nM)	compared	 to	 the	statine	 relatives	 (Ghosh	et	al.,	2005).	The	 lipophilic	modifications,	along	with	 increasing	potency	 in	both	BACE1	 inhibition	and	cell	activity	assays,	ensured	cell	permeability	(idem).		
	 The	work	of	Eli	Lilly	&	Company	on	structure-activity	relationship	studies	of	Phe-Ala	 hydroxyethylene	 (HE)	 isostere	 pentapeptide	 inhibitors	 revealed	 potent	 molecules,	
	Figure	8:	HE	based	inhibitor	‘14’,	which	has	a	BACE1	inhibition	IC50	of	20	nM.	Modified	from	(Ghosh,	Kumaragurubaran,	&	Tang,	2005).	
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including	BACE1	inhibitory	IC50	and	cellular	activity	IC50	results	(Ghosh	et	al.,	2005).	Merck	have	similarly	researched	HE	isosteres	reporting	Phe-Ala	HE	based	inhibitors	with	reduced	molecular	 weights	 (<	 600	 Da),	 through	 modifications	 at	 the	 P1′	 position	 (Brady	 et	 al.,	2004).			 Hydroxyethylamines	 (HEA)	 (Figure	 6)	 have	 been	 one	 of	 the	 most	 investigated	templates	 in	 BACE1	 inhibitor	 studies	 (Probst	 &	 Xu,	 2012).	 HEA	 based	 inhibitors	 have	opposite	 stereochemistry	 to	 the	 statine-based	 inhibitors	 and	 are	 less	 peptidic	 in	 nature	(Probst	&	Xu,	2012).	These	modifications	allow	this	class	of	inhibitors	greater	opportunity	for	penetration	into	the	CNS	and	capacity	for	lowering	of	CNS	Aβ	(Probst	&	Xu,	2012).		
	 In	vivo	studies	in	guinea	pigs	reported	that	the	HEA	compound	(Figure	9)	lowered	total	Aβ	in	the	brain	by	28%	and	in	the	CSF	by	32%	(5	doses	30mg/kg	in	2.5	days,	results	taken	6	hours	post	final	dose)	(Probst	&	Xu,	2012).	During	the	testing	for	off-target	effects	of	this	compound,	it	was	found	to	also	inhibit	the	non-target,	aspartic	protease,	cathepsin	D	(IC50	=	490	nM)	(idem).		
	 BACE1	 inhibitor	 IV	 is	a	hydroxyethylamine	containing	 inhibitor	with	an	 IC50	of	15	nM	 in	 human	 BACE1	 (Stachel	 et	 al.,	 2004).	 However,	 this	 compound	 displays	 poor	membrane	permeability	and	low	aqueous	solubility	(idem).			 Despite	 the	number	 of	BACE1	 inhibitors	 identified	 to	 date,	 there	 have	 been	more	failures	 than	 successes.	 Unsuccessful	 trials	 include	 the	 compounds	 tramiprosate,	 R-
	Figure	 9:	HEA	based	BACE1	 inhibitor	with	 potent	 off-target	 effects,	with	 inhibition	 seen	 in	 other	aspartyl	proteases.	Modified	from	(Probst	&	Xu,	2012).		
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flurbiprofen	 and	 semagacestat	 (Selkoe,	 2011).	 	 At	 the	 time	 writing,	 two	 small	 molecule	BACE1	inhibitors	are	in	late	stage	trials;	AstraZeneca	and	Eli	Lilly	co-development	inhibitor	AZD3293	trials	are	due	to	end	in	May	2019	and	Merck	are	testing	MK-8931	(Verubecestat)	in	mixed	phase	II/III	trials	estimated	to	end	in	July	2019.				 For	further	information	in	regard	to	the	history	and	success	of	BACE1	inhibitors,	the	reader	is	directed	to	the	review	article	by	Probst	and	Xu	(2012)	(Probst	&	Xu,	2012).	
1.7.2	Carrier	peptide		 Investigations	by	Chang	et	al.	(2004)	produced	BACE1	inhibitors	bound	to	a	carrier	protein	that	allowed	efficient	delivery	of	relatively	large	inhibitors	across	the	BBB	(Chang	et	 al.,	 2004).	 Inhibitors	 OM99-2	 and	 OM00-3,	 containing	 a	 FITC	 reporter	 and	 a	 9	 or	 12	residue	carrier	peptide	 sequence	entered	HEK293	cells	 at	 a	 concentration	of	4	 -	400	nM	(idem).	 These	 bound	 inhibitors	were	 not	 uniformly	 distributed	within	 the	HEK293	 cells,	suggesting	the	accumulation	or	organisation	into	specific	cell	areas	(idem).	The	conjugated	inhibitor	 Fs-[OM00-3]DR9	(D-arginine)	 halted	 the	 formation	 of	 both	 C99	 and	 Aβ	 through	inhibition	of	 intracellular	BACE1	 in	Tg2576	mice	 (idem).	 The	 standard	 inhibitor	OM00-3	(unconjugated)	 demonstrated	 no	 inhibition	 with	 the	 same	 delivery	 method	 (intra-peritoneal)	(idem).	The	modification	 from	a	 limited	chemical	 inhibitor	 to	a	cell	penetrant	inhibitor,	allowed	CoMentis	and	Chang	et	al.	to	produce	CTS-21166,	which	has	undergone	extensive	clinical	trials	(Ghosh	et	al.,	2008).	In	phase	I	clinical	trials,	CTS-21166	IV	injection	between	7.5	mg	and	225	mg	demonstrated	a	dose	dependant	reduction	in	plasma	Aβ,	with	80%	reduction	of	plasma	Aβ	at	the	maximal	concentration	of	225	mg	(IC50	=	1.2	-	3.6	nM	depending	on	cell	line)	(X.	Y.	Luo	&	Yan,	2010).		
1.7.3	Alternative	treatments	aimed	at	β-Amyloid		 There	are	many	avenues	of	 investigations	being	conducted	 into	AD	pathology	and	treatments,	 including	 β-amyloid	 and	 tau	 targeted	 treatments,	 immune	 stimulation,	 gene	
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therapy,	and	pharmaceuticals	 to	 target	 inflammation	of	 the	brain.	Alternative	 treatments	being	 researched	 that	 target	β-amyloid	 and	 the	production	of	β-amyloid	 in	 the	AD	brain	include	immune	therapy,	gene	therapy,	and	inhibitors	of	receptors	for	advanced	glycation	end-products	(RAGE).		
1.7.4	Immunisation			 β-amyloid	 immunotherapy	 is	 currently	 an	 active	 area	 of	 AD	 research.	 Antibodies	that	penetrate	the	BBB	and	bind	to	Aβ,	to	aid	the	processing	by	microglia/macrophage	or	with	 complement	 activation,	 are	 being	 investigated	 as	 therapeutics	 for	 AD	 (van	Marum,	2008).	The	reduction	of	plasma	Aβ	through	antibody	binding	and	immune	destruction	may	create	a	‘peripheral	sink’	to	draw	out	cerebral	Aβ	(DeMattos	et	al.,	2001).	In	vivo	studies	of	AD	mouse	models	with	solanezumab	(humanised	monoclonal	IgG1,	Eli	Lilly	Ltd),	a	soluble	Aβ	recognising	monoclonal	antibody,	demonstrated	reduced	Aβ	in	the	periphery	(Siemers	et	al.,	2016).	This	antibody	also	reduced	cerebral	Aβ	and	lead	to	improvements	in	murine	cognitive	 functions	 (DeMattos	 et	 al.,	 2001;	Dodart	 et	 al.,	 2002).	 Further	 investigations	of	solanezumab	have	indicated	that	action	may	not	be	to	clear	the	Aβ	through	immune	routes,	but	to	stabilise	the	non-toxic	monomeric	structures	of	Aβ,	 limiting	the	formation	of	more	toxic	 oligomers	 (Yamada	 et	 al.,	 2009).	 Mechanism	 aside,	 the	 use	 of	 this	 monoclonal	antibody	was	not	associated	with	 the	 commonly	 seen	cerebral	vessel	microhaemorrhage	(thought	 to	 be	 due	 to	 activated	 T-cells)	 that	 has	 troubled	 the	 progression	 of	 other	promising	monoclonal	antibodies	(Fu	et	al.,	2010;	Racke	et	al.,	2005).	However,	the	results	from	phase	III	double-blind	clinical	trials	by	Eli	Lilly	showed	no	improvement	to	cognition	or	functional	stability	in	mild	to	moderate	AD	sufferers	(Doody	et	al.,	2014).		 The	more	essential	target	of	these	antibodies	however,	could	be	seen	as	the	already	
in	 situ	 plaques,	 which	 potentially	 contribute	 to	 tau	 aggregation,	 altered	 synaptic	transmission	and	neuronal	death,	causing	the	symptoms	associated	with	AD.	Elimination	of	
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these	 existing	 plaques	 has	 also	 been	 a	 target	 for	 antibody	 research.	 The	 formulation	 of	these	 antibodies	 involves	 immunisation	 with	 pre-aggregated	 or	 soluble	 Aβ42	 with	 an	adjuvant	 to	 illicit	 an	 immune	response,	 create	antibody	 titre,	 and	propagate	an	anti-Aβ42	assault	 (Morgan,	 2011).	 The	 antibody	 AN1792	 (Janssen,	 Pfizer)	 was	 a	 version	 of	 this	treatment	 taken	 to	clinical	 trials	 (Elan/Wyeth	2000).	The	 trials	were	 terminated	 in	2002	due	 to	6%	of	 immunised	patients	 suffering	 from	sub-acute	 aseptic	meningioencephalitis,	with	white	matter	abnormalities	and	neurological	effects	(Orgogozo	et	al.,	2003).	Subjects	were	continually	monitored;	 the	drug	appeared	not	 to	have	any	 impact	 in	 the	prognosis,	with	 each	 patient	 continuing	 into	 severe	 dementia	 and	 death	 (idem).	 AD	 progression	continued	 despite	 the	 clearance	 of	 Aβ	 plaque	 and	 the	 expression	 of	 anti-Aβ	 antibodies;	patients	with	near	complete	removal	of	Aβ	plaques	shown	at	autopsy,	still	progressed	into	severe	dementia	(Haas,	2012).	This	suggests	the	removal	of	plaques	does	not	contribute	to	the	improvement	of	the	patient	and	may	not	be	therapeutically	viable	and	lends	credence	to	the	neurotoxic	Aβ	form	being	soluble	(C.	Holmes	et	al.,	2008).			 Passive	 immunisation	 using	 pooled	 intravenous	 immunoglobulin	 (IVIG)	 or	monoclonal	 antibodies	 raised	 to	 different	 regions	 of	 Aβ	 peptide,	 reduces	 the	 number	 of	adverse	 events	 and	 increases	 the	 number	 of	 subjects	 generating	 significant	 antibody	responses	 (van	 Marum,	 2008).	 In	 December	 2012,	 Baxter	 Healthcare	 Corp	 completed	 a	phase	III	trial	on	IVIG	in	mild	to	moderate	AD	patients	(NCT00818662).			 Monoclonal	antibody	AAB-001	(bapineuzumab)	had	varied	results	 in	clinical	 trials	with	 positive	 results	 being	 seen	 in	 non-ApoE4	 carriers,	 showing	 significant	 cognitive	improvement,	possibly	due	to	differences	in	microvasculature	in	the	basement	membrane	of	subjects	(with	adverse	effects	occurring	most	often	in	Apo-E4	carriers)	(Salloway	et	al.,	2002;	 Salloway	 et	 al.,	 2009).	 Bapineuzumab	 is	 undergoing	 multiple	 phase	 III	 trials	currently;	however	some	have	been	halted	due	to	findings	of	‘no	clinical	benefit’	to	patients	
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(NCT00676143).	 Studies	 are	 finished	 in	 non-ApoE4	 carrying	 patients	 but	 results	 (as	 of	September	2017)	are	yet	to	be	released	(NCT00575055).		
1.7.5	Gene	therapy		 Although	the	complete	removal	of	APP	transcript	and	protein	have	been	shown	to	have	 negative	 effects	 in	 cell	 function	 including	 in	 axonal	 transport	 and	 transmission,	dendritic	 length,	 neuronal	 cell	 survival	 and	 long-term	 cell	 health;	APP	knockout	mice	do	not	exhibit	a	damaged	phenotype	(Haas,	2012).	This	knockout	therapy	could	be	beneficial	to	 patients	 suffering	 from	 familial	 forms	 of	 AD.	 Viral	 delivery	 of	 micro	 RNA	 (miRNA),	targeting	the	3’	untranslated	region	of	APP	mRNA	transcripts	causes	a	reduction	of	protein	levels	 by	 2-3	 times	 (Patel	 et	 al.,	 2008).	 Short	 interfering	 RNA	 (shRNA)	 is	 also	 being	designed	to	target	specific	gene	mutations	associated	with	familial	AD,	which	binds	to	the	mutated	gene	blocking	transcription	with	the	wild-type	gene	being	the	only	template	then	available	 (Rodriguez-Lebron,	 Gouvion,	 Moore,	 Davidson,	 &	 Paulson,	 2009).	 In	 mouse	models	 used	 within	 this	 study,	 neural	 injection	 of	 shRNA	 resulted	 in	 significant	improvement	 in	 the	 cognitive	 performance	 equalling	 the	 performance	 by	 the	 wild-type	(unaffected)	control	group	(idem).	This	would	suggest	that	therapeutic	use	of	shRNA	have	the	potential	as	an	AD	treatment.		
1.7.6	RAGE	Inhibitors			 Receptors	 for	 advanced	 glycation	 end-products	 (RAGE)	 are	 associated	 with	 the	aberrant	formation	of	intracellular	plaques	through	Aβ	binding	on	both	the	cell	surface	and	the	BBB	 (V.	 Srikanth	 et	 al.,	 2011).	 For	 furthur	 information	 in	 regard	 to	RAGE	 in	AD,	 the	reader	is	directed	to	Ramasamy	et	al.	(2005)	(Ramasamy	et	al.,	2005).	The	RAGE	inhibitor	PF-04494700	(TransTech	Pharma	LLP)	has	now	reached	phase	III	study	(V.	Srikanth	et	al.,	2011)	with	results	due	in	2018.		
	 40	
1.8	Heparin	and	heparan	sulphate	in	Alzheimer’s	disease	
1.8.1	Heparan	sulphate	proteoglycans	and	Alzheimer’s	plaques			 HSPGs	have	been	linked	with	Aβ	in	AD	through	co-localisation	in	plaques	(Brunden,	Richtercook,	 Chaturvedi,	 &	 Frederickson,	 1993;	 Perlmutter,	 Chui,	 Saperia,	 &	 Athanikar,	1990)	catalysing	 the	polymerisation	of	Aβ	 into	plaques	 in	vitro	 (Castillo,	Ngo,	Cummings,	Wight,	&	Snow,	1997),	 and	have	been	demonstrated	 to	protect	plaques	 from	proteolysis,	halting	degradation	and	removal	(Bame,	Danda,	Hassall,	&	Tumova,	1997).	In	vivo	there	are	a	 number	 of	 molecules	 that	 are	 associated	 with	 the	 Aβ	 plaque	 architecture	 along	 with	HSPGs	 including	 apolipoprotein	 E	 (ε2,	 ε3,	 ε4),	 compliment	 factors	 C1q,	 C3c,	 C4d,	 C5b-9,	compliment	inhibition	factor	clusterin,	acute	phase	proteins	such	as	α1-antichymotrypsin	and	ICAM-1	(Verbeek,	Otte-Holler,	Veerhuis,	Ruiter,	&	De	Waal,	1998).	Snow	et	al.	(1994)	found	HSPGs	present	in	diffuse	plaques	in	the	hippocampus,	amygdala,	neocortex	and	the	cerebellum;	locations	usually	plagued	by	plaque	formation	in	AD	(Snow,	Sekiguchi,	Nochlin,	Kalaria,	 &	 Kimata,	 1994).	 	 The	 presence	 of	 the	 HSPG,	 perlecan,	 was	 thought	 to	 either	potentiate	 the	 formation	 of	 plaques	 (seeding)	 or	 to	 allow	 plaque	 formation	 to	 persist,	resisting	deconstruction	(idem).	HS	was	demonstrated	to	co-localise	with	Aβ	in	immature	amyloid	plaque	 formations	 in	 subjects	with	Down’s	 syndrome	and	AD,	 further	 adding	 to	the	evidence	that	HS	is	important	in	plaque	formation	(idem).			 A	 HSPG	 derived	 from	 a	 marine	 sponge	 (Microciona	 prolifera	 aggregation	 factor-	MAF)	 induced	 structural	 modifications	 in	 aggregates	 of	 Aβ40	 and	 Aβ42	 from	 random	formations	 to	 β-structures,	 seen	 in	 circular	 dichroism	 spectroscopy,	 that	 inhibit	proteolysis,	 perpetuate	 further	 formation	 and	 allow	 for	 improved	 stability	 (McLaurin,	Franklin,	Kuhns,	&	Fraser,	1999).		 Investigations	by	Watson	et	al.	(1997)	found	heparin	binds	to	fibrillar	but	not	non-fibrillar	Aβ	 in	vitro,	 indicating	this	 interaction	occurs	with	the	aggregated	state	Aβ	rather	
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than	 the	 primary	 sequence	 of	 the	 Aβ	 protein	 (Watson,	 Lander,	 &	 Selkoe,	 1997).	 This	research	 also	 found	 human	 amylin	 (found	 in	 pancreatic	 deposits	 associated	with	 type	 II	diabetes)	 binds	 heparin	 while	 non-amyloidogenic	 and	 non-toxic	 rat	 amylin	 does	 not;	indicating	 that	 the	ability	 to	bind	HSPG	may	be	 the	general	progressing	 factor	 from	non-amyloidogenic	to	amyloidogenic	proteins	(idem).			 A	 molecule	 with	 the	 ability	 to	 pass	 through	 the	 blood	 brain	 barrier	 (BBB)	 to	compete	 with	 HS	 may	 reduce	 HS/Aβ	 binding	 and	 therefore	 the	 preliminary	 stages	 of	plaque	formation	in	AD	(Leveugle	et	al.,	1998).	Low	molecular	weight	anionic	sulphate	or	sulphonate	 compounds	were	 tested	 for	 this	 capacity	 in	 a	 study	 done	 by	Kisilevsky	 et	al.	(1995)	on	splenic	amyloid	formations	in	animal	models	(Kisilevsky	et	al.,	1995).	Kisilevsky	
et	al.	(1995)	research	into	acute	amyloidogenesis	found	anionic	polyvinyl	sulphonate	(PVS)	inhibited	formation	of	virtually	all	deposited	amyloid	as	compared	to	control	mice	(idem).	Sodium	 1,2-ethanesulphonate	 and	 sodium	 1,3-propanesulphonate	 were	 more	 effective	inhibitors	 than	 other	 mono-sulphonates	 or	 their	 related	 sodium	 1,4-,	 1,5-	 and	 1,6-disuphonates	 (butane,	 pentane	 and	 hexane)	 (idem).	 Sodium	 1,3-propanediol	 disulphate	inhibited	the	formation	of	Aβ	plaques	and	exhibited	ability	to	disassemble	fibrils	(idem).			 The	ability	of	low	molecular	weight	heparin	(LMWH)	to	pass	through	the	BBB	was	initially	investigated	by	Leveugle	et	al.	(1998)	(Leveugle	et	al.,	1998).	This	research	utilised	a	BBB	model	 formed	using	a	co-culture	of	bovine	brain	capillary	endothelial	cells	and	rat	astrocytes	 (idem).	 Heparin	 and	 pentosan	 polysulphate	 (used	 due	 to	 its	 similarities	 to	heparin	 in	both	blood	anti-coagulation,	high	molecular	mass	and	sulphation	 levels)	could	not	pass	through	the	BBB	model,	except	for	passive	diffusion	expected	of	every	molecule	at	very	 low	 levels	 (after	 2.5	 hours	 incubation)	 (idem).	 However,	 all	 the	 depolymerised	heparins,	 including	 disaccharides,	 tetrasaccharides	 and	 a	 mixture	 of	 different	 sized	oligosaccharides	 were	 efficiently	 transported	 across	 the	 monolayer	 of	 the	 BBB	 model	(idem).	 Heparin	 fractions	 passing	 through	 the	 BBB	 model	 with	 increasing	 order	 of	
	 42	
efficiency	were	heparin	hexa-	and	octosaccharides	<	3	kDa	heparin	(10	-	18	saccharides)	<	heparin	disaccharides	<	heparin	tetrasaccharides,	with	analysis	showing	the	fractions	were	not	metabolised	throughout	the	passage	as	they	remained	identical	on	the	luminal	side	of	the	monolayer	(idem).			 The	heparin	derived	oligosaccharide	(HDO),	C3,	a	mixture	of	low	molecular	weight	HDO	 with	 fewer	 sulphate	 groups	 and	 an	 average	 molecular	 weight	 of	 2	 kDa,	 was	demonstrated	to	cross	the	BBB	by	Ma	et	al.	(2002);	however	the	mechanism	of	transport	was	not	determined	(Ma	et	al.,	2002).			 Using	step	gradient	affinity	chromatography	on	a	Aβ	column,	heparin	was	found	to	bind	 with	 high	 affinity	 to	 Aβ	 peptide	 while	 depolymerised	 fragments	 bound	 with	 low	affinity	 showing	 they	 do	 not	 directly	 bind	 to	 the	 Aβ	 to	 cause	 plaques,	 unlike	 heparin	(Leveugle	et	al.,	1998).	This	 suggests	multivalency	and	 the	size	of	GAG	chain	are	 the	key	factors	for	this	interaction	(idem).	Using	affinity	chromatography,	the	high	affinity	binding	of	 heparin	 to	 Aβ	 was	 inhibited	 by	 LMWHs	 dose	 dependently	 with	 disaccharides;	hexasaccharides	and	octasaccharides	being	particularly	successful	(idem).			 Small	et	al.	(1994)	identified	APP	as	a	HSPG	binding	protein	and	identified	at	least	two	distinct	heparin-binding	regions,	one	 low	affinity	site	between	APP96-110	(Small	et	al.,	1994)	 and	 a	 higher	 affinity	 site	 between	APP316-337	(Multhaup,	 1994).	 The	HSPG	 binding	domains	of	APP	were	further	elucidated	in	crystallisation	studies	where	APP	residues	96-110	were	found	to	form	a	highly	charged	basic	region	suitable	for	GAG	binding	(Rossjohn	et	al.,	1999).	The	residues	involved	in	forming	the	basic	patch	suitable	for	GAG	binding	are	Arg	40,	Lys	60,	Lys	99,	Arg	100,	Arg	102,	Lys	103	and	Lys	106	with	2	histidines,	His	108	and	His	110	creating	a	region	suitable	for	an	octasaccharide	heparin	fragment	(idem).	The	basic	region	between	residues	96	and	110	is	part	of	a	β-hairpin	loop	structure,	which	is	the	most	mobile	of	regions	on	the	APP	protein	(idem).	
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1.8.2	Heparin	and	heparan	sulphate	associations	with	BACE1		 Matsumoto	et	al.	(1996)	 found	HSPGs	bound	to	BACE1	sourced	from	human	brain	cortex	samples	(2	AD	patients	and	2	aged	controls)	using	2D	electrophoresis	and	antibody	adp-2	 to	 BACE1	 and	 10E4	 raised	 to	 HS,	 suggesting	 HSPG	 may	 be	 involved	 with	amyloidogenesis	 and	 therefore	 the	 toxicity	 of	 Aβ	 (Matsumoto,	 Matsumoto,	 Enomoto,	 &	Baba,	1996).			 In	1997,	a	seminal	paper	published	by	Leveugle	et	al.	 found	heparin	caused	a	 five	fold	 increase	 in	 the	 transcription	of	APP,	 increased	APP	secretion	 into	cell	media	up	 to	a	plateau	of	10	μg/ml	heparin	concentration	causing	a	four	fold	increase	and	promoted	the	production	 of	 sAPPβ	 in	 human	neuroblastoma	 SKNSH-SY5Y	 cells	 (Leveugle	 et	 al.,	 1997).	GAG	 size	 was	 shown	 to	 be	 important	 in	 increasing	 sAPPβ	 production,	 with	 full	 length	heparin	providing	the	most	effect,	and	reducing	saccharide	size	lowering	the	production	of	sAPPβ;	dextran,	CS	and	HA	had	no	effect	(idem).	Leveugle	et	al.	(1997)	postulated	a	ternary	structure	requirement	for	APP	processing,	which	includes	heparin/HS,	BACE1	and	APP,	but	the	interaction	between	BACE1	and	GAGs	could	not	be	verified,	possibly	due	to	the	choice	of	cell	line	used	in	validatory	experiments	(idem).			 Scholefield	et	al.	(2003)	further	investigated	the	action	of	HS	and	heparin	in	BACE1	activity	(Scholefield	et	al.,	2003).	Heparin	and	HS	were	both	found	to	inhibit	the	proteolytic	action	of	BACE1,	with	a	maximum	level	of	~50-60%	with	bovine	lung	heparin	(BLH)	(IC50	~	1-2	 μg/ml	 or	 100	 nM)	 (idem).	 The	 possibility	 of	 HS	 enhancing	 BACE1	 activity	 at	 low	concentrations	was	investigated	and	apart	from	a	slight	 increase	in	BACE1	activity	at	10-100	ng/ml	(~	5-10%),	no	enhancement	was	seen	under	these	conditions	(idem).	Using	APP	substrate,	in	vitro	experiments	into	the	action	of	BLH	and	PMH	found	inhibition	of	BACE1	cleavage	action	by	~90-100%	(BLH	IC50~	1-2	μg/ml	100	nM	and	PMH	IC50~	5	μg/ml	200	nM)	(Figure	10)	(idem).		
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	 HS	and	the	sulphated	analogue	heparin	are	effective	in	inhibiting	both	in	vivo	and	in	
vitro	 BACE1	 with	 the	 most	 effective	 heparin	 form	 in	 the	 SY-SY5Y	 cell	 model	 being	 full	length	 heparin,	 with	 chemically	 modified,	 N-acetylated	 heparin	 the	 second	 most	 potent	(Scholefield	et	al.,	2003).	 	Scholefield	et	al.	 suggest	 the	binding	of	heparin	may	occur	 in	a	region	close	to	or	in	the	active	site,	blocking	access	to	other	ligands	by	completive	means	(idem).	 These	 experiments	 have	determined	 the	 successful	 inhibition	 of	BACE1	does	not	occur	 through	 charge	 density	 of	 the	 molecule	 GAG,	 but	 results	 from	 specificity	 in	 the	structure	of	 the	binding	glycan	 (idem).	Experimental	 evidence	 for	 this	binding	 specificity	was	 presented	 through	 modifications	 to	 the	 glycans	 including	 the	 removal	 of	 the	 N-sulphates	 and	 replacement	 with	 N-acetyl	 groups	 (idem).	 This	 modification	 increases	inhibition,	 possibly	 through	 a	 reduction	 of	 charged	 groups	 causing	 an	 ‘enhanced	interaction’	 at	 the	 active	 site	 (idem).	 Removal	 of	 the	 iduronate-2-O-sulphate	 or	glucosamine	 6-O-sulphate	 caused	 a	 reduced	 inhibitory	 capacity	 at	 BACE1	 (idem).	 The	covalent	modification	of	 the	disaccharide	sugar	units	 leads	 to	adjustment	of	 the	 iduronic	acid	ring	and	glycosidic	linkage	conformation,	which	in	turn	changes	the	substrate-enzyme	specificity	(Yates	et	al.,	2000).	
Figure	10:	Dose	response	curve	for	percentage	inhibition	of	BACE1	with	BLH	and	PMH	using	FRET	APP	fluorescent	substrate	in	100	mM	sodium	acetate	buffer,	pH	4.5.	PMH	(empty	circle)	BLH	(solid	circle)	Original	 figure	 from	 (Scholefield	 et	al.,	 2003),	 Image	 reproduced	with	permission	 from	 the	rights	holder.	
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	 Immunofluorescence	 microscopy	 in	 SH-SY5H	 APPSW	 and	 HEK-BACE	 cells	 was	utilised	 to	 determine	 cellular	 localisation	 of	 both	 BACE1	 and	 HS,	 with	 co-localisation	occurring	 in	 both	 the	 cell	membrane	 and	 in	 the	Golgi	 complex	 (Scholefield	 et	 al.,	 2003).	This	paper	notes	only	a	fraction	of	the	cellular	HSPG	were	associated	with	BACE1,	and	the	HSPGs	preferentially	 associated	with	 the	protease	were	 smaller	 in	 size	 ranging	 from	70-100	kDa;	inclusion	of	a	competitive	inhibitor	to	HSPG	binding,	heparin,	eliminated	BACE1	mediated	immunoprecipitation	(idem).		 Beckman	 et	 al.	 (2006)	 published	 a	 paper	 to	 further	 investigate	 the	 relationship	between	 heparin	 and	 BACE1	 and	 found	 the	 relationship	 to	 be	 more	 complex,	 with	 low	concentrations	 of	 heparin	 (1	 μg/ml)	 exhibiting	 stimulated	 rBACE1	 activity,	while	 higher	concentrations	 (10	or	100	μg/ml)	displaying	 inhibitory	activities	 (Beckman,	Holsinger,	&	Small,	 2006).	 Heparin	 affinity	 chromatography	 was	 utilised	 to	 understand	 the	 binding	affinity	 between	 BACE1	 and	 heparin	 and	 found	 semi-active	 zymogen,	 pro-BACE1	 could	bind	 heparin	 with	 high	 affinity	 (1.2	 M	 NaCl	 fraction)	 (idem).	 This	 fraction	 was	 strongly	activated	by	low	concentrations	of	heparin	(1	μg/ml)	and	the	authors	suggest	this	is	due	to	the	pro-domain	including	5	positively	charged	residues,	(4	of	which	are	arginines)	forming	a	 high	 affinity	 heparin-binding	 region,	 absent	 in	 mature	 BACE1	 (idem).	 Removal	 of	 the	BACE1	 pro-domain	 abolished	 the	 stimulatory	 effect	 caused	 by	 heparin	 (1	 μg/ml),	suggesting	activation	of	BACE1	by	heparin	relies	on	the	presence	of	pro-BACE1	zymogen	in	
in	vitro	assays	(idem).	The	stimulatory	effect	was	 investigated	using	matrix	assisted	 laser	desorption	 ionisation	 time-of-flight	 (MALDI-TOF)	mass	 spectrometry	 (MS)	 to	 determine	whether	heparin	was	 triggering	autocatalytic	 cleavage	of	 the	pro-region,	 and	subsequent	efficacious	BACE1	activity;	heparin	was	shown	at	1	μg/ml	to	have	no	autocatalytic	activity	(idem).		 Patey	 et	 al.	 (2006)	 expanded	 on	 the	 work	 done	 by	 Scholefield	 et	 al.,	 exploring	 a	wider	range	of	structurally	modified	heparins	(Patey	et	al.,	2006).	The	chemically	modified	
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heparin	(CMH)	compounds	shown	 in	Figure	11	were	 tested	 for	 in	vitro	BACE1	 inhibitory	activity	and	screened	for	undesirable	off	target	effects	with	anti-factor	Xa,	cathepsin	D	and	renin	(idem).	Attenuation	of	these	off	target	effects	while	exhibiting	potent	BACE1	activity	was	 possible,	with	 the	most	 promising	 therapeutic	 ratio	 (BACE1	 inhibition/	 Xa	 activity)	achieved	 by	 de-N-sulphated	 re-N-acetylated	 porcine	 mucosal	 intestinal	 heparin	 (PMIH)	(Figure	 11)	 (idem).	 	 	 The	 inhibition	 of	 BACE1	measured	 by	 fluorescent	 resonant	 energy	transfer	 (FRET)	 in	 vitro	 assay,	 with	 full	 length	 PMIH	 yielding	 a	 half	 maximal	 inhibitory	concentration	(IC50)	of	28	ng/ml	with	de-N-sulphated	re-N-acetylated	PMIH	yielding	a	very	similar	IC50	of	31	ng/ml	(idem).	Figure	11	outlines	the	structural	modifications	of	PMIH	and	the	IC50	inhibition	of	BACE1	(idem).		
	
		Figure	 11:	 Chemically	modified	 heparin	 (CMH)	 structural	 information	 displayed	 in	 a	 schematic	with	BACE1	inhibitory	activity	as	determined	by	FRET	activity	assay,	and	anti-coagulant	activity	of	each	chemical	modification.	Adapted	from	(Patey	et	al.,	2006).		
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	 Specific	structural	modifications	show	neither	the	N-sulphate	nor	2-O-sulphate	are	specifically	 required	 to	 maintain	 an	 inhibitory	 capacity	 similar	 to	 PMIH	 when	 also	supplemented	 with	 6-O-sulphation	 (Patey	 et	 al.,	 2006).	 This	 is	 evidenced	 by	 the	 fully	desulphated	 CMH8	 maintaining	 none	 of	 the	 BACE1	 inhibitory	 capacity	 (idem).	 Per-sulphated	CMH9	is	additionally	sulphated	at	position	3	of	the	uronate	residue	and	displays	similar	BACE1	potency	to	PMIH,	CMH2	and	CMH3	(idem).	The	effect	of	these	CMH	on	the	coagulation	 cascade	was	measured	 through	anti-factor	Xa	activity,	which	was	attenuated	by	>3000	fold	with	de-N-sulphated	heparin	as	shown	in	compounds	CMH2,	CMH4,	CMH6,	and	CMH8	(idem).			 There	 are	 2	 GlcNS	 residues	 present	 in	 the	 antithrombin	 III	 (AT)	 pentasaccharide	binding	sequence	of	heparin;	the	chemical	modification	of	GlcNS	to	GlcNAc	in	compound	2	interrupts	the	anticoagulant	activity,	with	the	small	effect	seen	due	to	an	incomplete	de-N-sulphation	 reaction	 permitting	 minor	 activity	 (idem).	 A	 200-fold	 reduction	 in	 anti-coagulation	 capacity	 occurs	with	 the	 removal	 of	 2-O	 or	 6-O-sulphate	 groups	 (idem).	 The	pentasaccharide	 sequence	 includes	 6-O-sulphate	 in	 the	 three	 glucosamine	 residues	with	one	including	the	additional	and	rare	3-O-sulphate	modification	essential	for	anticoagulant	activity	and	a	2-O-sulphate	on	 iduronate;	removal	of	either/or	the	6-O-sulphate	and	2-O-sulphate	has	similarly	adverse	effects	(idem).			 Utilising	the	systematically	modified	heparin	library	in	Figure	11,	Patey	et	al.	found	heparin-based	 compounds	 with	 high	 potency	 in	 BACE1	 inhibition	 assays	 and	 desirable	diminished	anti-coagulant	capabilities	(Patey	et	al.,	2006).	The	off-target	effects	of	the	four	best	 BACE1	 inhibitors	 (PMH,	 CHM2,	 CMH3	 and	 CMH4)	were	 tested	with	 FRET	 cleavage	assays	 with	 related	 aspartyl	 proteases	 cathepsin	 D,	 pepsin	 and	 renin	 (idem).	 The	 study	found	PMIH	had	some	inhibitory	effects	with	pepsin	(IC50	of	0.23	μg/ml)	and	cathepsin	D	(IC50	of	0.1	μg/ml),	but	this	effect	was	reduced	by	14	fold	in	N-acetylated	heparin	and	had	no	activity	in	2-O-desulphated,	N-acetylated	heparin	(idem).	N-acetylated	heparin	and	2-O-
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desulphated	heparin	inhibited	cathepsin	D,	but	to	a	lesser	degree	than	PMIH	(IC50	of	0.27	μg/ml	and	IC50	of	0.77	μg/ml	respectively)	and	all	compounds	showed	no	inhibition	in	the	aspartyl	 protease,	 renin	 (idem).	 Hit	 compounds	 CMH2,	 CMH3,	 and	 CMH4	 showed	 less	inhibition	potency	 in	 renin,	 pepsin	 and	 cathepsin	D,	 than	did	 the	 currently	 administered	PMIH	(idem).			 Finally,	 size	 fractionation	 of	 the	 chemically	 modified	 heparins	 was	 completed	 to	identify	 the	 minimum	 size	 requirements	 for	 the	 BACE1	 inhibition	 activities;	 a	 ten-fold	increase	 in	 BACE1	 inhibition	 activity	 was	 seen	 between	 deca-	 and	 octa-	 saccharides	signifying	a	minimum	saccharide	size	for	potent	activity	(Patey	et	al.,	2006).	Furthermore,	the	 activity	of	 an	18-mer	 is	 equivalent	 to	 full	 length	PMIH	 (idem).	 Leveugle	et	al.	 (1998)	used	 a	 BBB	 model	 to	 demonstrate	 the	 passage	 of	 saccharides	 of	 3	 kDa	 (≈	10-18	 mer)	occurs	 through	 this	 endothelial	 BBB	 model,	 with	 disaccharide	 analysis	 confirming	 no	changes	 to	 the	 saccharide	 structure	 (Leveugle	et	 al.,	 1998).	The	potent	BACE1	 inhibitory	activity	 of	 the	 18-mer	 PMIH,	 chemical	 modifications	 retaining	 BACE1	 activity	 while	attenuating	 anti-factor	 Xa	 activity	 and	 the	 BBB	model	 success	 with	 heparin	 saccharides	suggest	chemically	modified	heparins	as	promising	compounds	for	further	study.			 Patey	et	al.	(2008)	subsequently	modified	the	PMIH	further,	retaining	2-O-sulphtion	and	6-O-sulphation	while	modifying	the	N-sulphate	with	increasingly	non-polar	groups	to	improve	BACE1	activity	and	BBB	permeability	(Patey	et	al.,	2008).		 The	 addition	 of	 an	 increasing	 length	 carbon	 chain	 in	 the	 form	 of	 N-propanoyl	heparin	 (CMH	 11)	 N-butanoyl	 heparin	 (CMH	 12)	 and	 only	 very	 slightly	 reduced	 the	inhibitory	capacity	of	BACE1	(Patey	et	al.,	2008).	The	free	amine	heparin	was	a	less	potent	inhibitor,	demonstrating	a	negative	or	neutral	charge	is	required	at	the	amino	moiety	in	the	glucosamine	 residue	 and/or	 the	modification	 of	 ring	 conformation	 under	 this	 condition	allows	 for	more	 tolerant	 binding	 (idem).	 The	 nitrogen	 in	 the	N-sulpho-aziridine	 heparin	bonds	to	both	C2	and	C3	and	the	iduronic	acid	is	3-sulphated;	these	modifications	endow	
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N-sulpho-aziridine	 heparin	 with	 a	 BACE1	 inhibitory	 potency	 akin	 to	 unmodified	 PMIH	(idem).	 Interestingly,	 the	 parent	 compound	 of	 N-sulpho-aziridine	 (Figure	 12)	 heparin	 is	persulphated	PMIH,	and	shows	improved	potency	than	this	more	highly	sulphated	parent	(persulphated	 heparin	 includes	 3-sulphate	 on	 the	 iduronic	 acid	 and	 3-O-sulphate	 on	 the	glucosamine),	 suggesting	 lower	 levels	of	 sulphation	can	exhibit	BACE1	 inhibitory	activity	(Table	 2)	 (idem).	 The	 activity	 of	 free	 amine	 heparin	 was	 reduced	 relative	 to	 N-acetyl	heparin	and	compared	 to	N-propanoyl	and	N-butanoyl	heparins,	demonstrating	a	carbon	containing	functional	group	at	this	position	is	required	for	potent	activity	(idem).		
	 Klaver	 et	 al.	 (2010)	 expanded	 the	 work	 done	 by	 Beckman	 et	 al.	 (2006)	 by	investigating	 the	 structural	 requirements	 for	 the	 interaction	 between	 heparin	 and	 pro-
	Figure	 12:	 Schematic	 of	 N-sulpho-aziridine	 heparin,	 demonstrating	 the	 four	 modifiable	 group	positions.	Figure	modified	from	(Patey,	Edwards,	Yates,	&	Turnbull,	2008).	
Table	2:	Further	chemical	modifications	to	heparin	with	modifications	at	the	N-sulphate	to	improve	BACE1	inhibitory	activity	(IC	50)	and	BBB	permeability.	Modified	from	(Patey	et	al.,	2008).		
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BACE1	 during	 enzyme	 activation	 (Klaver	 et	 al.,	 2010).	 The	 activation	 of	 pro-BACE1	required	 specific	 structural	 requirements	met	 by	 BLH,	 PMH,	 and	 kidney	HS	 (KHS).	 BLH,	PMH	and	KHS	activated	pro-BACE1	more	effectively	than	other	GAGs	but	CS	also	exhibited	significant	stimulatory	activity	 (idem).	Highly	sulphated	analogues	such	as	polysialic	acid	and	poly-D-glutamic	acid	were	also	tested	and	had	little	effect,	suggesting	charge	alone	is	not	sufficient	to	promote	the	activity	of	pro-BACE1	(idem).	More	highly	sulphated	BLH	at	1	μg/ml	 increased	 activity	 by	 1600%	 while	 PMH	 and	 KHS	 increased	 activity	 by	 900%	suggesting	 the	 extent	 of	 GAG	 sulphation	 is	 important	 for	 this	 effect	 (idem).	 	 GAG	 chain	length	was	also	 investigated,	with	5	kDa	chain	 length	stimulating	pro-BACE1	to	a	similar	level	to	PMH;	decreasing	chain	length	reduced	the	ability	of	PMH	to	stimulate	the	enzyme,	with	a	tetrasaccharide	able	to	stimulate	only	25%	the	amount	of	unfractionated	PMH	(PMH	>1000%	 activity	 tetrasaccharide	 ≈250%),	 and	 a	 disaccharide	 unable	 to	 stimulate	 the	enzyme	 (idem).	 Interestingly,	 although	 the	 disaccharide	 did	 not	 inhibit	 pro-BACE1,	 the	addition	 along	 side	PMH	 reduced	 the	 activation	of	 the	 enzyme,	 suggesting	 a	 competitive	action	between	the	GAGs	(idem).			 Structural	 analysis	 of	 pro-BACE1	 found	 a	 possible	 heparin-binding	 region	 of	positive	 electrostatic	 potential	 adjacent	 to	 the	 BACE1	 active	 site	 that	 includes	 the	prodomain	 (Klaver	 et	 al.,	 2010).	 The	 results	 also	 suggested	 flap	 constructed	 by	 the	 loop	region	would	be	in	the	open	position	to	accommodate	a	GAG	chain;	the	team	modelled	the	enzyme	 without	 this	 loop	 region	 and	 found	 a	 significantly	 larger	 positive	 electrostatic	region	(idem).	This	indicated	heparin	binding	could	require	the	loop	region	to	be	in	the	full	open	position,	away	from	the	active	site	with	multiple	GAG	binding	orientations	possible	in	the	large	positively	charged	region	(idem).			 The	paradox	of	both	the	inhibitive	and	promotive	activities	of	heparin	with	BACE1	may	 be	 explained	 by	 the	 binding	 orientation	 of	 the	 heparin	 chains	 (Klaver	 et	 al.,	 2010).	Some	 heparin	 binding	 positions	 in	 the	 BACE1	 enzyme	 affording	 higher	 affinity	 binding	
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occurring	 at	 relatively	 low	 concentrations,	 and	 lower	 affinity	 binding	 occurring	 at	relatively	high	heparin	concentrations	(idem).	The	high	binding	affinity	regions	therefore,	have	 the	 capacity	 to	modify	 the	 structure	 of	 the	 enzyme	 to	 stimulate	 ligand	 proteolysis,	while	lower	affinity	binding	positions	occupied	at	high	heparin	concentrations	modify	the	structure	alternatively,	causing	inhibition	in	proteolysis	of	APP	ligand	(idem).	The	specific	structural	 requirements	 for	 heparin	 inhibition	 including	 2-O-sulphation	 of	 the	 iduronic	acid	 and	 N-acetylation	 of	 the	 glucosamine	 may	 contribute	 to	 the	 binding	 in	 the	 lower	affinity	regions,	inhibiting	the	action	of	BACE1	(Patey	et	al.,	2006).			 Both	Klaver	et	al.	and	Scholefield	et	al.	postulate	a	model	for	BACE1	activity,	with	HS	co-localised	with	 pro-BACE1	 in	 the	 Golgi,	 and	 after	 the	 removal	 of	 the	 pro-domain	 by	 a	furin-like	pro-protein	convertase,	further	co-localised	into	the	ER,	endosomes	and	the	cell	membrane	 (Klaver	 et	 al.,	 2010;	 Scholefield	 et	 al.,	 2003).	 The	 heparin-binding	 domain	 on	APP	between	residues	96-110	is	a	mobile	region	formed	by	a	β-hairpin	loop	structure	that	may	afford	flexibility	in	spatial	orientation	(idem).	HS	may	act	to	modulate	the	enzyme	and	orientate	the	APP	ligand	for	proteolysis	by	BACE1	(idem).			 Recent	 development	 into	 HS	 based	 BACE1	 inhibitors	 has	 utilised	 disaccharide	building	blocks	to	formulate	a	library	of	16	compounds,	yielding	high	potency	octa-	deca-	and	 dodecasaccharides	 (IC50	 of	 1-5	 nM)	 (Schworer,	 Zubkova,	 Turnbull,	 &	 Tyler,	 2013).	Patey	et	al.	(2006)	previously	 found	 saccharides	 smaller	 than	decasaccharides	had	 a	10-fold	reduction	in	BACE1	inhibitory	activity;	some	modified	octasaccharides	in	the	Schworer	library	showed	activity	 similar	 to	decasaccharides	 in	 the	previous	work	 (Schworer	et	al.,	2013).	 The	 most	 potent	 octasaccharide	 tested	 had	 the	 structure	 GlcNAc6S-[IdoA2S-GlcNAc6S]3-IdoA2S	with	an	IC50	of	3.9	nM	(idem).		
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1.8.3	Challenges	of	heparin-based	therapeutics	for	Alzheimer’s	disease		 Unfractionated	heparin	has	been	utilised	as	an	anti-coagulant	for	over	90	years	and	has	become	one	of	the	most	widely	prescribed	drugs,	credited	for	the	survival	of	millions	of	people	(Wardrop	&	Keeling,	2008).	There	are	many	factors	that	preclude	this	polydisperse	mixture	 of	 GAGs	 as	 being	 a	 useful	 drug	 for	 treating	 anything	 other	 than	 haemostatic	problems.	Heparin	induced	thrombocytopaenia	(HIT)	is	a	decrease	in	the	platelet	count	of	a	heparinised	patient	caused	by	an	autoimmune	reaction	to	complexes	of	antibodies	raised	to	 heparin	 bound	 to	 platelet	 factor	 4	 (PF4)	 (Visentin,	 Ford,	 Scott,	 &	 Aster,	 1994).	Heparin:PF4:IgG	 complexes	 activate	 platelet	 FcϒIIa	 receptors	 through	 the	 IgG	 Fc	 region,	with	activated	platelet	aggregates	causing	clotting	and	thrombocytopaenia	(idem).			 Low	molecular	weight	 heparins	 still	 originate	 in	 porcine	 and	 bovine	mucosa	 and	have	 to	 be	 vigilantly	 purified	 before	 chemical	 or	 enzymatic	 digestion	 to	 produce	derivatives	 of	 smaller	 molecular	 weights.	 These	 preparations	 have	 attenuated	 anti-coagulant	 activity,	 with	 a	 reduced	 capability	 for	 platelet	 factor	 4	 binding	 and	 in	 bone	density	 reductions	 (which	 can	 lead	 to	 osteoporosis	 in	 the	 elderly	 in	 treatment	 is	prolonged)	 (Boneu	 &	 de	 Moerloose,	 2001).	 Elderly	 patients	 suffering	 from	 renal	insufficiency	 associated	 with	 advancing	 age	 must	 be	 monitored	 closely	 through	 the	biochemical	 testing	 of	 anti-factor	 Xa,	 to	 ensure	 the	 drugs	 are	 not	 causing	 renal	 damage;	insufficient	metabolism	of	the	drug	could	cause	toxicity	(i.e	increased	from	approximately	1.5	hours	 to	approximately	4.5	hours	half-life	 for	Enoxaparin	 in	patients	who	are	renally	impaired)(idem).			 The	 therapeutic	 use	 of	 heparin	 is	 limited	 due	 to	 poor	 oral	 availability	 (Hirsh	 &	Fuster,	1994).	 Intra-venous	 infusion	 is	 the	preferred	method	 for	 therapy,	with	 the	use	of	subcutaneous	 injection	 reducing	 the	 bioavailability	 (Hull	 et	 al.,	 1986).	 The	 use	 of	subcutaneous	heparin	administration,	allowing	for	more	flexible	treatment,	has	to	ensure	the	 initial	 dosage	 is	 higher	 to	 negate	 the	 reduction	 in	 bioavailability	 afforded	 by	 this	
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method	 (idem).	 The	 anticoagulant	 effect	 of	 a	 subcutaneous	 injection	 is	 delayed	 for	 2-3	hours	 due	 to	 the	 bioavailability,	 therefore	 requiring	 an	 IV	 bolus	 for	 immediate	 anti-coagulant	action	(Hirsh	&	Fuster,	1994).		 Upon	 administration,	 highly	 polyanionic	 heparin	 binds	 many	 plasma	 proteins	including	 heparin-binding	 proteins,	 endothelial	 cells	 and	 macrophages,	 reducing	 the	plasma	concentration	 (Hirsh	&	Fuster,	1994).	The	non-specific	binding	of	heparin	 in	vivo	causes	 variability	 in	 patient	 response,	 thromboembolic	 variation,	 and	 heparin	 resistance	(Young,	Prins,	Levine,	&	Hirsh,	1992).			 Metabolism	and	 clearance	 of	 heparin	 occurs	 in	 two	main	pathways	depending	 on	the	 concentration.	 Initial	 quick	 clearance	 occurs	 with	 the	 binding	 of	 heparin	 to	macrophages	 and	 endothelial	 cells;	 upon	 internalisation	 of	 heparin	 from	 the	 circulation,	heparin	 is	 depolymerised	 (Dawes	 &	 Pepper,	 1979).	 This	 is	 a	 rapid	 and	 saturable	mechanism	 due	 to	 the	 number	 of	 available	 heparin	 binding	 receptors	 present	 on	 these	circulating	 cells	 and	 is	 patient	 specific	 (idem).	 At	 higher	 heparin	 concentrations,	 above	saturation	of	the	cell-based	metabolism,	a	slower	hepatic	metabolism	and	renal	clearance	of	heparin	occurs	in	a	dose	dependant	manner	(Olsson,	Lagergren,	&	Ek,	1963).		 	The	 complexity	 regarding	 the	 bioavailability	 of	 heparin	 and	 heparin	 derivatives,	limiting	the	therapy	in	an	oral	form,	would	limit	the	potential	as	an	accessible,	worldwide	AD	 therapy.	 The	 challenges	 of	 a	 heparin-based	 AD	 drug	 include	 identifying	 a	 BACE1	inhibitor	with	the	ability	to	permeate	the	BBB	and	target	to	neurons	to	reach	BACE1.	This	inhibitor	would	 be	 tractable	 and	 unambiguous	 in	 source	 or	 design.	 The	 identification	 of	such	 compounds	with	 low	or	 no	 off-target	 effects	 and	 a	 specific	 binding	 pathway	would	allow	 the	 further	 development	 of	 administration	 methods.	 These	 could	 target	 the	 oral	route	 to	 make	 the	 therapy	 feasible	 for	 widespread	 use	 and	 would	 require	pharmacokinetics	and	dynamics	studies	prior	to	clinical	trials.			 	
	 54	
Chapter	2:	Materials	and	methods
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2.	1	Materials	8-Anilino-1-naphthalenesulfonic	acid,	Sigma,	UK.	Catalogue	No.	A1028	Acetic	acid,	99.5%.	Fisher,	Sweden.	Catalogue	No.	10230753	Acetic	acid,	glacial,	99.7%.	Fisher,	Sweden.	Catalogue	No.	A/0400/PB17	Acetone.	Fisher,	Sweden.	Catalogue	No.	10225900	Ammonium	chloride,	≥99.5%.	Sigma,	UK.	Catalogue	No.	9434	Ammonium	sulphate	99.5%,	Acros	Belgium.	Catalogue	No.	10731424	Antithrombin.	Hyphen	Biomed,	UK.	Catalogue	No.	PP004C	L(+)-Ascorbic	acid,	99%.	Acros,	Belgium.	Catalogue	No.	105021000	BACE1,	human,	Fc	tag.	Acro	Biosystems,	USA.	Catalogue	No.	BA1-H5261	BACE1,	human,	FLAG	tag.	Sigma,	UK.	Catalogue	No.	S4195	BACE1,	human,	tag	free.	Acro	Biosystems,	USA.	Catalogue	No.	BA1-H5213	Barium	chloride.	Sigma,	UK.	Catalogue	No.	342920	Barium	sulphate	extra	pure,	Acros	Belgium.	Catalogue	No.	10442031	β-Secretase	inhibitor	I.	AnaSpec,	USA.	Catalogue	No.AS-23958	β-Secretase	inhibitor	IV.	Merck	Millipore,	UK.	Catalogue	No.		565788	Bovine	lung	heparin,	sodium	salt	(149	IU.mg-1).	Calbiochem,	UK.	Catalogue	No.	375093	Bovine	serum	albumin	(fraction	V).	Sigma,	UK.	Catalogue	No.	05470	Calcium	chloride,	anhydrous.	Sigma,	UK.	Catalogue	No.	1023780500	Calcium	sulphate	99%,	Acros	Belgium.	Catalogue	No.	10308310	Copper	sulphate	pentahydrate	99+%,	Acros	Belgium.	Catalogue	No.	10604902	D-(+)-10-camphorsulfonic	acid.	Fisher,	Sweden.	Catalogue	No.	10030610	Chlorosulphonic	acid,	99%.	Sigma,	UK.	Catalogue	No.	571024	Citric	acid,	monohydrate.	Fisher,	Sweden.	Catalogue	No.	C/6200/53	
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Deuterium	oxide	99.9	atom	%	D.	Aldrich,	UK.	Catalogue	No.	151882	Dextran	sulphate,	Mr	≈	500	kDa.	Fluka,	UK.	Catalogue	No.	43097	Dimethylsulfoxide,	anhydrous,	≥99.9%.	Sigma,	UK.	Catalogue	No.	276855	Ethanol,	absolute.	Fisher,	Sweden.	Catalogue	No.	E/0650DF/17	Ethylenediamine	 tetraacetic	 acid,	 disodium	 salt	 dihydrate,	 99+%.	 Acros,	 Belgium.	Catalogue	No.	409971000	Factor	Xa.	Innovative	research,	USA.	Catalogue	No.	IBFXa-18496	Factor	Xa	substrate.	Biophen,	USA.	Catalogue	No.	CS-11(22)	HCl,	5M.	Fisher,	Sweden.	Catalogue	No.	J/4310/15	HPLC	(analytical)	grade	H2O.	Fisher,	Sweden.	Catalogue	No.	W/0106/17	Human	alpha-thrombin.	Innovative	Research,	USA.	Catalogue	No.	IHaT	IgG	UNLB,	Mouse.	Southern	Biotech,	USA.	Catalogue	No.		0107-01	IgG1k	anti-green	fluorescent	protein,	Human.	BioRad,	UK.	Catalogue	No.	HCA192	IgG2k	anti-green	fluorescent	protein,	Human.	BioRad,	UK.	Catalogue	No.	HCA193	IgM	anti-desipramine,	Mouse.	Fitzgerald	Industries,	USA.	Catalogue	No. 10C-CR2068M2	IgM	anti-GFP,	Human.	BioRad,	UK.	Catalogue	No.	HCA191S	Iron	(II)	sulphate	extra	pure,	Fisher	Sweden.	Catalogue	No.	10060010	Iron	(III)	sulphate,	Fisher	Sweden.	Catalogue	No.	10050210	Lithium	sulphate	99%	extra	pure,	Acros	Belgium.	Catalogue	No.	10184650	Magnesium	sulphate	99%,	Acros	Belgium.	Catalogue	No.	12198721	Manganese	(II)	sulphate	99+%,	Acros	Belgium.	Catalogue	No.	10701234	MCA-SEVNLDAEFRK(Dnp)RR-NH2	Fluorogenic	Peptide	Substrate.	R	and	D	Systems,	USA.	Catalogue	No.	ES004	Normal	citrated	human	plasma.	Technoclone,	Austria.	Catalogue	No.	3016137-004	
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OM99-2	 BACE1	 inhibitor	 (H-Glu-Val-Asn-[(2R,4S,5S)-5-amino-4-hydroxy-2,7-dimethyl-octanoyl]-Ala-Glu-Phe-OH	Trifluoroacetate	salt).	Bachem,	Sweden.	Catalogue	No.	H-5108	Pathromtin	SL.	Siemens,	UK.	Catalogue	No.	10484200	Phosphate	buffered	saline.	HyClone,	USA.	Catalogue	No.	SH30258.02	Polyethylene	glycol.	Fisher,	Sweden.	Catalogue	No.	25322-68-3	Porcine	 mucosal	 heparin	 sodium	 salt	 (201	 IU.mg-1).	 Celsus,	 USA.	 Catalogue	 No.	 PH-03004	Potassium	sulphate	≥	99%,	Fisher	Sweden.	Catalogue	No.	10214590	Purified	human	IgG	F(ab’)2/k.	Bethyl	Laboratories,	USA.	Catalogue	No.	P80-130	Purified	human	IgG	Fab.	Bethyl	Laboratories,	USA.	Catalogue	No.	P80-115	Purified	human	IgG	Fc,	Bethyl	Laboratories,	USA.	Catalogue	No.	P80-104	Pyridine	anhydrous,	99.8%.	Sigma,	UK.	Catalogue	No.		270970	Rhodizonic	acid,	disodium	salt,	98%.	Acros,	Belgium.	Catalogue	No.	132340050	Silver	sulphate	99%,	Acros	Belgium.	Catalogue	No.	10174930	Sodium	acetate	anhydrous	≥99.0%.	Sigma,	UK.	Catalogue	No.	S8750	Sodium	acetate	trihydrate	≥99.0%.	Sigma,	UK.	Catalogue	No.	S7670	Sodium	bicarbonate.	Fisher,	Sweden.	Catalogue	No.	10244683	Sodium	chloride	99.5%.	Fisher,	Sweden.	Catalogue	No.	S/3160/53	Sodium	chloride	HPLC	grade.	Fisher,	Sweden.	Catalogue	No.	10274392	Sodium	citrate	dihydrate	≥99.0%.	Sigma,	UK.	Catalogue	No.	W302600	Sodium	hydroxide	50%	wt	solution.	Acros,	Belgium.	Catalogue	No.	259860010	Sodium	sulphate	anhydrous,	99+%	extra	pure,	Fisher	Sweden.	Catalogue	No.	10606082	Sypro®	Orange	Protein	Gel	Stain.	Sigma,	UK.	Catalogue	No.	S5692	Thrombin	substrate.	Hyphen	Biomed,	USA.	Catalogue	No.	Biophen	CS-01(38)	Thromborel	S.	Siemens,	UK.	Catalogue	No.	10484202	
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Tris(hydroxymethyl)	methylamine.	Fisher,	Sweden.	Catalogue	No.	T/P630/60	Vanadyl	sulphate	hydrate	extra	pure,	Fisher	Sweden.	Catalogue	No.	10142450	Zinc	sulphate	heptahydrate	99%,	Acros	Belgium.	Catalogue	No.	10267273		
2.2	Equipment	400	MHz	NMR	spectrometer,	Bruker,	USA.	1.6	x	70	cm	HPLC	Column.	GE	Life	Sciences,	USA.	Catalogue	No.	19-5103-01	Black,	 non-sterile,	 flat-bottom,	 96-well	 reaction	 plate	 350	 μl,	 Sterilin.	 Fisher,	 Sweden.	Catalogue	No.	611F96BK	Clear,	non-sterile,	flat-bottom,	96-well	reaction	plate,	350	μl.	Fisher,	Sweden.	Catalogue	No.	11349163	Coagulation	analyser,	Thrombotrack.	Axis	Shield,	UK.		Coagulation	 cuvettes	 &	 ball	 bearings.	 Behnk	 Elektronik,	 Germany.	 Catalogue	 No.	 050-220	Dialysis	 tubing,	 3500	 Da	 MWCO	 cellulose	 acetate.	 Fisher,	 Sweden.	 Catalogue	 No.	11552541	Dowex	Marathon	ion	exchange	resin.	Acros,	Belgium.	Catalogue	No.	428787	Eppendorf	MiniSpin	centrifuge.	Eppendorf,	Germany.	Catalogue	No.		022620100	FT-IR	Nicolet	iS5	Spectrometer.	Thermo	Scientific,	UK.	HiTrap	 heparin	 affinity	 column	 1ml.	 GE	 Healthcare	 Sciences,	 USA.	 Catalogue	 No.	 17-0406-01	HPLC	Cecil	1100,	with	CE1200	wavelength	monitor.	Cecil,	UK.	Catalogue	No.	1100	Jasco	J1500	CD	Machine.	Jasco,	UK.	Catalogue	No.	J-1500	Lyophiliser,	ModulyoD.	Edwards	Modulyo,	UK.		
	 59	
MicroAmp®	optical	96-well	reaction	plate.	Fisher,	Sweden,	Catalogue	No.	10411785	MicroAmp™	optical	adhesive	film.	Fisher,	Sweden.	Catalogue	No.	10567414	OMNIC	series	software.	Thermo	Scientific,	UK.	Catalogue	No.	INQSOF018	PD10	desalting	HPLC	column.	GE	Life	Sciences,	USA.	Catalogue	No.	17-0851-01	Sephacryl®	100-HR,	MW	range	1000-100,000	Da	(globular	proteins).	GE	Life	sciences,	USA.	Catalogue	No.	S100-HR	Sephacryl®	 500-HR,	 MW	 range	 40-20,000	 KDa	 (globular	 proteins).	 GE	 Life	 sciences,	USA.	Catalogue	No.	S500-HR	Step	One	Plus	RT-PCR	machine.	Fisher,	Sweden.		Tecan	 Infinite	 M200	 Multiwell	 plate	 reader.	 Tecan,	 Switzerland.	 Catalogue	 No.	 M200
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2.3	Methods	
2.3.1	Far-ultraviolet	(UV)	circular	dichroism	Delivered	antibodies	and	 fragments	were	removed	 from	their	stabilizing	buffers	using	either	 10	 kDa	 or	 50	 kDa	 Corning	 spin	 filters	 at	 12100	 g	 in	 a	 Eppendorf®	MiniSpin	centrifuge	 for	 10	 minutes,	 washing	 with	 water	 three	 times	 before	 the	 protein	 was	reconstituted	with	desired	buffer	solution.		The	 J-1500	 Jasco	 circular	 dichrosim	 spectrometer	 was	 calibrated	 with	 D-(+)-10-camphorsulfonic	 acid	at	 a	 concentration	of	1	mg/ml	 (aq.),	with	peaks	observed	at	 λ	=	290.5	nm	and	λ	=	192.5	nm.		Human	antibody	 fragments,	whole	antibodies	and	BACE1	(3	μM)	were	assayed	on	a	 J-1500	 Jasco	 circular	 dichroism	 spectrometer	 in	 P/L	 0.2	 mm	 glass	 cuvette	 in	 50	 mM	sodium	 acetate	 pH	 4.0	 or	 PBS	 pH	 7.4	 to	 a	 final	 volume	 of	 32	 μl.	 Variables	 include	addition	of	3	μM	PMH	(17	kDa	mean	molecular	weight)	or	chemically	modified	heparin.	Chemically	modified	heparin	molecular	weight	ratios	are	as	follows:	IdoA(2S)-GlcNS(6S)	1,	CMH2	1.1,	CMH3	1.18,	CMH4	1.32,	CMH5	1.18,	CMH6	1.32,	CMH7	1.44,	CMH8	1.66,	CMH9	0.81.	Data	collection	was	completed	by	Spectral	Manager	II	and	data	analysis	was	done	 in	 Prism	 6	 with	 second	 order	 polynomial	 smoothed	 to	 10	 neighbors.	 BeStSel	analysis	was	completed	on	the	unsmoothed	data.	
2.3.2	Differential	scanning	fluorimetry	(DSF)	Differential	 scanning	 fluorimetry	was	 completed	with	 a	method	 by	Niesen	 et	al.	 2007	and	 Uniewicz	 et	 al	 2014	 with	 modifications	 for	 microplate	 use	 (Niesen	 et	 al.,	 2007)	(Uniewicz,	Ori,	Ahmed,	Yates,	&	Fernig,	2014).		
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Antibodies	 and	 antibody	 fragments	 were	 purified	 from	 their	 stabilising	 buffers	 using	either	 10	 kDa	 or	 50	 kDa	 Corning	 spin	 filters	 at	 12100	 g	 in	 a	 Eppendorf®	MiniSpin	centrifuge	for	10	minutes,	replacing	the	buffer	with	water	three	times	before	the	protein	was	reconstituted	with	desired	buffer	solution.		IgG1k	(Mw	146	kDa),	IgG2k	(146	kDa),	and	IgM	(950	kDa)	were	assayed	at	1	μM	in	96	well	PCR	plates	along	with	20x	Sypro	orange	in	50mM	sodium	acetate	pH	4.0	to	a	final	well	volume	of	40	μl.	Human	antibody	fragments	Fc	(32	kDa),	Fab	(50	kDa),	and	F(ab’)2	(110	kDa)	and	BACE1	were	assayed	at	3	μM	in	PCR	plates	along	with	20x	Sypro	orange	in	 50	mM	 sodium	 acetate	 pH	 4.0	 to	 a	 final	 well	 volume	 of	 40	 μl.	 PMH	 or	 chemically	modified	heparins	were	added	to	the	reaction	at	a	maximum	concentration	of	6	μM.		Modifications	 to	 the	 buffer	 system	 include	 ionic	 strength	 changes	 from	 20-100	 mM	sodium	acetate,	pH	changes	between	4.0,	4.5	and	5.0	and	phosphate	buffered	saline	pH	4.0	to	7.4.	Differential	 scanning	 fluorimetry	 assays	 were	 conducted	 on	 a	 StepOne	 plus	 RT-PCR	machine	 with	 TAMRA	 filter	 with	 an	 initial	 incubation	 phase	 of	 2	 minutes	 at	 25°C,	increasing	0.5°C	 increments	 every	30	 seconds	up	 to	 a	 final	 temperature	of	99°C.	Data	analysis	was	completed	in	Prism	6	with	first	derivative	plots	smoothed	to	4	neighbors	fitting	a	second	order	polynomial.		
2.3.3	Synthesis	of	cation	heparin	library	Dowex	marathon	ion	exchange	resin	beads	were	washed	in	HPLC	H2O,	the	supernatant	discarded,	 and	 immersed	 in	 1	 M	 HCl	 and	 mixed	 thoroughly.	 The	 beads	 were	 then	washed	 in	 HPLC	H2O	 until	 neutralised.	 Celsus	 PMH	 (150	mg/ml)	was	 incubated	with	prepared	 beans	 (1	 hr)	 and	 removed	with	 syringe	 filter;	 supernatant	 retained.	 10	mM	
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cation	 salt	was	 incubated	with	 supernatant,	 prior	 to	overnight	dialysis	 in	HPLC	water	with	1kDa	PlusOne	Mini	Dialysis	kits	and	further	PD10	desalting.	
2.3.4	Heparin	affinity	chromatography	Heparin	affinity	chromatography	used	a	Cecil	 Instruments	Q-ADEPT	Q-2,	Binary	HPLC	system.	 Antibodies	 and	 antibody	 fragments	 were	 loaded	 on	 to	 a	 1	 ml	 HPLC	 HiTrap	Heparin	column	(GE	Healthcare).	Runs	were	completed	either	in	50	mM	sodium	acetate	pH	4.0,	or	in	PBS	at	varying	pH	levels	(pH	4.0	–	7.0).	Unbound	material	was	isocratically	eluted	1	ml/min	with	0	–	2	minutes	100%	buffer,	then	bound	material	was	eluted	with	a	linear	2	–	17	minutes	0	–	100%	buffer	+	2M	NaCl.	Run	method	then	allowed	for	column	clearing	 and	 stabilising	 with	 17	 –	 19	minutes	 100%	 buffer	 +	 2M	 NaCl,	 then	 19	 –	 24	minutes	100	%	buffer.	40	μg	protein	was	loaded	and	detected	with	UV/vis	detector	λabs=	210	 nm	 (PBS)	 and	 λabs=	 280	 nm	 (C2H3NaO2).	 Standard	 antibody	 preservative	 NaN3	(sodium	 azide)	 was	 determined	 not	 to	 bind	 to	 the	 column.	 Data	 was	 collected	 in	PowerStream	CE4900	and	processed	in	Prism	6.		
2.3.5	Fluorescence	(Förster)	resonance	energy	transfer	(FRET)	To	determine	the	chemically	sulphated	polysaccharides	BACE1	inhibition	activity,	FRET	was	 employed	 to	 detect	 loss	 of	 fluorescence	 at	 λem=	 405	 nm.	 In	 a	 black	 96	 well	 flat	bottomed	microplate,	10	Sigma	units	of	BACE1	(C-terminal	FLAG-tag	Sigma)	were	added	alongside	aqueous	 test	 compound	of	 varying	 concentrations	or	water	only	and	10	μM	MCA-SEVNLDAEFRK(DNP)RR-NH2	 fluorogenic	 peptide	 substrate	 in	 50	 mM	 sodium	acetate	pH	4.0.	Upon	addition	of	fluorescent	substrate,	the	plates	were	measured	at	37	°C	 immediately	and	subsequently	every	5	minutes	 for	1	hour	at	λex=	320	nm	λem=	405	nm	on	a	Tecan	Infinite®	200	Pro	microplate	reader.	The	change	in	fluorescence	over	1	hour	 was	 calculated	 and	 was	 compared	 to	 a	 no-inhibitor	 control	 and	 substrate	 only	
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control	 representing	 both	 a	 full	 reaction	 and	 no	 fluorescence	 respectively	 to	demonstrate	 percentage	 inhibition	 of	 the	 BACE1	 activity.	 Prism	 6	 was	 used	 for	 data	analysis	after	calculation	of	normalised	percentage	inhibition	(NPI):	
𝑁𝑃𝐼 =  𝑐! −  𝑥!𝑐!  −  𝑐!		Where	𝑥! 	is	 the	 raw	 measurement	 on	 the	 ith	 compound	𝑐! and	𝑐! are	 means	 of	 the	positive	and	negative	controls	in	an	antagonist	assay	(Malo,	Hanley,	Cerquozzi,	Pelletier,	&	Nadon,	2006).	
2.3.6	Chemical	sulphation	of	polysaccharides	Chemical	 sulphation	of	polysaccharides	was	achieved	as	per	 the	method	of	Yoshida	et	al.,	1995	modified	as	below	(Yoshida	et	al.,	1988).	Polysaccharide	(0.5	g)	was	added	to	80	ml	anhydrous	pyridine	on	ice.	Chlorosulfonic	acid	(10	ml)	was	added	dropwise,	with	caution.	The	solution	was	heated	 to	95	 °C	 for	1	hour,	before	cooling	and	precipitation	with	 50%	 w/v	 NaOH	 on	 ice.	 The	 neutralised	 solution	 was	 further	 precipitated	 by	addition	 of	 ice-cold	 ethanol	 saturated	 with	 sodium	 acetate.	 	 The	 precipitate	 was	recovered	 and	 washed	 in	 ice-cold	 ethanol	 saturated	 with	 sodium	 acetate.	 The	precipitate	 was	 dissolved	 in	 water	 and	 dialysed	 (>3.5	 kDa)	 over	 three	 days	 against	running	 water;	 a	 final	 dialysis	 against	 HPLC	 grade	 water	 was	 performed.	 Dowex	marathon	 beads	 were	 prepared	 by	 first	 incubating	 with	 1	 M	 HCl	 for	 1	 hour,	 with	occasional	vortexing.	Acid	was	then	removed	with	Corning	spin	filters	and	a	bench	top	centrifuge.	 Marathon	 beads	 were	 washed	 with	 HPLC	 grade	 water	 removed	 using	 the	spin	filters	and	repeated	until	the	resulting	solution	was	neutralised.		The	 sulphated	 polysaccharide	 solution	 was	 incubated	 for	 1	 hour	 with	 H+	 Dowex	Marathon	ion	exchange	resin	pre-prepared	in	the	acid	form.	Beads	were	removed	with	a	
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spin	 filer	 and	 the	 resulting	 solution	 was	 neutralised	 dropwise	 by	 the	 addition	 of	saturated	 sodium	 hydrogen	 carbonate.	 The	 resulting	 polysaccharide	 solution	 was	desalted	 utilising	 a	 PD10	 column	 as	 per	 manufacturers	 instructions.	 Polysaccharides	were	then	frozen	(-80	°C),	 lyophilised,	and	weighed	to	calculate	yield	of	each	chemical	sulphation	of	polysaccharide.	
2.3.7	Activated	partial	thromboplastin	time	(aPTT)  A	cuvette,	ball	bearing,	50	mM	calcium	chloride	and	 test	 sample	 (or	water)	were	pre-warmed	 to	 37°C	 on	 coagulation	 analyser.	 50	 μl	 normal	 human	 citrated	 plasma,	 25	 μl	aqueous	 test	 sample	 or	 HPLC	 grade	 water	 and	 50	 μl	 Pathromtin	 SL	 reagent	 were	incubated	 in	 a	 cuvette	 for	 2	 minutes	 at	 37	 °C.	 Time	 for	 clot	 formation	 was	 read	immediately	 following	 the	 addition	of	 25	μl	 50mM	calcium	 chloride	 solution,	 time	 for	clot	recorded	to	a	maximum	of	2	minutes.	
2.3.8	Prothrombin	time	(PT)	Cuvettes,	 ball	 bearing,	 Thromborel	 S	 reagent	 and	 test	 sample	 (or	 controls)	were	 pre-warmed	 to	 37°C	 on	 coagulation	 analyser.	 In	 a	 cuvette,	 50	 μl	 normal	 human	 citrated	plasma	was	added	and	 incubated	 for	1	minute	at	37	°C.	Aqueous	 test	sample	or	HPLC	grade	water	(50	μl)	was	then	added	followed	by	50	μl	Thromborel	S	reagent,	with	time	for	clot	 formation	measured	 immediately	 following	addition	of	Thromborel	S,	 time	 for	clot	recorded	to	a	maximum	of	2	minutes.	
2.3.9	Factor	Xa	inhibition		Anti-thrombin,	factor	Xa	and	factor	Xa	substrate	were	all	diluted	into	experiment	buffer	50	mM	tris,	175	mM	NaCl,	7.5mM	EDTA,	0.1%	PEG	to	pH	8.4.	PMH	calibration	curve	was	completed	at	0,	0.25,	0.50,	0.75,	and	1.0	IU/ml.		
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On	 a	 clear	 96	 microwell	 plate	 incubated	 at	 37°C,	 28	 mIU	 anti-thrombin	 (30	 μl)	 was	added	to	30	μl	test	polysaccharide	or	water,	this	was	mixed	and	incubated	for	2	minutes	at	 37°C.	 To	 this,	 0.21	 nkats	 (30	 μl)	 of	 preincubated	 factor	 Xa	 was	 added	 and	 the	microwell	plate	was	mixed	and	 incubated	at	37°C	 for	exactly	2	minutes.	Preincubated	factor	 Xa	 substrate	 was	 then	 added	 at	 1	mg/ml	 (30	 μl)	 and	 the	microwell	 plate	 was	mixed	 and	 incubated	 at	 37°C	 for	 exactly	 2	 minute.	 The	 reaction	 was	 stopped	 upon	addition	of	20	mg/ml	citric	acid	(60	μl)	and	the	plate	was	read	at	λabs	=	405	nm.	
2.3.10	Factor	IIa	inhibition		Anti-thrombin,	 thrombin	 and	 thrombin	 substrate	 were	 all	 diluted	 into	 experiment	buffer	50	mM	tris,	175	mM	NaCl,	7.5	mM	EDTA,	0.2%	BSA	 to	pH	8.4.	PMH	calibration	curve	was	completed	at	0,	0.25,	0.50,	0.75,	and	1.0	IU/ml.		To	 a	 clear	 96	 microwell	 plate	 incubated	 at	 37°C,	 7.5	 μIU	 anti-thrombin	 (30	 μl)	 was	added	to	30	μl	test	polysaccharide	or	water,	this	was	mixed	and	incubated	for	2	minutes	at	37°C.	To	this,	0.720	NIH	U	(30μl)	 thrombin	was	added	and	the	microwell	plate	was	mixed	 and	 incubated	 at	 37°C	 for	 exactly	 2	minutes.	 Preincubated	 thrombin	 substrate	was	then	added	at	1	mg/ml	(30	μl)	and	the	microwell	plate	was	mixed	and	incubated	at	37°C	 for	exactly	1	minute.	The	reaction	was	stopped	upon	addition	of	20	mg/ml	citric	acid	(60	μl)	and	the	plate	was	read	at	λabs	=	405	nm.	
2.3.11	Colourimetric	determination	of	sulphate	level	Sulphate	 level	 determination	 was	 achieved	 as	 per	 the	 method	 of	 Terho	 and	 Hartiala	1971	modified	as	below	(Terho	&	Hartiala,	1971).	Test	polysaccharides	were	hydrolysed	at	1	mg/ml	in	solution	with	1	M	HCl	at	100°C	for	2	 hours	 and	 subsequently	 lyophilised	 and	 reconstituted	 in	 HPLC	 water	 at	 1	 mg/ml.	Dextran	sulphate	control	was	similarly	hydrolysed,	 lyophilised	and	reconstituted	at	25	
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mg/ml.	 A	 dilution	 series	 of	 each	 polysaccharide	 and	 dextran	 sulphate	 control	 was	assayed	to	allow	for	linear	range	analysis.		Equal	volumes	of	hydrolysed	polysaccharide	and	ethanol	(30μl)	were	added	to	a	96	well	microwell	plate,	along	with	barium	chloride	buffer	consisting	of	100	mM	acetic	acid,	50	μM	 BaCl2,	 800	 μM	 NaHCO3	 in	 ethanol,	 to	 a	 final	 well	 volume	 of	 120	 μl.	 Finally,	rhodizonate	 detection	 solution	 was	 added	 to	 a	 final	 concentration	 of	 0.14	 mM	rhodizonic	acid	and	3.4	mM	L(+)-ascorbic	acid	in	ethanol.	The	plate	was	shaken	during	colour	 development	 and	 allowed	 to	 stand	 in	 the	 dark	 for	 10	minutes	 to	 develop.	 The	microwell	plate	was	read	at	λabs	=	520	nm.	
2.3.12	Gel	permeation	chromatography	(GPC)	Gel	permeation	chromatography	(GPC)	was	completed	on	hit	compounds	using	a	Cecil	1100	HPLC	with	 2	 linked	 1.6	 x	 70	 cm	 columns,	 the	 first	 packed	with	 Sephacryl	 S100	matrix,	and	the	second	with	Sephacryl	S500,	reported	to	separate	1	×	103	–	1	×	105	Da	(peptides	 and	 small	 proteins)	 and	 4	 ×	 104	–	 2	 ×	 107	Da	 (Dextrans)	 respectively.	 An	isocratic	 250	 mM	 ammonium	 chloride	 was	 used	 to	 separate	 at	 0.5	 ml/min	 with	 a	sampling	rate	of	2.63	Hz	using	Analogue	devices	AD	7194	data	collection	software	at	λabs	=	210	nm	on	a	Cecil	CE1200	wavelength	monitor	with	 a	 run	 time	of	9.38	hours.	Void	volume	 was	 determined	 with	 dextran	 blue	 (λabs	 =	 380	 nm)	 before	 calibration	 with	gamma	globulin	(158	kDa),	ribonuclease	A	(13.7	kDa),	ovalbumin	(44	kDa)	and	vitamin	B12	(1350	Da)	at	0.5	ml/min	at	λabs	=	280	nm.	
2.3.14	Fourier	transform	infra-red	spectroscopy	(FTIR)	FTIR	 spectra	 were	 recorded	 using	 a	 Nicolet	 iS5	 IR-TF	 (Thermo	 Fisher)	 spectrometer	scanning	 in	 the	 4000–400	 cm-1	 region,	 with	 a	 spectral	 resolution	 of	 2	 cm-1	over	 128	scans.	 A	 background	 air	 spectrum	 was	 obtained	 and	 subtracted	 from	 all	 spectra.	 In	
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order	to	further	improve	the	comparison	between	samples,	the	mean	of	5	FTIR	spectra	per	 sample	 was	 normalized	 to	 %	 transmittance.	 All	 spectra	 were	 processed	 using	ThermoFisher	Omnics	software.	
2.3.14	Nuclear	magnetic	resonance	spectroscopy	(NMR)	Chemically	sulphated	polysaccharide	and	unmodified	polysaccharides	were	dissolved	in	deuterium	oxide.	1H	NMR	was	measured	with	a	Bruker	400	MHz	spectrometer,	ns	=	128	d	 =	 2	 sec,	with	water	 suppression.	 Spectra	 collected	with	 Topspin	 and	 analysed	with	iNMR.	
2.3.16	Correlation	analysis	Pearson	product-moment	 correlation	 coefficient	 (or	Pearson	 correlation	 coefficient,	 r)	measures	 the	 strength	 of	 a	 linear	 relationship	 between	 two	 variables.	 A	 two-tailed	correlation	matrix	of	r	is	computed	for	each	variable	within	a	dataset	(CI	95%).	Analysis	completed	with	Prism	6.	
2.3.17	Principle	component	analysis	(PCA)	Principle	component	analysis	was	completed	with	Minitab,	 inputting	data	 from	the	1St	derivative	 melt	 curves	 of	 DSF.	 Each	 concentration	 of	 CMH	 was	 inputted	 into	 a	correlation	matrix,	where	multivariate	analysis	was	completed	with	PCA	to	elucidate	the	eigenvalues	and	principle	 component	values.	Eigenvalues	accounting	 for	≥	85%	of	 the	variance	were	plotted,	with	principle	component	values	for	each	CMH	concentration	or	test	polysaccharide,	which	for	this	data	formed	a	PC1	v	PC2	plot.			
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CHAPTER	3:	The	effect	of	biochemical	tags	on	BACE1	
structure	
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3.1	Introduction		 Initial	investigations	were	conducted	to	identify	the	suitability	of	BACE1	enzyme	available	 for	 use	 in	 the	 fluorescent	 resonance	 energy	 transfer	 (FRET)	 assay	 that	 is	commonly	used	to	identify	BACE1	inhibitors.	Recombinant	human	BACE1	was	obtained	in	 various	 forms,	 containing	 biochemical	 tags	 and	 in	 the	 untagged,	 native	 form.	 Four	types	 of	 BACE1	were	 investigated	 in	 order	 to	 determine	 the	 effect	 of	 heparin	 on	 the	binding	and	any	structural	changes	seen	during	protein-heparin	binding.	Identification	of	the	most	suitable	form	of	BACE1	for	further	areas	of	this	study,	 including	structural	and	enzyme	activity	experiments,	was	completed.	The	typically	employed	buffer	system	of	BACE1	 in	vitro,	 acetate	 buffer	 and	 acidic	 pH	of	 pH	4.0	 –	 4.5,	 closely	 represents	 the	physiological	environment	experienced	by	BACE1	in	the	endosome.			 Ideally,	 native	 (untagged)	 BACE1	 would	 be	 used	 throughout	 the	 activity	 and	structural	experiments	to	ensure	there	are	no	adverse	changes	or	artifacts	arising	from	the	 presence	 of	 the	 included	 tag,	 but	 native	 BACE1	 is	 ≈	160	%	more	 expensive	 than	tagged	BACE1.	This	 increase	 in	price	 is	due	 to	 the	more	complex	and	 time-consuming	extraction	and	purification	required	for	tag-free	protein.			 Three	commercially	available	protein	tags	were	 investigated;	10-His	tag,	Fc	tag,	and	FLAG	tag	alongside	the	native	un-tagged	BACE1.		
3.1.1	Histidine	tag		 The	poly-histidine	tag	usually	comprises	of	between	6	and	14	histidine	residues	and	is	most	commonly	utilised	as	a	fast	and	convenient	method	for	protein	purification	in	 concert	with	 immobilised	metal	 affinity	 chromatography	 (IMAC)	 (Porath,	 Carlsson,	Olsson,	&	Belfrage,	1975).	IMAC	employs	metal	 ions	e.g	nickel	(Ni2+)	and	colbalt	(Co2+)	coated	beaded	agarose	resin,	which	enable	high	affinity	metal	ion	co-ordination	with	the	
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poly-histidine	 tag	region	of	 the	protein,	and	ensures	separation	of	 the	 labelled	protein	away	from	cell	culture	supernatant	(idem).			 The	 position,	 structure	 and	 sequence	 length	 of	 the	 histidine	 tag	 influences	protein	 purification,	 through	modifications	 to	 the	 expression	 rate,	 accessibility	 to	 the	metal	 cation	 during	 IMAC,	 protein	 structure,	 and	 crystal	 formation;	 this	 affects	ultimately	protein	solubility	and	bioactivity	(Block	et	al.,	2009).			 Variations	 in	 the	poly-histidine	 tag	size	allows	 for	purification	under	a	range	of	conditions.	 Soluble	protein	purification	may	 require	 a	hexahistidine	 tag	 (H6),	whereas	purification	of	a	membrane	protein	under	conditions	containing	detergent,	may	require	a	 longer	 histidine	 tag	 (H10/H14)	 or	 a	 linker	 region	 (Block	 et	 al.,	 2009).	 Furthermore,	detergent	micelles	may	encapsulate	some	of	the	tag	during	purification,	reducing	metal	cation	binding	(idem).	A	10-histidine	 tag	 is	currently	used	conjugated	 to	 the	BACE1	C-terminus	due	to	the	membrane	spanning	nature	of	the	enzyme.		
3.1.2	IgG	Fc	region	tag		 The	immunoglobulin	Fc	region	has	been	utilised	in	biomedical	research	since	the	CD4-Fc	fusion	agonists	developed	by	Capon	et	al.	(1989)	(Capon	et	al.,	1989).	The	fusion	of	the	IgG	Fc	peptide	confers	improved	plasma	retention	in	vivo	due	to	the	FcRn	salvage	interaction	 (Akilesh,	 Christianson,	 Roopenian,	 &	 Shaw,	 2007).	 IgG	 Fc	 improves	 the	solubility	of	fusion	proteins	both	in	vivo	and	in	vitro,	through	improvements	to	stability	(Kontermann,	2011).	The	addition	of	 IgG	Fc	 to	recombinant	protein	also	 increases	 the	circulating	time	of	fusion	proteins	through	attenuated	renal	clearance	(idem),	and	allows	cost-effective	 purification	 in	 protein	 A/G	 sepharose	 affinity	 chromatography	 (Carter,	2011).	 The	 IgG	 Fc	 region	 is	 additionally	 employed	 in	 the	 production	 of	 fusion-dimers	and	more	 complex	polymer	 structures	 due	 to	 propensity	 of	 the	 Fc	 region	 to	 dimerise	
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(idem)	and	permits	the	binding	of	fusion	molecules	to	a	variety	of	Fc	receptors,	including	immune	 cell	 receptors;	 acting	 as	 a	 delivery	 molecule	 (Jazayeri	 &	 Carroll,	 2008;	Nimmerjahn	&	Ravetch,	2008).			 Currently	used	protein-based	therapeutics	(≈	70	kDa	and	smaller)	are	eliminated	with	 a	 typical	 half-life	 of	 from	a	 few	minutes	 to	 a	 hours;	 the	 addition	 of	 an	 Fc	 region	enables	 neonatal	 Fc	 receptor	 (FcRn)	 recirculation,	 resisting	 renal	 elimination.	 The	serum	 half-life	 increases	 to	 days	 and	 weeks,	 therefore	 producing	 more	 efficacious	therapies	(Carter,	2011).			 Protein	 expression	 with	 an	 Fc	 tag	 allows	 for	 the	 simple	 and	 cost	 effective	purification	of	Fc-fusion	protein	through	protein	A	or	protein	G	beaded	agarose	affinity	chromatography	(Table	3).	Protein	A	is	a	42	kDa,	high	affinity	immunoglobulin	binding	protein	 found	on	 the	Staphylococcus	aureus	 cell	wall	 (Ey	 et	 al.,	 1978;	 Langone,	 1978).	This	protein	specifically	binds	IgG	Fc	and	the	VH3	of	Fab	regions	(Nilsson,	Abrahmsen,	&	Uhlen,	1985;	Uhlen	et	al.,	1983).	Protein	G	is	expressed	as	a	58	kDa	to	68	kDa	protein	in	group	 G	 Streptococcus	 (Akerstrom,	 Brodin,	 Reis,	 &	 Bjorck,	 1985;	 Bjorck	 &	 Kronvall,	1984).	
Table	 3:	 The	 affinity	 of	 protein	 A	 and	 protein	 G	 for	 the	 antibody	 fragments	 and	 whole	immunoglobulin.	 Strong	binding	 between	 the	 immunoglobulin	and	purification	protein	 allows	purification	 of	 the	 immunoglobulin	 through	 sepharose	 affinity	 chromatography	 (Langone,	1978).			
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	 Fc-fusion	 proteins	 can	 be	 utilised	 to	 both	 increase	 and	 decrease	 effector	functions	 of	 immune	 cells	 e.g	 NK	 cells	 through	 the	 interaction	 with	 the	 Fc	 receptor	FcϒRIIIA	promoting	antibody	dependent	cellular	toxicity	(ADCC)	in	cancer	cells	(Congy-Jolivetab,	Probst,	Watier,	&	Thibaulta,	2007),	and	mast	cell	downregulation	through	the	activation	of	inhibitory	Fc	receptor,	FcϒRIIB	(Daeron,	Malbec,	Latour,	Arock,	&	Fridman,	1995).			 Clinical	Fc-fusion	proteins	have	been	available	since	1998,	with	the	introduction	of	Etanercept	(‘Enbrel’	by	Amgen/Pfizer),	a	tumor	necrosis	factor	receptor	(TNFR)-IgG1	Fc	 fusion	 protein	 used	 in	 the	 treatment	 of	 rheumatoid	 arthritis	 (RA).	 Treatments	 for	psoriasis	 (Alefacept),	 transplant	 rejection	 (Alefacept	 and	 Betatacept),	 RA	 (Etanercept	and	 Abatacept),	 thrombocytopaenia	 (Romiplostim),	 cryopyrin-associated	 periodic	syndromes	 (genetic	 autoimmune	 disease)	 (Rilonacept),	 and	 age	 related	 macular	degeneration	 (Aflibercept)	 have	 all	 been	 developed	 utilising	 the	 Fc-fusion	mechanism	(Czajkowsky,	 Hu,	 Shao,	 &	 Pleass,	 2012).	 In	 2012,	 Fc	 fusion	 therapeutics	 represented	20%	 of	 the	 USA	 Food	 and	 Drug	 Administration	 (FDA)	 approved	 antibody-based	medicines	(idem).			 The	 fusion	 partner	 of	 Fc	 is	 commonly	 attached	 at	 the	 hinge	 region	 below	 the	constant	heavy	chain	immunoglobulin	domain	CH2,	through	a	modified	hinge,	with	the	Fc	regions	dimerising,	as	would	native	immunoglobulin	(Czajkowsky	et	al.,	2012).	Single	ligand	 specificity	 in	 bivalent	 fusion	 constructs	 such	 as	 the	 fibroblast	 growth	 factor	 I	(FGF1)	 Fc-fusion	 protein,	 function	 effectively	 with	 FGFR1	 on	 T-cells	 (Dikov,	 Reich,	Dworkin,	 Thomas,	 &	 Miller,	 1998),	 therapeutic	 examples	 that	 mimic	 this	 interaction	include	Abatacept	and	Alefacept	(Czajkowsky	et	al.,	2012).		 Cytokine	 traps	 are	 examples	 of	monovalent	 fusion	 constructs	with	multiligand	specificity	 such	 as	 Aflibercept,	 a	 vascular	 endothelial	 growth	 factor	 receptor	
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(VEGFR1/VEGFR2)	 Fc-fusion	 protein,	 designed	 to	 treat	 macular	 degeneration	(Czajkowsky	 et	 al.,	 2012).	 Multi-ligand	 binding	 domains	 co-operate	 to	 form	 a	 single	binding	region	capable	of	trapping	a	single	ligand	(Economides	et	al.,	2003).		 Multivalent	 fusion	 proteins	 with	 single-ligand	 specificity,	 are	 constructed	 from	multiple	copies	of	binding	regions	separated	by	 flexible	 linkers	 to	 form	a	 large	region,	possible	 for	 ligand	 interaction	 (Cines,	 Yasothan,	 &	 Kirkpatrick,	 2008).	 The	 Fc-fusion	protein	Romiplostim	is	utilized	in	thrombocytopenia,	to	regulate	platelet	production	by	mimicking	the	action	of	the	endogenous	protein	analogue	thrombopoietin	(idem).			 Single	 ligand	 specificity	 in	 multivalent	 fusion	 constructs	 bind	 large	 single	proteins	 between	 the	 dimer	 creating	 a	 stable	 scaffold	 for	 ligand	 binding.	 The	extracellular	 domain	 of	 the	 TNFα-receptor	 II	 is	 bound	 to	 the	 Fc	 dimer	 forming	 the	antagonist	therapy,	Etanercept	as	a	treatment	for	RA	(Scallon	et	al.,	2002).			 Non-clinical	 applications	 of	 Fc-fusion	 include	 the	 use	 of	 this	 tag	 in	 flow	cytometry,	 immunohistochemistry	 and	 ELISA,	 and	 in	 protein	microarray	 technologies	(Flanagan,	Arias,	Hu,	Khawli,	&	Epstein,	2007).	The	BACE1	selected	is	conjugated	to	a	C-terminal	Fc	tag.	
3.1.3	FLAG-tag		 The	FLAG-tag	is	constructed	of	the	hydrophilic	amino	acid	sequence	DYKDDDDK,	N-	 to	 C-	 terminus,	 which	 is	 designed	 to	 ensure	 the	 tag	 remains	 on	 the	 surface	 of	recombinant	 protein	 due	 to	 the	 hydrophilic	 nature	 of	 the	 tag	 (Terpe,	 2003).	 Protein	purification	 using	 FLAG-tag	 employs	 calcium	 dependant	 monoclonal	 (M1)	 antibody	epitope	 recognition	 for	 the	8	amino	acid	 tag,	with	 the	antibody	 conjugated	 to	agarose	beads	 enabling	 immunoprecipitation	 of	 the	 conjugated	 protein	 (idem).	 Purification	conditions	are	non-denaturing	so	they	can	accommodate	active	fusion	proteins,	with	the	
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antibody:FLAG	 epitope	 complex	 dissociated	 with	 decreasing	 pH	 or	 metal	 chelating	agents	such	as	EDTA	(idem).	
3.1.4	Other	commonly	used	protein	tags		 The	 polyarginine	 tag	 (Arg-tag)	 consists	 of	 5	 or	 6	 basic	 arginine	 residues	(Sassenfeld	&	Brewer,	1984)	and	is	purified	with	cation	exchange	sulfopropyl	(SP)	resin	and	is	eluted	with	NaCl	at	alkaline	pH	(Terpe,	2003).	However,	inclusion	of	the	Arg-tag	may	modify	tertiary	structure	in	protein	with	a	hydrophobic	C-terminal	such	as	BACE1,	which	contains	a	single	transmembrane	domain	near	its	C-terminus	(455-480)	(Cole	&	Vassar,	2007).			 The	c-myc	tag	consists	of	11	residues	EQKLISEEDL	recognised	by	the	monoclonal	antibody,	 9E10	 (Evan,	 Lewis,	 Ramsay,	 &	 Bishop,	 1985).	 Purification	 of	 recombinant	protein	 with	 a	 c-myc	 tag	 is	 conducted	 with	 divinyl	 sulphone-activated	 agarose	 at	physiological	pH,	 followed	by	elution	 in	acidic	conditions.	This	elution	step	can	have	a	denaturing	effect	on	protein	activity	(Terpe,	2003);	hence	why	this	tag	is	not	commonly	used	for	purification	processes.		 Polyarginine	 or	 c-myc	 tagged	 BACE1	 is	 currently	 not	 available	 commercially,	therefore	was	not	screened	in	this	study.		 Recombinant	 addition	 of	 a	 glutathione	 S-transferase	 tag	 produces	 a	 fusion	 of	glutathione	 S-transferase	 (GST),	which	 can	 be	 purified	 from	media	 using	 high	 affinity	binding	between	GST	and	reduced	glutathione	(GSH),	whereby	the	bound	fusion	protein	can	 be	 eluted	 with	 10	 mM	 GSH	 (Terpe,	 2003).	 A	 GST	 tag	 can	 be	 removed	 from	 the	protein	 with	 a	 site-specific	 protease	 such	 as	 thrombin	 or	 factor	 Xa	 and	 GSH-agarose	affinity	chromatography		(idem).		
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3.1.5	Native	BACE1			 BACE1	without	a	purification	tag	would	be	the	ideal	protein	for	both	activity	and	structural	 studies,	 but	 the	 increased	 cost	 of	 this	 form	 of	 protein	 causes	 us	 to	 look	elsewhere	for	a	suitable	replacement.			 	The	native	BACE1	used	in	this	study	is	expressed	with	a	tag,	which	is	removed	by	specific	proteolysis	by	an	enteropeptidase.	The	gene	sequence	 includes	 the	C-terminal	DDDDK	acting	as	a	recognition	site	for	the	enteropeptidase	proteolysis,	the	full	sequence	for	recombinant	native	BACE1	can	be	found	in	Appendix.		
3.1.6	Method	information	
3.1.6.1	Differential	scanning	fluorimetry		 Differential	scanning	fluorimetry	(DSF)	and	far-UV	circular	dichroism	(CD)	were	both	 employed	 in	 this	 chapter	 to	 study	 the	 changes	 in	 BACE1	 thermal	 stability	 and	secondary	structure	respectively,	upon	interaction	with	UF	PMH.		 In	 DSF,	 the	 hydrophobic	 dye	 Sypro	 Orange	 binds	 to	 regions	 of	 hydrophobicity	within	 the	 study	 protein.	 Sypro	 Orange	 is	 a	 merocyanine	 containing	 a	 quaternary	ammonium	 electron	 acceptor	 and	 a	 tertiary	 amino	 electron	 donor.	 The	 use	 of	 Sypro	Orange	 is	 preferred	 to	 1-anilino-naphthalene-8-sulfonate	 (1,8-ANS)	 with	 which	 the	technique	was	 initially	 engineered,	 as	 conventional	 quantitative	 real	 time	 polymerase	chain	 reaction	 (RT-PCR)	 machines	 utilise	 the	 dye	 TAMRA	 (tetramethylrhodamine),	which	 has	 excitation	 and	 emission	 wavelengths	 in	 the	 required	 range	 for	 Sypro	exploitation	(λex=	560	nm	λem=	582	nm)	(Semisotnov	et	al.,	1991;	Uniewicz	et	al.,	2010).	The	 precision	 of	 the	 peltier	 heating	 and	 ramping	 time	 in	 a	 RT-PCR	 machine	 are	 of	benefit	in	the	real-time	monitoring	of	protein	unfolding	(Niesen	et	al.,	2007).	Increasing	the	temperature	causes	the	protein	to	unfold	and	denature,	 increasing	the	exposure	of	
	 76	
hitherto	unexposed	hydrophobic	regions	within	 the	protein	(Figure	13).	Sypro	Orange	binds	 to	 these	 exposed	 regions,	 and	 fluoresces	 under	 hydrophobic	 conditions.	 This	fluorescence	 emission	 is	 detected	 in	 the	 similar	 range	 to	 the	 commonly	 used	 RT-PCR	fluorophore	TAMRA,	with	λexc=	542	nm	and	λem=	568	nm.		
	 Differential	scanning	fluorimetry	measures	changes	to	protein	thermal	stability,	to	determine	any	structural	change	conferred	in	BACE1,	which	may	suggest	the	binding	of	GAG	chain/s.	Protein	stability	is	related	to	the	temperature	dependant	on	Gibbs	free	energy	 of	 unfolding	 ΔGu,	 with	 increasing	 temperature	 reducing	 the	 ΔGu,	 until	 this	measure	reaches	zero	(Niesen	et	al.,	2007).	At	zero	ΔGu,	equilibrium	between	folded	and	denatured	protein	occurs	and	 is	 characterised	as	 the	melting	point	 (Tm)	 (idem).	Most	commonly,	 the	 binding	 of	 a	 ligand	 is	 thermodynamically	 advantageous,	 conferring	 an	increase	in	ΔGu,	a	more	stable	protein,	and	therefore	a	higher	Tm	(idem).		Investigations	
	Figure	13:	Differential	scanning	fluorimetry	of	the	unfolding	of	citrate	synthase	example	protein	with	 Sypro	 orange.	 Increasing	 the	 temperature	 causes	 protein	 unfolding	 from	 a	 globular	structure	at	position	LL,	exposing	hydrophobic	regions.	These	hydrophobic	regions	bind	Sypro	orange	dye	and	fluoresce	at	the	emission	wavelength,	shown	here	at	λem=	610	nm.	Lower	level	(LL)	and	upper	level	 (UL)	 fluorescence	 intensity	 is	 shown	(Niesen,	Berglund,	&	Vedadi,	2007).	Image	reproduced	with	permission	from	the	rights	holder	
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by	Matulis	et	al.	(2005)	and	Vedadi	et	al.	(2006)	demonstrate	the	increase	in	Tm	due	to	protein	 stabilisation	 is	 proportional	 to	 the	 ligand	 concentration,	 and	 binding	 affinity	(Matulis,	Kranz,	Salemme,	&	Todd,	2005;	Vedadi	et	al.,	2006).	However,	thermodynamic	elucidations	 must	 be	 limited,	 as	 the	 magnitude	 of	 the	 Tm	 shift	 is	 not	 unique	 to	 a	particular	binding	affinity	(Niesen	et	al.,	2007).	This	is	because	either	the	entropic	and	enthalpic	 components	may	 give	 rise	 to	 the	 same	 Tm	 shift,	 or	 competing	 components	could	 mask	 actual	 protein	 changes	 (idem).	 The	 comparison	 of	 Tm	 within	 a	 group	 of	ligands	 can	 be	 made	 when	 the	 group	 has	 similar	 physicochemical	 properties	 (idem).	This	ensures	in	the	later	chapters,	the	GAG	family,	chemically	modified	heparin	library	studies,	and	degree	of	polymerization	(d.p.)	studies	 in	DSF	give	Tm	results	that	can	be	compared	within	these	discrete	data	sets.	The	presence	or	absence	of	a	ligand	may	alter	the	melting	point	(Tm)	through	changes	to	the	protein	structure	and	therefore	thermal	stability.	Other	factors	that	influence	protein	structure	such	as	buffer	strength,	salts,	and	detergents	may	also	have	an	affect	on	Tm	in	DSF	(idem).		
3.1.6.2	Far-UV	circular	dichroism		 Circular	 dichroism	 spectroscopy	 is	 one	 of	 the	 most	 widley	 used	 methods	 for	characterising	 protein	 and	 peptide	 conformation	 in	 solution.	 This	 comparatively	 low-resolution	(when	compared	to	NMR	and	XRAY	crystallography)	spectroscopic	method	is	non-destructive,	 robust	 and	 simple	 to	both	use	and	 interpret	 (Greenfield,	Davidson,	&	Fasman,	 1967).	 The	 principle	 utilises	 the	 chromophore	 present	 in	 optically	 active	molecules	 to	 absorb	 left	 and	 right	 circularly	 polarised	 light	 to	 differing	 degrees;	therefore	 producing	 an	 absorption	 spectra	 specific	 to	 the	 test	 molecule	 in	 solution	(idem).	 Amino	 acids	 are	 especially	 suited	 to	 this	 form	 of	 spectroscopy	 due	 to	 the	enantiomeric	nature	of	the	amino	acid	(aside	from	glycine)	and	also	the	peptide	bond	in	
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peptides	and	proteins.	In	far-UV	CD	spectroscopy	(λabs	=	180	nm	-	240	nm)	this	peptide	bond	produces	two	bands,	an	intense	band	at	190	nm	and	weak	band	at	210	nm	(idem).	Addition	of	a	ligand	leading	to	backbone	conformational	changes	in	the	protein	modify	the	relative	absorbance	of	light	at	these	wavelengths,	causing	changes	to	the	CD	spectra.	High	concentrations	of	protein	(≈	10	mg/ml)	are	required	for	appreciable	spectra	in	CD	therefore	the	technique	can	be	financially	prohibitive.			 Circular	 dichroism	 (CD)	 provides	 low-resolution	 protein	 conformational	 data,	allowing	for	the	characterization	of	protein	structure	in	solution	and	upon	the	addition	of	potential	ligands.	Far-UV	circular	dichroism	was	utilised	to	determine	the	secondary	structural	 changes	 in	 BACE1	with	 the	 addition	 of	 UF	 PMH.	 Far-UV	 circular	 dichrosim	operates	 between	 λ	 =	 240	 nm	 and	 λ	 =	 180	 nm,	 and	 was	 employed	 to	 monitor	 the	secondary	 structural	 changes,	 such	 as	 α-helix	 and	β-sheet	 conformations,	 through	 the	peptide	bond	absorption	(W.	C.	Johnson,	1988).	Near-UV	range	(λ	=	320	nm	–	260	nm)	monitors	changes	to	the	environments	of	aromatic	amino	acids,	tryptophan	(λ	=	280	nm	–	300	nm),	phenylalanine	(λ	=	250	nm	-	270	nm)	and	tyrosine	(λ	=	270	nm	-	290	nm)	(idem).	Signal	strength	in	the	near-UV	range	is	much	lower	than	far-UV	CD	spectroscopy	and	therefore	requires	higher	concentrations	of	sample;	due	to	the	expense	of	this	and	the	problems	with	protein	aggregation,	far-UV	was	chosen	for	this	work	(idem).		 Heparin	does	not	absorb	light	in	the	visible	and	near-UV	range	(Barbara	Mulloy,	2012).	 Heparin	 has	 far-UV	 absorption	 spectra	 with	 a	 weak	 band	 at	 λ	 =	 234	 nm	corresponding	 to	 the	 unsaturated	 uronic	 acid	 present	 from	 β-elimination	 at	 the	 new	non-reducing	end	 (idem).	 Chemically	 sulphated	polysaccharides	were	 screened	 for	CD	spectra	 and	 appropriate	 controls	were	 conducted	 to	 ensure	 demonstration	 of	 protein	only	structural	changes.		
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	 Circular	dichroism	analysis	software	such	as	BeStSel	(Micsonai	et	al.,	2015)	uses	an	 idealised	 library	 of	 proteins	 with	 known	 structural	 motifs	 to	 determine	 the	secondary	 structure	 of	 the	 protein	 under	 study.	 The	 structural	 characteristics	 are	described	 as	 proportions	 of	 the	 common	 motifs,	 α-helix,	 β-sheet,	 and	 random	 coil,	quantifying	the	protein	secondary	structure	(Figure	14).	
3.1.7	Experimental	aims		 As	 heparin	 and	 other	 GAGs	 are	 highly	 negatively	 charged	 glycopolymers,	 their	influence	 on	 the	 structure	 and	 therefore	 function	 of	 BACE1,	 with	 and	 without	biochemical	tags,	will	be	assessed	to	determine	whether	a	proxy	for	native	BACE1	can	be	 identified	 for	 use	 in	 further	 experiments.	 This	 investigation	 will	 be	 conducted	employing	 far-UV	circular	dichroism	(far-UV	CD)	and	differential	 scanning	 fluorimetry	(DSF).	 Far-UV	 CD	 will	 illustrate	 changes	 to	 the	 protein	 secondary	 structure	 upon	addition	 of	 heparin.	 DSF	 will	 demonstrate	 changes	 in	 the	 protein	 stability	 upon	
	Figure	14:	Characteristic	 far-UV	circular	dichroism	spectra	of	α-helix,	β-sheet,	and	random	coil	secondary	protein	structures.	The	approximate	 fraction	of	 the	structural	motifs	present	 in	 the	protein	 under	 study	 can	 be	 determined	 by	 deconvolution	 of	 the	 resulting	 CD	 spectra	 with	analysis	software	such	as	BeStSel.	Protein	mutation,	 ligand	binding,	and	solution	effects	can	be	studied	by	the	resulting	change	in	structural	characteristics.	
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interaction	with	heparin,	measured	by	the	change	in	melting	temperature	of	the	protein.	All	 protein	 chosen	 for	 structural	 studies	 has	 been	 obtained	 from	manufacturers	with	quoted	batch	enzymic	activity	to	ensure	the	BACE1	enzyme	is	in	an	active	form.			 The	use	of	native,	untagged	BACE1	is	expensive	due	to	the	cost	of	production	for	an	 untagged	 protein	 and	 the	 comparatively	 large	 amount	 of	 protein	 required	 for	structural	 experiments.	DSF	 and	 far-UV	CD	have	 been	 employed	 to	 identify	 structural	changes	associated	with	the	addition	of	the	purification	tags	FLAG-tag,	10-His	tag,	Fc	tag	alongside	native	untagged	BACE1	for	comparison.	The	aim	of	this	study	was	to	identify	which	BACE1	 type	may	be	used	 for	 further	BACE1	structural	 studies	with	a	 library	of	chemically	modified	heparins,	other	GAG	compounds	and	to	aid	in	the	identification	of	‘hit’	chemically	sulphated	GAG	analogues	as	potential	BACE1	inhibitors.			 The	second	aim	of	this	chapter	was	to	demonstrate	changes	in	BACE1	structure	and	 stability,	 to	 gain	 an	 understanding	 as	 to	 how	 PMH	 studied	 by	 Scholefield	 et	 al.	(2003)	and	Patey	et	al.	(2006,	2008),	 inhibit	BACE1	activity	 in	vitro	(Patey	et	al.,	2006,	2008;	Scholefield	et	al.,	2003).		
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3.2	Results	
3.2.1	Far-UV	circular	dichroism	analysis	of	BACE1	and	the	effect	of	heparin		 The	far-UV	spectra	of	native	BACE1,	10-His	tagged	BACE1,	FLAG-tagged	BACE1,	and	Fc-BACE,	 are	 shown	 in	Figures	15	and	16,	 in	 addition	 to	 the	 spectra	obtained	 for	each	BACE1	type	with	UF	PMH,	 in	a	1:1	molar	concentration	ratio.	The	minor	spectral	contribution	of	UF	PMH	has	been	subtracted	from	the	relevant	BACE1	spectra,	to	ensure	accurate	comparison	of	the	change	in	BACE1	secondary	structure	 in	sodium	acetate	at	pH	4.0.	The	physiological	action	of	BACE1	occurs	in	the	endosome	and	the	enzyme	has	been	 shown	 to	 be	most	 active	 at	 pH	4.0,	 representative	 of	 this	 environment.	 The	 flap	region	 covering	 the	 active	 site	 of	 BACE1	 is	 open	 at	 this	 acidic	 pH,	 also	 signifying	 the	enzyme	is	in	the	active	state.		
	 Figure	15A	shows	 the	spectra	of	native	BACE1	with	no	purification	 tag	present	(i.e	native).	The	native	BACE1	spectrum	has	a	trough	at	a	λ	=	221	nm	and	a	peak	at	λ	=	199	nm.	When	UF	PMH	is	included,	the	spectra	is	shifted	into	a	more	negative	ellipticity,	with	peaks	at	λ	=	222	nm	and	λ	=	197	nm,	displaying	a	subtle	wavelength	shift.		
	Figure	15:	Far-UV	circular	dichroism	spectra	of	native	untagged	BACE1	and	FLAG-BACE1	±	UF	PMH	in	50	mM	sodium	acetate	pH	4.0.	A)	(−)	Native	BACE1,	(−)	native	BACE1	with	UF	PMH.	B)	(−)	FLAG-BACE1,	(−)	FLAG-BACE1	with	UF	PMH.		
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	 Figure	15B	 is	 the	 spectra	 of	 FLAG-tagged	BACE1	 in	 the	50	mM	sodium	acetate	buffer	at	pH	4.0.	FLAG-BACE1	has	two	spectral	peaks,	occurring	at	λ	=	217	nm	and	202	nm;	the	spectra	have	similar	features,	with	a	low	peak	at	λ	=	202	nm	and	a	peak	high	at	λ	=	217	nm.		
	 BACE1	with	a	10-His	tag	has	spectral	troughs	at	λ	=	219	nm	and	λ	=	190	nm,	with	a	high	peak	of	λ	=	201	nm	(Figure	16A).	With	the	addition	of	UF	PMH	the	wavelength	of	these	peaks	shifts	to	213	nm	and	188	nm	for	the	troughs,	and	202	nm	for	the	peak.	The	shift	from	219	nm	to	213	nm	is	the	largest	peak	transition	with	the	addition	of	heparin	in	the	four	BACE1	types	tested.	The	CD	spectrum	of	Fc-BACE1	(Figure	16B)	has	a	trough	with	λ	=	227	nm,	with	a	peak	at	λ	=	208	nm.	With	the	addition	of	UF	PMH,	the	low	peak	shifts	 to	 λ	 =	 230	 nm,	 but	 looses	 the	 clear	 peak	maxima,	 flattening	 the	 spectra	 at	 this	wavelength.	The	208	nm	peak	shifts	to	205	nm	with	the	addition	of	UF	PMH.			 BeStSel	structural	analysis	of	the	CD	spectra	was	conducted	to	quantify	changes	to	 the	BACE1	secondary	 structure	due	 to	 the	 tag	present	 and	 the	addition	of	UF	PMH	(Table	4).	Native	BACE1	comprised	of	35%	antiparallel	β-sheets,	and	20%	turn	regions.	This	proportion	changed	with	the	addition	of	UF	PMH,	to	31%	antiparallel	β-sheets	and	21%	 turn	 regions.	 The	 proportion	 of	 structure	 identified	 as	 ‘other’	 increased	 with	
	Figure	16:	 Far-UV	 circular	 dichroism	 spectra	 of	 10-His	BACE1	and	Fc-BACE1	±	UF	PMH	 in	50	mM	 sodium	acetate	 pH	4.0.	A)	 (−)	 10-His	BACE1,	 (−)	 10-His	BACE1	with	UF	PMH.	B)	 (−)	 Fc-BACE1,	(−)	Fc-BACE1	with	UF	PMH.		
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heparin	 addition,	 suggesting	 a	 move	 from	 ordered	 structure	 to	 a	 more	 disordered	assembly.		
	 Fc-BACE1	comprised	of	28%	antiparallel	β-sheets	and	23%	turn	regions,	which	translated	 to	35%	antiparallel	β-sheets	 and	20%	 turn	 regions	with	 the	addition	of	UF	PMH.	 The	 proportion	 of	 ‘other’	 regions,	 of	 undetermined	 secondary	 structure	 was	reduced	 in	 Fc-BACE1	 with	 the	 addition	 of	 heparin,	 suggesting	 a	 novel	 action	 to	 the	glycosaminoglycan	 interaction,	 which	 is	 not	 present	 in	 the	 native,	 untagged	 BACE1	protein	binding	to	heparin.			 FLAG-BACE1	contains	32%	antiparallel	β-sheets	and	20%	turn	regions,	with	the	addition	 of	 UF	 PMH	 reducing	 the	 proportion	 of	 antiparallel	 β-sheets	 to	 28%.	 The	addition	 of	 heparin	 does	 not	 change	 the	 levels	 of	 turn	 region,	 but	 does	 increase	 the	disordered	protein	structure	labelled	‘other’	by	2%.			 10-His	 tagged	 BACE1	 has	 antiparallel	 β-sheet,	 which	 constitutes	 34%	 of	 the	protein	 structure	 and	 20%	 turn	 regions.	 The	 inclusion	 of	 heparin	 into	 this	 CD	experiment	causes	a	change	in	antiparallel	β-sheet	proportion	to	33%,	and	a	increase	in	‘other’	regions	but	no	change	to	the	proportion	of	turn	regions.			 Native	BACE1	and	FLAG-BACE1	show	similar	secondary	structural	changes	with	the	addition	of	UF	PMH,	displaying	a	4%	reduction	 in	antiparallel	 β-sheets,	negligable	
Table	 4:	 Far-UV	 circular	 dichroism	 spectra	 analysed	 by	 BeStSel	 software,	 quantification	 of	antiparallel	β-sheets	and	turn	regions	in	BACE1	secondary	structure	±	UF	PMH.		
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change	 to	 the	 turn	 region	 component	 and	 a	 increase	 in	 the	 undefinable	 secondary	structure	characteristics	identified	as	‘other’	in	BeSeSel	analysis.			 Interestingly,	 the	 action	 of	 UF	 PMH	 on	 the	 Fc	 tagged	 BACE1	 increases	 the	proportion	of	antiparallel	β-sheet,	which	does	not	occur	in	the	other	BACE1	types	tested.	This	increase	is	due	to	the	increase	in	right-twisted	antiparallel	β-sheet	from	9%	to	17%	with	 heparin	 present.	 As	 this	 change	 is	 not	 seen	 in	 the	 other	BACE1	 types,	 it	may	 be	caused	by	the	presence	of	the	relatively	large	Fc	purification	tag;	this	is	investigated	in	Chapter	4.		
3.2.2	Differential	scanning	fluorimetry	of	BACE1	types	and	the	effect	of	heparin		 Differential	scanning	fluorimetry	(DSF)	is	a	method	for	the	analysing	the	stability	of	 a	 protein	 (with	 or	 without	 a	 ligand)	 under	 defined	 conditions	 using	 thermal	degradation	to	obtain	the	protein	melting	point	(Tm).	Here,	DSF	was	used	to	determine	whether	 the	 Tm,	 and	 therefore	 a	 measure	 of	 thermal	 stability	 of	 the	 BACE1	 protein,	changed	 upon	 inclusion	 of	 the	 known	 BACE1	 modulator,	 heparin.	 The	 known	hydroxyethylamine	 containing	 inhibitor	 IV	 (Figure	 17)	 was	 used	 to	 demonstrate	 the	effect	of	potent	inhibitor	binding	on	secondary	structure	of	BACE1.		
	 Figure	18A	shows	the	first	derivative	of	native,	untagged	human	BACE1	in	50	mM	sodium	acetate	at	pH	4.0	in	order	to	demonstrate	the	Tm	as	the	peak	maxima.	The	Tm	of	native	BACE1	with	no	ligand	present	in	the	pH	4.0	conditions	is	45.80	°C,	and	with	the	addition	 of	 3.0	 μM	 of	 inhibitor	 IV,	 the	 protein	 experiences	 no	 change	 in	 Tm.	 At	 this	
	Figure	17:	Chemical	structure	of	hydroxyethylamine	containing	BACE1	inhibitor	IV.	
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inhibitor	 IV	 concentration	 BACE1	 is	 inhibited	 (Stachel	 et	 al.,	 2004),	 therefore	 the	concentration	chosen	for	these	experiments	is	indicative	of	the	structural	change	upon	inhibitor	binding	and	action.	The	addition	of	heparin	at	 the	same	concentration	of	3.0	μM	caused	the	reduction	in	the	Tm	of	BACE1	to	38.78	°C,	suggesting	a	stability	change	that	causes	an	increase	in	BACE1	sensitivity	to	thermal	denaturation.		
	 The	thermal	denaturation	of	FLAG-BACE1	is	similar	to	the	native	BACE1,	with	a	Tm	 of	 45.38	 °C,	 but	 is	 slightly	 increased	with	 the	 addition	 of	 inhibitor	 IV	 to	 46.14	 °C	(Figure	 18B).	 The	 process	 of	 measuring	 the	 fluorescence	 of	 the	 hydrophobic	 region	binding	fluorophore	occurs	at	 temperature	 increments	of	0.5	°C,	with	the	temperature	error	of	the	RT-PCR	machine	of	±	0.19	°C.	Therefore,	Tm	changes	greater	than	0.5	°C	are	deemed	 meaningful.	 	 The	 addition	 of	 UF	 PMH	 causes	 the	 Tm	 of	 FLAG-BACE1	 to	 be	reduced,	 as	with	 native	BACE1,	 to	 39.95	 °C,	 similarly	 suggesting	 reduction	 in	 thermal	stability.			 10-His	tagged	BACE1	has	a	reduced	Tm	than	native	and	FLAG-tagged	BACE1.	The	Tm	of	this	BACE1	form	is	43.69	°C	(Figure	19B).	The	inclusion	of	inhibitor	IV	does	not	modify	 the	 Tm	 of	 10-His	 BACE1	 but	 UF	 PMH	 addition	 causes	 the	 reduction	 of	 Tm	 to	40.52	 °C.	 This	 suggests	 the	 addition	 of	 10-His	 enables	 BACE1	 to	 resist	 the	 structural	
	Figure	18:	First	derivative	melt	curve	of	differential	scanning	fluorimetry	data	of	native	BACE1	±	UF	PMH	and	 inhibitor	 IV	 in	50	mM	sodium	acetate	pH	4.0.	 	A)	 (−)	Native	BACE1	(−)	native	BACE1	with	inhibitor	IV,	(−)	native	BACE1	with	UF	PMH.	B)	(−)	FLAG-BACE1	(−)	FLAG-BACE1	with	inhibitor	IV,	(−)	FLAG-BACE1	with	UF	PMH.		
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change	caused	by	the	addition	of	heparin	seen	with	both	native	and	FLAG-BACE1	seen	above.		
	 Fc-tagged	BACE1	has	a	Tm	of	44.24	°C,	which	does	not	change	with	the	addition	of	ligand	inhibitor	IV	(Figure	19B).	However,	the	addition	of	UF	PMH	causes	the	Tm	of	Fc-BACE1	to	drop	to	35.35	°C.	This	8.9	°C	temperature	reduction	is	the	 largest	seen	in	the	 four	 types	 of	 BACE1	 tested,	 suggesting	 an	 interaction	 caused	 by	 the	 Fc	 region,	 Fc	specifically	bound	to	BACE1	or	a	combination	of	these.		
	Figure	19:	First	derivative	melt	curve	of	differential	scanning	fluorimetry	data	of	10-His	BACE1	and	Fc-BACE1	±	UF	PMH	and	inhibitor	IV	in	50	mM	sodium	acetate	pH	4.0.	A)	(−)	10-His	BACE1.	(−)	 10-His	BACE1	with	 inhibitor	 IV,	 (−)	10-His	BACE1	with	UF	PMH.	B)	(−)	Fc-BACE1.	 (−)	Fc-BACE1	with	inhibitor	IV,	(−)	Fc-BACE1	with	UF	PMH.		
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3.3	Discussion		 The	far-UV	spectra	of	native	BACE1	is	most	similar	to	that	of	FLAG-tagged	BACE1.	The	peak	positioned	at	λ	=	221	nm	in	native	BACE1	shifts	by	λ	=	1	nm	with	the	addition	of	UF	PMH,	and	the	trough	by	λ	=	2	nm.	Of	the	three	purification	tagged	BACE1	proteins,	FLAG-BACE1	has	more	similar	spectra	to	native,	with	no	change	occurring	at	the	trough	and	a	λ	=	2	nm	change	at	the	peak.	Analysis	of	the	secondary	structural	characteristics	of	the	CD	spectra	for	both	types	of	BACE1	enzyme	shows	similar	structural	changes	with	the	addition	of	UF	PMH.	Heparin	causes	the	reduction	in	antiparallel	β-sheets	by	4%	in	both	 protein	 types,	 and	 a	 similar	 increase	 of	 turn	 regions.	 The	 level	 of	 unordered	 or	indefinable	disordered	protein	regions	increases	in	both	native	and	FLAG-tagged	BACE1	types.		 Cimmperman	et	al.	 (2008)	demonstrates	 ligand	binding	 to	most	protein	 causes	an	 increase	 in	 thermal	 stability	 (Tm)	 when	 detected	 by	 thermal	 calorimetry	(Cimmperman	et	al.,	2008).	This	increase	in	Tm	is	due	to	ligand-binding	stabilising	the	protein	 structure	 (idem).	 One	 of	 the	 main	 methods	 of	 drug	 candidate	 screening	 is	thermal	 shift	 assay	 (ThermoFluor)	 which	 enables	 high	 throughput	 screening	 of	candidate	 libraries	 (Pantoliano	 et	 al.,	 2001).	 This	 method	 identifies	 high	 affinity	stabilising	ligands,	which	increase	the	Tm	of	the	target	protein,	as	most	ligands	stabilise	protein	when	bound	(idem).			 Ligand	binding	causes	protein	unfolding	or	binds	preferentially	 to	 the	unfolded	state	of	a	protein	and	causing	a	reduction	in	thermal	stability	(Tm)	(Cimmperman	et	al.,	2008).	Ligand	binding	was	revealed	to	contribute	to	the	destabilisation	of	target	protein	(idem).	 Heparin	 binding	 to	 native	 BACE1	 demonstrated	 a	 large	 Tm	 shift	 to	 lower	temperatures,	 suggesting	 either	 heparin	 bound	 the	 unfolded	 protein	 preferentially,	
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causing	a	destabilisation	or	heparin	bound	to	the	unfolded	state,	halting	normal	protein	folding	equlibria.	Hayley	et	al.	 (2009)	demonstrated	BACE1	 in	 the	 inactive	 form	at	pH	7.4	 was	 structurally	 more	 stable	 than	 the	 active	 form	 at	 pH	 4.8	 (Hayley,	 Perspicace,	Schulthess,	 &	 Seelig,	 2009).	 BACE1	 is	 less-stable	 at	 low	 pH,	 signifying	 structural	equilibrium	of	the	protein	is	shifted	toward	the	unfolded	state	at	this	pH	(Robertson	&	Murphy,	 1997).	 Therefore,	 this	 interaction	 could	 be	 described	 by	 heparin	 binding	preferentially	 to	 BACE1	 in	 an	 more	 unfolded	 state,	 causing	 destabilisation	 and	 a	reduction	in	Tm.			 GAG	 interactions	with	other	proteases,	 such	as	 the	 cathepsin	 family,	have	been	shown	 to	 occur	 through	 destabilisation	 of	 the	 pro-domain,	 but	 in	 these	 cases	 the	destabilisation	causes	a	stimulation	of	enzyme	activity	(Caglic,	Pungercar,	Pejler,	Turk,	&	Turk,	2007).	Beckman	et	al.	(2006)	also	demonstrated	a	heparin-binding	site	in	the	pro-domain	 of	 BACE1	 (Beckman	 et	 al.,	 2006)	with	 the	 same	 group	 investigating	 the	 GAG	structural	 requirements	 for	 this	 interaction	 (Klaver	 et	 al.,	 2010).	However,	 this	 group	found	heparin	has	 stimulating	 effect	 on	BACE1	 at	 low	 concentrations	 (1 μg/ml),	with	inhibition	occurring	only	at	 the	high	concentrations	 tested	(100 μg/ml).	Scholefield	et	
al.	 (2003)	 and	 Patey	 et	al.	 (2006)	 only	 identify	 heparin/	HS	 and	modified	 heparin	 as	inhibitors	of	BACE1	(Patey	et	al.,	2006;	Scholefield	et	al.,	2003).			 DSF	demonstrates	a	similar	melting	temperature	for	the	native	and	FLAG-tagged	BACE1	proteins.	 The	 addition	 of	UF	PMH	 causes	 a	 large	 shift	 in	Tm	 to	 a	 lower	Tm	of	38.78	 °C	 in	 native	 BACE1	 and	 39.95	 °C	 in	 FLAG-BACE1.	 The	 action	 of	 the	hydroxyethylene	containing	inhibitor	IV	is	also	similar	with	both	proteins,	with	Tm	of	≈	46	°C	in	both	FLAG-tagged	and	native	BACE1.	This	suggests	the	small	size	of	the	FLAG	tag,	being	8	amino	acids	in	length	and	hydrophilic	in	nature,	does	not	alter	the	structure	of	 BACE1	 sufficiently,	 or	 display	 an	 interaction	 with	 the	 UF	 PMH	 added,	 to	 cause	 a	
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change	 in	 both	 secondary	 structure	 and	 resulting	melting	 temperature.	 The	 similarity	between	 native	 BACE1	melt	 curves,	with	 and	without	 the	 added	 ligands	 suggests	 the	FLAG-BACE1	can	be	used	as	a	more	economical	native	BACE1	proxy,	when	conducting	studies	 including	 heparin	 and	 heparin	 derivatives.	 Therefore,	 in	 the	 activity	 studies	required	to	detect	new	glycosaminoglycan-like	inhibitors	of	BACE1,	FLAG-tagged	BACE1	will	be	used	for	the	large	library	screening	required	to	identify	hit	inhibitor	compounds	in	Chapter	8.			 The	10-His	 tagged	BACE1	displays	a	 resistance	 to	 the	destabilising	effect	of	UF	PMH	in	these	thermal	stability	experiments.	A	change	is	seen	in	the	far-UV	CD	spectra	of	10-His	 BACE1	when	 challenged	with	 UF	 PMH,	 suggesting	 heparin	 binding	 still	 occurs	causing	a	secondary	structural	change	to	the	protein	conformation.	This	may	suggest	the	inclusion	 of	 this	 type	 of	 positively	 charged	 tag	 affords	 the	 protein	 resistance	 to	 the	destabilisation	caused	by	heparin	binding	to	the	unfolded	state	at	pH	4.0.	This	could	be	caused	by	the	interaction	with	the	positively	charged	10-His	tag	and	negatively	charged	heparin,	 rather	 than	 the	 BACE1-heparin	 interaction,	 seen	with	 other	 types	 of	 BACE1.	Beckman	et	al.	(2006)	showed	the	BACE1	stimulation	activity	of	heparin	did	not	occur	due	 to	 the	presence	of	 the	10-His	 tag	on	BACE1,	 and	used	 this	 form	 for	FRET	activity	assays	 (Beckman	 et	 al.,	 2006),	 but	 this	 does	 not	 conclude	 whether	 a	 structural	 or	destabilisation	event	occurs	with	10-His	tag.			 Fc-BACE1	 demonstrated	 the	 greatest	 change	 in	 thermal	 destabilisation	 and	 in	secondary	structure	with	the	addition	of	UF	PMH.	Uniewicz	et	al.	(2014)	used	IgG	Fc	as	a	scaffold	 to	 dimerise	 the	 membrane	 protein	 neuropilin-1,	 to	 characterise	 the	 heparin	binding	 interactions	of	 this	protein	 (Uniewicz	et	al.,	2014).	Heparin	binding	regions	of	the	IgG	Fc	region	of	the	recombinant	protein	were	seen,	however,	the	optical	biosensor	and	DSF	experimentation	did	not	highlight	any	heparin	interaction	between	the	IgG	Fc	
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and	heparin	in	pH	7.4	PBS	(idem).	The	weak	heparin	binding	was	thought	to	be	due	to	the	neuropilin-1	acting	as	a	scaffold	to	 form	weak	heparin	binding	sites	on	IgG	Fc	and	the	 other	 b1-b2	domain	 outside	 of	 the	 neuropilin-1	moiety	 (idem).	West	et	al.	 (2005)	also	worked	with	 an	Fc-fusion	neuropilin-1	 and	determined	no	binding	was	observed	between	IgG	Fc	and	heparin	in	a	resonant	mirror	biosensor	(IAsys)	experiment	(West	et	al.,	 2005).	However,	 the	DSF	data	 shown	here	 demonstrates	 a	 thermal	 destabilisation	event	stronger	in	Fc-BACE1	than	in	native	BACE1,	suggesting	some	aspect	of	the	fusion	protein	 causes	 a	 greater	 reduction	 in	 the	 Tm.	 The	 far-UV	 CD	 spectrum	 of	 Fc-BACE1	shows	an	increase	in	antiparallel	β-sheets	and	a	reduction	in	‘other’	non-specific	regions	as	identified	in	BeStSel	CD	analysis	software.			 Investigation	 into	 the	 role	 of	 the	 Fc	 part	 of	 this	 fusion	 BACE1	 protein	 will	 be	made	in	the	next	chapter	to	determine	if	heparin	has	a	direct	effect	on	the	IgG	Fc	region	in	 the	 conditions	 required	 for	 BACE1	 enzyme	 activity	 analysis	 (Chapter	 4).	 Later,	 the	specific	structural	requirements	for	the	heparin/HS	interaction	with	native	BACE1	will	be	 identified	 (Chapter	 7)	 and	 the	 activity	 of	 PMH	 and	 BLH	 will	 be	 demonstrated,	 to	accept	or	refute	the	action	of	heparin	as	an	inhibitor	or	stimulator	of	BACE1	activity	at	different	concentrations,	using	FLAG-BACE1	(Chapter	8).			 	
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Chapter	4:	Investigations	into	the	interaction	between	IgG	Fc	
and	glycosaminoglycans
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4.1	Introduction	
4.1.1	Humoral	immunity	and	the	antibody		 The	mammalian	 immune	system	can	be	broadly	characterised	 into	2	pathways,	encompassing	the	initial	response	to	pathogens	through	innate	immunity,	and	the	more	specific	 and	 enduring,	 adaptive	 immunity.	 Innate	 immunity	 utilises	 phagocytes,	examples	 of	which	 are	 neutrophils	 and	macrophages,	 to	 remove	pathogens,	 alongside	soluble	 molecules	 with	 pattern	 recognition	 capabilities,	 e.g	 INF	 and	 complement.	Antigen	 stimulated	 B-lymphocytes	 proliferate	 and	 differentiate	 into	 plasma	 cells	 and	memory	 cells.	 Antibodies	 produced	 by	 plasma	 cells	 mediate	 adaptive	 immunity,	 also	known	 as	 humoral	 immunity,	 with	 memory	 cells	 retained	 ready	 for	 future	 immune	events.	Each	antibody	is	highly	specific	for	an	antigen,	with	antibodies	produced	for	each	possible	 antigen	 encountered	 throughout	 the	 lifetime	of	 an	 individual.	 The	number	of	specific	 antibodies	 is	 thought	 to	 reach	 109	 (limited	 by	 B-lymphocyte	 number);	 this	library	of	immunoglobulins	produced	is	generally	refered	to	as	the	antibody	repertoire	(Parham,	2015).	Each	B-lymphocyte	displays	a	specific	membrane	bound	antibody,	upon	clonal	selection	with	the	corresponding	antigen,	the	B-cell	proliferates	and	differentiates	into	antibody	producing	plasma	cells	and	memory	cells	(Nossal	&	Lederberg,	1958).	The	antibody	 is	 commonly	presented	 to	by	helper	TFH	 lymphocytes	 in	 the	 lymph	nodes	or	spleen	(idem).		
4.1.2	Antibody	structure		 The	 antibody	 molecule	 is	 composed	 of	 four	 polypeptide	 chains;	 two	 identical	heavy	chains	(H)	of	approximately	55	kDa	(≈	450	residues)	or	more	and	two	identical	light	 chains	 (L)	 of	 approximately	 22	 kDa	 (≈	 220	 residues)	 (Ionescu,	 Vlasak,	 Price,	 &	
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Kirchmeier,	 2008).	 These	 chains	 fold	 into	 domains	 of	 ≈	 110	 residues	 each	 forming	 a	distinct	β-sheet	fold	known	as	the	immunoglobulin	domain	(Ig	domain)	with	light	chains	being	bound	to	heavy	chains	through	salt	bridges,	hydrogen	bonding,	and	hydrophobic	interactions	 (Brown,	 Newcomb,	 &	 Ishizaka,	 1970).	 Heavy	 chains	 are	 bound	 through	disulphide	bonding,	creating	a	‘dimer	of	dimers’	(idem).	Each	antibody	domain	structure	comprising	 of	 seven	 to	 nine	 anti-parallel	 β-strands	 in	 a	 pleated	 sheet	 structure,	 that	form	 an	 overall	 β-sandwich	 structure	 (Bork,	 Holm,	 &	 Sander,	 1994).	 The	 tertiary	structure	of	the	antibody	is	generated	from	the	β-sheet	forming	globular	domains.	The	heavy	and	 light	chain	globular	regions	 interact	at	 the	 tertiary	 level,	which	allows	both	simultaneous	antigen	binding	and	effector	function.		
	 The	initial	110	amino	acid	residues	at	the	N-terminal	of	both	the	heavy	and	light	chains	contribute	to	the	variable	(V)	region	of	the	antibody	(VL	and	VH)	(Figure	20).	This	variable	region	functions	as	the	antigen	recognition	and	binding	site	and	is	known	as	the	complementarity-determining	 region	 (CDR)	 (Ionescu	 et	 al.,	 2008).	 The	 second	 region	
	Figure	 20:	 Schematic	 of	 an	 IgG	 antibody,	 with	 the	 VH/VL	 and	 the	 CH1/CL	 regions	 cleaved	removing	the	hinge	region	constitutes	the	Fab.	VH/VL	and	the	CH1/CL	regions	cleaved	including	the	hinge	region	constitutes	the	F(ab’)2.	CH2	and	CH3	region	cleaved	including	the	hinge	region	constitutes	the	Fc.	Figure	modified	from	(Goldsby.R.A,	2000).	
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forms	the	last	Ig	domain	of	the	Fab	region,	with	the	first	constant	(C)	domain	of	the	light	chain	(CL)	and	the	first	constant	domain	of	the	heavy	chain	(CH1)	(idem).	Light	chains	in	humans	exist	in	2	forms,	κ	and	λ,	with	≈	60%	of	light	chains	being	κ,	whereas	in	mice	≈	95%	of	the	chains	are	κ	(Parham,	2015).	Each	antibody	contains	soley	κ	or	λ	light	chain	(idem).	Subtypes	of	λ,	characterised	by	subtle	changes	in	sequence	are	subdivided	into	λ1,	λ2,	λ3	and	λ4	(idem).		 Upon	 papain	 digestion	 the	 antibody	molecule	 is	 cleaved	 at	 the	 hinge	 region	 to	yield	 the	 fragment	 antigen	 binding	 (Fab)	 region	 (45	 kDa)	 and	 fragment	 crystalizable	(Fc)	region	(50	kDa)	(Parham,	2015).	In	humans,	the	Fc	region	is	formed	by	a	dimer	of	identical	 constant	 regions	 CH2	 and	 CH3.	 Υ,	 δ,	 α	 heavy	 chains	 contain	 different	 amino	acid	sequences	forming	CH2	and	CH3,	with	an	additional	heavy	chain	region,	CH4,	in	μ	and	ε	heavy	chains	 (idem).	The	 type	of	heavy	chain	present	denotes	antibody	 isotype;	IgD	contains	δ,	IgA	contains	α,	IgG	contains	Υ,	IgM	contains	μ,	and	IgE	contains	ε	heavy	chains	(idem).	There	are	2	subtypes	of	IgA	α1	and	α2	(IgA1	and	IgA2),	four	subtypes	of	Υ1,	Υ2,	Υ3	and	Υ4	(IgG1,	IgG2,	IgG3	and	IgG4)	(idem).			 The	 CH2	contains	 a	 N-linked	 glycan	 at	 an	 asparagine	 residue.	 This	 N-glycan	 is	predominantly	a	diantennary	complex-type	N-glycan,	comprised	of	a	α-1,6-fucose,	0-	to	2-	galactose	residues,	1	or	2	α-2,6-sialic	acids	with	small	amounts	of	branching	GlcNAc	(Stadlmann,	 Pabst,	 Kolarich,	 Kunert,	 &	 Altmann,	 2008).	 Recombinantly	 produced	antibodies	 yield	 simpler	 N-glycan	 structures,	 often	 omitting	 fucosylated	 residues	 and	branching	 GlcNAc	 (idem).	 Human	 glycosylation	 patterns	 require	 a	 group	 of	 complex	enzymes	 not	 present	 in	 cells	 such	 as	 murine	 cell	 lines	 NS0	 and	 Sp2/0,	 utilised	 in	recombinant	anibody	production	(Hossler,	Khattak,	&	Li,	2009).	The	position	of	 the	N-glycan	 leads	to	a	distended	globular	structure	at	 the	CH2	regions,	which	allows	access	for	 complement	 and	 other	 antibody	 binding	 molecules	 (Stadlmann	 et	 al.,	 2008).	
	 95	
Digestion	with	pepsin	liberates	an	alternate	active	fragment,	F(ab’)2,	with	the	remaining	fragment	digested	to	smaller	peptides	(Parham,	2015).		
4.1.3	The	role	of	Fc	in	complement	activation		 The	 complement	 system	 is	 an	 enzyme	 cascade	 of	 plasma	 proteins	 that	 causes	opsonisation	 of	 pathogens	 and	 inflammation	 (Janeway	 C.A	 2001).	 A	 small	 number	 of	activated	 complement	 enzymes	 proteolytically	 cleave	 the	 zymogen	 targets,	 which	themselves	become	active	complement	enzymes	(with	a	different	zymogen	target),	in	a	cascade	 arrangement	 (idem).	 Each	 enzyme	activation	 amplifies	 the	 original	 activation,	rapidly	 triggering	a	 large-scale	 immune	response	 (idem).	There	are	 three	mechanisms	by	which	 complement	 can	 be	 activated:	 the	 classical	 pathway,	mannan-binding	 lectin	pathway,	and	the	alternative	pathway	(idem).		 The	classical	pathway	of	complement	can	be	activated	through	the	direct	binding	of	 protein	 complex	 C1q,	 to	 a	 bacterial	 surface,	 or	 through	 more	 specific	 forms	 of	immunoglobulin	binding	(Karsten	&	Kohl,	2012).	The	initial	immune	effector	molecules,	IgM,	along	with	IgG3,	are	highly	effective	at	activating	the	major	innate	mechanism	for	effector	cell	 recruitment	 (idem).	Activation	of	 the	complement	cascade	occurs	 through	the	binding	of	globular	heads	of	C1q	to	the	antigen	activated	IgM	pentamer,	at	the	CH2	domain	of	 the	Fc	regions	of	each	antibody	(Duncan	&	Winter,	1988).	C1q	binds	 to	 the	CH2	residues	at	Glu318,	Lys320	and	Lys322,	with	these	residues	highly	conserved	in	IgG	subclasses	(Duncan	&	Winter,	1988).	The	relative	potency	of	C1q	activation	by	the	IgG	subclasses	is	thought	to	be	due	to	the	differing	hinge	region	lengths	between	Fc	and	Fab	regions.	IgG1	and	IgG3,	the	most	potent	of	IgG	complement	activators,	have	longer	hinge	regions	 allowing	 greater	 Fab/Fc	 region	 flexibility	 and	 therefore	 accessibility	 for	 C1q	globular	heads	(Karsten	&	Kohl,	2012).	However,	a	modified	IgG3	with	the	shorter	and	
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more	 rigid	 hinge	 region	 of	 IgG4	 displays	 high	 potency	 in	 complement	 activation	(Norderhaug	et	al.,	1991)	and	modified	IgG4	with	the	longer	more	flexible	hinge	region	from	 IgG3	 possesses	 no	 detectable	 activation	 of	 complement	 (Tan,	 Shopes,	 Oi,	 &	Morrison,	1990)	(Karsten	&	Kohl,	2012).	Reduction	of	the	disulphide	bridge	between	the	Fc	region	dimer	also	negated	complement	activation	(Schur	&	Christian,	1964).		 Variation	 of	 the	 amino	 acid	 sequence	 of	 CH2	 domain	 in	 IgG4	 to	 an	 IgG1	 CH2	domain	created	a	mutant	nearly	as	functional	as	IgG1	(Greenwood,	Clark,	&	Waldmann,	1993).	 Other	 amino	 acid	 modifications	 have	 been	 assessed	 for	 contributions	 to	 the	subclass	variation	displayed,	the	study	by	Tao	et	al.	1993	suggests	other	residues	than	positions	318,	320	and	322	can	modify	the	potency	of	complement	response	to	IgG	(Tao,	Smith,	&	Morrison,	1993).	Furthermore,	a	functional	and	dimerised	CH3	domain	of	IgG	is	required	 for	optimal	 complement	 activation,	 irrespective	of	 the	non-binding	nature	of	this	 immunoglobulin	 region	 (Utsumi,	 Okada,	 Udaka,	 &	 Amano,	 1985).	 These	 varied	amino	acid	 sequence	modifications	 suggest	neither	 the	orientation	of	CH	domains	nor	the	 functional	 orientation	 of	 the	 C1q	 binding	 site	 alone	 are	 the	 sole	 reason	 for	 the	variation	in	subclass	complement	potency	(Karsten	&	Kohl,	2012).			 Residues	on	the	corresponding	heavy	chain	region	in	IgM,	CH3,	that	are	required	for	 C1q	binding	 are	Asp432,	 Pro434,	 Pro436,	Asp356	 and	Asp417	 (Arya	 et	 al.,	 1994),	which	demonstrates	that	the	binding	site	for	C1q	is	not	identical	in	IgG	and	IgM	(Karsten	&	Kohl,	2012).	Karsten	and	Köhl	 (2012)	state	 that	 several	 features	 in	 the	C1q	binding	regions	 of	 IgG	 and	 IgM	 promote	 the	 successful	 activation	 of	 complement	 through	 the	common	 pathway	 (idem),	 suggesting	 the	 modification	 to	 the	 Fc	 structure,	 through	disulphide	 reduction,	 hinge	 region	 modification	 or	 CH	 residue	 changes	 will	 alter	 the	ability	of	the	immunoglobulin	to	activate	complement	effectively.		
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	 C1q	binding	has	10,000-fold	lower	affinity	to	monomeric	IgG	than	the	binding	of	immune	 complexed	 IgG	 (Burton	 &	 Woof,	 1992).	 Upon	 activation,	 a	 conformational	change	 in	 the	 C1q	 bound	 C1r2:C1s2	 proenzyme	 complex	 causes	 autolysis	 of	 C1r;	 this	continues	 the	 further	 downstream	 activations	 (Karsten	&	Kohl,	 2012).	 Ultimately,	 the	coating	 of	 the	 pathogen	 with	 C3b	 stimulates	 either	 neutrophil	 or	 macrophage	phagocytosis	through	the	CR1	receptor,	or	 further	complement	progress	to	membrane	attack	complex	formation	and	cell	membrane	rupture	(Parham,	2015).	The	activation	of	complement	in	this	manner	is	an	example	of	adaptive	immunity	lending	specificity,	with	innate	 immunity	 contributing	 strength	 to	 the	 host	 response	 to	 an	 invading	 pathogen	(idem).	
4.1.4	Fc	receptors		 The	 Fc	 receptors	 are	 a	 group	 of	 surface	 membrane	 molecules	 that	 recognise	homologous	 or	 heterologous	 immunoglobulin	 through	 the	 Fc	 region,	 mediating	biological	 function	 (Unkeless,	 Scigliano,	 &	 Freedman,	 1988).	 Fc	 receptors	 (FcR)	 are	involved	in	a	wide	range	of	critical	activities,	including	receptor	mediated	endocytosis	of	antigen:antibody	complexes,	antibody	dependent	cell-mediated	cytotoxicity	and	ligand-triggered	transmission	across	plasma	membranes	(Ravetch	&	Kinet,	1991).	Fc	receptors	are	 found	 on	 the	 surface	 of	 immune	 cells	 e.g	 macrophages	 and	 neutrophils	 (Dickler,	1976),	on	cells	e.g	hepatocytes	and	brain	parenchyma	(Nyland	&	Nilsen,	1982),	and	 in	cells	that	do	not	express	FcR	e.g	fibroblasts	post	viral	infection	(Para,	Baucke,	&	Spear,	1980).	 The	 wide	 variety	 of	 cellular	 responses	 caused	 by	 antibody/immune	 complex	binding	can	be	attributed	to	FcR	structural	heterogeneity	(Ravetch	&	Kinet,	1991).	The	Fc	 region	 binding	 domains	 of	 these	 FcR	 have	 minimal	 structural	 heterogeneity,	 but	
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differ	 in	 the	 transmembrane	 and	 intracellular	domain	 structures,	 eliciting	 a	 variety	 of	distinct	cellular	responses.		 FcR	 mediated	 endocytosis	 of	 antibody	 or	 antibody	 complex	 occurs	 through	pinocytosis	 of	 soluble	 complexes	 or	 phagocytosis	 of	 larger	 particles	 by	 natural	 killer	(NK)	cells	and	macrophages	(Ravetch	&	Kinet,	1991).	IgG1	and	IgG3	opsonized	antigen	complexes	are	phagocytosed	by	macrophages	through	interaction	with	the	high	affinity	FcγRI	 (CD64)	 on	 the	 cell	 surface,	 which	 deliver	 the	 complexes	 to	 endosome	 and	ultimately	 lysosomal	 compartments	 (Ravetch	 &	 Kinet,	 1991).	 This	 IgG:FcγRI	 binding	occurs	 at	 the	 lower	 hinge	 region	 of	 CH2	 in	 the	 Fc	 region	 of	 IgG	 (Parham,	 2015).	FcγRI:IgG	 binding	 is	 unique	 among	 the	 FcR	 as	 it	 can	 occur	 in	 the	 absence	 of	 antigen;	macrophages,	 dendritic	 cells	 and	 neutrophils	 utilise	 this	 receptor	 binding	 to	 trap	antigenic	molecules	acting	as	antigen	presenting	cells	 (idem).	Two	 lower	affinity	FcγR,	FcγRII	 (CD32)	 and	 FcγRIII	 (CD16)	 contain	 two	 Ig-like	 domains,	 rather	 than	 three	 in	FcγRI	(idem).	These	lower	affinity	receptors	require	multiple	cross-linked	IgG	binding	to	antigen	prior	to	activation.	This	enables	the	more	specific	antibody	response	to	antigen,	which	triggers	opsonization,	and	stops	non-specific	IgG	blocking	(idem).		 FcγRIII	is	the	only	receptor	present	on	the	cell	surface	of	NK	cells	and	is	utilised	in	the	detection	of	IgG1	and	IgG3	antibodies	specific	for	cell	surface	antigens.	FcγRIII:IgG	binding	on	NK	cells	triggers	antibody	dependant	cell-mediated	cytotoxicity	through	the	release	 of	 lytic	 granuals	 from	 the	NK	 cell,	 causing	 apoptosis	 of	 the	 IgG-opsonized	 cell	(idem).			 IgE	 is	 found	bound	 to	FcεRI	 on	mast	 cells,	 basophils	 and	 activated	 eosinophils.	Upon	 binding	 to	 the	 antigen,	 the	 IgE:FcεRI	 complex	 activates	 a	 transmembrane	signalling	 event	 to	 release	 the	 contents	 of	 inflammatory	 granules,	 which	 include	
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histamine,	 cytokines,	 proteolytic	 enzymes,	 and	 reactive	 oxygen	 species,	 to	 defend	parasite	invasion.			 The	 IgG	 receptor	 FcRn	 is	 thought	 to	 be	 involved	 with	 maintaining	 the	 high	concentration	of	IgG	in	extracellular	space	through	the	high	affinity	binding	of	two	FcRn	on	the	surface	of	epithelial	cells	to	one	IgG	molecule	in	the	serum,	transcytosis	releases	the	IgG	on	the	basolateral	cell	surface,	increasing	IgG	concentration.	FcRn	acts	to	protect	circulating	IgG	from	normal	plasma	protein	degradation,	explaining	the	increased	half-life	 of	 this	 antibody	 isotype	 (Pyzik,	 Rath,	 Lencer,	 Baker,	&	Blumberg,	 2015).	 FcRn	 are	involved	 in	 transport	 of	 maternal	 IgG	 through	 the	 human	 placental	 membranes,	providing	neonatal	immunity,	prior	to	birth.				 Fifteen	highly	conserved	residues	are	involved	in	the	binding	of	IgG	subtypes	and	FcRn	at	the	CH2-CH3	IgG	domain	interface;	Ile253	and	His310	being	key	residues	(J.	K.	Kim,	Tsen,	Ghetie,	&	Ward,	1994;	Medesan,	Radu,	Kim,	Ghetie,	&	Ward,	1996).	Utilising	human-mouse	chimeric	IgGs,	regions	distal	to	the	CH2-CH3	domain	interface	have	been	identified	 as	 required	 for	 the	 binding	 to	 FcRn	 (Zuckier,	 Chang,	 Scharff,	 &	 Morrison,	1998).	CH	domain	shuffling	between	IgG	subtypes	found	the	IgG:FcRn	coupling	could	be	effected	by	residues	other	than	the	required	fifteen	identified,	with	these	modifications	occurring	in	proximal	β-strand	regions,	but	distal	in	the	amino	acid	sequence	(Ghetie	&	Ward,	 2000).	 The	 removal	 of	 the	 Fc	 hinge	 region	 results	 in	 a	 shorter	 serum	 half-life	through	the	inability	to	bind	protective	FcRn	(J.	K.	Kim,	Tsen,	Ghetie,	&	Ward,	1995).	The	FcRn	 does	 not	 interact	 directly	 with	 the	 Fc	 hinge	 region,	 rather	 the	 hinge	 acts	 to	orientate	the	CH2-CH3	domain	interface	for	optimal	FcRn	binding	(J.	K.	Kim	et	al.,	1995).	FcR	 binding	 is	 highly	 conformationally	 dependent,	 as	 seen	with	 classical	 complement	activation	through	IgG	and	IgM	interactions	with	C1q	(Ghetie	&	Ward,	2000).		
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	 Transcytosis	of	 IgG	across	membranes	using	FcRn	 requires	a	net	pH	difference	between	 the	 luminal	 (pH	 6.0	 –	 6.5)	 and	 basolateral	 epithelial	 surfaces	 (pH	 7.4)	(Raghavan,	 Bonagura,	 Morrison,	 &	 Bjorkman,	 1995).	 IgG	 binds	 FcRn	 in	 acidic	environments,	is	transported	as	a	complex	in	acidic	clathrin-coated	pits,	and	dissociates	upon	 encountering	 pH	 7.4	 (Rodewald	 &	 Kraehenbuhl,	 1984).	 The	 FcRn:IgG	 affinity	 is	reduced	 by	 two	 orders	 of	 magnitude	 across	 from	 luminal	 to	 basolateral	 surfaces,	triggering	 dissociation	 of	 the	 complex	 (Raghavan	 et	 al.,	 1995).	 The	 pH	dependence	 of	this	interaction	is	caused	by	the	imidazole	side	chains	of	histidine	residues	(His310	and	His	433)	present	in	the	CH2-CH3	domain	interface	of	Fc	being	deprotonated	over	the	pH	6.0	to	pH	7.0	range	(idem).	Two	histidine	residues	(His250	and	His251),	present	within	the	 FcRn	 heavy	 chain,	 also	 become	 deprotonated	 over	 this	 pH	 range,	 adding	 to	 the	dissociative	effect	(idem).		
4.1.5	The	effect	of	temperature	on	IgG	Fc	stability		 With	a	pI	of	7.2,	the	human	IgG1	Fc	region	has	a	net	positive	charge	at	lower	pH	(<	7.2)	(Zhang-van	Enk	et	al.,	2013).	The	Linderstrom-Lang	model	of	thermal	stability	of	proteins	 suggests	 the	 maximal	 stability	 and	 therefore	 Tm	 will	 be	 highest	 at	 the	isoelectric	point	(pI)	of	a	protein.	The	Tm	of	IgG	Fc	being	higher	at	pH	7.2	than	the	Tm	at	pH	4.8	evidences	this	(Zhang-van	Enk	et	al.,	2013).	Buffer	constituents	for	example	pH,	salt	 and	 ion	 concentration	 are	 also	 important	 for	 the	 stability	 of	 the	 Fc	 region	(Tischenko,	Abramov,	&	Zav'yalov,	1998).	The	CH2	region	of	the	Fc	fragment	has	a	lower	melting	 temperature	 than	 the	 CH3	 region,	 suggesting	 that	 it	 may	 unfold	 first	 during	thermal	denaturation	(idem);	denaturation	was	shown	to	be	 irreversible	after	the	CH3	domain	unfolded	(Zhang-van	Enk	et	al.,	2013)	
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	 Tischenko	 et	 al.	 (1998)	 demonstrated	 the	 Fc	 region	 from	 rabbit	 IgG	 has	 four	cooperative	transitions	upon	thermal	denaturation,	with	the	most	stable	being	the	CH3	interaction	at	 the	C-terminal,	when	tested	between	pH	2.5	and	5.5	 in	MES	and	glycine	buffers	 (Tischenko	 et	 al.,	 1998).	 This	 thermal	 denaturation	 represents	 two	 unequal	stages	that	cannot	be	characterised	by	melting	of	the	homodimer	(idem).	Tischenko	et	al.	(1998)	postulated	this	unequal	thermal	denaturation	might	be	due	to	the	CH3	domain	containing	 two	non-identical	 subdomains,	which	are	bound	 to	 the	opposite	domain	 in	the	diamer	in	a	non-symmetric	manner	(idem).			 The	melting	temperature	of	CH2	is	lower	than	that	of	CH3,	but	follows	the	same	pattern	 of	 unequal	 stage	 thermal	 denaturation,	which	 is	 attributed	 to	 the	 presence	 of	sub-domain	 structure	within	 the	CH2	domain;	binding	 in	 the	dimer	with	 the	opposite	subdomain	creating	a	heterodimer	of	sorts	(Tischenko	et	al.,	1998).	This	two	transition	melting	 is	 seen	 in	 thermal	 denaturation	data	 between	pH	4.2	 and	8.0	 (10mM	glycine,	10mM	acetate	and	10mM	phosphate	buffers)	(Tischenko	et	al.,	1998).	CH2	domains	are	glycosylated	 at	 Asp297	 with	 the	 N-glycans	 held	 between	 the	 heavy	 chain	 regions,	thereby	 blocking	 the	 binding	 between	 these	 domains,	 a	 distinction	 from	 the	 other	domains	 (Janeway	 C.A	 2001).	 This	 reduced	 association	 explains	 the	 CH2	 domain	structure	 decrease	 in	 thermal	 stability.	 At	 pH	 8,	 the	 more	 stable	 CH3	 domain	 lends	stability	to	the	CH2	domain	through	cis	 interactions	(reducing	CH3	ΔG)	(idem).	At	pH	3.8,	dimerisation	of	 the	CH3	domains	have	been	shown	to	strongly	stabilize	 the	dimer	but	CH2	domains	no	longer	gain	stability	from	the	CH3	domain	(idem).	While	structural	changes	of	the	F(ab)	region	are	most	sensitive	to	heat	treatment,	the	structure	of	the	Fc	region	is	most	sensitive	to	the	lowering	of	pH	(Vermeer	&	Norde,	2000).		
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4.1.6	The	effect	of	anions	on	the	stability	of	the	IgG	Fc	region			 Zhang-van	Enk	et	al.	(2013)	investigated	the	effects	of	Hofmeister	anions	on	the	thermal	 degredation	 of	 human	 IgG1	 Fc	 region	 (Zhang-van	 Enk	 et	 al.,	 2013).	 The	Hofmeister	 series	 is	 commonly	used	 to	predict	 the	 stabilising	 effect	 of	 a	 buffer	 salt	 at	high	 concentrations	 (idem).	Hofmeister	 anions	 can	 confer	 stability,	 improve	 solubility,	and	can	reduce	denaturation	of	proteins	(idem).	Low	concentrations	of	a	given	salt	can	have	 stabilising	 or	 destabilizing	 effects	 according	 to	 the	 specific	 protein	 (idem).	 Low	concentrations	of	counterions	bind	the	surface	of	proteins	causing	neutralization	in	net	charge,	 reducing	 the	 repulsive	 electrostatic	 effects	 and	 therefore	 promoting	destabilisation	 and/or	 aggregation	 (idem).	 Hofmeister	 anions	 can	 confer	 a	 stabilising	effect	 through	 the	 organisation	 of	 water	 molecules;	 this	 reduces	 the	 fluidity	 of	 the	solution	and	improves	protein	stability	(Zhao,	2016).	
4.1.7	Low	molecular	weight	heparins		 Low	 molecular	 weight	 heparins	 are	 defined	 as	 heparins	 between	 1000	 and	10,000	Da	in	size	and	are	a	class	of	anti-coagulants	that	have	a	more	specific	activity	in	the	coagulation	cascade	than	that	of	UF	PMH.		Five	types	of	LMWH	are	employed	in	this	work	to	act	as	LMW	proxies	of	heparin.	Dalteparin	(Fragmin)	is	prepared	by	nitrous	acid	depolymerisation	of	UF	PMH,	followed	by	a	reduction	to	form	an	anhydromannitol	ring	at	 the	 reducing	 end	 (Bisio	 et	 al.,	 2017),	 with	 a	 mean	 molecular	 weight	 of	 4-6	 kDa.	Tinzaparin	 (Innohep)	 is	 prepared	 through	 enzymatic	 depolymerisation	 of	 UF	 PMH	yielding	an	average	molecular	weight	of	5.5	to	7.5	kDa.	Enoxaparin	(Lovenox/Clexane)	is	produced	through	β-elimination	of	the	benzyl	ester	of	UF	PMH	with	a	mean	molecular	weight	 of	 4	 -	 4.5	 kDa.	 Reviparin	 (Clivarine)	 is	 produced	 by	 nitrous	 acid	 digestion	 of	UFPMH	 with	 an	 average	 molecular	 weight	 of	 3.9	 kDa.	 Fondaparinux	 (arixtra)	 is	 a	
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synthetic	 pentasaccharide	 representing	 the	 binding	 region	 required	 for	 factor	 Xa	inhibition,	with	no	binding	 region	 for	 interaction	with	 thrombin.	The	 reduction	of	 the	18-saccharide	 binding	 region	 negates	 the	 possibility	 of	 heparin-induced	thrombocytopenia.	The	molecular	weight	is	1,727	Da.				
4.1.8	Method	information	Three	 biochemical	 assays	were	 utilised	 to	 investigate	 the	 interaction	 between	 IgG	 Fc	region	and	GAGs	e.g	heparin.	These	were	differential	 scanning	 fluorimetry	 and	 far-UV	circular	dichroism	used	in	the	previous	chapter	and	heparin	affinity	HPLC.	
4.1.8.1	Heparin	affinity	HPLC		 Heparin	 affinity	HPLC	utilises	 heparin	 covalently	 attached	 to	 a	 beaded	 agarose	matrix	produced	by	the	N-hydroxysuccinamide	coupling	of	beaded	agarose	media	to	N-unsubstituted	 glucosamines	 of	 heparin	 (Iverius,	 1971).	 The	 N-hydroxysuccinamide	containing	 cross-linking	 agent	 includes	 a	 spacer	 (i.e	 five	 carbon	 or	 eight	 carbon)	 on	which	 N-unsubstituted	 amine	 groups	 of	 heparin	 attach	 under	mildly	 basic	 conditions	(Hage.D.S,	 2005).	 HiTrap	 heparin	 HPLC	 is	 deployed	 commonly	 for	 the	 purification	 of	heparin	binding	proteins	(e.g.	coagulation	factors	and	lipoproteins),	with	elution	usually	performed	with	a	linear	or	stepwise	NaCl	gradient.	In	these	experiments,	the	human	IgG	Fc	region	is	eluted	with	a	linear	0	-	2	M	NaCl	gradient.	The	two	buffer	systems	employed	in	this	study	were	sodium	acetate	buffer	and	PBS	(containing	137	mM	NaCl).	
4.1.9	Experimental	aims		 Building	on	the	stability	experiments	of	biochemically	tagged	BACE1	in	Chapter	3,	the	immunoglobulin	fragment,	Fc	region,	has	been	investigated	for	interactions	with	heparin	 and	 chemically	 modified	 heparins.	 This	 work	 was	 conducted	 to	 further	
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understand	 the	 relative	 stability	 changes	 seen	 in	 DSF	with	 BACE-1	 Fc	 fusion	 protein.	Detailed	 DSF	 experiments	 using	 a	 chemically	 modified	 heparin	 library	 and	 size	fractionated	heparin	have	been	employed	to	inform	the	structural	requirements	for	the	interactions	observed	with	IgG	Fc.		 BACE-1	 experiments	 have	 been	 conducted	 at	 an	 acidic	 pH,	 as	 the	 aspartyl-protease	demonstrates	highest	activity	in	subcellular	compartments	of	the	Golgi,	trans-Golgi	network	and	the	endosomes,	which	maintain	an	acidic	enviroment.	Destabilisation	effects	 were	 seen	 in	 the	 BACE-1-Fc	 thermal	 stability	 assays	 when	 challenged	 with	heparin	 in	 a	 concentration	 dependant	 manner.	 However,	 this	 action	 could	 not	 be	attributed	to	the	interaction	between	BACE-1	and	the	GAG,	as	the	positively	charged	Fc	tag	at	pH	4	could	also	be	binding	the	negatively	charged	GAG	molecules.			 Initial	 investigations	have	been	conducted	 to	determine	 the	Fc-heparin	binding	affinity	and	whether	the	counterion	and	salt	concentration	present	in	the	chosen	buffer	solution	affected	the	nature	of	the	Fc-heparin	interaction.			 Next,	 titrations	 of	 heparin,	 chemically	 modified	 heparin	 derivatives,	 and	 size	defined	 heparin	 fragments	 (d.p.2	 –	 d.p.20)	 were	 employed	 to	 elucidate	 specific	structural	requirements	and	minimum	size	requirements	for	any	Fc-heparin	interaction.			 Finally,	a	library	of	defined	cation	forms	of	heparin	was	used	with	DSF	to	identify	differences	between	thermal	stability	of	IgG	Fc	with	distinct	cation	forms	of	heparin.			 	
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4.2	Results		 Investigation	 into	 the	 action	 of	 heparin	 with	 the	 Fc-fusion	 protein,	 BACE1-Fc,	exhibited	 different	 structural	 stability	 results	 when	 compared	 to	 native	 BACE1	 alone	and	 in	 the	 presence	 of	 BACE1	 inhibitor	 OM99-2	 in	 solution	 (Figure	 21).	 The	melting	point	 (Tm)	 of	BACE1-Fc	 and	BACE1-Fc	with	 1	mM	OM99-2	 in	 50	mM	 sodium	acetate	buffer	pH	4.5	was	45°C,	while	addition	of	50	mM	PMH	to	BACE1-Fc	in	the	same	buffer	reduced	the	Tm	to	36°C	(Figure	21).	This	nine	degree	reduction	 in	Tm	of	BACE1-Fc	 in	this	buffer	system	could	be	caused	by	PMH	binding	impacting	the	stability	of	the	enzyme	or	binding	to	the	Fc	tag,	alongside	BACE1	binding,	modifying	the	thermal	denaturation	rate	 of	 the	 enzyme.	 In	 order	 to	 understand	 the	 difference	 between	 these	 two	 protein	stabilities,	examination	of	 the	 ineraction	between	heparin	and	human	IgG	Fc	 fragment	was	 undertaken	 to	 aid	 understanding	 of	 this	 effect.	 Fc-fusion	 proteins	 are	 used	commonly	to	aid	purification	and	to	promote	native	dimerization	and	stabilisation.	
	 The	following	investigations	into	the	effect	of	PMH	on	the	protein	tag	IgG	Fc	were	completed	to	determine	whether	PMH	binds	human	IgG	Fc	region	and	causes	the	lower	Tm	exhibited	during	the	thermal	denaturation	of	BACE1-Fc	fusion	protein.	
	Figure	21:	DSF	melt	curve	(1st	derivative)	of	Native	BACE1	±	UF	PMH	and	inhibitor	IV	(−)	Native	BACE1,	 (−)	 native	 BACE1	 with	 inhibitor	 IV,	 and	 (−)	 native	 BACE1	 with	 UF	 PMH,	 in	 50	 mM	sodium	acetate	pH	4.0.	 	
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4.2.1	Human	IgG	Fc	region	binds	to	heparin	in	acidic	conditions			 Heparin	HiTrap	High	Performance	Liquid	Chromatography	(HPLC)	is	commonly	utilised	 to	 purify	 heparin-binding	 proteins	 from	 solution,	 including	 lipoproteins,	coagulation	 factors	and	protein	synthesis	 factors.	Heparin	sepharose	HiTrap	HPLC	has	also	been	utilised	 in	 the	 identification	and	elucidation	of	binding	affinity	 in	previously	unknown	heparin	binding	proteins.		
	 Human	IgG	Fc	region	(purified	polyclonal	IgG	from	human	plasma)	was	utilised	in	heparin	HiTrap	HPLC	 to	determine	 if	 this	 heavy	 chain	 antibody	 fragment	bound	 to	heparin-sepharose	under	 the	 same	buffer	 conditions	as	BACE1	proteolytic	 cleavage	of	APP	 is	 measured.	 Heparin	 HiTrap	 HPLC	 (over	 24	 minutes	 with	 elution	 with	 a	 linear	gradient	of	2M	NaCl)	demonstrates	IgG	Fc	binding	to	heparin	sepharose	matrix	with	an	affinity	of	981	mM	NaCl,	in	the	presence	of	50	mM	sodium	acetate	at	pH	4.0	(Figure	22).	Acetate	ions	absorb	strongly	at	the	prefered	absorbance	wavelength	for	peptide	bonds	of	 λabs	 =	 215	 nm.	 The	 absorbance	 therefore	 was	 read	 at	 λabs	 =	 280	 nm	 to	 detect	 the	aromatic	 rings	 of	 amino	 acids	 such	 as	 Phe,	 Tyr	 and	 Trp.	 	 The	 antibody	 fragment	
	Figure	22:	Heparin	Hi-Trap	affinity	HPLC	of	Human	IgG	Fc	region,	 in	50	mM	sodium	acetate	at	pH	4.0	with	a	linear	gradient	of	2	M	NaCl.		 	
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preservative,	sodium	azide,	was	also	accounted	for	in	the	blank	runs	and	did	not	bind	to	the	column;	this	ensured	the	remaining	peaks	were	Fc	fragment	only	(data	not	shown).			 To	 determine	 if	 the	 binding	 of	 human	 IgG	 Fc	 region	 was	 dependent	 on	 the	presence	 of	 BACE1	 buffer	 sodium	 acetate,	 the	 heparin	 HiTrap	 HPLC	 was	 run	 in	phosphate	buffered	saline	(PBS)	at	a	range	of	pHs,	to	determine	a	relationship	between	buffer	constituents	and	pH.	HPLC	absorbance	was	detected	at	λabs	=	215	nm	to	recognise	the	peptide	bond.		
	 The	dimer	of	heavy	chain	 regions	constructing	 the	Fc	 fragment	of	human	 IgG1,	made	by	cleavage	with	papain,	was	tested	in	heparin	HiTrap	HPLC	in	PBS	at	varying	pHs	with	elution	by	a	linear	gradient	of	2M	NaCl	(Figure	23).	At	each	pH	tested,	a	proportion	of	the	protein	did	not	bind	the	heparin	column.	At	pH	4.0,	the	IgG	Fc	region	bound	to	the	column,	released	as	a	rounded	double	peak	with	895	mM	and	992	mM	NaCl.	Increasing	
	Figure	23:	Human	IgG	Fc	region	in	heparin	HiTrap	affinity	HPLC.	PBS	buffer	at	differing	pH	and	elution	with	2M	NaCl	linear	gradient.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.	 	
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the	 pH	 to	 5.0,	 shifts	 the	 Fc	 region	 elution	 to	 247	mM	NaCl,	with	 a	 small	 hump	 at	 the	greater	concentration	of	910	mM	NaCl,	as	shown	in	Figure	23.			 Another	source	of	human	IgG	Fc	region	was	obtained	from	Southern	Biotech	to	corroborate	the	Fc-heparin	binding	interaction	demonstrated	in	Figures	22	and	23.	This	purified	 human	polyclonal	 IgG	 fragment	was	 run	 in	 heparin	HiTrap	HPLC	 in	 PBS	 at	 a	variety	of	pH,	with	elution	by	a	linear	gradient	of	2	M	NaCl.	At	pH	6	-	7.4,	the	protein	did	not	bind	the	heparin	column.	At	pH	4.0,	the	IgG	Fc	region	bound	to	the	column,	released	as	a	rounded	double	peak	with	810	mM	and	977	mM	NaCl	with	a	similar	peak	shape	to	the	IgG	Fc	region	from	Bethyl	Labs.	Increasing	the	pH	to	5.0	shifts	Fc	region	elution	to	the	lower	affinity,	390	mM	NaCl,	with	a	small	amount	protein	not	binding	to	the	column	and	eluting	prior	to	the	NaCl	gradient,	shown	in	Figure	24.	
	Figure	24:	Human	IgG	Fc	region	in	heparin	HiTrap	affinity	HPLC	in	PBS	buffer	at	differing	pH	and	elution	with	linear	gradient	of	2M	NaCl.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.		 	
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	 Human	 IgG	 Fc	 region	 binds	 heparin	 sepharose	 in	HiTrap	HPLC	 in	 both	 50	mM	sodium	acetate	at	pH	4.5	and	in	PBS	more	strongly	at	pH	4.0	than	5.0	but	does	not	bind	at	pH	>	5.0.			 Investigations	 into	 the	 stability	of	 the	Fc	 region	of	human	 IgG	 led	 to	 the	use	of	DSF	as	 a	method	 to	determine	 the	melting	 temperature	 (Tm)	and	 changes	 in	 stability	that	can	occur	upon	addition	of	a	ligand.			 Initially	 experiments	 were	 conducted	 in	 PBS	 with	 different	 pH	 levels.	 The	average	melting	point	 (Tm)	 change	of	human	 IgG	Fc	with	addition	of	6.0	μM	UF	PMH	was	 1.5°C	 lower	 than	 the	 IgG	 Fc	 region	 alone.	 A	 greater	 change	 of	 Tm	 is	 seen	 in	 the	secondary	peak	than	the	primary	peak,	but	this	secondary	peak	is	not	present	at	pH	≥	7.0	(Figure	23).	The	two	peaks	may	represent	two	stages	of	protein	denaturation	at	the	lower	pH	values	 tested,	with	 the	 single	peak	 in	 the	pH	7.0	experiments	having	higher	fluorescence	intensity.	This	may	suggest	full	IgG	Fc	region	denaturation	occurs	at	65°C	with	no	secondary	stage	of	denaturation	or	secondary	protein	population,	even	with	the	addition	of	heparin.			
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	 When	human	IgG	Fc	region	in	pH	4.0	50	mM	sodium	acetate	was	assayed	in	DSF,	the	addition	of	heparin	destabilised	 the	protein,	 shifting	 the	Tm	of	 the	Fc	 region	 from	45.54°C	with	a	secondary	peak	at	70.70°C,	to	34.66°C	with	a	secondary	peak	at	66.67°C	upon	 addition	 of	 6.0	 μM	 UF	 PMH.	 At	 a	 higher	 pH	 of	 5.0,	 IgG	 Fc	 region	 has	 a	 Tm	 of	56.82°C,	with	a	secondary	peak	at	81.72°C.	With	the	addition	of	6.0	μM	UF	PMH,	the	Tm	is	 reduced	 to	 similar	 Tm	 as	 with	 pH	 4.0	 sodium	 acetate	 buffer	 (35.10°C	 and	68.48°C)(Figure	25).	The	binding	of	UF	PMH	occluding	the	exposed	hydrophobic	regions	of	 the	 Fc	 region	 could	 cause	 this	 reduction	 in	 fluorescence	 of	 Sypro	 orange.	 UF	 PMH	binding	 excess	 Sypro	 orange,	 reducing	 the	 amount	 of	 free	 dye	 available	 for	 protein	binding	could	also	explain	this	reduction.	
	 An	investigation	into	the	stability	of	human	IgG	Fc	in	sodium	acetate	buffer	was	conducted	 at	 pH	4.0	 and	5.0	 to	 elucidate	 structural	 changes	 occurring	 at	 different	 pH	values.		
	Figure	25:	Differential	scanning	fluorimetry	in	PBS	pH	4.0-7.0	with	3	μM	human	IgG	Fc	region.	
A=	PBS	pH	4.0,	B=	PBS	pH	5.0	C=	PBS	pH	6.0	D=	PBS	pH	7.0.	(−)	IgG	Fc	region	in	PBS,	(−)	IgG	Fc	region	with	3	μM	UF	PMH		
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	 IgG	Fc	region	is	more	stable	at	pH	5.0	in	sodium	acetate	buffer	(Figure	26),	with	this	 increase	 in	 stability	 echoed	 in	 PBS	 DSF	 experiments	 in	 Figure	 25,	 displaying	increasing	protein	stability	with	increasing	pH	up	to	a	most	stable	conformation	around	pH	7.	In	50	mM	sodium	acetate	at	pH	4.0,	IgG	Fc	has	a	Tm	of	47.30°C,	which	is	increased	to	56.56°C	at	pH	5.0.	With	the	addition	of	6	μM	UF	PMH	these	Tm	are	reduced	to	34.12°C	at	pH	4.0	and	35.19°C	at	pH	5.0.	The	secondary	peaks	also	show	a	reduction	in	Tm	with	the	 addition	 of	 UF	 PMH,	 going	 from	 72.65°C	 (pH	 4.0)	 and	 81.44°C	 (pH	 5.0)	 to	 lower	temperatures	 of	 66.10°C	 (pH	4.0)	 and	68.22°C	 (pH	5.0).	 The	peak	 shapes	 and	Tm	are	similar	with	the	addition	of	UF	PMH	and	do	not	show	a	pH	variation	as	seen	with	IgG	Fc	region.			 To	determine	whether	the	dramatic	reduction	in	Tm	of	IgG	Fc	with	the	addition	of	 heparin	 is	 caused	 by	 the	 denaturation	 of	 the	 protein	 prior	 to	 denaturation	temperatures,	 circular	dichrosim	 (CD)	was	used	 to	 identify	protein	 structural	 changes	with	the	addition	of	PMH	in	these	buffers.		
	Figure	 26:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 3	 μM	 in	 50	 mM	 acetate	buffer	pH	4.0	and	5.0	±	UF	PMH	(−)	50	mM	sodium	acetate	buffer	pH	4.0	and	(−)	50	mM	sodium	acetate	buffer	pH	5.0,	(−)	50	mM	sodium	acetate	buffer	pH	4.0	with	6	μM	UF	PMH	and	(−)	50	mM	sodium	acetate	buffer	pH	5.0	with	6	μM	UF	PMH.			
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	 The	 CD	 spectra	 of	 IgG	 Fc	 in	 50mM	 sodium	 acetate	 pH	 4.0	 smoothed	 and	normalised	to	λ	=	260	nm	demonstrates	a	change	upon	addition	of	30	μM	UF	PMH	and	IdoA-GlcNAc	 at	 the	 same	 molar	 concentration	 (Figure	 27).	 Completely	 desulphated	heparin	was	 used	 to	 determine	 if	 the	 addition	 of	 disaccharide	 alone	was	 required	 to	stimulate	a	structural	shift	that	indicated	heparin	binding,	or	whether	the	presence	of	a	sulphate	functional	group	was	required.			 The	 circular	 dichroism	 spectrum	 of	 human	 IgG	 Fc	 region	 in	 50	 mM	 sodium	acetate	buffer	pH	4.0	has	a	structure	representing	a	protein	secondary	structure	rich	in	β-sheet	 structure,	 which	 is	 the	 main	 structural	 component	 of	 the	 immunoglobulin	domain	(Figure	27).	The	addition	of	UF	PMH	(30	μM)	causes	the	spectra	to	shift	from	a	peak	at	λ	=	220	nm	to	λ	=	230	nm.	This	may	suggest	a	shift	 toward	more	random	coil	formation	 due	 to	 the	 progress	 of	 the	 peak	 back	 toward	 zero	 elipticity	 at	 these	wavelengths.	The	addition	of	IdoA-GlcNAc	heparin	produces	a	peak	at	λ	=	215	nm,	a	shift	of	λ	=	5	nm	in	the	opposite	direction,	with	greater	elipticity	(Figure	27).	 IgG	Fc	region	alone	has	a	peak	maxima	at	λ	=	203	nm,	which	is	present	also	with	UF	PMH	but	absent	with	IdoA-GlcNAc;	at	λ	>	240	nm,	all	three	spectra	have	similar	characteristics.	
	Figure	 27:	 Far-UV	 circular	 dichroism	 spectra	 of	 human	 IgG	 Fc	 region	 ±	 UF	 PMH	 and	 IdoA-GlcNAc,	calibrated	with	D-(+)-10-camphorsulfonic	acid.	Reaction	buffer	50	mM	sodium	acetate	pH	4.0.	 (−)	3	 μM	 IgG	Fc	 region,	 (−)	3	μM	 IgG	Fc	 region	with	30	μM	UF	PMH.	 (−)	3	 μM	 IgG	Fc	region	with	30	μM	IdoA-GlcNAc		
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	 Both	 the	 addition	 of	 UF	 PMH	 and	 IdoA-GlcNAc	 cause	 a	 structrural	 change	 in	human	 IgG	 Fc	 in	 50	 mM	 sodium	 acetate	 buffer	 pH	 4.0,	 but	 this	 structural	 change	 is	distinct	for	both	GAGs	tested.	There	are	no	similar	spectral	changes	seen	in	IgG	Fc	in	the	presence	of	UF	PMH	in	the	physiological	buffer	PBS	as	seen	in	Figure	28.		
	 To	 try	 to	 identify	 the	 structural	 requirements	 for	 heparin	 binding	 to	 IgG	 Fc	region,	 a	 library	 of	 chemically	 distinct	 heparin	 chains	 were	 employed.	 The	 discrete	structural	 characteristics	 of	 these	 compounds	may	 elucidate	 specific	 functional	 group	features	required	for	the	binding	of	heparin.		
4.2.2	Structural	requirements	for	the	binding	of	heparin	to	the	IgG	Fc	region		 Human	 IgG	 Fc	 was	 screened	 in	 DSF	 with	 a	 library	 of	 chemically	 modified	heparins,	representing	the	most	common	structural	features	of	HS/heparin.	This	library	is	 constructed	 of	 heparin	 derivatives	 refered	 to	 as	 CMH	 1-9	 as	 shown	 in	 Figure	 29	alongside	the	chemical	structure	of	these	glycopolymers.			 The	most	common	chemical	modifications	 in	heterogeneous	UF	PMH	are	CMH1	and	CMH6.	Nine	chemically	modified	heparins,	including	a	per-sulphated	heparin	CMH9,	were	used	in	DSF	to	probe	structural	requirements	for	the	binding	of	heparin	to	the	IgG	
	Figure	28:	Far-UV	circular	dichroism	spectra	of	IgG	Fc	region	±	UF	PMH	in	PBS,	calibrated	with	D-(+)-10-camphorsulfonic	acid.	Reaction	buffer	PBS	pH	7.4.	(−)	3	μM	IgG	Fc	region,	(−)	3	μM	IgG	Fc	region	with	3	μM	UF	PMH.		
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Fc	region,	with	the	structural	modifications	to	the	constituent	disaccharides	taken	in	to	account	 when	 calculating	 the	 molecular	 weight	 of	 each	 heparin	 modification.	 The	binding	 between	 heparin	 and	 protein	 is	 represented	 by	 a	 change	 in	 melting	temperature.	 An	 investigation	 into	 the	 concentration	 dependency	 of	 this	 interaction	using	a	concentration	gradient	of	chemically	modified	heparin	indicated	the	strength	of	heparin	binding	responsible	for	structural	changes.		
	 The	Fc	region	alone	in	DSF	gives	a	peak	Tm	at	45.54°C,	with	a	secondary	peak	at	a	higher	 temperature	 of	 70.70°C	 (Figure	 30A).	 The	 reduction	 in	 Tm	 from	 the	major	 Fc	region	peak	with	6.0	μM	CMH1	 included	 is	15.73°C	 (Figure	30A).	At	concentrations	of	3.0	 μM	 to	 0.75	 μM	 the	 curve	 follows	 the	 same	 structure	 as	 6.0	 μM	with	 both	 curves	shifted	to	lower	temperatures	compared	to	6.0	μM.	At	3.0	μM	the	intensity	of	the	peak	at	29.8°C	 is	 increased	 to	4000	ΔFU	and	at	0.75	μM	 the	 secondary	peak	 shifts	 to	 a	Tm	of	60.53°C	with	 an	 intensity	 of	 600	ΔFU.	At	 0.38	μM	 the	 curve	has	 a	Tm	of	 33.51°C	 and	
	Figure	29:	Chemically	modified	heparin	reference	structures	for	CMH1	to	CMH9	including	a	schematic	for	the	heparin	disaccharide.		
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60.53°C.	The	concentration	of	CMH1	at	0.19	μM	has	a	more	intermediate	shape	with	a	shouldered	 initial	 peak	 with	 the	 main	 Tm	 of	 46.8°C	 and	 a	 shoulder	 at	 a	 lower	temperature	mirroring	the	more	concentration	CMH1	peaks	at	34.72°C.	The	secondary,	high	temperature	peak	exists	as	70.69°C,	in	the	same	region	as	the	lower	concentration	CMH1	curves	and	the	protein	only	Fc	peak.	The	intensity	of	the	shouldered	peak	of	0.19	μM	CMH1	is	4400	ΔFU	with	a	shoulder	of	1300	ΔFU,	with	the	secondary	peak	intensity	at	800	ΔFU.	Lower	concentrations	of	CMH1	(0.09	μM	and	0.05	μM)	have	the	same	shape	as	the	Fc	only	curve,	with	Tm	of	46.3°C	and	45.69°C	respectively	and	secondary	peaks	at	70.7°C.	The	Δ	fluorescence	intensity	of	the	two	lowest	concentrations	of	CMH1	increases	up	to	the	value	of	Fc	region	alone.		
	 Principle	 component	 analysis	 (PCA)	 of	 the	 first	 derivative	 DSF	 melt	 curve	 of	human	 IgG	 Fc	with	 CMH1	 is	 shown	 in	 Figure	 31.	 Correlation	 analysis	 of	 the	 variance	within	 CMH1	 concentration	 dataset	 demonstrates	 the	 first	 two	 principle	 components	from	the	data	in	Figure	30.	Fc	alone	is	grouped	with	0.05	μM	and	0.09	μM	CMH1,	with	0.19	μM	more	similar	to	this	group	in	the	PC1,	but	shows	variation	in	the	PC2.	0.19	μM	and	0.38	μM	have	similar	PC2	values	but	demonstrate	variance	in	the	PC1.	The	second	grouping	is	constructed	of	the	higher	concentrations	of	CMH1.		
	Figure	 30:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH1	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	A=	 (−)	 3	 μM	 IgG	 Fc	 region	with	 (−)	 6.0	 μM	 CMH1,	 (−)	 3.0	 μM	CMH1,	1.5	μM	CMH1,	(−)	0.75	μM	CMH1.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH1,	(−)	0.19	μM	CMH1,	(−)	0.09	μM	CMH1,	(−)	0.05	μM	CMH1.		
	 116	
	 The	 IgG	 Fc	 region	 with	 CMH2	 follows	 a	 similar	 change	 as	 CMH1	 with	 the	reduction	 of	 Tm	 upon	 addition	 of	 6.0	 μM	 CMH2	 of	 15.02°C,	 seen	 in	 Figure	 32A.	 The	intensity	 of	 the	 initial	 peak	 is	 4600	ΔFU	 and	 the	higher	 temperature	peak	 is	 lower	 at	2300	ΔFU.	Figure	32A	indicates	3.0	μM	CMH2	follows	the	same	pattern	but	has	a	slight	reduction	in	intensity	at	the	lower	Tm	(4100	ΔFU).	The	1.5	μM	concentration	of	CMH2	has	 an	 increased	Tm	with	 initial	 shift	 at	 33.05°C	 and	a	 secondary	Tm	at	61.06°C.	The	primary	peak	of	CMH2	at	0.75	μM	8.8	nM	has	a	Tm	if	34.9°C	and	intensity	3770	units,	and	a	secondary	peak	at	63.59°C	with	intensity	of	2800	ΔFU.		
	Figure	 32:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH2	 in	 50	 mM	sodium	acetate	 buffer	 pH	4.0.	 A=	 (−)	3	 μM	 IgG	Fc	 region	with	 (−)	 6.0	μM	CMH2,	 (−)	 3.0	μM	CMH2,	(−)	1.5	μM	CMH2,	(−)	0.75	μM	CMH2.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH2,	(−)	0.19	μM	CMH2,	(−)	0.09	μM	CMH2,	(−)	0.05	μM	CMH2.		
	Figure	31:	PCA	of	human	IgG	Fc	region	with	different	concentrations	of	CMH1	from	DSF	(1st	derivative	data)	in	50	mM	sodium	acetate	pH	4.0.		
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	 The	difference	between	IgG	Fc	alone	and	6.0	μM	CMH3	is	a	Tm	change	of	12.8°C	between	 the	 initial	 peaks	 of	 both	 concentrations	 (Figure	 33A).	 Each	 concentration	tested	has	two	peaks,	with	the	immunoglobulin	fragment	initial	peak	at	45.69°C	with	an	intensity	 of	 14200	ΔFU	and	 a	 secondary	peak	 at	 69.44°C.	 CMH3	at	 6.0	μM	 shifts	 both	peaks	to	32.89°C	with	a	lower	intensity	of	4300	ΔFU	and	the	secondary	peak	to	60.68°C	with	 a	 higher	 intensity	 than	 Fc	 only	 at	 2150	 ΔFU.	 Intensity	 and	 curve	 shape	 changes	with	0.38	μM	CMH3,	with	the	initial	Tm	at	36.91°C	with	a	reduced	intensity	of	1680	ΔFU	and	 a	 secondary	 peal	 at	 68.59	 °C,	which	mimics	 the	 Ig	 only	 secondary	 peak	 but	with	higher	 intensity	 of	 1600	 ΔFU.	 At	 0.19	 μM	 CMH3,	 the	 curve	 further	 flattens	 into	 an	intermediate	shape	with	 three	peaks	visible;	at	Tm	38.06°C,	47.43°C	and	69.02°C.	The	concentrations	 of	 0.09	 μM	 and	 0.05	 μM	 have	 initial	 Tm	 that	 are	 slightly	 increased	compared	to	the	Tm	of	IgG	Fc	alone.			 Addition	of	6.0	μM	CMH4	to	IgG	Fc	changes	the	Tm	from	45.54°C	to	a	lower	Tm	of	30.06°C,	a	difference	of	15.48°C	(Figure	34A).	The	intensity	change	between	these	two	peaks	 is	 11300	 ΔFU.	 The	 secondary	 peaks	 also	 displays	 a	 difference	 in	 Tm	 of	 13.0°C,	with	Fc	Tm	of	71.15°C	and	6.0	μM	Tm	of	58.13°C.	At	3.0	μM,	the	Tm	of	the	initial	peak	is	30.04°C	with	a	secondary	peak	at	58.52°C,	with	intensities	mirroring	that	of	the	higher	concentration	6.0	μM	CMH4.	At	0.38	μM,	 the	Tm	shifts	at	35.0°C	and	66.61°C	with	 the	
	Figure	 33:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH3	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	A=	 (−)	 3	 μM	 IgG	 Fc	 region	 with	 (−)	 6.0	 μM	 CMH3,	 (−)	 3.0	 μM	CMH3,	(−)	1.5	μM	CMH3,	(−)	0.75	μM	CMH3.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH3,	(−)	0.19	μM	CMH3,	(−)	0.09	μM	CMH3,	(−)	0.05	μM	CMH3.		
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secondary	peak	in	a	more	intermediate	location	between	peaks	of	higher	concentration	CMH4	and	their	more	dilute	counterparts.		
	 The	drop	in	Tm	seen	upon	addition	of	6.0	μM	CMH5	is	14.48°C	to	32.07°C,	with	a	secondary	 peak	 also	 at	 the	 lower	 melting	 temperature	 of	 61.93°C	 (Figure	 35A).	Concentrations	 of	 CMH5	 tested	 down	 to	 0.38	 μM	 have	 the	 same	 peak	 shape	 with	approximately	 equal	 peak	 intensities,	 but	 the	 Tm	 of	 both	 peak	 one	 and	 peak	 two	increase	 with	 decreasing	 CMH5	 concentration,	 with	 the	 exception	 of	 0.38	 μM,	 with	intensity	of	peak	one	reduced	to	2300	ΔFU.	At	0.19	μM	CMH5,	the	peak	shifts	to	48.09°C	(7500	 ΔFU)	 and	 has	 a	 small	 hump	 at	 lower	 temperatures	 (1700	 ΔFU).	 Peak	 2	 at	 this	concentration	occurs	at	similar	Tm	as	Fc	only	 (71.28°C),	with	 intensity	higher	 than	Fc	only	 (850	 ΔFU).	 CMH5	 concentrations	 of	 0.09	 μM	 and	 0.05	 μM	 show	 the	 same	characteristics	as	in	the	other	chemically	modified	heparins	tested.		
	Figure	 35:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH5	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	A=	 (−)	 3	 μM	 IgG	 Fc	 region	 with	 (−)	 6.0	 μM	 CMH5,	 (−)	 3.0	 μM	CMH5,	(−)	1.5	μM	CMH5,	(−)	0.75	μM	CMH5.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH5,	(−)	IgG	0.19	μM	CMH5,	(−)	0.09	μM	CMH5,	(−)	0.05	μM	CMH5.		
	Figure	 34:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH4	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	A=	 (−)	 3	 μM	 IgG	 Fc	 region	 with	 (−)	 6.0	 μM	 CMH4,	 (−)	 3.0	 μM	CMH4,	(−)	1.5	μM	CMH4,	(−)	0.75	μM	CMH4.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH4,	(−)	0.19	μM	CMH4,	(−)	0.09	μM	CMH4,	(−)	0.05	μM	CMH4.		
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	 IgG	Fc	with	6.0	μM	CMH6	has	a	Tm	of	30.98°C	with	a	second	peak	at	61.2°C.	The	Tm	of	the	first	peak	at	1.5	μM	CMH6	drops	to	32.98°C	and	a	secondary	Tm	of	63.74	°C.	An	 intermediate	 concentration	 of	 0.38	 μM	 CMH6	 yields	 3	 peaks	 with	 Tm	 of	 34.6	 °C,	48.38	°C	and	69.36	°C;	each	peak	at	this	concentration	has	an	intensity	of	approximatley	2000	 ΔFU.	 The	 first	 peak	 mirrors	 higher	 concentrations	 of	 CMH6,	 the	 centre	 peak	mimics	 the	 Fc	 region	 only	 peak	 and	 the	 final	 peak	 Tm	 mimics	 the	 Fc	 region	 only	secondary	 peak,	 but	 retains	 the	 intensity	 seen	 in	 secondary	 peaks	 at	 higher	concentrations	of	CMH6.	At	concentrations	of	CMH6	lower	than	this	intermediate	peak,	≤	0.19	μM,	CMH6	the	curves	have	initial	peak	Tm	above	Fc	only,	with	secondary	Tm	the	same	as	IgG	Fc	only;	 in	a	similar	way	to	the	 lower	concentrations	seen	in	other	IgG	Fc	graphs.			 The	reduction	in	Tm	seen	upon	addition	of	6.0	μM	CMH7	on	the	secondary	peak	is	 11.84°C	 but	 in	 this	 case	 an	 increase	 in	 intensity	 is	 seen	 (3100	 ΔFU).	 Decreasing	concentrations	of	CMH7	increase	the	Tm	of	IgG	Fc	moving	to	a	initial	Tm	of	35.41°C	and	secondary	Tm	of	64.69°C	at	0.38	μM.	At	these	concentrations	the	intensity	of	the	peaks	remains	similar	to	6.0	μM	CMH7.	The	peak	shape	at	0.19	μM	is	different	from	the	higher	concentrations	of	CMH7	as	the	peaks	are	shifted	to	a	higher	melting	temperature	more	
	Figure	 36:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH6	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	A=	 (−)	 3	 μM	 IgG	 Fc	 region	 with	 (−)	 6.0	 μM	 CMH6,	 (−)	 3.0	 μM	CMH6,	(−)	1.5	μM	CMH6,	(−)	0.75	μM	CMH6.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH6,	(−)	0.19	μM	CMH6,	(−)	0.09	μM	CMH6,	(−)	0.05	μM	CMH6.		
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significantly	 in	 both	 the	 primary	 and	 secondary	 regions	 (37.11°C	 and	 69.9°C).	 The	position	of	 the	secondary	peak	at	 this	concentration	has	 the	same	Tm	as	 IgG	Fc	alone,	and	 remains	 at	 this	 temperature	 with	 decreasing	 concentrations	 of	 CMH7.	 At	 lower	concentrations	of	CMH7	(0.09	μM	and	0.05	μM),	the	curves	follow	the	same	pattern	as	above	with	the	initial	Tm	slightly	higher	than	Ig	alone.		
	 The	 smallest	 change	 on	 addition	 of	 6.0	 μM	 the	 chemically	 modified	 heparin	library	 is	seen	 in	CMH8,	with	a	change	 in	Tm	of	9.2°C	(Figure	38A).	The	Tm	at	6.0	μM	CMH8	is	36.2°C	(2900	ΔFU),	with	a	 larger	secondary	peak	at	67.02°C	(3700	ΔFU).	The	peaks	 remain	 similar	 for	 concentrations	 to	 0.75	 μM,	 with	 approximately	 the	 same	intensity.	At	0.38	μM	CMH8,	the	initial	peak	shifts	too	a	higher	melting	point	of	46.76°C	
	Figure	 38:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH8	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	 A=	 (−)	 3	 μM	 IgG	 Fc	 region	with	 (−)	 6.0	 μM	 CMH8,	 (−)	 3.0	 μM	CMH8,	(−)	1.5	μM	CMH8,	(−)	0.75	μM	CMH8.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH8,	(−)	0.19	μM	CMH8,	(−)	0.09	μM	CMH8,	(−)	0.05	μM	CMH8.		
	Figure	 37:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH7	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	A=	 (−)	 3	 μM	 IgG	 Fc	 region	 with	 (−)	 6.0	 μM	 CMH7,	 (−)	 3.0	 μM	CMH7,	(−)	1.5	μM	CMH7,	(−)	0.75	μM	CMH7.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH7,	(−)	0.19	μM	CMH7,	(−)	0.09	μM	CMH7,	(−)	0.05	μM	CMH7.		
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and	a	secondary	peak	at	70.25°C.	These	Tm	are	then	the	same	the	lower	concentrations	(0.19	μM,	0.09	μM	and	0.05	μM)	tested,	with	the	initial	Tm	slightly	increased	compared	to	IgG	Fc	alone.			 The	 difference	 between	 the	 no	 CMH9	 and	 6.0	 μM	CMH9	with	 human	 IgG	 Fc	 is	14.54°C	in	this	experiment	(Figure	39A).	At	concentrations	tested	0.75	μM	to	6.0	μM	the	curve	shape	is	different	from	other	IgG	Fc	graphs,	with	an	initial	flattened	hump	with	no	further	 peak	 structure	 at	 higher	 temperatures.	 CMH9	 at	 0.38	 μM	 the	 intensity	 of	 the	initial	 peak	 increases	 to	 2400	 ΔFU	 with	 a	 Tm	 of	 32.24°C,	 and	 a	 flattened	 secondary	hump	at	68.96	°C.	At	0.19	μM	CMH9	and	below,	the	peaks	resemble	the	IgG	Fc	only	peak	and	the	lower	concentrations	seen	in	the	other	chemically	modified	heparins.	The	initial	Tm	of	≤	0.19	μM	CMH9	are	all	slightly	higher	than	IgG	Fc	alone.	
	 The	largest	reduction	in	Tm	and	therefore	destabilisation	of	IgG	Fc	was	seen	with	the	addition	of	6.0	μM	of	CMH1	at	15.73	°C,	followed	by	6.0	μM	CMH4	at	15.48	°C.			 Principle	 component	 analysis	 of	 the	 DSF	 data	 (1st	 derivative)	 demonstrate	 a	similarity	between	the	resulting	thermal	stability	IgG	Fc	with	CMH1	(Figure	40),	CMH2,	CMH4,	 CMH5,	 CMH7	 and	 CMH9	 (Figure	 40).	 The	 PCA	 analysis	 of	 CMH6	 and	 CMH8	exhibit	similar	groupings.	The	concentrations	of	CMH3	tested,	when	analysed	with	PCA	
	Figure	 39:	 Differential	 scanning	 fluorimetry	 of	 human	 IgG	 Fc	 region	 with	 CMH9	 in	 50	 mM	sodium	 acetate	 buffer	 pH	 4.0,	A=	 (−)	 3	 μM	 IgG	 Fc	 region	 with	 (−)	 6.0	 μM	 CMH9,	 (−)	 3.0	 μM	CMH9,	(−)	1.5	μM	CMH9,	(−)	0.75	μM	CMH9,	B=	(−)	3	μM	IgG	Fc	region	with	(−)	0.38	μM	CMH9,		(−)	0.19	μM	CMH9,	(−)	0.09	μM	CMH9,	(−)	0.05	μM	CMH9.	
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have	a	different	grouping	pattern,	but	still	maintains	the	grouping	separation	of	high	vs	low	CMH	concentration,	demonstrated	with	the	whole	CMH	library	with	IgG	Fc.		
	Figure	40:	PCA	analysis	of	1st	derivative	DSF	 thermal	 stability	data	of	 IgG	Fc	 region	with	CMH2-CMH9.	 Scree	 plots	 indicated	 PC1	 and	 PC2	 represent	 	 >85%	 of	 the	 data	 variance	(data	not	shown).	
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4.2.3	Circular	dichroism	of	the	Fc	region	and	chemically	modified	heparin			 Far-UV	circular	dichroism	was	employed	to	determine	the	secondary	structural	change	in	IgG	Fc	region	with	the	addition	of	each	chemically	modified	heparin.	Even	the	least	modified	heparin,	CMH8	has	an	effect	on	 the	 stability	 if	human	 IgG	Fc	 in	50	mM	sodium	acetate	pH	4.0.	However	this	modification	shows	the	 least	change	 in	Tm	when	compared	 to	 the	other	 chemically	modified	heparins	 tested.	CMH6	 (Figure	42B)	has	a	similar	 Tm	 to	 that	 of	 CMH8	 (Figure	 42D)	 at	 3.0	 μM,	 with	 Tm	 mimicking	 that	 of	 no	heparin;	this	suggests	at	3.0	μM	these	two	heparins	do	not	affect	the	structural	stability	of	IgG	Fc	unlike	the	other	heparins	at	this	concentration.	Both	CMH6	and	CMH8	include	an	unmodified	GlcNAc,	which	is	unique	in	this	library.			
	Figure	41:	Far-UV	circular	dichroism	spectra	of	human	IgG	Fc	region	with	CMH	1-4,	calibrated	with	D-(+)-10-camphorsulfonic	acid,	reaction	buffer	50	mM	sodium	acetate	pH	4.0.	A)(−)	3	μM	IgG	Fc	 region	with	 (−)	 3	 μM	CMH1,	B)(−)	 IgG	 Fc	 region	with	 (−)	 3	 μM	 CMH2,	C)(−)	 IgG	 Fc	region	with	(−)	3	μM	CMH3	D)(−)	IgG	Fc	region	with	(−)	3	μM	CMH4.		
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4.2.4	 The	 effect	 of	 other	 glycosaminoglycan	 and	 sulphated	 compounds	 on	 the	 Fc	
region		 In	 order	 to	 identify	 if	 the	 change	 in	 structure	 of	 human	 IgG	 Fc	was	 due	 to	 the	addition	of	 sulphate	alone,	DSF	with	an	equivalent	molar	 concentration	of	 sulphate	 in	the	form	of	sodium	sulphate	was	completed	(representing	the	highest	concentration	of	PMH	 tested).	 This	 experiment	 showed	 no	 change	 in	 structure	 with	 the	 addition	 of	sodium	 sulphate;	 suggesting	 the	 inclusion	 of	 these	 anions	 is	 not	 solely	 the	 cause	 of	structural	changes	(Figure	43).	Na2SO4	does	not	modify	the	Tm	of	IgG	Fc	region.		
	Figure	42:	Far-UV	circular	dichroism	spectra	of	human	IgG	Fc	region	with	CMH	5-9,	 calibrated	with	D-(+)-10-camphorsulfonic	acid.	Reaction	buffer	50	mM	sodium	acetate	pH	4.0	A)(−)	3	μM	IgG	Fc	region	with	(−)	3	μM	CMH5,	B)(−)	IgG	Fc	region	with	(−)	3	μM	CMH6,	C)(−)	IgG	Fc	region		with	(−)	3	μM	CMH7	D)(−)	IgG	Fc	region	with	(−)	3	μM	CMH8,	E)(−)	IgG	Fc	region	with	(−)	3	μM	CMH9.	
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	 The	trisulphated	HS/heparin	disaccharide	UA(2S)-GlcNS(6S)	shifts	the	Tm	of	IgG	Fc	 to	 a	 lower	 temperature	by	2.6°C	 (Figure	43),	 suggesting	 some	 interaction	between	the	protein	and	disaccharide.	Disaccharide	standard	UA(2S)-GlcNS(6S)	reduces	the	Tm	by	2.56°C	to	42.38°C	with	intensity	of	9800	ΔFU	with	the	second	peak	Tm	at	68.66°C.		 Heparan	 sulphate	was	 used	 at	 2x	 concentration	 to	 represent	 the	 presence	 of	 a	similar	level	of	sulphate	as	the	PMH	experiment,	with	the	structure	and	functional	group	positioning	 remaining	 similar	 to	 the	 polymer	 structure	 of	 heparin.	 HS	 and	 PMH	destabilised	the	IgG	Fc	region,	reducing	the	Tm	by	14°C	(Figure	43).		
	 The	effect	of	these	other	GAG	compounds	on	the	Tm	of	IgG	Fc	region	in	DSF	from	greatest	 to	 least	 structural	 change	 in	 Tm	 is	 PMH/HS>CSC>CSA>DS>HA>UA(2S)-		GlcNS(6S)>Na2SO4	as	demonstrated	by	 the	PCA	analysis	of	 first	derivative	DSF	data	 in	Figure	43.	PMH	at	6.0	μM	causes	a	reduction	in	stability	equivalent	to	a	decrease	in	Tm	of	14.72°C	with	Fc	region	Tm	at	an	average	of	44.96°C	±	0.115	°C	and	the	PMH	Tm	at	30.24	°C	with	intensity	of	3720	ΔFU.			 The	 Tm	 change	 seen	with	HS	 and	 the	 IgG	 Fc	 region	 has	 the	 same	 initial	 curve	shape	as	PMH,	with	Tm	of	30.28°C	but	the	second	peak	is	more	defined	than	with	PMH,	
	Figure	43:	PCA	of	first	derivative	DSF	of	human	IgG	Fc	region	with	glycosaminoglycans	(PMH,	HS,	CSC,	CSA,	DS,	HA)	and	sulphate	controls.	
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with	a	 increased	Tm	of	59.22°C.	The	 initial	peak	of	chondroitin	sulphate	C	(CSC)	has	a	Tm	with	 Fc	 region	 occuring	 at	 31.55°C,	 which	 is	 14.41°C	 less	 than	 the	 IgG	 Fc	 region	alone	(Figure	44).	The	shift	seen	of	the	secondary	peak	is	larger	with	dermatan	sulphate	(DS)	(8.18°C)	than	with	CSC.		
	 Chondroitin	 sulphate	A	 (CSA)	addition	causes	a	 reduction	 in	Tm	of	13.9°C,	 to	a	Tm	of	31.06	°C	for	the	first	peak.	The	second	peak	shift	is	7.07°C	to	62.13°C.	DS	with	Fc	region	has	 a	 similar	 shaped	 curve	 to	HS,	 including	 a	 higher	 intensity	 secondary	 peak.	The	Tm	of	the	initial	peak	is	at	31.57°C	(4220	ΔFU).	The	Tm	shift	seen	in	the	initial	peak	from	Fc	alone	 is	13.39°C	with	DS,	 and	 the	 secondary	peak	 shift	 is	8.18°C.	This	 similar	effect	 to	 HS	 and	 UF	 PMH	 could	 be	 due	 to	 all	 having	 iduronic	 acid	 present	 in	 the	glycopolymer.	Adding	hyaluronic	acid	(HA)	produces	an	 intermediate	 initial	peak	with	
	Figure	44:	Differential	scanning	fluorimetry	with	human	IgG	Fc	region	with	GAGs	and	sulphate	controls	in	50	mM	sodium	acetate	buffer	pH	4.0.	A)	(−)	3	μM	human	IgG	Fc	region	with	(−)	6.0	μM	UF	PMH,	(−)	500	nM	sodium	sulphate,	B)	(−)	3	μM	human	IgG	Fc	region	(−)	6.0	μM	UA(2S)-GlcNS(6S)	(−)	12.0	μM	HS,	C)	(−)	3	μM	human	IgG	Fc	region	with	(−)	6.0	μM	CSA,	(−)	6.0	μM	CSC,	
D)	(−)	3	μM	human	IgG	Fc	region	with	(−)	6.0	μM	DS,	(−)	6.0	μM	HA.		
	 127	
Tm	of	37.70°C	(Tm	Δ	7.26°C),	which	 is	 flattened	compared	 to	 the	other	GAGs	at	2100	ΔFU.		
4.2.5	The	size	requirements	for	heparin/HS:IgG	Fc	region	binding		 A	 library	 of	 size	 fractionated	 heparin	 oligosaccharides	 ranging	 from	 a	disaccharide	 (d.p.2)	 to	 eicosaccharide	 (d.p.20)	 was	 utilised	 in	 DSF	 to	 identify	 any	minimum	size	requirement	for	heparin	binding	to	human	IgG	Fc	region.	A	change	in	Tm	is	indicative	of	an	effect	of	oligosaccharide	binding.		
	 IgG	Fc	region	with	(molar	equivalent	to	UF	PMH)	d.p.2	has	the	same	curve	shape	with	similar	Tm	and	intensity.	A	d.p.4	reduces	the	Tm	of	the	first	peak	to	38.54°C	with	intensity	of	6650	ΔFU	and	the	secondary	peak	to	a	lesser	extent	with	Tm	of	68.39	°C	but	increased	 intensity	 of	 2770	 ΔFU.	 The	 Tm	 of	 the	 initial	 population	 peak	 reduces	 with	increasing	saccharide	length	to	a	minimum	of	30.81°C	with	the	d.p.20,	with	the	Tm	of	UF	PMH,	 29.85°C.	 The	 secondary	 peak	 population	 Tm	 also	 decreases	 with	 increasing	saccharide	 size,	 with	 the	 d.p.18	 with	 Tm	most	 like	 that	 of	 UF	 PMH.	 A	 Tm	 reduction	between	d.p.4	and	d.p.6	of	4.6°C	is	the	greatest	change	upon	addition	of	a	disaccharide;	further	reductions	in	Tm	with	increasing	oligosaccharide	size	are	gradual.	This	suggests	
Table	5:	The	DSF	Tm	of	each	PMH	polymerization	(d.p.)	fragment	with	IgG	Fc	region	in	50	mM	sodium	acetate	buffer	pH	4.0.			
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a	 minimum	 hexasaccharide	 requirement	 for	 a	 notable	 change	 in	 Tm,	 and	 therefore	interaction	with	IgG	Fc	region.	The	PCA	analysis	of	this	data	in	Figure	45	demonstrates	a	d.p.4	 has	 an	 intermediate	 effect,	 with	 hexasaccharide	 grouped	 with	 the	 larger	 PMH	fragments.		
4.2.6	The	effect	of	other	heparin	based	anti-coagulants	on	the	IgG	Fc	region	
	 Low	 molecular	 weight	 heparins	 (dalteparin,	 enoxaparin,	 tinzaparin	 and	reviparin)	and	a	synthetic	heparin	(fondaparinux),	were	assayed	to	determine	whether	
	Figure	 45:	 PCA	 analysis	 of	 the	 heparin	 size	 requirement	 for	 human	 IgG	 Fc	 thermal	destabilisation	as	measured	in	DSF.	
	Figure	46:	Differential	 scanning	 fluorimetry	of	 human	 IgG	Fc	 region	with	 LMWHs	 in	 50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fc	region	with	(−)	6.0	μM	dalteparin	(−)	6.0	μM	enoxaparin,	(−)	6.0	μM	tinzaparin.	B=	(−)	3	μM	IgG	Fc	region	with	(−)	6.0	μM	UF	PMH	(−)	6.0	μM	reviparin,	(−)	6.0	μM	fondaparinux.		
	 129	
low	molecular	weight	heparins	also	bind	to	change	the	stability	of	human	IgG	Fc	region	in	DSF.			 Dalteparin,	 enoxaparin,	 tinzaparin	 and	 reviparin	 the	 same	molar	 concentration	as	PMH	have	similar	Tm	at	30.50°C	and	58.90°C.	Fondaparinux	has	Tm	at	32.97°C	and	64.79°C.	 LMWH/synthetic	 heparins	 were	 assayed	 6.0	 μM	 and	 dalteparin,	 enoxaparin,	tinzaparin	and	reviparin	each	reduce	IgG	Fc	region	stability	to	the	same	Tm	as	UF	PMH.	The	 minimum	 requirements	 for	 GAG	 binding	 to	 IgG	 Fc	 are	 met	 in	 these	 LMWHs,	suggesting	a	 similar	manner	of	 action	 to	PMH;	 this	 is	demonstrated	 in	Figure	47	with	PCA	analysis.		
4.2.7	Sodium	acetate	buffer	concentration	experiments	with	BACE1		 The	 effect	 of	 increasing	 buffer	 strength	 on	 the	 stability	 of	 the	 human	 IgG	 Fc	region	was	 investigated,	with	 the	 addition	of	UF	PMH	 to	 identify	 any	 requirement	 for	binding.				
	Figure	47:	PCA	analysis	of	the	first	derivative	DSF	melt	curve	of	IgG	Fc	region	with	LMWHs.	
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	 Table	6:	Differential	scanning	fluorimetry	of	human	IgG	Fc	region	(3	μM)	in	20	mm	–	100	mM	buffer	strength	and	pH	4.0	–	5.0	sodium	acetate,	±	6.0	μM	UFPMH.	The	Tm	from	the	first	derivative	graphs	of	each	melt	curve	is	found	below.		
		
	 131	
	 This	buffer	screen	was	completed	for	sodium	acetate	at	varying	buffer	strengths	at	pH	4.0,	4.5	and	5.0,	with	and	without	6.0	μM	UF	PMH.	The	Fc	region	is	most	stable	in	the	concentrations	of	acetate	buffer	tested,	at	50	mM	acetate	buffer	at	pH	5.0	and	least	stable	 at	 100	mM	 acetate	 buffer	 pH	 4.0.	 The	 shape	 of	 the	 first	 derivative	melt	 curve	along	with	 the	 Tm	with	 the	 addition	 of	 UF	 PMH	 at	 all	 sodium	 acetate	 concentrations	tested	mimic	the	effect	seen	with	100	mM	sodium	acetate	without	UF	PMH;	this	suggests	a	similar	degree	of	structural	change	in	both	instances.	Increasing	the	pH	from	4.0	to	5.0	leads	 to	an	 increase	 in	Tm	 in	 the	Fc	 region	when	 tested	without	UF	PMH	 indicating	a	more	 stable	 conformation,	 as	expected,	 as	physiological	pH	 is	7.4.	The	peak	Tm	range	increases	at	each	pH	value	tested,	with	increasing	acetate	concentration.	PCA	analysis	of	the	first	derivative	melt	curves	determined	by	DSF	are	shown	in	Figure	48.			 Increasing	 the	 acetate	 concentration	 (including	 the	 acetic	 acid	 required	 to	 pH	solution)	increases	the	Tm	difference	at	the	three	pH	tested,	in	both	the	main	peak	and	secondary	smaller	peak.			 The	 addition	 of	 6.0	 μM	 UF	 PMH	 to	 the	 IgG	 Fc	 region	 with	 acetate	 buffer	 at	different	 concentrations	 and	 pH	 levels,	 does	 not	 show	 a	 similar	 relationship.	 Peak	 1	variation	in	Tm	seen	at	each	concentration	across	the	three	pH	tested	is	lower	with	PMH	added,	with	no	pattern	to	the	range	of	Tm	from	pH	change	seen	in	20	mM	to	100	mM	acetate	 buffer.	 The	 most	 stable	 pH	 acetate	 buffer	 is	 pH	 4.5	 across	 all	 concentrations	tested.	The	 lowest	Tm	with	PMH	varies	with	 the	 two	 lowest	concentrations	at	20	mM	and	30	mM	being	pH	5.0,	and	higher	concentrations	≥	40	mM	least	stable	at	pH	4.0	as	shown	in	Table	6.	
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4.2.8	IgG	Fc	region	studies	with	cation	forms	of	heparin		 Highly	polyanionic	heparin	chains	are	associated	with	positively	charged	ions	in	solution.	Data	 published	 shows	 the	 presence	 and	modification	 of	 these	 bound	 cations	can	have	an	effect	on	the	heparin	function.	It	is	not	known	whether	the	resulting	change	
	Figure	 48:	 PCA	 from	 1st	 derivative	 DSF	 of	 IgG	 Fc	 region	 buffer	 experiments	 ±	 UF	 PMH,	 Tm	stated	in	Table	6.	50	mM	Sodium	acetate	buffer	A)	pH	4.0,	B)	pH	4.0	with	UF	PMH,	C)	pH	4.5,	
D)	pH	4.5	with	UF	PMH,	E)	pH	5.0	F)	pH	5.0	with	UF	PMH.		
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in	properties	are	due	to	the	change	in	charge	distrubution	or	an	altered	polymer	chain	conformation	(Meneghetti	et	al.,	2015).			 Fourteen	 cation	heparins	were	prepared	 and	 tested	 in	DSF	with	human	 IgG	Fc	region	 to	 identify	 any	 modifications	 to	 the	 protein	 melting	 temperature,	 implying	alterations	 to	 protein	 binding	 and	 stability.	 Table	 7	 includes	 the	 Tm	 of	 the	 first	 peak	taken	from	the	first	derivative	of	the	melt	curve	for	human	IgG	Fc	region.		The	data	at	the	lower	concentrations	tested	exhibited	most	variation	between	cation	forms.		 At	 0.75	 μM	 each	 prepared	 cation	 PMH	 tested	 caused	 accelerated	 thermal	denaturation	of	IgG	Fc	region	to	a	similar	degree	(35°C	-37°C)	(Table	7).		
	 Unmodified	Celsus	PMH	in	the	sodium	form	causes	the	greatest	shift	 in	melting	temperature	than	any	prepared	cation	heparin	at	all	concentrations	tested,	apart	 from	the	 smallest	 concentration	 0.09	 μM.	 The	 greater	 the	 concentration	 of	 Celsus	 heparin	tested,	 the	 greater	 the	 difference	 Celsus	 heparin	 and	 the	 cation	 heparins	 tested.	 The	
Table	 7:	DSF	 of	human	 IgG	Fc	with	 defined	 cation	 forms	 of	heparin	 in	 50	mM	sodium	acetate	buffer	pH	4.0.	Cation	heparin	concentrations	ranging	from	0.75	μM	to	0.09	μM.			
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sodium	 form	 of	 heparin	 tested	 in	 DSF	 displays	 the	 most	 dramatic	 difference	 from	unmodified	Celsus	PMH	(sodium	 form)	at	0.19	μM,	with	unmodified	PMH	exhibiting	a	
Tm	of	35.44°C	and	sodium	PMH	a	Tm	of	49.06°C;	a	melt	temperature	higher	than	that	of	the	IgG	Fc	region	with	no	heparin	present	(45.34°C).			 The	trend	of	increased	resistance	to	temperature	denaturation	is	also	present	in	the	lowest	concentration	of	sodium	PMH	tested	(0.09	μM).	At	0.09	μM	only,	Celsus	PMH	also	shows	increased	resistance	to	temperature	denaturation.	All	other	cation	forms	of	PMH	 enhance	 the	 stability	 of	 IgG	 Fc	 region	 in	 this	 DSF	 experiment,	 at	 different	concentrations	and	to	different	degrees.	Potassium,	ammonium,	calcium,	zinc,	silver	and	vanadium	forms	of	PMH	at	0.38	μM	increase	the	Tm	of	IgG	Fc	region,	and	improve	the	resistance	 to	 thermal	 denaturation.	 At	 0.38	 μM,	 sodium,	 lithium,	magnesium,	 barium,	
	Figure	49:	PCA	analysis	of	1st	derivative	DSF	data	of	IgG	Fc	region	with	6	μM	defined	cation	form	of	PMH.		
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iron	 (II)	 and	 iron	 (III),	 copper	 and	 manganese	 PMH	 each	 destabilise	 IgG	 Fc	 region,	leading	to	a	reduction	in	melting	temperature	and	promotion	of	thermal	denaturation.		 At	 0.19	 μM	 and	 0.09	 μM	 each	 cation	 heparin	 improves	 the	 stability	 of	 IgG	 Fc	region,	as	 shown	 through	an	 increased	Tm	when	compared	with	 the	protein	alone.	Of	these	two	concentrations,	the	stabilising	effect	is	more	prominent	at	0.19	μM	than	0.09	μM.			 PCA	of	the	highest	concentration	of	each	defined	cation	heparin	type	from	the	1st	derivative	DSF	data	of	IgG	Fc	(Figure	49)	shows	potassium	heparin	is	the	most	similar	to	Celsus	PMH	in	both	principle	components	(PC)	1	and	2,	however,	vanadium	PMH	is	most	similar	to	Celsus	PMH	in	the	PC1	alone,	and	the	most	different	of	the	cation	forms	in	PC2.	Zinc	and	magnesium,	both	divalent	cations,	have	the	same	effect	 in	the	variance	of	the	data.		
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4.3	Discussion		 Initial	investigations	into	the	change	in	stability	of	BACE1	with	a	IgG	Fc	tag	in	the	presence	 of	 PMH	 indicated	 that	 in	 FRET	 conditions	 of	 50	mM	 sodium	 acetate	 pH	4.0,	PMH	 reduced	 the	 melting	 temperature	 of	 BACE1-Fc	 by	 9 °C,	 a	 change	 in	 the	conformation	of	the	protein	caused	by	the	action	of	UF	PMH.	To	measure	the	strength	of	binding	 affinity	 between	 the	 IgG	 Fc	 region	 and	 PMH,	 HiTrap	 heparin	 affinity	chromatography	was	 completed	 in	 the	 same	 buffer	 system.	 This	 indicated	 a	 981	mM	binding	 affinity	 between	 IgG	 Fc	 region	 and	 the	 heparin-sepharose	 column	 in	 50	 mM	sodium	acetate	 pH	4.0.	 Binding	 of	 PMH	 in	 50	mM	 sodium	acetate	 at	 pH	4.0	 to	 the	 Fc	region	 could	 be	 occurring	 through	 the	 positively	 charged	 amino	 acids	 present	 in	 the	domain	structure	such	as	Lys248	and	Lys338	exposed	in	the	CH2	α-helices	which	form	the	 CH3-CH2	 domain	 interface	 (Latypov,	 Hogan,	 Lau,	 Gadgil,	 &	 Liu,	 2012).	 Positively	charged	imidazole	ions	of	histidine	and	guanidinium	ions	of	arginine	are	equally	 likely	to	 have	 a	 role	 in	 heparin	 binding	 at	 this	 pH	 (Zhang-van	 Enk	 et	 al.,	 2013).	 The	 highly	sulphated	 nature	 of	 PMH	may	 allow	 sulphate	 ions	 to	 act	 as	 chaotrophes	 through	 the	disordering	of	hydrogen	bonding.	This	change	in	covelent	bonding	structure	in	the	CH2-CH3	domain	structure	of	IgG	Fc	due	to	the	presence	of	highly	charged	PMH	could	be	the	cause	of	the	reduction	in	melting	temperature	seen	in	the	DSF	experiments	with	BACE1-Fc	fusion.		 Ejima	 et	 al.	 (2007)	 showed	 during	 the	 purification	 process	 for	 monoclonal	antibodies	and	Fc-fusion	proteins,	immunoglobulins	are	exposed	to	low	pH	conditions	in	affinity	resin	elution	and	to	inactivate	viral	particles	(Ejima	et	al.,	2007).	In	pH	2.7	-	3.9,	0.1	M	citrate	buffer,	humanised	IgG4	and	mouse	monoclonal	antibodies	tested	by	Ejima	
et	al.	 (2007)	displayed	only	 limited	 conformation	modifications	 and	did	not	 reach	 the	
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‘molton	 globule	 structure’	 associated	 with	 acid	 treatment	 of	 multi-domain	 protein	(idem).	 The	 IgG	 remaned	 stable	 and	 in	monomeric	 form,	but	had	a	 reduced	Tm	when	compared	to	antibodies	at	pH	6	(idem).			 Hari	et	al.	 (2010)	 investigated	 the	unfolding	 and	 aggregation	kinetics	 of	 IgG	Fc	region	under	acidic	conditions	(Hari,	Lau,	Razinkov,	Chen,	&	Latypov,	2010).	At	25	°C	in	pH	 3.5	 acetate	 buffer,	 IgG1	 was	 resistant	 to	 aggregation	 but	 IgG2	 aggregated	 in	 the	presence	 of	 0.5	M	 sodium	 chloride	 (idem).	 At	 the	 same	 pH,	 acetate	 and	 citrate	 buffer	systems	 had	 differing	 effects	 on	 IgG	 aggregation,	 with	 thermal	 stability	 of	 antibodies	higher	in	equivalent	citrate	buffer	than	acetate	(idem).			 At	 pH	 5.5,	 Vlasov	 et	 al.	 (1996)	 demonstrated	 the	 CH2	 domain	 of	 rabbit	 IgG	displayed	significant	reductions	in	co-operation	and	lower	levels	of	interaction	with	the	surrounding	 domains,	 in	 a	 transition	 independent	 to	 the	whole	 IgG	molecule	 (Vlasov,	Kravchuk,	&	Martsev,	1996).	At	pH	3.0,	 the	CH2	domain	undergoes	 tertiary	unfolding,	with	 the	 rest	 of	 the	 IgG	 retaining	 native	 secondary	 and	 tertiary	 structure	 (idem).	 The	increase	of	pH	>	3.0	leads	to	a	conformer	with	reduced	domain	interaction	between	the	CH2	 and	 CH3	 Fc	 regions,	 resulting	 in	 contrary	 modifications	 to	 effector	 functions;	improved	C1q	binding	and	reduced	affinity	for	protein	A	(idem).		 DSF	experiments	in	PBS	rather	than	sodium	acetate	indicate	only	a	small	change	in	 structure	 at	 low	 pH	 upon	 addition	 of	 PMH,	 suggesting	 the	 sodium	 acetate	 buffer	system	 promotes	 the	 destabilising	 action	 of	 PMH.	 HiTrap	 heparin	 affinity	chromatography	of	IgG	Fc	in	PBS	across	a	pH	range	between	4.0	and	7.4	shows	binding	at	 a	 similar	 affinity	 to	 sodium	 acetate	 at	 pH	 4.0	 (977	 mM	 NaCl)	 and	 lower	 affinity	binding	 at	 pH	 5.0,	 with	 a	 similar	 lack	 of	 binding	 at	 more	 neutral	 pH.	 With	 the	physiological	 buffer	 system	 PBS	 prompting	 only	 a	 negligable	 structural	 change	 in	 the	presence	of	PMH,	 the	binding	of	 IgG	Fc	at	pH	4.0	and	5.0	may	 suggest	 a	possibility	of	
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physiological	action	in	regions	of	localised	acidic	pH	(e.g	inflammation	or	trauma)	or	in	specific	 regions	 of	 favourable	 conditions	 (e.g	 endosomes,	 lysosomes,	 and	 secretory	granules).			 The	melting	 temperature	of	 IgG	Fc	 is	more	variable	between	pH	4.0	and	5.0	 in	sodium	acetate	 than	 in	PBS,	 by	 the	 addition	 of	 PMH	 to	 these	 conditions	produces	 the	same	structural	change	to	result	in	a	significant	reduction	of	Tm.				 Sulphate	groups	present	throughout	PMH	may	more	readily	bind	to	the	Fc	region	through	electrostatic	 interactions	 in	pH	4.0	and	5.0	sodium	acetate	buffers.	Zhang-van	Enk	et	al.	 (2013)	noted	the	addition	of	sulphate	 ions	to	 IgG	Fc	contradict	 the	standard	kosmotrophic	action	of	sulphate	ions,	with	sulphate	acting	more	potently	than	SCN-	as	a	strongly	 destabilising	 chaotrope	 (Zhang-van	 Enk	 et	 al.,	 2013).	 Zhang-van	 Enk	 et	 al.	(2013)	postulated	the	cause	of	this	destabilisation	could	be	due	to	the	interaction	of	the	divalent	anion	and	positively	charged	side	chains,	causing	solubilisation	of	hydrophobic	regions	and	disruption	of	intra-protein	covelent	bonding,	triggering	a	net	change	in	CH2	domain	 structure	 (idem)	 and	 a	 reduction	 in	melting	 point.	 The	 IgG	 Fc	 region	 has	 net	negative	 charge	 at	 pH	 lower	 than	7.2,	 and	 the	CH2	domain	has	 a	 lower	melting	point	than	 CH3	 with	 the	 denaturation	 of	 the	 Fc	 fragment	 irreversible	 after	 CH3	 unfolding	(idem).		 Hofmeister	 anions	 have	 conflicting	 actions	 with	 different	 proteins,	 as	demonstrated	 with	 SO42-	 with	 human	 IgG1	 Fc	 region	 (Zhang-van	 Enk	 et	 al.,	 2013).	Sulphate	 ions	 typically	 exhibit	 protein-stabilising	 (kosmotropic)	 activities;	 reduce	 the	solubility	of	proteins,	reduce	the	denaturation	rate	and	increase	protein	stability	(idem).	At	pH	4.8,	the	protonated	CH2	domain	of	IgG	Fc	region	was	destabilised	by	the	addition	of	SO42-,	more	potent	than	the	strongly	destabilising	chaotrope	SCN-	(idem).		
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	 Zhang-van	 Enk	 et	 al.	 (2013)	 suggested	 at	 pH	 4.8,	 the	 anions	 tested	 follow	 the	order	SO42-	>	SCN-	>	Cl-	>	F-	in	the	ability	of	the	anion	to	reduce	the	Tm	of	IgG	Fc	region	at	salt	concentrations	below	50	mM;	with	KF-	increasing	the	Tm	at	this	pH	(Zhang-van	Enk	et	al.,	2013).	At	pH	7.2,	the	destabilizing	effect	on	IgG	Fc	region	was	attenuated,	with	concentrations	below	100	mM	showing	a	slightly	different	effect	on	the	Tm;	SCN-	≅ SO42-	>	Cl-	>	F-	(idem).			 Heparin	 is	 a	 polymer	 containing	 multiple	 anionic	 groups,	 with	 sulphates	accounting	for	70%	of	charged	groups	present	on	the	polysaccharide	(Diakun,	Edwards,	Wedlock,	 Allen,	 &	 Phillips,	 1978).	 Protein	 binding	 to	 heparin	 causes	 some	 portion	 of	heparin	neutralisation	through	the	liberation	of	charged	moities	such	as	sulphate	groups	(Mascotti	&	Lohman,	1995).	Replacing	SO42-	from	sodium	sulphate	(Zhang-van	Enk	et	al.,	2013)	with	the	sulphated	glycosaminoglycan	heparin,	the	change	in	structural	stability	witnessed	 upon	 addition	 of	 the	 hofmeister	 anion	 SO42-	 in	 IgG	 Fc	 region	 has	 been	demonstrated.		 Circular	 dichroism	 demonstrates	 the	 secondary	 structure	 of	 IgG	 Fc	 is	 different	with	 the	 addition	 of	 PMH	 and	 un-sulphated	 CMH8.	 This	may	 suggest	 the	 presence	 of	CMH8	has	an	effect	on	the	secondary	structure	of	IgG	Fc	in	a	different	way	to	the	highly	polyanionic	PMH.			 Utilising	 a	 library	 of	 heparin	 derivatives	 displaying	 a	 range	 of	 structural	characteristics	 found	 commonly	 in	 heparan	 sulphate,	 investigations	 into	 the	 effect	 of	specific	 chemical	modifications	 in	 IgG	 Fc	 binding	was	 completed.	 DSF	was	 utilised	 to	indicate	the	change	in	IgG	Fc	associated	with	the	binding	of	polysaccharide.			 Each	 of	 the	 nine	 chemically	 modified	 heparins	 tested	 at	 high	 concentration,	reduced	 the	melting	point	of	 IgG	Fc,	 suggesting	 a	 reduction	 in	 stability	of	 the	protein.	The	 smallest	 effect	 was	 seen	 in	 the	 addition	 of	 unsulphated	 CMH8,	 with	 a	maximum	
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reduction	 in	 Tm	 of	 9.2	 °C.	 Conversley	 the	 greatest	 change	 in	 Tm	 and	 therefore	destabilisation	effect	was	seen	with	high	concentrations	of	CMH1.	The	addition	of	6.0	μM	of	CMH1	at	15.73	°C	displays	the	highest	level	of	IgG	Fc	destabilisation	followed	by	the	6.0	μM	CMH4	at	15.48	°C.	The	number	of	sulphates	per	disaccharide	does	not	completely	correspond	to	the	stability	of	the	Fc	region,	with	persulphated	heparin	CMH9	not	having	a	more	marked	Tm	reducing	destabilisation	effect	than	CMH1.	Both	CMH3	and	CMH7	act	to	destabilise	IgG	Fc	at	0.09	μM,	whereas	all	other	heparins	tested	had	little	to	no	action	at	this	concentration,	suggesting	more	effective	binding	or	more	potent	destabilisation	at	this	concentration.	Both	CMH3	and	CMH7	have	unsubstituted	iduronic	acid	residues	and	N-sulpho-glucosamine	 residues	 present,	which	 is	 unique	 in	 this	 library.	 This	may	suggest	a	role	of	unsubstituted	IdoA	bound	to	a	GlcNS	as	a	binding	requirement.			 Principle	component	analysis	of	the	CMH	library	with	IgG	Fc	region	indicated	two	groupings	 of	 CMH	 with	 similar	 principle	 components;	 one	 group	 containing	 CMH1,	CMH2,	 CMH4,	 CMH5,	 CMH7	 and	 CMH9,	 another	 group	 containing	 CMH6	 and	 CMH8.	CMH3	demonstrates	a	different	layout	of	the	PCA	data.		Interestingly,	CMH6	and	CMH8	are	the	only	library	members	to	both	contain	an	unsulphated	GlcNAc	residue,	which	may	suggest	this	modification	produces	a	change	in	the	effect	of	Fc	destabilisation	therefore	an	altered	effect	on	the	variance	of	the	1st	derivative.		 The	effect	of	the	sulphate	anions	alone	on	the	stability	of	IgG	Fc	region,	without	the	presence	of	the	glycosaminoglycan	scaffold	structure	allowed	clarification	of	the	role	of	 these	 moieties.	 At	 sulphate	 concentrations	 equivalent	 to	 the	 most	 perturbing	chemically	 modified	 disaccharide	 CMH1,	 Na2SO4	 did	 not	 destabilise	 IgG	 Fc	 structure,	indicating	 a	 important	 role	 for	 the	 GAG	 structure	 alongside	 the	 presence	 of	 sulphate	anion	alone.		
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	 The	presence	of	more	discrete	domain	structure	was	investigated	with	the	use	of	heparan	 sulphate	 in	 DSF	 with	 IgG	 Fc	 region.	 HS	 was	 used	 at	 double	 the	 molar	concentration	of	PMH	in	order	to	replicate	the	sulphate	levels	associated	with	PMH.	The	structural	changes,	therefore,	could	be	attributed	to	structural	differences	between	the	GAGs,	and	not	soley	 the	sulphate	 levels.	The	effect	of	HS	was	the	same	as	PMH	in	DSF	with	IgG	Fc,	indicating	these	GAGs	have	a	similar	effect	on	the	stability	of	the	Fc	region.		This	may	be	due	to	the	presence	of	sulphate	moieties	presented	in	a	similar	way	in	both	heparin	 and	 HS	 to	modify	 hydrogen	 bonding	 and	 therefore	 structure	 of	 IgG	 Fc	when	bound.		 The	 effect	 of	 other	 GAGs	 on	 the	 stability	 of	 IgG	 Fc	was	 investigated	 to	 identify	structural	 requirements	 for	 the	 interaction.	 The	 action	 of	 each	 GAG	 in	 DSF	 was	determined	from	most	to	least	change	in	Tm	as	PMH/HS>CSC>CSA>DS>HA>	IdoA(2S)-GlcNS(6S)	>Na2SO4.	The	GAGs	CSC,	CSA	and	DS	all	display	similar	changes	to	the	melting	point	of	IgG	Fc,	with	the	Tm	of	these	GAGs	separated	by	only	0.5	°C,	this	may	be	due	to	the	similarities	in	the	level	of	sulphation.	The	addition	of	HA	has	a	smaller	effect	on	the	stability	of	IgG	Fc	but	still	shows	perturbation	of	Fc	melting,	demonstrating	the	absence	of	 sulphate	 in	 this	 GAG	 still	 allows	 for	 destabilisation	 of	 the	 protein.	 The	 reduced	structural	effect	of	HA	in	DSF	of	Fc	shows	a	role	of	an	unsulphated	GAG	in	destabilisation	of	the	immunoglobulin	fragment	that	was	shown	with	CMH8,	and	alluded	to	with	HS,	but	not	 fully	 shown.	 These	 results	 suggest	 the	 presence	 of	 sulphate	 anions	 for	 the	 full	reduction	 in	 Tm	 seen	with	 the	 other	 saccharides.	 The	 intermediate	 nature	 of	 the	 Tm	change	could	be	a	result	of	diminished	GAG	binding	to	the	Fc	region	therefore	disrupting	less	 of	 the	 hydrogen	 bonding	 and	 therefore	 retaining	 more	 of	 the	 stable	 CH2-CH3	domain	structure.		
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	 Investigation	 into	 the	 size	 requirement	 of	 the	 HS	 oligosaccharide	 required	 for	reduction	 of	 IgG	 Fc	 melting	 point	 and	 therefore	 indication	 of	 GAG	 binding	 and	destabilisation	was	made.	The	presence	of	a	HS	disaccharide	did	not	markedly	change	in	the	 melting	 point	 of	 IgG	 Fc,	 an	 intermediate	 change	 in	 Tm	 was	 produced	 with	 the	presence	of	a	d.p.4,	with	a	greater	change	seen	upon	addition	of	d.p.6.	This	reduction	in	Tm	was	produced	with	the	greatest	change	seen	with	d.p.20.	The	addition	of	d.p.20	was	most	similar	to	the	effects	seen	with	PMH.	The	disaccharide	tested	showed	no	change	in	stability	 indicating	binding,	with	 the	 tetrasaccharide	 showing	 an	 intermediate	 level	 of	destabilisation	 indicating	some	effect,	but	 the	 increase	 from	a	4mer	 to	hexasaccharide	showed	the	greatest	change	 in	melting	point.	As	a	pentasaccharide	was	not	tested,	 the	minimum	size	requirement	of	heparin	oligosaccharide	in	IgG	Fc	binding	has	been	shown	to	 require	 a	 6mer,	 this	 could	 also	 have	 the	 same	 effect	 with	 a	 5mer.	 This	 sized	oligosaccharide	 was	 screened	 in	 the	 form	 of	 the	 synthetic	 LMWH	 pentasaccharide,	fondaparinux.			 Low	molecular	weight	heparins	were	tested	in	DSF	with	IgG	Fc	and	acetate	buffer	to	determine	if	depolymerised	heparins	dalteparin,	enoxaparin,	tinzaparin	and	reviparin	and	the	synthetic	pentasaccharide	fondaparinux	showed	any	binding	activity	of	IgG	Fc.	The	derived	LMWHs	dalteparin,	enoxaparin,	tinzaparin	and	reviparin,	at	the	same	molar	concentration	as	PMH,	displayed	similar	destabilisation	of	the	IgG	fragment	than	PMH.	This	may	suggest	at	6.0	μM	these	LMWH	mimic	the	binding	and	destabilisation	of	PMH,	and	 with	 a	 d.p.6	 only	 required	 to	 show	 a	 large	 destabilisation	 effect	 in	 DSF,	 the	sulphation	 level	 and	 GAG	 size	 of	 these	 derivatives	 is	 sufficient	 to	 mimic	 PMH.	Fondaparinux	 however,	 is	 a	 synthetic	 d.p.5	 representing	 only	 the	 pentasaccharide	sequence	sufficient	for	antithrombin	III	binding.	This	synthetic	GAG	did	not	destabilise	
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IgG	Fc	 to	 the	 same	extent	 as	 the	derived	LMWH	 tested	 suggesting	 it	 does	not	bind	as	effectively	to	the	immunoglobulin	fragment.			 Investigations	were	made	in	to	the	effects	of	increasing	acetate	concentration	in	IgG	Fc	DSF	at	pH	4.0.	In	acetate	buffer	at	all	strengths	tested	(20	mM	to	100	mM)	IgG	Fc	is	destabilised.	This	destabilisation	caused	by	sodium	acetate	increases	with	increasing	acetate	 concentration	 until	 80	 mM.	 However,	 a	 significant	 structural	 destabilisation	occurred	between	80	mM	sodium	acetate	and	100	mM	sodium	acetate,	reducing	the	Tm	by	a	further	10.67°C.	At	this	acetate	concentration,	buffer	ions	may	act	more	strongly	on	the	 protein	 structure	 through	 electrostatic	 interactions	 to	 destabilise	 the	 IgG	 Fc	fragment.			 In	DSF	with	the	same	concentration	gradient	of	acetate	buffer	with	the	addition	of	 6.0	 μM	PMH,	 IgG	Fc	 stability	 curves	have	 the	 same	appearance	 as	100	mM	sodium	acetate	 without	 PMH.	 This	 suggests	 the	 degree	 of	 destabilisation	 of	 100	mM	 sodium	acetate	on	this	Ig	fragment	is	similar	to	the	destabilisation	seen	with	the	binding	of	PMH	and	the	other	GAG	fragments	tested.	This	destabilisation	could	be	due	to	weakening	of	the	hydrophobic	effect,	solubilisation	of	hydrophobic	regions	and	disruption	of	internal	non-covelent	bonding,	 triggering	a	net	change	 in	protein	 folding.	The	100	mM	sodium	acetate	 with	 PMH	 experiments	 does	 not	 further	 decrease	 the	 Tm,	 signifying	 no	cumulative	effect	with	these	two	factors.				 The	 conformation	 of	 IgG	 Fc	 region	 was	 investigated	 with	 NMR	 1H-15N	 HSQC	analysis	 between	 pH	 2.5	 and	 4.7	 (Latypov	 et	 al.,	 2012).	 At	 pH	 4.7,	 amide	 peaks	 (117	assigned	resonances)	were	highly	dispersed	indicating	a	folded	conformation,	at	pH	3.5	a	 similar	 degree	 of	 dispersity	 was	 seen	 (116	 assigned	 resonances)	 but	 a	 number	 of	peaks	 had	 reduced	 intensity	 and	 new	 peaks	were	 seen	 not	 present	 at	 pH	 4.7	 (idem).	These	 structural	 changes	 are	 indicative	 of	 protonation	 of	 acidic	 side-chains	 such	 as	
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Glu380	and	Glu430,	which	 form	salt	bridges	with	Lys248	and	Lys388	 in	 the	native	Fc	region	 (idem).	 At	 pH	 3.1,	 some	 peaks	 present	 at	 higher	 pH	 disappeared	 (46	 assigned	resonances)	and	were	replaced	with	peaks	seen	at	pH	3.5,	suggesting	a	more	disordered	protein	conformation	(idem).	At	pH	2.5	the	remaining	native	peaks	disappeared	(idem).	The	 most	 prominent	 changes	 in	 chemical	 shift	 between	 pH	 4.7	 and	 3.5	 occurred	between	residues	250-255	and	310-315,	both	regions	of	interface	between	the	CH2	and	CH3	 Fc	 domains	 (idem).	 This	 interface	 region	 formed	 by	 CH2	 α-helices	 is	 the	 region	containing	 the	 corresponding	 Lys248	 and	 Lys338	 residues	 involved	 in	 salt	 bridge	formation	with	protonated	glutamic	acid	residues	at	pH	3.5	(idem).	The	peaks	indicating	the	presence	of	CH2	domain	structure	were	not	present	at	pH	3.1	suggesting	unfolding	of	this	immunoglobulin	fold	structure	(idem).			 An	investigation	into	the	effects	of	concentration	and	pH	of	sodium	acetate	buffer	was	expanded	to	cover	20	mM	to	100	mM	at	pH	4.0,	4.5	and	5.0.	The	melting	point	of	IgG	Fc	region	was	determined	by	DSF.	This	determined	the	Ig	Fc	fragment	was	more	stable	at	 pH	 5.0	 than	 pH	 4.0	 as	 expected	 as	 binding	 to	 FcRn	 on	 luminal	 surfaces	 occurs	 at	around	pH	6.0	when	His310	and	His433	are	protonated	and	dissociates	at	pH	7.4	on	the	basolateral	 surfaces	due	 to	deprotonation	 (Raghavan	et	 al.,	 1995).	The	working	pH	of	this	Ig	fragment	therefore	occurs	over	pH	range	of	6.0	to	7.4	and	therefore	is	required	to	maintain	structural	stability	in	this	range,	however	in	sodium	acetate	buffer	this	pH	may	differ.	With	the	addition	of	6	μM	PMH,	the	most	stable	pH	of	IgG	Fc	is	reduced	to	pH	4.5.			 Due	to	the	highly	polyanionic	nature	of	heparin,	the	HS	and	heparin	are	present	physiologically	 with	 bound	 cations	 which	 act	 to	 neutralise	 the	 highly	 charged	 GAG	chains.	Heparin	pharmaceutical	preparations	 are	 available	 in	 the	 sodium,	 calcium	and	lithium	 forms.	 The	 effect	 of	 the	 bound	 cations	 has	 been	 investigated	 in	 biological	systems	 where	 heparin	 and	 HS	 are	 utilised,	 such	 as	 in	 the	 FGF/FGFR	 signalling	
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pathways.	Rudd	et	al.	(2007)	utilised	Synchrotron	Radiation	Circular	Dichroism	(SRCD)	to	 illustrate	 sodium,	 potassium,	magnesium,	 calcium,	manganese	 (II),	 copper	 and	 iron	(III)	PMH	each	had	unique	spectra	and	the	binding	of	these	cations	subtly	modified	PMH	conformation	 and	 flexibility	when	measured	 by	NMR.	 The	 conversion	 between	 cation	states,	 for	 example	 from	potassium	 form	 into	 copper	 form,	 changed	 the	 bioactivity	 of	PMH	 in	 fibroblast	 growth	 factor	 2	 (FGF2):FGFR1c	 signalling	 from	 an	 inactive	 state	 to	active	(Rudd	et	al.,	2007).		 Unmodified	Celsus	heparin	had	the	most	destabilising	effect	on	IgG	Fc	region	at	the	three	highest	concentrations	tested	(18.8	nM,	9.4	nM	and	4.7	nM).	A	stabilising	effect	was	 seen	 at	 the	0.09	μM	 cation-PMH	 concentration	which	 increased	 the	Tm	of	 the	 Fc	fragment	when	compared	to	the	melting	temperature	of	 the	fragment	alone	 in	sodium	acetate	buffer.			 A	stabilising	effect	is	seen	with	0.19	μM	and	0.09	μM	of	all	of	the	cation	forms	of	heparin	 tested.	 This	 suggests	 either	 the	 process	 of	 preparing	 cation	 forms	 of	 heparin	reduces	 the	 magnitude	 of	 destabilising	 effect	 of	 heparin	 in	 this	 assay,	 or	 unmodified	Celsus	heparin	includes	unknown	factors	that	enhance	the	action	in	DSF	with	Fc	region.	This	unknown	factor	could	be	attributed	to	the	mixture	of	cations	bound	to	the	heparin	chain,	 the	 unmodified	 chain	 structure	 retaining	 a	 asset	 removed	 in	 the	 cation	formulation	process,	or	some	other	undefined	effect.				 The	effect	of	cation	on	the	stability	of	IgG	Fc	region	at	0.38	μM	can	be	identified	as	either	promoting	or	protecting	from	thermal	denaturation,	when	compared	to	the	IgG	Fc	protein	 alone.	 One	 group	 of	 cation	 heparin	 including	 potassium,	 ammonium,	 calcium,	zinc,	silver	and	vanadium	PMH	increased	the	Tm	and	therefore	IgG	Fc	region	stability	at	a	 concentration	 of	 0.38	 μM.	 Another	 group	 containing	 sodium,	 lithium,	 magnesium,	barium,	 iron	 (II),	 iron	 (III),	 copper	 and	manganese	 PMH	 decreased	 the	 Tm	 of	 IgG	 Fc	
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region	in	DSF	and	therefore	the	fragment	stability	at	this	concentration.	The	two	groups	of	cation	forms	do	not	ascribe	to	simple	explanations	such	as	separation	by	valency	or	similar	 atomic	 radii;	 with	 a	 range	 of	 valencies	 and	 radii	 included	 in	 each	 group.	Chevalier	et	al.	(2002)	indentified	the	presence	of	Ca2+	binding	sites	on	the	heparin/HS	chain,	 which	 acted	 to	 stiffen	 the	 molecule	 through	 specific	 binding	 regions	 between	iduronate	 and	 glucosamine	 residues;	 similar	 specific	 binding	 sites	 for	 other	 divalent	cations	were	not	identified	(Chevalier,	Angulo,	Lucas,	Nieto,	&	Martin-Lomas,	2002).	The	action	of	divalent	cations	in	both	increasing	and	decreasing	the	Tm	of	Fc	region	suggests	this	possible	‘stiffening’	of	the	PMH	chain	upon	cation	binding	is	not	solely	the	cause	of	the	change	in	Fc	region	binding	and	variations	in	stability.			 The	increase	of	Tm	seen	at	0.19	μM	and	0.09	μM	in	3	μM	IgG	Fc	with	the	cation	PMH	suggests	the	presence	of	low	concentrations	of	single	cation	heparin	binds	IgG	Fc	region	and	promotes	stability	of	the	protein;	at	these	concentrations	the	differentiation	of	cation	is	not	relevant.				 Previous	work	done	by	Rudd	et	al.	 (2007)	on	the	FGF/FGFR	signalling	pathway	grouped	the	cation	forms	of	PMH	tested	using	principle	component	analysis	of	the	SRCD	data;	 iron	 (III),	 manganese,	 potassium	 and	 sodium	 into	 one	 group,	 calcium	 and	magnesium	 into	 another	 group	 and	 copper	 as	 the	 sole	 member	 of	 the	 third	 group	(idem).	This	group	structure	is	not	reflected	in	the	cation	PMH	forms	tested	in	this	work,	with	 potassium	 and	 calcium	 improving	 Fc	 stability	 at	 the	 low	 concentrations	 tested,	while	 sodium,	 magnesium,	 iron	 (III),	 copper	 and	 manganese	 PMH	 forms	 promoting	thermal	degredation.			
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Chapter	5:	Investigations	of	glycosaminoglycan	
interactions	with	whole	immunoglobulin		
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5.1	Introduction		 To	determine	whether	the	 interaction	between	the	glycosaminoglycans	and	IgG	Fc	 region	 at	 pH	4.0	 –	 5.0	 seen	 in	 Chapter	 4	was	 a	 product	 of	 the	 formation	 of	 IgG	 Fc	region	from	a	whole	IgG	or	a	property	endowed	by	the	immuloglobulin	Fc	region	in	the	physiological	molecule,	in	this	chapter,	work	was	done	to	evaluate	the	effect	of	heparin,	and	the	library	of	screening	glycosaminoglycans	employed	in	the	previous	chapter,	on	a	wider	range	of	immunoglobulins	to	further	understand	this	interaction.		
5.1.1	Antibody	action		 In	 humans,	 approximately	 80%	of	 expressed	 antibodies	 are	 IgG	 class,	with	 the	subclass	expression	of	IgG1	to	IgG4,	named	according	to	physiologic	abundance.	5-10%	of	immuglobulin	is	IgM,	which	is	expressed	in	a	pentameric	form	from	plasma	cells,	but	as	 a	monomer	when	membrane	bound	on	B-lymphocytes.	 IgM	 is	utilised	 in	 the	 initial	stage	of	a	humoural	immune	response	but	has	a	short	half-life,	therefore	the	presence	of	these	antibodies	 suggests	an	acute	or	 recent	 infection.	Pentameric	 IgM	has	10	antigen	binding	sites	making	it	practical	as	an	agglutinin	and	in	complement	activation.			 This	 study	 focuses	 on	 the	 IgG	 and	 IgM	 antibody	 as	 the	 most	 abundantly	expressed	 antibody	 classes	 and	 due	 to	 time	 constraints,	 IgE,	 IgA	 and	 IgD	 were	 not	investigated.		
5.1.2	IgG	structure		 IgG	 hinge	 region	 size,	 number	 of	 disulphide	 bonds,	 and	 position	 of	 disulphide	bonds,	differentiate	the	four	subclasses	of	IgG	present	in	humans	(Schroeder	&	Cavacini,	2010).	 These	 subclass	 variations	 are	 caused	 by	 amino	 acid	 sequence	 differences	 and	allow	 for	 the	 variation	 in	 IgG	 biological	 activity	 (idem).	 IgG1,	 3,	 and	 4	 can	 cross	 the	
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placenta,	while	IgG1,	2,	and	3	can	activate	compliment.	Fc	receptors	bind	IgG	subclasses	with	varying	affinity;	with	IgG1	and	3	demonstrating	the	highest	binding	affinity	(idem).			 To	 complete	 this	 study,	 three	 types	 of	 IgG	 antibody	 will	 be	 challenged	 with	heparin	in	various	forms,	to	identify	if	the	IgG	Fc	binding	seen	in	Chapter	4	exists	when	in	the	complete	immunoglobulin	protein	form.			 If	 an	 antibody	 is	 chosen	 that	 has	 been	 raised	 to	 a	 possible	 heparin/HS/GAG	binding	 domain,	 there	 may	 be	 a	 possibility	 that	 addition	 of	 heparin	 to	 this	 antigen	binding	site	will	cause	antibody	binding;	this	will	mask	the	evidence	of	heparin	binding	to	 the	 non-antigen	 binding	 antibody	 regions.	 Therefore,	 antibodies	 were	 chosen	 in	 a	manner	 to	ensure	no	possible	GAG/heparin/HS	recognition.	Green	 fluorescent	protein	(GFP)	is	a	234-residue	protein	from	Aequorea	victoria	jellyfish,	but	is	commonly	used	as	a	gene	expression	 reporter	 (Tsien,	1998).	No	heparin	binding	 interactions	have	 so	 far	been	 reported	with	 this	 protein.	Human	 IgG1k	 and	 IgG2k	 raised	 to	GFP	were	 used	 in	these	 experiments	 to	 determine	 heparin	 binding	 and	 specific	 structural	 changes	associated	with	the	binding	interaction.	
5.1.3	IgM	structure			 IgM	has	an	additional	heavy	chain	 immunoglobulin	domain	CH4,	 increasing	 the	size	of	the	Fc	region	(Schroeder	&	Cavacini,	2010).	The	pentamer	of	IgM	is	constructed	by	 additional	 disulphate	 bridges	 between	 this	 extra	 CH4	 domain	 of	 the	 5	monomers,	alongside	 the	 J-chain	or	 joining	chain	 (idem).	The	 J-chain	 is	a	137	amino	acid	cysteine	rich	polypeptide	present	in	both	IgM	and	IgA	to	allow	for	polymerisation	(idem).	The	J-chain	 in	 IgM	allows	 for	 the	secretion	of	pentameric	 IgM	to	mucosal	surfaces	alongside	IgA	(idem).	
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	 Desipramine	 (Norpramin,	 Pertofane)	 is	 a	 tricyclic	 (selective	 nor-adrenaline/	serotonin	re-uptake	inhibitor)	anti-depressant	(TCA).	The	anti-desipramine	monoclonal	IgM	 antibody	 is	 used	 to	 detect	 the	 presence	 of	 this	 pharmaceutical	 in	 patient	 blood	samples	to	assess	patient	therapeutic	regime	and	to	identify	potential	overdose.	In	this	chapter,	anti-desipramine	IgM	will	be	used	to	determine	heparin	binding.	
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5.2	Results		 Initial	experimentation	using	thermal	stability	assay	DSF	was	employed	to	study	the	stability	of	whole	immunoglobulin	with	structurally	defined	heparins.	
5.2.1	IgG1k	stability	in	the	presence	of	chemically	modified	heparins	
	 IgG1k	1st	derivative	melt	curve	demonstrated	a	peak	at	a	temperature	of	53.3°C.	The	difference	between	the	Tm	of	6	μM	CMH1	and	IgG1k	alone	is	14.86°C.	CMH1	at	6	μM	to	1.5	μM	moves	the	first	derivative	peak	to	a	lower	temperature,	with	a	shoulder	on	the	curve	at	38.4°C	and	a	lower	intensity,	suggesting	the	population	of	the	protein	only	peak	has	 been	 spread	 representing	 more	 of	 a	 range	 of	 conformations	 or	 stabilities,	 with	different	Tm	with	CMH1	present	to	1.5	μM	concentration.	The	higher	intensity	peak	at	these	CMH1	concentrations	 is	shifted	to	a	 lower	Tm	also	compared	to	 the	 IgG1k	peak,	shifting	 from	Tm	53.3°C	 to	Tm	48.7°C.	At	 0.75	μM	CMH1	 concentration,	 the	 flattened,	more	 spread	 peak	 moves	 to	 a	 main	 peak	 at	 42.0°C	 with	 a	 shoulder	 at	 a	 lower	temperature	of	51.0°C.	At	0.38	μM,	 the	main	peak	 is	present	at	 the	same	Tm	as	 IgG1k	only,	and	with	decreasing	concentrations	of	CMH1,	stays	at	 this	Tm.	The	curve	at	0.38	μM	 is	 different	 from	 subsequent	 lower	 CMH1	 concentrations	 by	 the	 slight	 shoulder	
	Figure	50:	DSF	of	human	IgG1k	with	CMH1	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH1,	(−)	3.0	μM	CMH1,	(−)	1.5	μM	CMH1,	(−)	0.75	μM	CMH1.	B=	(−)	1	μM	human	IgG1k	with	(−)	0.38	μM	CMH1,	(−)	0.19	μM	CMH1,	(−)	0.09	μM	CMH1,	(−)	0.05	μM	CMH1.		
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present	at	44.5°C,	mirroring	the	shape	seen	in	higher	CMH1	concentrations,	but	without	the	 defined	 peak.	 The	 intensity	 of	 the	 fluorescence	 increases	 in	 inverse	 proportion	 to	CMH1	concentration,	with	highest	peak	intensity	seen	in	IgG1k	alone.	The	full	range	of	CMH1	dilutions	are	assayed	with	Sypro	Orange	without	protein	to	ensure	no	change	in	fluorescence	was	seen	(data	not	shown).	
	 The	 difference	 between	 the	 Tm	 of	 the	most	 concentrated	 CMH2	 (6.0	 μM)	 and	IgG1k	only	Tm	is	4.34°C.	The	Tm	of	6.0	μM	and	3.0	μM	CMH2	is	50.53°C,	compared	to	the	IgG1k	 only	 peak	 at	 54.69°C.	 The	 peaks	 of	 6.0	 μM	 and	 3.0	 μM	 CMH2	 have	 a	 sloping	shoulder,	unlike	the	more	clear	shoulder	on	IgG1k	with	CMH1.		
	 The	change	in	Tm	between	6.0	μM	CMH3	(highest	concentration	tested)	and	the	IgG1k	only	 control	 is	 9.95°C.	 The	CMH3	 concentrations	 of	 6.0,	 3.0,	 and	1.5	 μM	have	 a	
	Figure	51:	DSF	of	human	IgG1k	with	CMH2	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH2,	(−)	3.0	μM	CMH2,	(−)	1.5	μM	CMH2,	(−)	0.75	μM	CMH2.	B=	(−)	1	μM	human	IgG1k	with	(−)	0.38	μM	CMH2,	(−)	0.19	μM	CMH2,	(−)	0.09	μM	CMH2,	(−)	0.05	μM	CMH2.		
	Figure	52:	DSF	of	human	IgG1k	with	CMH3	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH3,	(−)	3.0	μM	CMH3,	(−)	1.5	μM	CMH3,	(−)	0.75	μM	CMH3.	B=	(−)	1	μM	human	IgG1k	with	(−)	0.38	μM	CMH3,	(−)	0.19	μM	CMH3,	(−)	0.09	μM	CMH3,	(−)	0.05	μM	CMH3.		
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shoulder	step	at	≈	43°C,	moving	into	peaks	at	51.8°C	to	46.9°C.	CMH3	at	0.75	μM	gives	a	curve	with	only	a	discernable	shoulder	at	46.96	°C,	with	the	peak	of	 this	 flat	region	at	54.0°C.	The	intensity	of	the	peaks	then	increases	with	decreasing	CMH3	concentration.		
	 The	 highest	 concentration	 of	 CMH4	 tested	 (6.0	 μM)	 tested	 compared	with	 the	IgG1k	control	gives	a	Δ	Tm	of	12.7°C.	6.0	μM	and	3.0	μM	CMH4	exhibit	melt	curves	with	a	shoulder	at	40.24°C	and	41.67°C	respectively,	with	a	major	peak	at	49.50°C.	CMH4	at	1.5	 μM	 gives	 a	 long	 stretched	 out	 peak	with	 a	 shoulder	 at	 a	 temperature	 of	 43.25°C,	leading	in	to	a	peak	at	50.29°C.	At	0.75	μM	the	curve	no	longer	has	a	typical	‘peak’	with	a	long	 flattened	curve	with	maximal	height	at	51.78°C.	Subsequent	concentrations	show	slight	but	not	significant	increases	in	Tm	compared	to	the	IgG1k	only.	
	 The	difference	in	Tm	between	the	highest	concentration	of	CMH5	and	the	IgG1k	control	 is	9.09°C.	The	peak	of	CMH5	with	6.0	μM	has	a	shoulder	at	Tm	45.36°C,	with	a	
	Figure	53:	DSF	of	human	IgG1k	with	CMH4	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH4,	(−)	3.0	μM	CMH4,	(−)	1.5	μM	CMH4,	(−)	0.75	μM	CMH4.	B=	(−)	1	μM	human	IgG1k	with	(−)	0.38	μM	CMH4,	(−)	0.19	μM	CMH4,	(−)	0.09	μM	CMH4,	(−)	0.05	μM	CMH4.		
	Figure	54:	DSF	of	human	IgG1k	with	CMH5	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH5,	(−)	3.0	μM	CMH5,	(−)	1.5	μM	CMH5,	(−)	0.75	μM	CMH5.	
B=	(−)	1	μM	human	IgG1k	with	(−)	0.38	μM	CMH5,	(−)	0.19	μM	CMH5,	(−)	0.09	μM	CMH5,	(−)	0.05	μM	CMH5.		
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maxima	at	51.89°C.	This	peak	shape	is	mirrored	by	3.0	μM	with	IgG1k,	with	a	shoulder	at	45.99°C	and	a	main	peak	at	51.68°C.	The	peak	at	0.75	μM	is	a	more	traditional	shape	with	 Tm	 at	 54.43°C,	 with	 a	 higher	 peak	 intensity	 than	 that	 of	 1.5	 μM.	 Successive	decreasing	concentrations	retain	approximately	the	same	Tm.		
	 Comparing	 the	highest	 concentration	of	CMH6	 tested	against	 the	 IgG1k	 control	has	a	difference	in	Tm	of	8.93°C.	The	IgG1k	with	6.0	μM	peak	has	a	Tm	of	51.99°C,	with	a	shoulder	of	lower	Tm	at	45.01°C.	At	1.5	μM,	the	peak	is	more	flat,	not	giving	the	defined	shoulder	 of	 the	more	 concentrated	peaks,	with	 a	 graduated	peak	 stopping	 at	 a	 Tm	of	54.24°C.	 The	 Tm	 of	 0.38	 μM	with	 IgG1k	 is	 54.38°C	with	 decreasing	 concentrations	 of	CMH6	remaining	with	the	same	Tm	of	54.37°C.		
	Figure	55:	DSF	of	human	IgG1k	with	CMH6	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH6,	(−)	3.0	μM	CMH6,	(−)	1.5	μM	CMH6,	(−)	0.75	μM	CMH6.	B=	(−)	1	μM	human	IgG1k	with	(−)	0.38	μM	CMH6,	(−)	0.19	μM	CMH6,	(−)	0.09	μM	CMH6,	(−)	0.05	μM	CMH6.		
	Figure	56:	DSF	with	human	IgG1k	with	CMH7	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH7,	(−)	3.0	μM	CMH7,	(−)	1.5	μM	CMH7,	(−)	0.75	μM	CMH7.	
B=	(−)	1	μM	human	IgG1k	with	 (−)	0.38	μM	CMH7,	 (−)	0.19	μM	CMH7,	(−)	0.09	μM	CMH7,	 (−)	0.05	μM	CMH7.		
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	 The	 difference	 between	 6.0	 μM	 CMH7	 and	 protein	 only	 in	 this	 IgG1k	 DSF	 is	4.04°C.	The	6.0,	3.0,	and	1.5	μM	concentrations	of	CMH7	have	Tm	curves	with	a	sloping	shoulder	but	with	no	discernable	peak	at	the	lower	Tm.	The	Tm	peaks	for	6.0	and	3.0	μM	are	 50.34	 and	 50.43°C,	 with	 the	 peak	 of	 1.5	 μM	 at	 51.56°C.	 The	 shape	 of	 the	 peak	remains	 for	 0.75	 μM	 concentration	 of	 CMH7,	 but	 shifted	 toward	 the	 higher	temperatures,	with	the	peak	at	53.50°C.	Both	0.09	and	0.05	μM	have	a	slightly	increased	Tm	 compared	 to	 IgG1k	 only,	 55.1°C	 and	 55.71°C	 respectively,	 with	 IgG1k	 only	 Tm	54.38°C.			 The	highest	concentration	of	CMH8	with	IgG1k	gives	a	Tm	of	51.51°C	compared	to	 IgG1k	 only	 Tm	 of	 53.1°C.	 This	 gives	 a	 difference	 in	 Tm	 of	 1.59°C,	 the	 smallest	difference	seen	 in	this	group	of	chemically	modified	heparins.	At	3.0	μM	the	Tm	is	 the	same	as	6.0	μM,	with	1.5	μM	giving	a	Tm	of	52.67°C.	The	Tm	of	the	subsequent	CMH8	concentrations	gives	Tm	slightly	higher	than	that	of	IgG1k	only.			
	Figure	57:	DSF	with	human	IgG1k	with	CMH8	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH8,	(−)	3.0	μM	CMH8,	(−)	1.5	μM	CMH8,	(−)	0.75	μM	CMH8.	
B=	(−)	1	μM	human	IgG1k	with	 (−)	0.38	μM	CMH8,	(−)	0.19	μM	CMH8,	(−)	0.09	μM	CMH8,	 (−)	0.05	μM	CMH8.		
	Figure	58:	DSF	of	human	IgG1k	with	CMH9	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	CMH9,	(−)	3.0	μM	CMH9,	(−)	1.5	μM	CMH9,	(−)	0.75	μM	CMH9.	B=	(−)	1	μM	human	IgG1k	with	(−)	0.38	μM	CMH9,	(−)	0.19	μM	CMH9,	(−)	0.09	μM	CMH9,	(−)	0.05	μM	CMH9.	
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	 Of	 all	 the	 chemically	 modified	 heparins	 tested	 with	 IgG1k,	 CMH9	 displays	 the	most	 disruption	 to	 the	 protein	 in	 DSF	 as	 seen	 in	 the	 flattening	 of	 the	melt	 curves	 at	concentrations	 >	 0.38	 μM	 CMH9.	 The	 difference	 in	 Tm	 between	 the	 highest	concentration	 of	 CMH9	 tested	 (6.0	 μM)	 and	 the	 protein	 only	 control	 is	 17.39°C.	However,	 the	 curves	 for	 the	 6.0	 -	 0.75	 μM	 experiments	 do	 not	 give	 a	 defined	 initial	shoulder	 but	 they	 do	 show	 a	 broad	 peak	 beginning	 at	 ≈	35°C.	 The	 curve	 for	 6.0	 μM	shows	a	broad	peak	with	initial	maxima	at	34.97°C,	with	a	more	defined	peak	at	45.97°C.	This	shape	is	mimicked	by	3.0	μM	CMH9,	with	1.5	μM	showing	a	shift	in	the	shoulder	to	a	Tm	of	 35.45°C	with	 a	peak	 at	 47.2	 °C.	 The	0.75	μM	 concentration	of	 CMH9	 curve	 is	wider,	 with	 less	 defined	 peak	 regions	 across	 the	 whole	 of	 the	 curve.	 At	 lower	concentrations	of	CMH9,	 the	1st	derivative	melt	curves	 follow	a	more	traditional	curve	structure.	The	last	4	concentrations	studied	showing	a	slight	stabilisation	versus	IgG1k	control.		
	Figure	59:	Differential	scanning	fluorimetry	of	IgG1k	with	CMH	in	50	mM	sodium	acetate	buffer	pH	4.0	Δ	Tm	from	DSF	plotted	as	a	function	of	CMH	concentration	(compared	to	IgG1k	alone).	IgG1k	with	A)	6	μM	CMH1	EC50	=	0.667	μM	B)	6	μM	CMH8	EC50	=	1.513	μM	C)	6	μM	CMH9	EC50	=	0.623	μM.	
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		 Plotting	the	change	in	Tm	observed	by	the	addition	of	increasing	concentrations	of	chemically	modified	heparin,	produces	a	simple	graphical	representation	of	the	DSF	data.	 Figure	 59	 shows	 the	 greatest	 change	 is	 seen	 with	 the	 addition	 of	 persulphated	CMH9	heparin,	with	CMH1	following	closely	behind.	Unsulphated	CMH8	has	the	highest	number	 of	 concentrations	 with	 no	 change	 in	 Tm,	 and	 at	 the	 highest	 CMH8	concentrations	tested	this	Tm	change	remains	the	lowest	of	the	library	tested.			
	 PCA	 of	 CMH1	with	 IgG1k	 demonstrates	 a	 relationship	 between	 0.75	 μM	CMH1	and	the	protein	only	control	in	principle	component	1,	but	a	difference	between	0.75	μM	CMH1	and	the	protein	only	control	in	the	principle	component	2.	The	concentrations	of	CMH1	<	0.19	μM	are	grouped	with	the	IgG1k	protein	only	control.	PCA	analysis	of	CMH	2-9	 is	 shown	 in	 Figure	 61.	 CMH2-9	 with	 IgG1k	 in	 Figure	 61	 exhibit	 analogous	 PCA	spectra	 to	CMH1,	with	PC1	 increasing	with	decreasing	CMH1	concentration	 to	 the	 IgG	protein	 only	 control	 value,	 before	 switching	 and	 decreasing	 again	 with	 the	 low	concentrations	of	CMH1	shown	to	have	a	stabilising	effect	in	the	1st	derivative	DSF	data	(Figures	 61).	 This	 suggests	 both	 the	 destabilising	 and	 stabilising	 effects	 of	 CMH1	represent	+/-	structural	transitions,	which	pass	through	the	same	intermediate.	
	Figure	 60:	 PCA	 of	 the	 1st	 derivative	 DSF	 melt	 curve	 of	 human	 IgG1k	 with	 CMH1	 at	 varying	concentrations.	
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	Figure	61:	PCA	of	the	1st	derivative	DSF	data	of	IgG1k	with	varying	concentrations	of	CMH	2-9.		
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	 In	order	to	complete	a	full	screen	on	the	chemical	modifications	and	their	ability	to	modify	the	CD	spectra	of	IgG1k,	a	mouse	IgG	isotype	control	antibody	was	selected	for	further	circular	dichroism	experiments	because	of	the	amount	of	material	needed,	and	the	cost	of	this.			 The	 addition	 of	 each	 form	 of	 chemically	 modified	 heparin	 removes	 the	 peak	intensity	around	λ	=	219	nm	to	differing	degrees,	with	peak	shift	approximately	λ	=	2	nm	
	Figure	62:	Far-UV	circular	dichroism	spectra	of	mouse	IgG	with	CMH1-4.	Reaction	buffer	50	mM	sodium	acetate	pH	4.0.	(−)	3	μM	mouse	IgG	with	A)	(−)	3	μM	CMH1,	B)	(−)	3	μM	CMH2,	C)	(−)	3	μM	CMH3,	D)	(−)	3	μM	CMH4.	
Table	8:	DSF	of	human	IgG1k	with	CMH	in	50	mM	sodium	acetate	buffer	pH	4.0,	Δ	Tm	compared	to	IgG1k	alone.			
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to	the	right	in	all	cases	(Figure	62).	Both	IgG	with	CMH2	(Figure	62B)	and	CMH3	(Figure	62C)	have	a	similar	spectral	shapes.				 Figure	63	below	shows	the	peak	at	λ	=	219	nm	is	removed	completely	with	the	addition	of	CMH6	(Figure	63B),	and	is	only	very	slightly	discernable	with	the	addition	of	CMH5	(Figure	63A)	and	the	persulphated	modification,	CMH9	(Figure	63E).	Mouse	IgG	with	unsulphated	CMH8	displays	the	least	change	to	secondary	structure	with	a	spectral	shift	occurring	of	2	nm	to	λ	=	220	nm	with	a	CD	intensity	most	similar	to	that	of	the	IgG	only	control	spectra	(Figure	63D).		
	 This	CD	data	 show	chemically	modified	heparin	 forms,	 analogues	 to	 the	 varied	regions	 seen	 in	 heparan	 sulphate	 and	 heparin,	 change	 the	 secondary	 structure	 of	 the	
	Figure	63:	Far-UV	circular	dichroism	spectra	of	mouse	IgG	with	CMH5-9.	Reaction	buffer	50	mM	sodium	acetate	pH	4.0.	(−)	3	μM	mouse	IgG	with	A)	(−)	3	μM	CMH5,	B)	(−)	3	μM	CMH6,	C)	(−)	3	μM	CMH7,	D)	(−)	3	μM	CMH8,	E)	(−)	3	μM	CMH9.			
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immunoglobulin,	 IgG.	 This	 structural	 change	 shows	 no	 simple	 correlation	 between	spectral	 features	and	 the	arrangement	of	sulphate	groups	on	both	 the	uronic	acid	and	glucosamine	residues.			 However,	two	modified	heparins	CMH5	and	CMH6	show	the	most	perturbation	in	CD	spectra,	apart	from	the	per-sulphated	heparin.	This	anomaly	is	repeated	in	the	DSF	data,	 with	 the	 least	 change	 in	 Tm	 with	 the	 addition	 of	 6	 μM	 seen	 in	 the	 same	 two	compounds,	 apart	 from	 unsulphated	 CMH8	 (Table	 8).	 This	 shows	 the	 change	 in	secondary	structure	identified	in	CD	does	not	always	lead	to	a	change	in	protein	thermal	destabilisation	and	vice	versa.		
5.2.2	IgG1k	stability	in	the	presence	of	low	molecular	weight	heparins	
	 	A	 library	 of	 low	 molecular	 weight	 heparins	 (LMWH)	 were	 utilised	 in	 DSF	 to	represent	 modified	 structures	 from	 depolymerisation	 and	 synthesis,	 with	 known	structural	features.	Tm	of	human	IgG1k	alone	is	53.46°C	with	a	wide	peak	(Figure	64).	With	the	addition	of	6.0	μM	CMH1,	the	peak	Tm	shifts	to	a	shouldered	peak	with	Tm	of	38.04°C	and	49.78°C	with	the	highest	intensity	peak	at	49.78°C.	Addition	of	dalteparin	at	6.0	μM	gives	a	similar	shouldered	peak	at	Tm	of	38.79°C	and	50.23°C	with	the	highest	intensity	at	50.23°C.	Enoxaparin	at	the	same	molar	concentration	gives	a	peak	Tm	with	IgG1k	at	40.47°C	and	51.38	°C,	with	the	51.38°C	peak	the	same	intensity	as	dalteparin.	
	Figure	64:	DSF	of	human	IgG1k	with	LMWH	in	50	mM	sodium	acetate	buffer	pH	4.0.	A)	(−)	1	μM	human	IgG1k	with	(−)	6.0	μM	dalteparin,	 (−)	6.0	μM	enoxaparin	B)	(−)	1	μM	human	IgG1k	(−)	6.0	μM	tinzaparin,	(−)	6.0	μM	reviparin,	(−)	6.0	μM	fondaparinux.		
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The	tinzaparin	peak	is	the	same	shape	as	dalteparin	and	enoxaparin	and	the	Tm	of	the	peak	 and	 shoulder	 is	 between	 these	 two	 LMWH,	 at	 a	 temperature	 of	 39.62°C	 and	50.61°C.	 Reviparin	 at	 the	 same	 molar	 concentration	 has	 a	 peak	 with	 a	 less	 defined	shoulder,	with	the	Tm	at	50.66°C.	Fondaparinux	with	IgG1k	gives	a	double	peak	with	Tm	of	42.62°C	and	53.17°C.	The	main	peak	of	fondaparinux	mirrors	the	high	intensity	peak	of	IgG1k	protein	control.			 The	synthetic	pentasaccharide	 fondaparinux	has	a	 limited	effect	on	the	 thermal	stability	if	human	IgG1k,	with	the	PCA	demonstrating	grouping	with	IgG1k	protein	only	control,	compared	to	the	distribution	of	the	other	LMWH	tested.	Dalteparin	is	the	most	similar	 to	UF	PMH	in	the	PCA,	which	 is	corroborated	 in	 the	1st	derivative	DSF	spectra.	Dalteparin,	reviparin	and	tinzaparin	are	grouped	together	with	enoxaparin	occupying	a	intermediate	position	between	the	LMWH	group	and	fondaparinux	with	IgG1k	(Figure	65).	
	Figure	65:	PCA	of	1st	derivative	DSF	of	human	IgG1k	with	LMWH	in	50	mM	sodium	acetate	buffer	pH	4.0.		
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5.2.3	IgG1k	stability	in	the	presence	of	GAGs	and	heparin	controls		 Other	 GAGs	 were	 then	 assessed	 for	 their	 ability	 to	 perturb	 the	 Tm	 of	 IgG1k	(Figure	66).	Alongside	these	GAGs,	a	Na2SO4	control	was	also	conducted	to	identify	any	action	 due	 to	 sulphate	 moieties	 alone,	 and	 the	 disaccharide	 standard	 6	 (UA(2S)–GlcNS(6S))	was	used	as	a	depolymerised	heparin	control.			 The	 greatest	 change	 in	 Tm	 seen	 with	 all	 that	 GAGs,	 disaccharides	 and	 Na2SO4	tested	is	seen	on	the	addition	of	6.0	μM	UF	PMH;	a	Tm	change	of	14.26°C.	The	Tm	shift	between	 IgG1k	alone	and	 the	highest	 intensity	peak	at	 6.0	μM	UF	PMH	 is	3.80°C.	The	Na2SO4	 control	 does	not	 appreciably	 change	 the	Tm	of	 IgG1k	 (Figure	66A)	 suggesting	the	incidence	of	sulphate	functional	groups	on	the	glycopolymer	are	not	the	sole	cause	of	protein	thermal	destabilisation.	Addition	of	12.0	μM	HS	exhibits	a	main	peak	with	a	shoulder	with	Tm	43.97°C	and	a	peak	Tm	of	51.22°C.		The	reduction	in	Tm	from	IgG1k	alone	to	12.0	μM	HS	to	the	shoulder	Tm	gives	a	9.06°C	change	in	Tm.		
	Figure	66:	Differential	scanning	fluorimetry	of	human	IgG1k	with	GAGs	and	sulphate	controls	in	50	mM	sodium	acetate	buffer	pH	4.0	(−)	1	μM	human	IgG1k	A)	(−)	6.0	μM	UF	PMH,	(−)	500	nM	sodium	sulphate,	 B)	(−)	6.0	μM	UA(2S)-GlcNS(6S)	disaccharide	 (−)	12.0	μM	HS,	C)	(−)	6.0	μM	CSA,	(−)	6.0	μM	CSC,	D	(−)	6.0	μM	DS,	(−)	6.0	μM	HA.	
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	 In	DS	the	peak	shape	also	includes	a	shoulder	peak	at	Tm	45.72°C,	with	the	larger	fluorescence	 peak	 Tm	 of	 52.62°C.	 The	 change	 in	 Tm	 seen	 with	 DS	 is	 7.31°C	 if	 the	shoulder	Tm	is	compared	to	IgG1k	alone.	The	next	largest	shift	in	Tm	is	seen	with	CSC,	with	the	reduction	in	Tm	on	addition	of	6.0	μM	CSC	of	4.61°C,	which	is	a	greater	change	than	 comparing	 the	 highest	 intensity	 peak	 of	 UF	 PMH	 and	 IgG1k.	 The	 Tm	 of	 CSC	 is	48.42°C,	with	a	long	sloping	curve	up	to	the	peak	maxima.	CSA	then	follows,	with	6.0	μM	CSA	with	 IgG1k	causing	a	Tm	reduction	of	3.15°C	to	a	Tm	of	49.88°C.	HA	and	UA(2S)-GlcNS(6S)	 (DS6)	 both	 have	 the	 same	 Tm	 with	 IgG1k,	 with	 Tm	 of	 52.05°C	 with	 a	negligible	change	in	Tm	compared	to	IgG1k	only	of	0.98°C.			 The	 PCA	 analysis	 of	 the	 DSF	 data	 from	 Figure	 67	 indicates	 a	 similarity	 in	 the	principle	components	of	CSA	and	UF	PMH	in	the	thermal	denaturation	spectra	of	IgG1k.	CSC	and	CSA	demonstrate	differences	in	principle	component	1	suggesting	the	carbon-4	vs	carbon-6	sulphation	shows	a	distinction	in	the	thermal	denaturation	of	IgG1k.	
	Figure	67:	PCA	from	DSF	1st	derivative	data	of	human	IgG1k	with	GAGs	and	sulphate	controls.		
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5.2.4	IgG1k	stability	in	the	presence	of	size	defined	heparin	fractions		 The	addition	of	d.p.2	has	the	same	melt	curve	shape	as	IgG1k	alone,	with	a	small	increase	 in	Tm	increase	of	1.03°C.	 IgG1k	with	d.p.4	changes	 the	curve	shape	 to	a	 two-peak	structure	with	the	Tm	of	50.30°C	and	57.89°C.	Addition	of	d.p.6	modifies	the	curve	shape	 again	 to	 a	 smaller	 initial	 peak	with	 larger	main	 peak,	 with	 Tm	 of	 45.61°C	 and	54.96°C	 respectively.	 Increasing	 the	 heparin	 size	 with	 d.p.8	 produces	 a	 peak	 with	shoulder	 at	 lower	 temperatures	with	 the	Tm	being	 44.87°C	 and	53.58°C	 for	 the	main	peak.	The	d.p.12	fraction	demonstrates	shoulder	peak	Tm	at	44.82°C	with	the	main	peak	at	 51.88°C.	 Each	 subsequent	 increasing	 d.p.	 has	 similar	 curve	 shape	 to	 d.p.12,	 with	progressive	 reduction	 in	 the	 Tm.	 Only	 d.p.14	 with	 IgG1k	 does	 not	 have	 a	 clear	 peak	shoulder.	The	size	fragment	with	the	Tm	closest	to	that	of	UF	PMH	is	d.p.18.	The	fraction	to	d.p.20	has	a	higher	main	peak	Tm	at	52.35°C	and	is	comparable	with	the	Tm	of	d.p.10.		
Table	9:	DSF	Tm	of	PMH	polymerization	(d.p.)	fragment	with	human	IgG1k	in	50	mM	sodium	acetate	buffer	pH	4.0.		
	
	 166	
5.2.5	IgG1k	stability	changes	at	differing	buffer	concentrations	and	pH	
	 In	 order	 to	 determine	 the	 buffer	 concentration	 and	 pH	 dependence	 of	 the	interaction	between	IgG1k	and	UF	PMH,	structural	stability	changes	of	IgG1k	with	DSF	were	determined.			 DSF	 with	 human	 IgG1k	 in	 PBS	 buffer	 was	 conducted	 to	 resolve	 if	 the	 heparin	destabilisation	of	IgG1k	occurred	at	pH	7.4	in	physiological	buffer	(Figure	68).	This	DSF	experiment	showed	no	structural	stability	change	(Tm	of	68°C)	with	the	addition	of	UF	PMH	in	PBS	buffer	pH	7.4.			 The	 binding	 affinity	 between	 IgG1k	 and	 heparin	 has	 been	 determined	 using	affinity	Hi-Trap	HPLC	with	sodium	acetate	and	PBS	buffer	tested	under	a	range	of	pH.			 Figure	 69	 is	 the	 heparin	 affinity	 chromatogram	of	 human	 IgG1k	 in	 heparin	Hi-Trap	 HPLC,	 demonstrating	 heparin	 binding	 with	 both	 pH	 4.0	 and	 pH	 5.0	 PBS,	 but	indicates	no	heparin	binding	at	pH	6.0.	At	pH	5.0	IgG1k	binds	heparin	with	an	affinity	of	928	mM,	with	the	affinity	for	heparin	increasing	to	1.08	M	at	the	lower	pH	4.0	(Figure	69).	 The	DSF	 in	 Figure	68	 suggests	 changes	 in	 thermal	 stability	 signify	 no	 interaction	between	the	human	IgG1k	and	UF	PMH	in	PBS	at	pH	7.4,	and	the	heparin	binding	affinity	at	 this	 pH	 reflects	 this	 (Figure	 69).	 Heparin	 binding	 affinity	 of	 human	 IgG1k	 in	 the	original	buffer	of	50	mM	sodium	acetate	pH	4.0	is	given	as	849	mM	as	shown	in	Figure	
	Figure	68:	DSF	of	human	IgG1k	with	UF	PMH	in	PBS	buffer	pH	7.4	±	UF	PMH	A)	(−)	1	μM	human	IgG1k	region	with	(−)	6.0	μM	UF	PMH,	(−)	137	mM	NaCl.	
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70.	Across	 two	different	 buffers	 at	 pH	4.0,	 both	mouse	 and	human	 IgG	 tested	 bind	 to	heparin	as	shown	through	heparin	hi-trap	affinity	chromatography,	with	elution	by	2M	NaCl.		
	 The	mouse	isotype	control	IgG	(Figure	71)	used	as	a	cheaper	IgG	proxy	in	far-UV	CD	demonstrated	heparin	binding	in	PBS,	between	pH	4.0	and	6.0.	At	pH	6.0,	the	IgG1k	affinity	for	heparin	is	704	mM,	increasing	to	933	mM	at	pH	5.0,	and	further	increasing	to	1.05	M	affinity	at	pH	4.0.	At	a	pH	closer	to	physiological	(pH	≥	7.0)	mouse	IgG1k	does	not	bind	the	heparin	column.		
	Figure	70:	Human	IgG1k	in	heparin	HiTrap	affinity	HPLC	in	50	mM	sodium	acetate	pH	4.0	with	2M	NaCl	elution		
	Figure	69:	Human	IgG1k	 in	heparin	HiTrap	affinity	HPLC	in	PBS	at	differing	pH	(4.0	–	7.4)	and	elution	with	linear	gradient	of	2M	NaCl.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.		
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5.2.6	IgG2k	stability	in	the	presence	of	chemically	modified	heparins	
	 The	 IgG2k	 1st	 derivative	 melt	 peak	 has	 a	 Tm	 of	 54.12°C	 and	 the	 difference	between	the	highest	concentration	of	CMH1	tested	(6.0	μM)	and	IgG2k	alone	is	15.38°C.	CMH1	at	6.0	μM	with	IgG2k	has	a	peak	Tm	at	38.74°C,	however	this	peak	is	more	broad	than	the	protein	only	peak.	Concentrations	of	3.0	μM	and	1.5	μM	CMH1	mirror	the	shape	
	Figure	71:	Mouse	 IgG	 isotype	control	 in	heparin	HiTrap	affinity	HPLC	 in	PBS	at	differing	pH	and	elution	with	2M	NaCl.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.	
	Figure	72:	DSF	of	human	IgG2k	with	CMH1	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG2k	with	(−)	6.0	μM	CMH1,	(−)	3.0	μM	CMH1,	(−)	1.5	μM	CMH1,	(−)	0.75	μM	CMH1.	B=	(−)	1	μM	human	IgG2k	with	(−)	0.38	μM	CMH1,	(−)	0.19	μM	CMH1,	(−)	0.09	μM	CMH1,	(−)	0.05	μM	CMH1.		
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of	 6.0	 μM	 CMH1	 with	 IgG2k.	 The	 Tm	 of	 CMH1	 at	 0.75	 μM	 is	 shifted	 to	 a	 higher	temperature	 compared	 to	 the	 first	 3	 concentrations	 tested	with	 a	Tm	of	 42.33°C.	 The	peak	 of	 CMH1	 at	 0.75	 μM	 is	 wide	 toward	 the	 higher	 temperature	 end,	 but	 does	 not	feature	a	shoulder	or	peak	at	higher	temperatures	like	the	higher	CMH1	concentrations.	The	peak	shape	then	changes	with	decreasing	concentration	of	CMH1,	with	the	0.19	μM	concentration	 curve	 containing	 a	 small	 shoulder	 peak	 to	mirror	 the	main	 peak	 of	 the	higher	 concentrations	 (at	 44.17°C)	 but	 the	major	 peak	 at	 this	 concentration	 being	 at	54.09°C,	 approximately	 the	 same	 concentration	 of	 the	 shoulder	 at	 concentration	 0.38	μM.			 The	difference	between	 the	 IgG2k	peak	and	 the	highest	 concentration	of	CMH2	tested	is	14.05°C.	The	CMH2	and	IgG2k	peak	at	6.0	μM	has	a	double	peak	with	the	first	peak	Tm	at	40.27°C	and	the	second	at	49.59°C.	CMH2	at	3.0	μM	and	1.5	μM	also	have	this	double	peak	structure,	with	the	Tm	of	peaks	at	3.0	μM	41.44°C	and	50.42°C.	The	curve	of	0.75	 μM	 CMH2	 seems	 to	 hold	 an	 intermediate	 position	 between	 the	 two	 peak	concentrations	and	more	standard	single	peak	at	concentrations	of	0.38	μM	CMH2	and	lower.	At	0.75	μM	the	peak	shape	is	a	wide	peak	with	Tm	of	53.91°C	and	concentrations	of	0.38	μM	and	below	have	approximately	the	same	Tm	of	around	54°C.		
	Figure	 73:	DSF	 of	 IgG2k	with	CMH2	 in	 50	mM	 sodium	acetate	 buffer	 pH	 4.0	A=	 (−)	 1	 μM	human	IgG2k	with	(−)	6.0	μM	CMH2,	(−)	3.0	μM	CMH2,	(−)	1.5	μM	CMH2,	(−)	0.75	μM	CMH2.	
B=	(−)	1	μM	human	IgG2k	with	(−)	0.38	μM	CMH2,	(−)	0.19	μM	CMH2,	(−)	0.09	μM	CMH2,	(−)	0.05	μM	CMH2.		
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	 The	change	in	Tm	between	no	CMH3	and	the	6.0	μM	CMH3	is	12.21°C.	With	6.0	μM,	the	Tm	of	IgG2k	shifts	to	a	lower	temperature	of	41.72°C,	with	a	small	shoulder	at	approximately	50	°C.	CMH3	at	3.0	μM	gives	a	higher	intensity	peak	at	its	Tm	of	43.60°C,	however	 the	 shoulder	 at	 50°C	 is	 less	 pronounced.	 At	 1.5	 μM	 the	 Tm	 with	 IgG2k	 is	43.74°C	with	the	same	intensity	as	6.0	μM	CMH3,	including	a	similar	shaped	shoulder	at	50°C.	The	intermediate	concentration	between	the	two	families	of	peaks	is	0.75	μM,	with	this	 curve	 more	 broad	 and	 flattened,	 demonstrating	 a	 Tm	 of	 46.77°C,	 mirroring	 the	shape	of	the	shoulder	on	the	peaks	at	higher	concentrations	of	CMH3.	The	subsequent	lower	concentration	peaks	mimic	the	shape	of	the	IgG2k	only	peak	with	the	Tm	for	the	peaks	the	same	at	53.54°C.		
	Figure	74:	DSF	of	IgG2k	with	CMH3	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	1	μM	human	IgG2k	with	(−)	6.0	μM	CMH3,	(−)	3.0	μM	CMH3,	(−)	1.5	μM	CMH3,	(−)	0.75	μM	CMH3.	B=	(−)	1	μM	human	IgG2k	with	 (−)	0.38	μM	CMH3,	 (−)	0.19	μM	CMH3,	 (−)	0.09	μM	CMH3,	(−)	0.05	μM	CMH3.		
	Figure	75:	DSF	of	IgG2k	with	CMH4	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG2k	with	(−)	6.0	μM	CMH4,	(−)	3.0	μM	CMH4,	(−)	1.5	μM	CMH4,	(−)	0.75	μM	CMH4.	B=	(−)	1	μM	human	IgG2k	with	 (−)	0.38	μM	CMH4,	 (−)	0.19	μM	CMH4,	 (−)	0.09	μM	CMH4,	(−)	0.05	μM	CMH4.		
	 171	
	 The	Tm	shift	seen	when	measuring	the	fluorescence	with	6	μM	of	CMH4	versus	IgG2k	 alone	 is	 13.56°C.	 Melting	 temperature	 of	 the	 protein	 alone	 in	 this	 assay	 was	53.8°C.	The	Tm	shift	with	addition	of	6.0	μM	CMH4	moves	 to	a	main	peak	at	40.24°C,	with	 a	 smaller	 shoulder	 peak	 at	 49.02°C.	 This	 peak	 shape	 is	 similar	 at	 3.0	 μM	CMH4,	with	Tm	 at	 this	 concentration	 being	 40.97°C	 and	 shoulder	 at	 49.34°C.	 Tm	 at	 0.75	 μM	CMH4	 is	 43.58°C.	 At	 lower	 concentrations,	 the	 peaks	 change	 shape	 to	 resemble	 the	protein	only	peak	with	0.19	μM	CMH4	Tm	at	54.33°C,	and	a	sloping	shoulder	at	 lower	temperature	(Tm	of	46.80°C)	similar	to	the	major	peaks	seen	at	higher	concentrations.	The	further	2	lower	concentrations	tested	of	0.09	μM	and	0.05	μM	have	Tm	of	54.20°C	and	53.89°C	respectively.		
	 The	shift	in	Tm	seen	upon	addition	of	6.0	μM	of	CMH5	with	IgG2k	is	4.1°C,	with	IgG1k	alone	Tm	of	54.46°C.	CMH5	at	6.0	μM	also	has	a	secondary	shoulder	at	62.63°C.	The	3.0	μM	CMH5	concentration	has	a	Tm	of	50.75°C	and	a	shoulder	at	62.97	°C.	The	Tm	then	shifts	with	1.5	μM	to	51.87°C,	with	a	more	pronounced	shoulder	peak	at	65.02°C.	CMH5	 at	 0.75	 μM	 again	 acts	 as	 an	 intermediate	 peak	 at	 lower	 intensity	 with	 Tm	 of	53.16°C	and	shoulder	at	68.06°C.	CMH5	at	0.38	μM	has	a	Tm	of	54.9°C	with	a	shoulder	at	67.86°C.		
	Figure	76:	DSF	of	IgG2k	with	CMH5	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG2k	with	(−)	6.0	μM	CMH5,	(−)	3.0	μM	CMH5,	(−)	1.5	μM	CMH5,	(−)	0.75	μM	CMH5.	B=	(−)	1	μM	human	IgG2k	with	 (−)	0.38	μM	CMH5,	 (−)	0.19	μM	CMH5,	 (−)	0.09	μM	CMH5,	(−)	0.05	μM	CMH5.		
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		 The	IgG2k	peak	 is	shifted	to	a	 lower	Tm	upon	addition	of	6.0	μM	CMH6,	with	a	Tm	 change	 of	 3.97°C.	 The	6.0	 μM	CMH6	peak	has	 a	Tm	of	 49.91°C,	 and	 a	 shoulder	 at	51.99	°C.	Decreasing	concentrations	of	CMH6	increase	the	Tm	of	IgG2k	with	3.0	μM	Tm	of	45.51°C	with	a	shoulder	at	52.49°C.	At	1.5	μM,	the	peak	increases	to	54.24°C	with	a	shoulder	peak	at	65.39°C.	The	intensity	drops	to	its	lowest	in	0.75	μM	CMH6	with	IgG2k,	with	 the	 Tm	 65.67°C,	 with	 the	 shoulder	 the	 highest	 with	 a	 Tm	 of	 67.90°C.	 A	concentration	of	0.38	μM	CMH6	gives	a	Tm	of	54.38°C	with	 increased	 intensity	versus	0.75	μM,	with	no	shoulder.		
	 The	IgG2k	peak,	with	addition	of	6.0	μM	CMH7,	causes	the	Tm	to	drop	to	40.01°C,	a	reduction	in	Tm	of	14.24°C.	The	shape	of	the	6.0	μM	to	0.75	μM	peaks	is	that	of	a	major	
	Figure	78:	DSF	of	IgG2k	with	CMH7	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG2k	with	(−)	6.0	μM	CMH7,	(−)	3.0	μM	CMH7,	(−)	1.5	μM	CMH7,	(−)	0.75	μM	CMH7.	B=	(−)	1	μM	human	IgG2k	with	 (−)	0.38	μM	CMH7,	 (−)	0.19	μM	CMH7,	 (−)	0.09	μM	CMH7,	(−)	0.05	μM	CMH7.		
	Figure	 77:	 DSF	 of	 IgG2k	 with	 CMH6	 in	 50	 mM	 sodium	 acetate	 buffer	 pH	 4.0.	 A=	 (−)	 1	 μM	human	IgG2k	with	(−)	6.0	μM	CMH6,	(−)	3.0	μM	CMH6,	(−)	1.5	μM	CMH6,	(−)	0.75	μM	CMH6.	
B=	(−)	1	μM	human	IgG2k	with	(−)	0.38	μM	CMH6,	(−)	0.19	μM	CMH6,	(−)	0.09	μM	CMH6,	(−)	0.05	μM	CMH6.		
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peak	with	 a	 large	 shoulder	 peak	 at	 a	 higher	 temperature,	 and	 a	 shoulder	 region	 at	 ≈	69°C.	The	largest	peak	of	6.0	μM	occurs	with	a	Tm	of	40.01°C,	the	second	occurs	at	51.07	°C	with	a	third	flattened	hump	at	68.45°C.	This	pattern	 is	 the	same	in	3.0	μM	with	the	Tm	 of	 these	 three	 regions	 at	 40.76°C,	 50.38°C	 and	 69.66°C.	 The	 intermediate	 peak	occurs	 at	 0.38	 μM	with	 a	 wide	 curve	with	 Tm	 of	 46.91°C	 and	 55.06°C	 and	 a	 smaller	shoulder	at	69.90°C.	At	concentrations	of	0.19	μM,	the	CMH7	and	IgG2k	peak	resembles	the	protein	only	peak,	with	a	Tm	of	55.25°C	and	no	discernable	shoulder	peak.		
	 The	IgG2k	1st	derivative	DSF	peaks	from	CMH8	show	the	least	change	in	thermal	stability	upon	addition	of	a	member	of	the	chemically	modified	heparin	library,	with	the	reduction	in	Tm	seen	on	addition	of	6.0	μM	CMH8	only	0.5°C.			 	The	difference	between	the	Tm	of	IgG2k	with	6.0	μM	CMH9	is	the	largest	shift	in	Tm	seen	with	 this	 immunoglobulin	 is	17.89°C.	At	6.0	μM	the	peak	 is	 shifted	 to	a	wide	shape	with	Tm	of	34.97°C.	This	shape	is	also	seen	in	concentrations	up	to	0.75	μM,	with	Tm	 of	 35.02°C	 (3.0	 μM),	 35.9°C	 (1.5	 μM)	 and	 37.46°C	 (0.75	 μM).	 There	 are	 two	intermediate	peaks	 at	0.38	μM	and	0.19	μM	CMH9.	At	0.38	μM,	 the	major	peak	Tm	 is	38.94°C,	and	a	second	peak	at	54.14°C,	which	mimics	the	Tm	the	lower	concentrations.	
	Figure	79:	DSF	of	IgG2k	with	CMH8	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	human	IgG2k	with	(−)	6.0	μM	CMH8,	(−)	3.0	μM	CMH8,	(−)	1.5	μM	CMH8,	(−)	0.75	μM	CMH8.	B=	(−)	1	μM	human	IgG2k	with	(−)	0.38	μM	CMH8,	(−)	0.19	μM	CMH8,	(−)	0.09	μM	CMH8,	(−)	0.05	μM	CMH8.		
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At	0.19	μM	the	major	peak	is	shifted	to	the	higher	temperature	of	54.06°C,	but	a	minor	peak	remains	at	the	lower	Tm	of	38.95°C.		
	 	Plotting	the	change	in	Tm	observed	by	the	addition	of	differing	concentrations	of	chemically	 modified	 heparin	 produces	 a	 simple	 graphical	 representation	 of	 the	 DSF	data.	 Figure	 81	 demonstrates	 the	 greatest	 change	 is	 seen	 with	 the	 addition	 of	
	Figure	81:	DSF	Tm	taken	from	1st	derivative	data	of	IgG2k	with	CMH	in	50	mM	sodium	acetate	buffer	pH	4.0. Δ	Tm	(compared	to	IgG2k	control).	IgG2k	with	A)	6	μM	CMH1	EC50	=	0.243	μM	
B)	6	μM	CMH8	EC50	=	3.327	μM	C)	6	μM	CMH9	EC50	=	0.1863	μM		
	Figure	80:	DSF	of	IgG2k	with	CMH9	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	1	μM	human	IgG2k	with	(−)	6.0	μM	CMH9,	(−)	3.0	μM	CMH9,	(−)	1.5	μM	CMH9,	(−)	0.75	μM	CMH9.	B=	(−)	1	μM	human	IgG2k	with	 (−)	0.38	μM	CMH9,	 (−)	0.19	μM	CMH9,	 (−)	0.09	μM	CMH9,	 (−)	0.05	μM	CMH9.		
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persulphated	 CMH9	 heparin.	 Unsulphated	 CMH8	 has	 the	 highest	 number	 of	concentrations	with	 no	 change	 in	Tm,	 and	 at	 the	 highest	 CMH8	 concentrations	 tested	this	Tm	change	is	the	smallest	of	the	chemically	modified	heparin	library.			 PCA	of	 the	 CMH	with	 IgG2k	demonstrated	 the	 similarities	 in	 variance	 between	each	 concentration	 of	 CMH	 explored	 in	 the	 thermal	 denaturation	 DSF	 experiments.	CMH1	PCA	 is	 shown	 in	 Figure	82	with	 the	 full	 CMH	 library	with	 IgG2k	 in	 Figures	 72.	CMH	1,	4	and	9	display	similar	relationships	in	the	PC2,	and	CMH	2,	3,	5,	6	and	7	have	similar	distrubutions.	CMH8	has	no	variation	 in	PC1,	with	spread	occuring	only	 in	 the	second	principle	component.		
	
	Figure	82:	PCA	from	the	1st	derivative	DSF	data	of	CMH1	with	human	IgG2k.			
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	Figure	83:	PCA	of	1st	derivative	DSF	data	of	CMH2-9	with	human	IgG2k.		
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		 The	 far-UV	 CD	 spectra	 of	 IgG2k	 in	 50	 mM	 sodium	 acetate	 buffer	 is	 shown	 in	Figure	84,	with	the	addition	of	UF	PMH	shifting	the	λ	=	219	nm	signal	for	β-sheet	to	λ	=	222	nm.	IgG2k	alone	in	this	buffer	does	not	have	a	positive	ellipticity	reading,	but	with	CMH1,	the	spectra	are	shifted	toward	the	positive.	IgG2k	in	pH	7.4	PBS	the	spectrum	has	similar	features,	suggesting	no	heparin	interaction	causing	secondary	structure	changes.		
5.2.7	IgG2k	stability	in	the	presence	of	low	molecular	weight	heparins	
	 A	 library	 of	 low	 molecular	 weight	 heparins	 (LMWH)	 are	 utilised	 to	 represent	more	 complex	 heparin	 structure.	 The	 IgG2k	 peak	 gives	 a	 Tm	 of	 53.66°C	with	 a	 small	shoulder	at	59.23	°C	(Figure	85).	Dalteparin,	enoxaparin,	tinzaparin	and	reviparin	follow	
	Figure	 85:	 DSF	 of	 IgG2k	 with	 LMWH	 in	 50	 mM	 sodium	 acetate	 buffer	 pH	 4.0	A)	 (−)	 1	 μM	human	IgG2k	with	(−)	6.0	μM	dalteparin,	(−)	6.0	μM	enoxaparin	B)	(−)	1	μM	human	IgG2k	with		(−)	6.0	μM	tinzaparin,	(−)	6.0	μM	reviparin,	(−)	6.0	μM	fondaparinux.			
	Figure	84:	Far-UV	CD	spectra	of	human	IgG2k	±	UF	PMH	in	acetate	buffer	and	PBS	A)	50	mM	sodium	acetate	 buffer	 pH	4.0	with	 (−)	 3	 μM	human	 IgG2k	with	 (−)	 3	 μM	UF	PMH	B)	 PBS	buffer	pH	7.4	with	(−)	3	μM	human	IgG2k	with	(−)	3	μM	UF	PMH.		
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the	same	peak	structure	with	a	double	peak	with	Tm	of	≈	40.0°C	and	51.5°C.	Dalteparin,	enoxaparin,	 reviparin	 and	 tinzaparin	 have	 a	 small	 hump	 at	 approximatley	 71°.	Fondaparinux	at	6.0	μM	with	IgG2k	has	a	peak	at	Tm	of	52.39°C	with	a	small	secondary	peak	at	64.52°C.		
5.2.8	IgG2k	stability	in	the	presence	of	GAGs	and	heparin	controls		 The	largest	reduction	in	the	Tm	of	IgG2k	is	seen	on	with	the	inclusion	of	6.0	μM	UF	PMH	with	a	Tm	of	38.46	°C	with	a	shoulder	at	Tm	of	59.50	°C	(Figure	86).	The	change	in	Tm	with	6.0	μM	UF	PMH	is	15.09°C.	As	with	IgG1k,	the	second	largest	Tm	shift	is	seen	with	12.0	μM	HS,	with	the	Tm	of	40.35°C,	a	reduction	of	13.20°C.	This	curve	has	double	peaks	with	second	Tm	at	48.54°C.	An	11.68°C	Tm	reduction	 is	seen	on	addition	of	DS,	with	 this	 curve	 also	displaying	 a	double	 linked	peak	 shape,	 but	with	 a	more	 flattened	appearance	than	that	of	HS.	The	Tm	of	the	double	peaks	are	41.87°C	and	50.03°C.			 As	with	IgG1k,	CSC	is	the	more	destabilising	of	the	two	CS,	with	a	Tm	reduction	of	4.49°C	compared	to	IgG2k	alone.	The	curve	has	a	shoulder	peak	at	melting	temperatures	higher	than	that	of	IgG1k,	at	62.72°C.		 The	 Tm	 does	 not	 change	 with	 the	 inclusion	 of	 HA,	 with	 only	 the	 fluorescence	intensity	of	 the	melting	peak	 increasing.	No	change	 is	 seen	 in	Tm	with	 the	addition	of	UA(2S)-GlcNS(6S)	disaccharide	and	Na2SO4.	The	peak	shape	includes	a	small	shoulder	in	IgG2k	with	Na2SO4,	but	this	feature	is	not	present	in	the	UA(2S)-GlcNS(6S)	disaccharide	peak	with	IgG2k.		
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5.2.9	IgG2k	stability	in	the	presence	of	size	defined	heparin	fractions		 The	d.p.2	heparin	fragment	stabilises	the	IgG2k	to	a	Tm	of	54.37°C	with	a	small	shoulder	at	≈	60°C	which	 is	mirrored	in	IgG2k	alone.	Addition	of	d.p.4	destabilises	the	IgG2k	to	a	Tm	of	52.94°C.	With	d.p.6,	the	main	peak	Tm	is	53.44°C,	but	a	secondary	peak	occurs	 at	 67.57°C.	With	 d.p.8,	 the	 peak	 shape	 changes	 to	 a	 3	 peak	 structure,	with	 the	initial	peak	at	42.44°C,	the	largest	peak	at	53.34°C	and	the	minor	peak	at	66.55°C.	This	three	peak	structure	is	modified	with	d.p.10,	with	the	first	2	peaks	occurring	in	the	same	region	of	the	first	peak	of	d.p.8	and	no	peak	occurring	>	54°C.	With	d.p.>10,	two	peaks	with	 similar	 intensity	 occur	 below	 54°C.	 The	 occurrence	 of	 the	 higher	 fluorescence	intensity	 peak	 at	 a	 Tm	 of	 ≈	 38°C	 mimics	 the	 UF	 PMH	 at	 6.0	 μM	 in	 IgG2k	 but	 the	population	at	the	higher	Tm	of	≈	50°C	is	still	present	at	these	d.p.	PMH	fragments.		
	Figure	86:	DSF	of	IgG2k	with	GAGs	and	sulphated	controls	 in	50	mM	sodium	acetate	buffer	pH	4.0	(−)	1	μM	human	IgG2k	with	A)	(−)	6.0	μM	UF	PMH,	(−)	500	nM	sodium	sulphate,	B)	(−)	6.0	μM	UA(2S)-GlcNS(6S)	(−)	12.0	μM	HS,	C)	(−)	6.0	μM	CSA,	(−)	6.0	μM	CSC,	D)	(−)	6.0	μM	DS,	(−)	6.0	μM	HA.		
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	 PCA	analysis	of	the	d.p.	heparin	fractions	suggests	d.p.4	and	d.p.6	have	the	same	eigenvalues	in	both	PC1	and	PC2	and	d.p.18	has	the	an	effect	on	IgG2k	most	similar	to	that	of	UF	PMH,	but	larger	d.p.	fragments	would	require	testing	to	identify	polymer	size	identical	to	that	of	UF	PMH.	
5.2.10	IgG2k	binding	at	differing	buffer	concentrations	and	pH		 Heparin	affinity	Hitrap	HPLC	experiments	demonstrate	IgG2k	binds	to	heparin	at	pH	4.0	and	pH	5.0	in	PBS	buffer.	At	pH	4.0	two	small	peaks	at	1.01	M	and	1.48	M	suggest	
	Figure	87:	PCA	of	1st	derivative	DSF	data	of	IgG2k	with	d.p.	heparin	fractions.		
Table	10:	DSF	Tm	of	human	IgG2k	with	each	PMH	polymerization	(d.p.)	fragment	in	50	mM	sodium	acetate	buffer	pH	4.0.			
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two	populations	of	protein	with	different	binding	affinities.	At	pH	5.0,	binding	affinity	of	the	small	peak	is	937	mM.	The	IgG2k	binds	more	strongly	to	heparin	at	a	more	acidic	pH.			
5.2.11	IgM	stability	in	the	presence	of	chemically	modified	heparins		 The	reduction	in	Tm	seen	upon	addition	of	6.0	μM	CMH1	to	human	anti-GFP	IgM	is	16.98°C,	with	the	IgM	only	Tm	of	53.27°C	and	6.0	μM	CMH1	with	IgM	is	37.45°C,	with	a	 further	 double	 peak	 at	 the	 higher	 temperatures	 of	 63.51°C	 and	 68.87°C.	 At	 3.0	 μM	CMH1,	the	curve	remains	in	the	same	position	for	the	lower	Tm	at	37.45°,	but	the	second	peak	is	a	single	feature	with	the	Tm	622.82	°C.	CMH1	at	1.5	μM	to	0.38	μM	have	the	same	structure,	with	 the	 first	Tm	at	37.45°C	 (1.5	μM),	38.62°C	 (0.75	μM)	and	41.44°C	 (0.38	μM).	At	0.19	μM	CMH1,	the	curve	moves	to	a	flattened	shape,	with	less	well	defined	peak	structures	with	 Tm	 of	 43.75°C	 and	 53.74°C.	 The	 largest	 peak	 at	 0.09	 μM	 has	 a	 shape	similar	 to	 the	 IgM	 only	 peak,	 with	 a	 Tm	 of	 54.3°C,	 but	 has	 a	 secondary	 peak	 which	
	Figure	88:	Human	IgG2k	in	heparin	HiTrap	affinity	HPLC	in	PBS	at	differing	pH	(4.0	–	7.4)	and	elution	with	2M	NaCl.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.		
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mimics	 the	 shape	of	 the	 second	of	 the	double	peaks	 seen	at	 the	 concentration	6.0	μM	CMH1.		
	
	 The	Tm	change	between	IgM	only	and	6	μM	CMH2	is	15.30°C,	with	the	Tm	of	IgM	only	 54.30°C	 and	6	 μM	CMH2	with	 IgM	of	 39.0°C.	 The	peak	 of	 CMH2	 at	 6.0	 μM	has	 a	second	Tm	at	62.84°C.	Peaks	of	CMH2	at	3.0	μM	and	1.5	μM	and	0.75	μM	have	the	same	structure	of	6	μM,	with	Tm	of	39.94	°C,	40.52	°C	and	41.84	°C.	The	Tm	of	the	secondary	peak	at	these	concentrations	varies	between	63.19°C	and	64.84°C.	The	initial	peak	shifts	further	 at	 0.38	 μM,	 with	 a	 Tm	 of	 54.01°C	 and	 69.21°C.	 The	 two	 further	 lower	concentrations	(0.19	μM	and	0.09	μM)	have	more	regular	peak	structure,	with	only	0.19	
	Figure	90:	DSF	of	IgM	with	CMH2	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	1	μM	IgM	with	(−)	6.0	μM	CMH2,	(−)	3.0	μM	CMH2,	(−)	1.5	μM	CMH2,	(−)	0.75	μM	CMH2.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH2,	(−)	0.19	μM	CMH2,	(−)	0.09	μM	CMH2,	(−)	0.05	μM	CMH2.		
	Figure	89:	DSF	of	 IgM	with	CMH1	 in	50	mM	sodium	acetate	buffer	 pH	4.0.	A=	(−)	1	μM	 IgM	with	(−)	6.0	μM	CMH1,	 (−)	3.0	μM	CMH1,	(−)	1.5	μM	CMH1,	(−)	0.75	μM	CMH1.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH1,	(−)	0.19	μM	CMH1,	(−)	0.09	μM	CMH1,	(−)	0.05	μM	CMH1.		
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μM	exhibiting	a	secondary	peak	at	higher	Tm.	CMH2	at	0.19	μM	has	a	Tm	of	54.01°C	and	69.21°C;	which	is	the	highest	Tm	seen	with	this	chemically	modified	heparin.	At	CMH2	concentration	of	0.09	μM,	the	peak	shape	mirrors	that	of	IgM	only,	with	a	Tm	of	54.29°C.		
	 	Tm	change	upon	addition	of	6.0	μM	CMH3	is	12.21°C,	with	Tm	of	the	initial	peak	at	6.0	μM	CMH3	at	38.94°C,	and	a	secondary	peak	at	the	same	position	as	the	secondary	peak	of	CMH1	at	6.0	μM,	at	69.33°C.	CMH3	concentrations	between	0.75	μM	and	3.0	μM	show	similar	curve	shape,	with	Tm	of	39.44°C	(3.0	μM),	40.12°C	(1.5	μM)	and	42.37°C	(0.75	μM).	The	peak	shifts	to	an	increased	Tm	at	0.19	μM	with	a	Tm	of	53.76°C.			 		The	reduction	in	Tm	after	the	addition	of	the	highest	concentration	of	CMH4	is	16.48°C,	with	a	decrease	 in	melting	 temperature	 from	54.21°C	to	37.73°C	with	6.0	μM	CMH4.	A	second	peak	at	this	concentration	occurs	at	64.42°C.	Tm	at	3.0	μM	is	38.65°C,	
	Figure	91:	DSF	of	IgM	with	CMH3	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	IgM	with	(−)	6.0	μM	CMH3,	(−)	3.0	μM	CMH3,	(−)	1.5	μM	CMH1,	(−)	0.75	μM	CMH3.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH3,	(−)	0.19	μM	CMH3,	(−)	0.09	μM	CMH3,	(−)	0.05	μM	CMH3.		
	Figure	92:	DSF	of	IgM	with	CMH4	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	1	μM	IgM	with	(−)	6.0	μM	CMH4,	(−)	3.0	μM	CMH4,	(−)	1.5	μM	CMH4	(−)	0.75	μM	CMH4.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH4,	(−)	0.19	μM	CMH4,	(−)	0.09	μM	CMH4,	(−)	0.05	μM	CMH4.		
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with	a	second	Tm	at	65.24°C.	The	CMH4	concentration	of	0.75	μM	with	IgM	has	an	initial	Tm	at	39.0°C	with	a	secondary	peak	at	64.01°C	with	an	intensity	between	that	of	6.0	μM	and	3.0	μM	CMH4.	CMH4	at	0.75	μM	and	0.38	μM	have	first	peak	Tm	at	38.92°C	and	40.0	°C	respectively	and	secondary	peaks	at	65.02°C	and	66.31°C.	The	Tm	of	0.09	μM	CMH4	with	IgM	is	the	same	as	IgM	alone	at	53.89°C.		
	 The	change	in	Tm	seen	in	IgM	with	the	highest	concentration	of	CMH5	tested	(6.0	μM)	 is	10.39°C.	At	6.0	μM	CMH5	the	Tm	of	 IgM	 is	43.72°C.	This	Tm	gradual	 increased	with	decreasing	concentration	of	CMH5,	with	3.0	μM	giving	a	Tm	of	44.5°C,	1.5	μM	Tm	of	44.96°C,	 0.75	 μM	 Tm	 of	 46.61°C	 and	 0.38	 μM	 Tm	 of	 47.6°C.	 The	 peak	 then	 shifts	 to	mirror	the	IgM	only	peak,	giving	a	Tm	of	53.92	°C.	At	the	lowest	concentration	of	CMH5	tested	(0.09	μM)	the	Tm	is	54.09°C.		
	Figure	93:	DSF	of	IgM	with	CMH5	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	IgM	with	(−)	6.0	μM	CMH5,	(−)	3.0	μM	CMH5,	(−)	1.5	μM	CMH5,	(−)	0.75	μM	CMH5.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH5,	(−)	0.19	μM	CMH5,	(−)	0.09	μM	CMH5,	(−)	0.05	μM	CMH5.		
	Figure	94:	DSF	of	 IgM	with	CMH6	 in	50	mM	sodium	acetate	buffer	 pH	4.0.	A=	(−)	1	μM	 IgM	with	(−)	6.0	μM	CMH6,	 (−)	3.0	μM	CMH6,	(−)	1.5	μM	CMH6,	(−)	0.75	μM	CMH6.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH6,	(−)	0.19	μM	CMH6,	(−)	0.09	μM	CMH6,	(−)	0.05	μM	CMH6.		
	 185	
	 The	Tm	shift	with	6.0	μM	CMH6	(Tm	of	43.53°C)	is	10.39°C	compared	to	IgM	only	with	a	Tm	of	53.92°C.	Concentrations	of	3.0	μM	and	1.5	μM	have	similar	shaped	curves	with	 Tm	 of	 43.48°C	 and	 44.86°C.	 At	 0.75	 μM	 the	 Tm	 increases	 to	 46.22°C.	 The	intermediate	peak	at	0.38	μM	has	a	Tm	of	49.95°C	and	at	0.19	μM	the	curve	resembles	the	shape	seen	in	IgM	only,	with	a	Tm	of	54.11°C.	At	the	lowest	concentration	of	CMH6	tested	(0.09	μM),	the	Tm	is	54.55°C,	which	suggests	an	increase	in	protein	stability.			 The	difference	between	IgM	only	Tm	and	the	Tm	with	6.0	μM	CMH7	is	15.75°C,	with	6.0	μM	Tm	shifting	to	a	lower	temperature	of	38.24°C,	with	a	shoulder	at	a	higher	temperature	than	the	Tm	of	IgM	only,	at	64.21°C.	Reducing	concentrations	of	CMH7	to	0.38	μM	follow	the	same	peak	shape	as	the	6.0	μM	CMH7.	At	0.19	μM	CMH7	shifts	the	Tm	 to	 43.72°C	 with	 no	 discernable	 secondary	 peak	 at	 Tm	 >	 60°C.	 At	 the	 lowest	concentration	 of	 CMH7	 tested	 (0.09	 μM)	 the	 peak	 has	 a	 Tm	 of	 53.61°C,	 however	 the	secondary	 peak	 returns	 with	 a	 Tm	 of	 68.42°C,	 mimicking	 the	 peak	 seen	 at	 this	temperature	with	0.75	μM	CMH7.		 CMH8	shows	the	least	disruption	to	the	Tm	of	IgM,	with	the	difference	between	6.0	 μM	 CMH8	 and	 IgM	 only	 being	 5.95°C.	 The	 Tm	 increases	 with	 decreasing	concentration	of	CMH8	up	to	0.19	μM	where	the	Tm	is	the	same	as	IgM	alone.		
	Figure	95:	DSF	of	IgM	with	CMH7	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	IgM	with	(−)	6.0	μM	CMH7,	(−)	3.0	μM	CMH7,	(−)	1.5	μM	CMH7,	(−)	0.75	μM	CMH7.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH7,	(−)	0.19	μM	CMH7,	(−)	0.09	μM	CMH7,	(−)	0.05	μM	CMH7.		
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	 	The	greatest	change	in	Tm	is	seen	upon	addition	of	CMH9	at	6.0	μM	decreasing	to	33.93	 °C.	The	 concentrations	of	CMH9	decreasing	 to	0.75	μM	 follow	 the	 same	peak	shape	with	higher	fluorescence	peak	occurring	at	≈	61°C.	At	0.38	μM	the	secondary	peak	occurs	at	a	higher	temperature	of	68.99°C.	At	0.09	μM	the	peak	at	54.38°C	mimics	the	peak	seen	at	0.19	μM.		
	Figure	97:	DSF	of	 IgM	with	CMH9	 in	50	mM	sodium	acetate	buffer	 pH	4.0.	A=	(−)	1	μM	 IgM	with	(−)	6.0	μM	CMH9,	 (−)	3.0	μM	CMH9,	(−)	1.5	μM	CMH9,	(−)	0.75	μM	CMH9.	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH9,	(−)	0.19	μM	CMH9,	(−)	0.09	μM	CMH9,	(−)	0.05	μM	CMH9.	
	Figure	96:	DSF	of	IgM	with	CMH8	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	1	μM	IgM	with	(−)	6.0	μM	CMH8,	(−)	3.0	μM	CMH8,	(−)	1.5	μM	CMH8,	(−)	0.75	μM	CMH8	B=	(−)	1	μM	IgM	with	(−)	0.38	μM	CMH8,	(−)	0.19	μM	CMH8,	(−)	0.09	μM	CMH8,	(−)	0.05	μM	CMH8.		
	Figure	98:	PCA	of	1st	derivative	DSF	data	of	IgM	with	CMH1.	
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	Figure	99:	PCA	of	1st	derivative	DSF	data	of	IgM	with	CMH2-9.	
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	 CMH1	with	IgM	in	PCA	demonstrates	no	variance	at	the	concentrations	of	3.0	μM	and	1.5	μM	(Figure	98).	The	distribution	of	data	points	in	the	PCA	of	IgM	with	differing	concentrations	 of	 CMH	 follows	 two	 distinct	 patterns;	 CMH1,	 2,	 3,	 4,	 7	 and	 9	 can	 be	grouped	 according	 to	 the	 PC1	 v	 PC2	 data	 arrangement,	 while	 CMH5,	 6	 and	 8	 can	 be	classified	as	similar	in	distrubution	(Figure	99).		CMH5	and	6	both	have	an	absence	of	6-O-sulphate,	 and	 have	 2-O-sulphate	 modifications,	 but	 CMH8	 does	 not	 have	 this	 2-O-sulphate.	CMH5,	6	and	8	have	2,	1	and	zero	sulphate	groups	per	disaccharide,	suggesting	no	link	to	heparin	disaccharide	charge.		 Plotting	the	change	in	Tm	observed	by	the	addition	of	differing	concentrations	of	chemically	 modified	 heparin	 produces	 a	 simple	 graphical	 representation	 of	 the	 DSF	data.	Figure	100	shows	 the	greatest	change	 is	 seem	with	 the	addition	of	persulphated	CMH9	heparin,	with	CMH1	following	closely	behind.	This	pattern	follows	both	IgG1k	and	IgG2k	in	DSF	with	the	chemically	modified	heparin	library.		
	Figure	100:	DSF	1st	 derivative	of	 IgM	with	CMH1,	 CMH8	 and	CMH9	 in	 50	mM	 sodium	acetate	buffer	 pH	 4.0,	 Δ	 Tm	 (compared	 to	 IgM	 alone)	 from	 DSF	 plotted	 as	 a	 function	 of	 chemically	modified	heparin	concentration.	IgM	with	A)	6	μM	CMH1	EC50	=	0.231	μM,	B)	6	μM	CMH8	EC50	=	2.605	μM	C)	6	μM	CMH9	EC50	=	0.215	μM.				
	 189	
	 The	 far-UV	 CD	 spectra	 of	 a	 human	 IgM	 antibody,	 raised	 to	 green	 fluorescent	protein,	 the	 same	 epitope	 as	 the	 IgG1	 and	 IgG2	 antibodies	 used	 in	 the	 earlier	 in	 this	chapter.	Human	IgM	anti-GFP	in	sodium	acetate	buffer	(50	mM)	pH	4.0	and	PBS	buffer	in	far-UV	CD	have	a	similar	spectra	at	wavelengths	between	λ	=	210nm	–	260	nm	(Figure	101).	 In	 acetate	buffer,	 IgM	has	a	 trough	at	 λ	=	220	nm,	with	 the	addition	of	UF	PMH	shifting	this	peak	to	λ	=	222	nm.	The	peak	shape	of	IgM	in	this	buffer	however,	both	with	and	without	PMH,	has	a	similar	spectral	shape	at	all	wavelengths,	but	at	λ	=	>	220	nm	the	magnitude	 of	 ellipticity	 is	 increased	 in	 the	 IgM	 spectra	 including	UF	 PMH	 (Figure	101A).		
	 In	PBS	pH	7.4	(Figure	101B),	 the	CD	spectrum	if	 the	human	IgM	has	a	negative	peak	at	218	nm,	with	the	addition	of	UF	PMH	retaining	a	similar	spectral	shape,	with	the	negative	ellipticity	peak	occurring	at	217	nm.	At	wavelengths	 lower	 than	210	nm,	 the	spectra	 of	 human	 IgM	 in	PBS	 and	 IgM	with	UF	PMH	 in	PBS	diverge,	with	 the	heparin	containing	experiment	causing	an	increase	in	absorbance	in	the	region	<	210	nm.		
	Figure	 101:	 Far-UV	 CD	 spectra	 of	 IgM	 ±	 UF	 PMH	 in	 sodium	 acetate	 buffer	 and	 PBS	A)	 50	mM	sodium	acetate	buffer	pH	4.0	with	(−)	3	μM	IgM	with	(−)	3	μM	UF	PMH	B)	PBS	buffer	pH	7.4	with	(−)	3	μM	IgM	with	(−)	3	μM	UF	PMH.		
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	 Table	 11	 suggests	 a	 greater	 change	 in	 seconfary	 structural	 motifs	 with	 the	addition	 of	UF	 PMH	 in	 sodium	 acetate	 buffer	 pH	4.0	 than	 PBS	 at	 pH	7.4.	 This	 change	increases	 the	 proportion	 of	 α-helix	 and	 reduces	 the	 anti-parallel	 β-sheet	 proportion,	which	predominates	the	immunoglobulin	fold.		
5.2.12	IgM	stability	in	the	presence	of	low	molecular	weight	heparins	
	 The	library	of	low	molecular	weight	heparins	(LMWH)	were	utilised	to	represent	more	complex	heparin	structure	with	known	structural	features.	The	IgM	Tm	is	53.42	°C	with	fluorescence	intensity	of	5150	ΔFU	(Figure	102).	The	addition	of	UF	PMH	at	6.0	μM	shifts	the	Tm	to	the	lower	temperature	of	37.45°C	with	further	peaks	in	a	double	joined	peak	at	Tm	of	63.61°C	and	69.02°C.	The	LMWH	dalteparin,	enoxaparin,	 tinzaparin	and	reviparin	 have	 similar	 curve	 shapes	 with	 IgM,	 with	 2	 wide	 peaks	 formed.	 The	 initial	
Table	11:	BeStSel	analysis	of	far-UV	CD	of	IgM	in	sodium	acetate	and	PBS	buffer	±	UF	PMH,	quantifying	%	secondary	structure	motif	changes	with	the	addition	of	UF	PMH.	
	
	Figure	102:	DSF	of	 IgM	with	LMWH	 in	 50	mM	sodium	acetate	buffer	pH	4.0.	A)	 (−)	1	μM	 IgM	with	(−)	6.0	μM	dalteparin,	(−)	6.0	μM	enoxaparin	B)	(−)	1	μM	IgM	with	(−)	6.0	μM	tinzaparin,	(−)	6.0	μM	reviparin,	(−)	6.0	μM	fondaparinux.			
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peak	 occurs	 at	 Tm	 of	 37.45°C	 with	 the	 secondary	 peaks	 occurring	 in	 the	 same	 area	(dalteparin	 64.16°C,	 enoxaparin	 65.16°C,	 tinzaparin	 63.67°C	 and	 reviparin	 63.95°C).	Fondaparinux	at	6.0	μM	has	a	single	hump	structure	with	a	Tm	of	43.63°C	which	occurs	between	the	other	LMWH/CMH1	and	IgM	protein	only	control.		 The	PCA	of	IgM	with	LMWH	demonstrates	a	similar	pattern	of	data	distribution	as	 IgG1k	 and	 IgG2k	 with	 LMWH;	 naturally	 derived	 LMWH	 group	 together,	 with	 the	synthetic	pentasaccharide	fondaparinux	more	similar	to	the	protein	only	control	(Figure	103).		
5.2.13	IgM	stability	in	the	presence	of	GAGs	and	heparin	controls		 The	addition	of	DS	causes	a	destabilisation	with	IgM	to	reduce	the	Tm	to	39.17°C	(14.37°C	change).	The	curve	structure	 is	 similar	 to	CMH1	with	 intensity	of	1130	units	and	a	secondary	small	shoulder	at	62.84°C.	HS	at	12.0	μM	mimics	the	curve	shape	seen	with	 DS,	 and	 has	 a	 slightly	 increased	 Tm	 compared	 to	 DS	 at	 39.26°C	 but	 a	 slightly	reduced	second	Tm	at	63.07°C.	The	change	from	IgM	alone	is	14.28°C	with	the	addition	of	HS.		
	Figure	103:	PCA	of	1st	derivative	DSF	data	of	LMWH	with	IgM.			
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	 The	difference	between	CSC	and	CSA	is	smaller	with	IgM,	with	CSC	still	displaying	the	 larger	 reduction	 in	 Tm	 compared	 to	 IgM	 alone	 at	 9.87°C	 whereas	 CSA	 change	 is	9.82°C.				 The	6.0	μM	UA(2S)-GlcNS(6S)	disaccharide	only	reduces	the	Tm	of	IgM	by	0.92°C.	IgM	 alone	 and	 IgM	 with	 Na2SO4	 have	 the	 same	 Tm,	 peak	 intensity	 and	 curve	 shape	suggesting	sulphate	alone	does	not	reduce	IgM	Tm	and	therefore	protein	stability.	
5.2.14	IgM	stability	in	the	presence	of	size	defined	heparin	fractions		 The	average	Tm	of	IgM	is	53.45°C	in	this	data,	with	addition	of	6.0	μM	UF	PMH	change	 in	Tm	 to	 the	 first	peak	at	37.40°C	of	16.05°C.	The	peak	 shape	with	6.0	μM	UF	PMH	is	one	peak	at	low	temperatures	with	a	double	peak	at	63°C	–	68°C	with	all	three	having	similar	peak	fluorescence	intensity.		
	Figure	104:	DSF	of	IgM	with	GAGs	and	sulphated	controls	in	50	mM	sodium	acetate	buffer	pH	4.0.	 (−)	 1	 μM	 IgM	with	A)	 (−)	 6.0	 μM	UF	PMH,	 (−)	 500	 nM	 sodium	 sulphate,	B)	 (−)	 6.0	 μM	UA(2S)-GlcNS(6S)	(−)	12.0	μM	HS,	C)	(−)	6.0	μM	CSA,	(−)	6.0	μM	CSC,	D)	(−)	6.0	μM	DS,	(−)6.0	μM	HA.		
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	 Adding	d.p.2	to	IgM	at	the	same	concentration	of	UF	PMH	shows	no	change	in	Tm	or	intensity	compared	to	IgM	alone.	IgM	with	d.p.4	reduces	the	Tm	by	3.3°C	to	50.37°C,	with	 the	 occurrence	 of	 another	 peak	 at	 63.55°C	which	mirrors	 the	 initial	 peak	 in	 the	double	structure	seen	with	UF	PMH	addition.	IgM	with	d.p.6	has	no	clear	peak	structure	across	 the	 whole	 temperature	 spectrum	 with	 the	 only	 increase	 resembling	 peak	structure	at	45.68	°C.	The	curve	of	d.p	8	with	IgM	is	similar	to	d.p	6	but	with	a	wide,	low	fluorescence	curve	with	maximum	at	Tm	of	38.32°C.			
Table	12:	The	Tm	of	each	PMH	polymerization	(D.P)	 fragment	with	 IgM	 from	the	DSF	of	IgM	in	50	mM	sodium	acetate	buffer	pH	4.0.			
	
	Figure	105:	PCA	of	first	derivative	DSF	data	of	IgM	with	heparin	d.p.	fragments		
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	 	With	heparin	sizes	greater	than	d.p.10,	the	Tm	are	similar,	with	a	peak	structure	at	very	low	intensity	and	only	a	simgle	discernable	peak	at	≈	37°C	-	38°C.	The	heparin	disaccharide	size	which	has	similar	Tm	to	UF	PMH	is	a	decasaccharide,	but	this	size	does	not	have	identical	features	to	the	UF	PMH	with	IgM.			 PCA	 of	 the	 heparin	 d.p.	 fragments	 show	 the	 minimum	 size	 requirement	 for	 a	change	 in	 DSF	 spectra	 is	 a	 d.p.4,	 with	 increasing	 d.p.	 size	 >	 d.p.4	 having	 a	 more	pronounced	effect.	As	with	the	Tm	from	the	1st	derivative	DSF	data,	d.p.10	 is	 the	most	similar	to	UF	PMH	in	PCA.		
5.2.15	IgM	stability	changes	at	differing	buffer	concentrations	and	pH		 Figure	106	demonstrates,	as	with	IgG1k	and	IgG2k,	IgM	binds	heparin	in	Hi-Trap	affinity	HPLC	in	PBS	at	pH	4.0	and	5.0,	with	binding	also	shown	at	pH	6.0	PBS.	At	pH	4.0,	IgM	has	heparin	binding	affinity	 in	PBS	at	1.03	M,	with	increasing	pH	to	5.0	 leading	to	binding	affinity	of	917	mM,	and	further	increase	to	pH	6.0	PBS	demonstrating	698	mM	heparin	binding	affinity.	Heparin	binding	affinity	of	 the	 immunoglobulins	decreases	as	pH	increases.		
	Figure	106:	IgM	in	heparin	HiTrap	affinity	HPLC	in	PBS	at	differing	pH	(4.0	–	7.4)	and	elution	with	2M	NaCl.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.		
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5.3	Discussion		 A	 library	 of	 chemically	 modified	 heparins	 represent	 8	 commonly	 found	structures	in	the	heparan	sulphate	polymer	and	per-sulphated	heparin.	The	structure	of	the	 more	 homogenous	 glycopolymer,	 heparin,	 is	 constructed	 primarily	 (70-80%	 of	IdoA(2S)-GlcNS(6S)	 (CMH1).	 In	 the	 presence	 of	 IgG1k	 and	 IgG2k	 the	 effects	 of	 this	library	 of	 heparins	 cause	 modifications	 to	 the	 melting	 temperature	 and	 secondary	structure	 of	 the	 immunoglobulin.	 Variation	 in	 melting	 temperature	 and	 secondary	structure	 of	 the	 immunoglobulin	 occur	 due	 to	 structural	 changes	 conferred	 by	 the	differing	functional	groups	position,	functional	group	conformation,	and	linkage	region	conformation	of	 the	glycopolymer.	 IdoA-GlcNAc	(CMH8)	has	dramatically	 less	capacity	to	 affect	 the	 protein	 stability	 indicators	 of	 Tm	 and	 secondary	 structure	 change	 as	measured	by	 far-UV	CD.	 Per-sulphated	CMH9	has	 a	 greater	 destabilising	 effect	 on	 the	immunoglobulins.	 The	 data	 does	 not	 point	 to	 a	 select	 disaccharide	 composition	 nor	functional	 group	 requirement	 for	 the	 resulting	 protein	 structure	 changes.	 Singularly	sulphated	heparins	show	equal	ability	to	peturb	the	stability	of	Ig	than	do	tri-sulphated	heparins.		 However,	 the	 structural	 complexity	 of	 the	 differing	 heparins	 related	 to	 the	presence	and	position	of	the	sulphate	groups,	both	O-sulphate	and	N-sulphate,	is	unclear	when	 trying	 to	 isolate	 patterns	 in	 this	 data.	 In	 addition	 to	 the	 functional	 groups,	 the	conformation	 and	 size	 of	 the	 chemically	 modified	 heparins	 may	 effect	 the	immunoglobulin	 interaction.	The	presence	of	 iduronic	 acid	 in	 the	 sequence	 allows	 for	levels	of	conformational	flexibility	to	alter	the	spatial	orientation	of	the	sulphate	groups	(Shriver,	Capila,	Venkataraman,	&	Sasisekharan,	2012).	The	1C4	chair	and	2S0	skew	boat	conformations	 of	 IdoA	 exist	 in	 relative	 equilibrium	 in	 solution,	 and	 the	 rate	 of	
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interchange	 between	 these	 forms	 is	 sufficiently	 fast	 to	 produce	 exchange-average	(blended)	chemical	shifts	in	1H	and	13C	NMR	spectra	(Ferro	et	al.,	1986).		 Protein-ligand	 interactions,	 demonstrated	 in	 thermal	 degradation	 experiments	such	 as	DSF,	 illustrate	protein	 stability	 improvements	with	 the	 addition	of	 the	 ligand;	the	Tm	of	the	protein	in	DSF	increases	in	the	presence	of	the	ligand.	In	common	protein-ligand	interactions,	such	as	catalytic	events,	 ligand	interaction	with	protein	 induces	an	increase	 in	 thermostability	due	 to	 the	 coupling	of	binding,	with	unfolding	 equilibrium	(Celej,	 Montich,	 &	 Fidelio,	 2003).	 Equlibrium	 binding	 ligands	 usually	 increase	 the	thermal	 stability	 of	 protein	 in	 a	 concentration	 and	 affinity	 dependant	 manner	(Cimmperman	 et	 al.,	 2008).	 The	 addition	 of	 the	 sulphated	 members	 of	 the	 heparin	library	causes	a	reduction	in	the	melting	temperature	of	the	immunoglobulin	at	low	pH,	and	 therefore	 suggests	 an	 aspect	 of	 structural	 destabilisation	 to	 promote	 untimely	melting.			 Destabilisation	occurs	when	tested	 in	acidic	conditions	(pH	4)	 to	each	antibody	type	 tested,	 IgG1k,	 IgG2k	 and	 IgM;	 raised	 to	 common	 antigen	 or	 isotype	 controls.	 A	model	 created	 by	 Cimmperman	 et	 al.,	 2008,	 suggests	 ligand	 that	 acts	 to	 reduce	 the	protein	 melting	 temperature	 in	 DSF	 binds	 to	 the	 unfolded	 denatured	 protein,	destabilising	 it	 (Cimmperman	 et	 al.,	 2008).	 Ligand	 that	 binds	 to	 the	 native,	 folded	protein	 stabilises	 the	 protein	 and	 therefore	 shows	 increased	 thermal	 stability	 (idem).	However,	 several	weakly	 binding	 ligands	 that	 have	 preferential	 affinity	 to	 a	 unfolded	protein	structure	may	have	a	cumulative	effect	 to	reduce	the	Tm	in	a	similar	way	to	a	high	affinity	ligand	to	the	fully	denatured	protein	structure	(idem).	The	ability	of	some	chemically	modified	heparin	 to	 act	 as	destabilisers	 at	high	 concentrations	 tested,	may	suggest	 the	 low	pH	environment	pH	4.0	denatures	 some	 immunoglobulin	 to	 allow	 for	the	 binding	 of	 the	 heparin	 based	 ligand.	 This	 model	 by	 Cimmperman	 et	 al.	 2008,	
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however,	 assumes	 a	 single	 unfolded	 protein	 structure	 rather	 than	 a	 range	 of	 semi-flexible	conformational	states.			 Regions	 of	 cellular	 apoptosis,	 necrosis,	 inflammation,	 and	 injury	 have	 the	potential	 to	harbour	 an	 acidic	 environment	due	 to	 the	 lysing	of	 acidic	 organelles.	The	lysing	of	the	lysosome,	endosome,	and	secretory	granules	could	cause	local	pH	reduction	to	 <	 pH	 6.	 The	 heparin	 binding	 activity	 of	 the	 immunoglobulins	 demonstrated	 in	 this	study	 have	 the	 potential	 to	 be	 physiologically	 and	 pathologically	 relevant	 in	 these	conditions.			 Low	molecular	weight	heparins	are	also	tested	for	the	destabilising	effect	seen,	as	a	 preliminary	 screen	 for	 activity.	 The	 type	of	 pharmaceutical	 heparin	 administered	 to	patients	is	primarily	low	molecular	weight,	due	to	the	negative	effects	of	unfractionated	heparin,	 such	 as	 heparin-induced	 thrombocytopenia	 (HIT)	 and	 unpredictable	pharmacokinetics.	 The	 plasma	 concentration	 of	 these	 drugs	 will	 be	 higher	 upon	administration	 than	 physiological	 heparin/HS.	 The	 preliminary	 screen	 for	 LMWH	destabilisation	of	whole	immunoglobulins	suggests	an	interaction,	which	needs	further	investigation.	This	will	ensure	administration	of	LMWH	do	not	have	an	adverse	effect	on	the	humoral	immune	system.			 The	synthetic	pentasaccharide	fondaparinux	has	the	lowest	molecular	weight	of	the	 LMWH	 tested,	 and	 is	 constructed	 including	 the	 factor	 Xa	 binding	 region	 only.	Fondaparinux	had	significantly	less	effect	on	the	stability	of	the	whole	immunoglobulins	tested,	 suggesting	 the	 size	 or	 biochemical	 structure	 were	 not	 conducive	 to	immunoglobulin	interaction.			 Experiments	 with	 sodium	 sulphate	 as	 a	 crude	 sulphate-containing	 compound	indicated	 that	 sulphate	 alone	 (or	negatively	 charged	 functional	 groups	 in	 general)	did	not	 fulfil	 the	role	 in	 immunoglobulin	destabilisation.	Naturally	unsulphated	hyaluronic	
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acid	was	also	shown	to	have	no	effect	in	the	destabilisation	of	the	IgG	tested,	suggesting	the	glycopolymeric	backbone	was	not	the	singularly	essential	factor.					 Determining	the	size	requirement	for	this	interaction,	a	library	of	depolymerised	heparin	fractions	was	utilised.	The	results	from	these	experiments	suggest	a	difference	in	glycopolymer	size	requirements	in	each	isotype	or	subclass.	IgG1k	required	a	minimal	saccharide	 size	 of	 d.p.4	 to	 begin	 to	 destabilise	 (reduce	 Tm),	 with	 d.p.18	 displaying	similar	melting	characteristics	of	full-length	heparin.	IgG2k	demonstrated	a	reduced	Tm	with	 a	 d.p.8,	 but	 the	 Tm	 is	 similar	 to	 unfractionated	 heparin	 after	 d.p.12.	 IgM	demonstrates	a	requirement	for	d.p.8	as	a	minimum	saccharide	size.			 Heparin	 affinity	 chromatography	 was	 employed	 to	 define	 the	 heparin	 binding	affinity	of	a	range	of	immunoglobulins.	As	with	the	Fc	region	investigated	in	Chapter	4,	the	 binding	 of	 these	whole	 immunoglobulins	 to	 the	 heparin	 column	occurred	 at	most	commonly	pH	4	and	5.			 IgG1k	bound	heparin	in	PBS	pH	4	with	an	affinity	of	1.03	M,	at	pH	5.0	with	933	mM	 affinity	 and	 at	 pH	 6	 with	 an	 affinity	 of	 704	mM.	 IgG1k	 binds	 pH	 4	 with	 1.08	 M	affinity	and	at	pH	5.0	with	928	mM	affinity.	This	is	mirrored	in	sodium	acetate	buffer	at	pH	4.0	with	binding	affinity	of	849	mM	NaCl.	IgG2k	has	a	heparin	binding	affinity	of	1.03	M	 in	 PBS	 at	 pH	 4.0,	 the	 same	 as	 IgG1k,	 suggesting	 the	 changes	 in	 hinge	 region	 that	differentiated	these	immunoglobulins	does	not	have	a	effect	on	heparin	binding.	IgG2k	binds	at	pH	6.0	PBS	similarly	to	IgG1k	(698	mM	NaCl).			 IgM	binds	heparin	in	PBS	pH	4.0	and	elutes	with	two	peaks,	at	989	mM	and	755	mM.	This	may	indicate	a	heterogenous	mixture	of	pentameric	IgM	or	the	variation	due	to	 access	 to	 the	 heparin	 matrix.	 The	 IgM	 structure	 is	 more	 structurally	 inaccessible,	apart	 from	 in	 the	 antigen	 recognition	 region.	 The	 two	 elution	 peaks	 could	 indicate	
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binding	 affinities	 of	 singular	 or	 numerous	 heparin-binding	 occurances	 across	 the	pentamer.			 Heparin	binding	affinity	of	antithrombin	III	in	Hi-trap	affinity	chromatography	in	0.25	M	citrate	buffer	pH	7.4	is	quoted	as	0.8	M	NaCl	(Jin	et	al.,	1997)	suggesting	heparin-immunoglobulin	 binding	 is	 not	 a	 ‘weak’	 interaction	 under	 these	 specified	 conditions.	Expansion	 of	 the	 buffer	 type	 and	 pH	 range	 is	 required	 to	 investigate	 further	 the	parameters	for	this	binding	interaction;	this	requires	completion	in	the	future.		 The	reduction	in	binding	affinity	with	decreasing	PBS	pH	suggests	charge	based	binding.	 González-Iglesias	 et	 al.	 (2002)	 showed	 that	 the	 heparin-prion	 protein	interaction	at	acid	pH	values	could	be	due	to	histidine	imidazole	protonation;	this	was	termed	 the	 acid	 pH-stabilised	 form	 of	 the	 protein	 (Gonzalez-Iglesias	 et	 al.,	 2002).	Chapter	4	discussed	the	action	of	PMH	and	other	chemically	modified	heparins	on	the	stability	 of	 the	 IgG	 Fc	 region	 as	 a	 possible	 interaction	 between	 positively	 charged	residues	such	as	Lys248	and	Lys388	in	the	CH2	region	of	Fc	(Latypov	et	al.,	2012).	The	action	of	imidazole	ions	of	histidine	and	guanidinium	ions	of	arginine	at	acidic	pH	may	also	 have	 heparin-binding	 effect	 (Zhang-van	 Enk	 et	 al.,	 2013).	 The	 IgM	 pentamer	therefore,	 comprises	 of	multiple	 regions	 for	 polyanionic	 binding	 to	 ionised	 positively	charged	residues,	across	the	5	IgG-like	monomers.		 To	 further	 the	 investigation	 into	 the	 effects	 of	 glycosaminoglycans	 with	immunoglobulins,	the	antigen	binding	regions	Fab/k	and	F(ab’)2	will	be	investigated	for	heparin	binding	properties.					
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Chapter	6:	Antigen	binding	immunoglobulin	domains	and	
their	interactions	with	glycosaminoglycans	
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6.1	Introduction	
6.1.1	Antigen	binding	domain			 The	 antigen-binding	 fragment	 of	 an	 immunoglobulin	 is	 composed	 of	 a	 single	variable	domain	and	a	 single	constant	domain	of	both	 the	 light	and	heavy	chains.	The	antigen-binding	 region	 is	 formed	 from	 three	 non-consecutive	 variable	 amino	 acid	sequences	 on	 each	 chain,	 which	 when	 folded,	 correspond	 to	 the	 complementary	determining	regions	(CDR).			 CDR1	and	CDR2	are	located	in	the	‘variable’	(V)	region	of	the	gene,	while	CDR3	is	located	in	across	variable	(V	region),	diversity	(D	region	in	heavy	chain	only)	and	joining	(J)	 regions	 (Brack,	 Hirama,	 Lenhardschuller,	 &	 Tonegawa,	 1978;	 Sakano,	 Huppi,	Heinrich,	&	Tonegawa,	1979;	Sakano,	Maki,	Kurosawa,	Roeder,	&	Tonegawa,	1980).	The	heavy	 chain	 and	 two	 light	 chain	 genes	 are	 located	 in	 different	 chromosomes,	 heavy	chain	at	chromosome	14,	kappa	light	chain	at	chromosome	2	and	lambda	light	chain	at	chromosome	 22	 (Janeway	 C.A	 2001).	 Each	 gene	 locus	 contains	 the	 V(D)J	 regions	required	for	recombination	(idem).	The	process	by	which	antibodies	form	in	immature	B-cells,	creating	unique	CDR	regions	is	called	somatic	recombination	(Brack	et	al.,	1978;	Sakano	et	al.,	1979;	Sakano	et	al.,	1980).			 Papain	 digestion	 of	 the	 whole	 IgG	 antibody	 yields	 an	 Fc	 region	 and	 two	 Fab	regions	(fragment	antigen	binding)	by	cutting	at	the	amino	side	of	the	disulphide	bonds	joining	 the	CH2	heavy	chain	regions,	whereas	pepsin	digestion	of	 the	 immunoglobulin	occurs	 at	 the	 carboxy-terminal	 side	 of	 the	disulphide	bonds	 (Janeway	C.A	2001).	 This	yields	a	 larger	F(ab’)2	 fragment	which	contains	more	of	 the	hinge	 region	and	 the	 two	antigen	 binding	 arms,	 and	 yields	 an	 additional,	 smaller	 pFc’	 region	 (idem).	 Unlike	 the	Fab	fragment,	the	larger	F(ab’)2	fragment	can	elicit	a	serologic	reaction.		
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6.1.2	The	immunoglobulin	fold		 An	 IgG	molecule	 contains	 12	 immunoglobulin	 domain	 structures,	 each	 domain	contains	 sequence	 features	 that	 cause	 protein	 folding	 to	 form	 a	 immunoglobulin	 fold	(Peterson,	 Berggard,	 Edelman,	 &	 Cunningham,	 1972).	 The	 immunoglobulin	 fold	 is	characterised	 by	 2	 β-sheets	 sandwiched	 together,	 constructed	 by	 5-10	 antiparallel	 β-strands	(Williams	&	Barclay,	1988).	The	strands	form	what	is	termed	a	Greek	key	motif,	where	 4	 neighboring	 antiparallel	 β-strands	 are	 linked;	 3	 by	 hairpin	 loops	 and	 the	 4th	linked	adjacent	 to	 the	 first	 strand,	by	a	 longer	chain	 region	 from	strand	3	 (idem).	The	sandwiched	 β-sheets	 surround	 a	 hydrophobic	 protein	 core	 and	 are	 connected	 by	 a	disulphide	 bond,	 with	 this	 bond	 essential	 for	 immunoglobulin	 fold	 stability	 and	therefore,	 activity	 of	 the	protein	 (K.	 J.	 Zhang	&	Filbin,	 1994).	 65-75	 residues	 separate	this	 disulphide	bond	 in	 primary	 sequence,	 in	 the	 variable	 domain	 of	 immunoglobulin.	The	disulphide	bond	in	the	constant	domain	has	a	shorter	separation	of	55-60	residues	(Williams	 &	 Barclay,	 1988).	 Some	 non-antibody	 immunoglobulin	 fold	 containing	proteins	have	as	few	as	40	residues	separating	the	inter-sheet	disulphide	bond	(idem).		 The	 three	 loops	 at	 the	 end	 of	 the	 β-strands	 contain	 the	 hypervariable	 regions	containing	CDRs,	which	form	the	antigen-binding	surface	on	both	antibodies	and	T-cell	receptors	 (Capra,	 1971).	 The	 N-	 and	 C-	 termini	 occupy	 opposing	 sides	 of	 the	immunoglobulin	fold,	allowing	subsequent	addition	of	further	immunoglobulin	domains,	as	seen	in	the	antibody	heavy	and	light	chains	(Berg,	2002)		 More	than	750	genes	encode	proteins	with	a	primary	sequence	immunoglobulin	fold	 in	multicellular	organisms,	 this	 structural	motif	has	not	yet	been	characterised	 in	yeast	or	plant	species	(Berg,	2002).			
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6.1.3	Experimental	aims		 This	chapter	will	 identify	whether	the	effector	binding	(heavy	chain	Fc)	regions	of	 immunoglobulin	only	binds	heparin	and	other	GAGs,	or	 if	heparin	and	related	GAGs	bind	the	antigen	binding,	immunoglobulin	fragments.		 	
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6.2	Results	
6.2.1	Fab/k	stability	in	the	presence	of	chemically	modified	heparins		 The	Fab/k	1st	derivative	peak	has	a	Tm	of	60.21°C.	On	addition	of	6.0	μM	CMH1,	this	 Tm	 is	 reduced	 by	 7.78°C	 to	 52.43°C.	 The	 concentrations	 of	 chemically	 modified	heparon	of	3.0	μM,	1.5	μM	and	0.75	μM	all	demonstrate	the	same	peak	shape	with	Tm	of	52.41°C,	52.63°C	and	53.25°C	respectively.	At	0.38	μM	the	Tm	is	shifted	to	55.32	°C.	The	peak	shape	at	this	concentration	is	wider	with	a	shoulder	at	the	higher	temperature	of	approximately	 64°C,	 which	 mirrors	 the	 peaks	 at	 lower	 concentrations	 of	 CMH1.	 The	CMH1	concentration	of	0.19	μM	has	an	intermediate	structure	with	a	double	joined	peak	shape;	 the	 Tm	 of	 these	 peaks	 is	 55.30°C	 and	 65.81°C.	 The	 peak	 at	 0.09	 μM	 of	 CMH1	occurs	at	63.22°C,	which	is	higher	than	the	IgG	Fab/k	only	peak,	but	has	a	shoulder	at	lower	temperatures,	mirroring	the	peaks	at	higher	CMH1	concentrations.	At	the	lowest	concentration	tested	(0.05	μM),	the	curve	has	the	Tm	60.52°C.	
		Figure	107:	DSF	of	Fab/k	with	CMH1	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH1,	(−)	3.0	μM	CMH1,	(−)	1.5	μM	CMH1,	(−)	0.75	μM	CMH1.	B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH1,	(−)	0.19	μM	CMH1,	(−)	0.09	μM	CMH1,	(−)	0.05	μM	CMH1.		
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		 The	change	in	Tm	of	Fab/k	on	addition	of	6.0	μM	CMH2	is	7.48°C,	with	the	Tm	of	Fab/k	 at	 this	 concentration	 being	 52.80°C.	 CMH2	 at	 3.0	 μM	 has	 a	 peak	 shape,	fluorescence	intensity	and	Tm	like	that	of	6.0	μM,	with	a	Tm	of	53.21°C.	At	1.5	μM	the	Tm	 increases	 to	52.55	 °C,	with	0.75	μM	CMH2	 further	 increasing	 in	Tm	to	54.97°C.	At	0.19	μM	CMH2	the	peak	has	a	more	intermediate	shape	containing	a	peak	with	a	large	shoulder.	The	peak	occurs	 at	Tm	of	 64.48°C	with	 a	 shoulder	 at	 56.14°C.	The	 shape	of	peaks	at	0.09	μM	and	0.05	μM	are	similar;	the	Tm	of	these	two	peaks	of	62.36°C	(0.09	μM)	and	60.94°C	(0.05	μM).		
	 The	reduction	in	Tm	seen	in	IgG	Fab/k	with	6.0	μM	CMH3	is	6.97°C,	with	the	6.0	μM	CMH3	Tm	of	53.29°C.	The	peaks	of	1.5	μM	and	0.75	μM	have	similar	shapes,	with	the	
	Figure	108:	DSF	of	Fab/k	with	CMH2	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH2,	(−)	3.0	μM	CMH2,	(−)	1.5	μM	CMH2,	(−)	0.75	μM	CMH2.	B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH2,	(−)	0.19	μM	CMH2,	(−)	0.09	μM	CMH2,	(−)	0.05	μM	CMH2.		
	Figure	109:	DSF	of	Fab/k	with	CMH3	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH3,	(−)	3.0	μM	CMH3,	(−)	1.5	μM	CMH3,	(−)	0.75	μM	CMH3.	
B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH3,	(−)	0.19	μM	CMH3,	(−)	0.09	μM	CMH3,	(−)	0.05	μM	CMH3.		
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Tm	of	these	peaks	at	55.10°C	and	55.91°C	respectively.	At	CMH3	concentration	of	0.38	μM	the	peak	is	more	broad,	with	a	Tm	of	58.03°C	and	moves	to	an	intermediate	peak	at	0.19	μM	(64.14°C),	with	a	shoulder	at	56.67°C.	The	highest	fluorescence	intensity	peak	in	 the	 data	 belongs	 to	 0.09	 μM	 CMH3	 (Tm	 62.60°C)	 with	 the	 0.05	 μM	 CMH3	 peak	occurring	at	a	lower	intensity	(60.93°C).			 The	addition	of	6.0	μM	CMH4	reduces	the	IgG	Fc	Tm	to	53.07°C.	With	addition	of	reducing	concentrations	of	CMH4,	the	Tm	increases	up	to	0.38	μM	with	a	Tm	of	56.26°C.	At	0.19	μM	CMH4	 the	peak	splits	 into	 two	 joined	peaks	with	Tm	56.84°C	and	64.86°C	respectively.		
	 The	addition	of	6.0	μM	CMH5	reduces	the	Tm	of	Fab/k	to	55.97°C	(Δ	4.11°C).	This	change	however,	is	not	the	largest	Tm	shift	in	this	data,	with	the	difference	between	6.0	μM	and	0.19	μM	CMH5	of	12.33°C.	At	3.0	μM	CMH5	displays	the	same	peak	shape	as	at	6.0	 μM,	with	 a	Tm	of	 56.56°C.	 The	CMH5	 concentrations	 of	 1.5	 μM	and	0.75	μM	have	with	Tm	of	57.15°C	and	58.30°C.	At	0.19	μM	CMH5,	the	IgG	Fab/k	peak	occurs	at	Tm	of	64.55°C	 The	 peaks	 at	 0.09	 μM	 and	 0.05	 μM	 have	 both	 higher	 Tm	 than	 IgG	 Fab/k	 at	62.55°C	and	61.45°C.		
	Figure	110:	DSF	of	Fab/k	with	CMH4	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH4,	(−)	3.0	μM	CMH4,	(−)	1.5	μM	CMH4,	(−)	0.75	μM	CMH4.	
B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH4,	(−)	0.19	μM	CMH4,	(−)	0.09	μM	CMH4,	(−)	0.05	μM	CMH4.		
	 207	
	 The	largest	shift	in	Tm	seen	with	the	addition	of	CMH6	is	the	difference	between	6.0	μM	CMH6	and	0.19	μM	CMH5	of	7.48°C,	also	seen	in	CMH5	with	IgG	Fab/k.	The	Tm	Tm	shift	seen	from	IgG	Fab/k	to	the	inclusion	of	6.0	μM	CMH6	is	3.94°C.	The	peaks	of	6.0	μM,	3.0	μM,	1.5	μM	and	0.75	μM	increase	in	Tm	from	the	6.0	μM	Tm	of	56.14°C	to	0.75	μM	Tm	at	 57.17°C.	 The	CMH6	 concentration	 of	 0.19	 μM	has	 a	 Tm	of	 63.62°C;	 greater	than	IgG	Fab/k	only.		
	Figure	111:	DSF	of	Fab/k	with	CMH5	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH5,	(−)	3.0	μM	CMH5,	(−)	1.5	μM	CMH5,	(−)	0.75	μM	CMH5.	B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH5,	(−)	0.19	μM	CMH5,	(−)	0.09	μM	CMH5,	(−)	0.05	μM	CMH5.		
	Figure	112:	DSF	of	Fab/k	with	CMH6	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH6,	(−)	3.0	μM	CMH6,	(−)	1.5	μM	CMH6,	(−)	0.75	μM	CMH6.	B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH6,	(−)	0.19	μM	CMH6,	(−)	0.09	μM	CMH6,	(−)	0.05	μM	CMH6	
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	 The	difference	between	the	Tm	between	IgG	Fab/k	and	6.0	μM	CMH7	follows	the	same	 trend	 of	 the	 other	 chemically	 modified	 heparins	 with	 this	 immunoglobulin	fragment;	the	greatest	difference	in	Tm	seen	is	between	6.0	μM	and	0.19	μM	CMH7.	The	concentrations	of	6.0	μM,	3.0	μM,	and	1.5	μM	CMH7	have	the	same	Tm	at	approximately	53°C.	 The	 peak	 shape	 remains	 the	 same	 for	 0.75	 μM	 and	 0.38	 μM	CMH7,	 but	 the	 Tm	increases	to	54.79°C	and	55.53°C	respectively.		
	 	All	 concentrations	 of	 CMH8	 lead	 to	 an	 increased	 Tm	 compared	 to	 IgG	 Fab/k	alone.	The	IgG	Fab/k	Tm	is	60.60°C,	with	all	CMH8	concentrations	tested	with	IgG	Fab/k	Tm	at	63.20°C.		
	Figure	113:	DSF	of	Fab/k	with	CMH7	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH7,	(−)	3.0	μM	CMH7,	(−)	1.5	μM	CMH7,	(−)	0.75	μM	CMH7.	B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH7,	(−)	0.19	μM	CMH7,	(−)	0.09	μM	CMH7,	(−)	0.05	μM	CMH7		
	Figure	114:	DSF	of	Fab/k	with	CMH8	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH8,	(−)	3.0	μM	CMH8,	(−)	1.5	μM	CMH8,	(−)	0.75	μM	CMH8.	B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH8,	(−)	0.19	μM	CMH8,	(−)	0.09	μM	CMH8,	(−)	0.05	μM	CMH8.		
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	 The	greatest	Tm	shift	 seen	with	CMH9	 is	 the	difference	 in	Tm	between	6.0	μM	and	0.75	μM	CMH9	12.79°C.	The	6.0	μM	Tm	peak	occurs	at	51.86°C.	The	3.0	μM	curve	follows	the	same	peak	shape	with	similar	Tm.	CMH9	concentration	of	1.5	μM	and	0.75	μM	have	 equivalent	 shaped	 curves	with	Tm	52.70°C.	At	0.38	μM	CMH9,	 the	Tm	shifts	further	to	a	higher	melting	temperature,	at	53.64°C.	CMH9	concentration	0.19	μM	gives	an	intermediate	peak	with	a	double-peak	structure	at	Tm	of	55.55°C	and	64.65°C	with	peak.		
	 The	PCA	of	Fab/k	the	1st	derivative	DSF	data	with	CMH	1-7	and	CMH9	follow	the	same	data	distrubition	of	CMH1	in	Figure	116	The	protein	only	Fab/k	control	occurs	as	a	mid-point	within	the	concentrations	of	CMH	tested.	CMH8	however,	the	PC1	shows	little	variation	and	covers	93.3%	of	the	variance	of	the	data,	suggesting	all	concentrations	of	CMH8	tested	in	DSF	have	a	minimal	effect	on	the	thermal	stability	of	Fab/k.	
	Figure	 116:	 PCA	 of	 1st	 derivative	 DSF	melt	 curves	 of	 Fab/k	with	 CMH1	 and	 CMH8	 in	 50	mM	sodium	acetate	pH	4.0.		
	Figure	115:	DSF	of	Fab/k	with	CMH9	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	Fab/k	region	with	(−)	6.0	μM	CMH9	(−)	3.0	μM	CMH9	(−)	1.5	μM	CMH9	(−)	0.75	μM	CMH9	B=	(−)	3	μM	IgG	Fab/k	region	with	(−)	0.38	μM	CMH9	(−)	0.19	μM	CMH9	(−)	0.09	μM	CMH9	(−)	0.05	μM	CMH9.		
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6.2.2	Circular	dichroism	with	IgG	Fab/k	region	and	chemically	modified	heparins		 Far	 UV	 circular	 dichroism	 was	 utilised	 to	 show	 changes	 in	 Fab/k	 secondary	structure	upon	addition	of	each	member	of	the	chemically	modified	heparin	library.			 Each	 chemically	 modified	 heparin	 modified	 the	 Fab/k	 spectra	 to	 different	degrees.	The	positive	ellipticity	peak	occurring	at	λ	=	207	nm	is	altered	to	λ	=	209	nm	with	CMH1,	with	the	trough	at	λ	=	228	nm	in	Fab/k	alone	shifted	to	λ	=	231	nm	with	the	CMH1	 (Figure	 117).	 The	 two-sulphated	 CMH2	 shown	 in	 Figure	 117B	 with	 Fab/k	 no	longer	retains	the	negative	peak	feature	at	λ	=	228	nm,	with	a	peak	reading	occurring	at	this	wavelength.	The	positive	λ	=	207	nm	peak	is	also	shifted	to	a	higher	CD	reading	at	λ	=	210	nm.	CMH3	contains	a	similar	spectral	feature	to	CMH2	in	that	the	spectral	trough	is	absent,	and	the	positive	mdeg	peak	occurs	at	λ	=	211	nm	(Figure	117C).	The	singularly	sulphated	CMH4	spectra	 incudes	both	 the	 return	of	 the	 trough	at	λ	=	231	nm	and	 the	smaller	shift	of	the	positive	peak	at	λ	=	209	nm,	like	CMH1,		(Figure	117D).		
	Figure	117:	Far-UV	CD	spectra	of	Fab/k	with	CMH	1-4	in	50	mM	sodium	acetate	pH	4.0.	(−)	3	μM	IgG	Fab/k	region	with	A)	(−)	3	μM	CMH1,	 B)	 (−)	3	μM	CMH2,	C)	(−)	3	 μM	CMH3	D)	 (−)	3	 μM	CMH4.		
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	 Figure	118	continues	these	CD	spectra	of	Fab/k	including	CMH5,	which	consists	of	a	 small	 trough	at	λ	=	229	nm	and	a	higher	 intensity	peak	at	λ	=	208	nm.	While	 the	wavelengths	of	the	peaks	do	not	differ	largely	from	the	Fab/k	only	spectra,	the	intensity	of	 the	 CD	 spectra	 differs	 from	 the	 protein	 only	 spectra,	 showing	 that	 the	 two	 are	 not	superimposable.		
	 The	 CMH6	 spectra	 at	wavelength	 greater	 than	 λ	 =	 220	 nm	 is	 all	 in	 the	 region,	unlike	each	other	chemically	modified	heparin	tested	(Figure	118A).	The	peak	occurs	at	λ	=	215	nm	with	a	similar	intensity	as	the	Fab/k	only	peak	at	λ	=	207	nm.	CMH7	shifts	
	Figure	118:	Far-UV	circular	dichroism	spectra	of	Fab	with	CMH	5-9	in	50	mM	sodium	acetate	pH	4.0.	A)(−)	3	μM	IgG	Fab/k	region	(−)	IgG	Fab/k	region	with	3	μM	CMH5,	B)(−)	IgG	Fab/k	region	(−)	IgG	Fab/k	region	with	3	μM	CMH6,	C)(−)	IgG	Fab/k	region	(−)	IgG	Fab/k	region	with	3	μM	CMH7	D)(−)	IgG	Fab/k	region	(−)	IgG	Fab/k	region	with	3	μM	CMH8,	E)(−)	IgG	Fab/k	region	(−)	IgG	Fab/k	region	with	3	μM	CMH9.		
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the	trough	to	λ	=	331	nm	from	the	protein	only	λ	=	228	nm	(Figure	118C).	The	positive	peak	 at	 λ	 =	 207	 nm	 the	 same	 as	 the	 protein	 only	 peak,	 but	 the	 intensity	 is	 greater.	Unsulphated	CMH8	shows	no	change	to	 the	Fab/k	 far-UV	CD	spectra.	Unlike	 the	other	immunoglobulins	 tested	 thus	 far,	 per-sulphated	 CMH9	 does	 not	 have	 the	 greatest	structural	change	in	Fab/k.	The	trough	reaches	λ	=	230	nm,	from	the	protein	only	peak	of	λ	=	228	nm	and	the	peak	occurs	at	λ	=	212	nm,	from	the	protein	only	peak	of	λ	=	207	nm	(Figure	118E).		
6.2.3	Fab/k	stability	in	the	presence	of	low	molecular	weight	heparins		 Five	pharmaceutically	relevant	low	molecular	weight	heparins	were	employed	to	determine	 the	 effect	 of	 these	 drugs	 on	 the	 stability	 of	 Fab/k	 fragment	 of	immunoglobulin.	In	DSF	the	Fab/k	only	peak	has	a	Tm	of	60.86°C.	Fondaparinux	has	a	similar	 Tm	 to	 Fab	 only	 of	 60.65°C.	 Addition	 of	 6.0	 μM	 of	 UF	 PMH	 reduces	 the	 Tm	 to	52.42°C;	the	remaining	LMWH	have	Tm	all	of	≈	53°C	with	peak	shape	similar	to	that	of	CMH1.		
	Figure	119:	DSF	of	Fab/k	with	LMWH	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	IgG	Fc	region	(−)	IgG	Fc	region	with	6.0	μM	dalteparin	(−)	IgG	Fc	region	with	6.0	μM	enoxaparin.	B=	(−)	3	 μM	 IgG	 Fc	 region	 (−)	 IgG	 Fc	 region	 with	 6.0	 μM	 tinzaparin	 (−)	 IgG	 Fc	 region	 with	 6.0	 μM	reviparin,	(−)	IgG	Fc	region	with	6.0	μM	fondaparinux.			
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6.2.4	Fab/k	stability	in	the	presence	of	GAGs	and	heparin	controls		 Sodium	 sulphate	 and	 UA(2S)-GlcNS(6S)	 (disaccharide	 standard	 6)	 both	 do	 not	alter	 the	 structural	 stability	 of	 Fab/k	 as	 shown	 in	 Figure	 120	A&B.	Heparan	 sulphate	reduces	the	Tm	of	this	protein	similarly	to	CMH1	to	55.72°C.	Chondroitin	sulphate	A	and	B	do	not	change	the	Tm	of	Fab/k	in	DSF	to	the	same	degree	as	HS	with	a	Tm	of	59.13°C	(Figure	120C).		
	
6.2.5	Fab/k	stability	in	the	presence	of	size	defined	heparin	fractions	With	the	addition	of	6.0	μM	full	 length	CMH1	to	human	IgG	Fab/k	fragment	 in	50	mM	sodium	acetate	pH	4.0	in	DSF,	the	Tm	of	the	protein	is	reduced	from	62.82°C	to	54.39°C	(Table	13).		 The	three	smallest	d.p.	 fragments	 increase	the	Tm	of	the	Fab/k	fragment	alone,	with	d.p.2	Tm	of	65.13°C.	Saccharide	of	d.p.20	has	a	Tm	of	54.32°C	which	is	most	similar	
	Figure	120:	DSF	of	Fab/k	with	GAGs	and	sulphate	controls	in	50	mM	sodium	acetate	buffer	pH	4.0	(−)	3	μM	human	IgG	Fab/k	region	with	A)	(−)	6.0	μM	UF	PMH,	(−)	500	nM	sodium	sulphate,	
B)	(−)	6.0	μM	DS6	(−)	12.0	μM	HS,	C)	(−)	6.0	μM	CSA,	(−)	6.0	μM	CSC.		
	 214	
to	UF	PMH	(0.07°C	different)	with	Fab/k,	with	saccharides	of	d.p.12	and	d.p.16	also	have	Tm	 similar	 to	 full	 length	Fab	 (54.92°C	 and	54.81°C	 respectively).	However,	 the	 d.p.14	has	an	increased	Tm	of	56.76°C	which	is	2.37°C	above	that	of	UF	PMH.	
6.2.6	Fab/k	binds	heparin	in	Hi-trap	HPLC			 Heparin	 affinity	 chromatography	 with	 IgG	 Fab/k	 in	 PBS	 at	 various	 pH	determined	 heparin	 binding	 occurred	 at	 pH	 4.0	 and	 5.0,	 however	 the	majority	 of	 the	protein	was	eluted	prior	to	the	2M	NaCl	gradient	suggesting	no	binding	to	the	column	(Figure	121).	PBS	at	pH	5.0	gave	a	247	mM	heparin	affinity,	with	pH	4	PBS	allowing	a	stronger	heparin	binding	at	755	mM	and	989	mM.			 Fab/k	 in	heparin	hi-trap	affinity	 chromatography	 in	50	mM	sodium	acetate	pH	4.0	has	a	797	mM	binding	affinity;	between	the	two	binding	affinities	seen	in	pH	4	PBS	(Figure	122).	This	data	 gives	 a	 clear	peak	when	 compared	 to	 the	non-binding	protein	elution	prior	to	salt	gradient.	
Table	13:	The	Tm	from	DSF	of	Fab/k	with	each	PMH	polymerization	(D.P)	fragment	in	50	mM	sodium	acetate	buffer	pH	4.0.			
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	Figure	121:	Human	IgG	Fab/k	fragment	 in	heparin	HiTrap	affinity	HPLC	in	PBS	at	differing	pH	(4.0	–	7.4)	and	elution	with	2M	NaCl.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.		
	Figure	122:	Human	IgG	Fab/k	in	heparin	HiTrap	affinity	HPLC	in	50	mM	sodium	acetate	pH	4.0	with	2M	NaCl	elution.		
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6.2.7	F(ab’)2	stability	in	the	presence	of	chemically	modified	heparins	
	 The	IgG	F(ab’)2	alone	has	a	Tm	of	63.14°C.	On	addition	of	6.0	μM	CMH1,	the	Tm	shifts	8.93°C,	to	a	lower	Tm	of	54.21°C	with	a	fluorescence	intensity	4400	ΔFU.	Addition	of	3.0	μM	and	1.5	μM	CMH1	yields	the	same	curve	shape	with	Tm	of	54.58°C	and	54.38°C	respectively.	The	CMH1	concentration	of	0.38	μM	with	IgG	F(ab’)2	has	a	Tm	of	57.10°C,	with	a	slightly	lower	fluorescence	intensity	than	that	of	the	higher	CMH1	concentrations	(3400	ΔFU).	The	peak	of	0.19	μM	CMH1	has	a	Tm	of	57.10°C	with	a	secondary	peak	at	Tm	of	69.08°C.		
	
	Figure	123:	DSF	of	F(ab’)2	with	CMH1	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH1,	(−)	3.0	μM	CMH1,	(−)	1.5	μM	CMH1,	(−)	0.75	μM	CMH1.	B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH1,	(−)	0.19	μM	CMH1,	(−)	0.09	μM	CMH1,	(−)	0.05	μM	CMH1.		
	Figure	124:	DSF	of	F(ab’)2	with	CMH2	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH2,	(−)	3.0	μM	CMH2,	(−)	1.5	μM	CMH2,	(−)	0.75	μM	CMH2.	
B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)0.38	μM	CMH2,	(−)	0.19	μM	CMH2,	(−)	0.09	μM	CMH2,	(−)	0.05	μM	CMH2.		
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	 The	difference	in	Tm	between	IgG	F(ab’)2	alone	and	6.0	μM	CMH2	is	larger	than	with	CMH1	at	9.60°C.	The	addition	of	decreasing	concentrations	of	CMH2	increases	the	Tm	 and	 reduces	 the	 fluorescence	 intensity	 of	 the	 peaks.	 The	 peak	 shape	 at	 0.38	 μM	CMH2	 is	 wider	 and	 flattened	 than	 that	 of	 higher	 concentrations	 of	 CMH2.	 At	concentrations	at	0.19	μM	CMH2	has	Tm	above	that	of	IgG	F(ab’)2	alone.		
		 The	greatest	shift	in	Tm	with	CMH3	occurs	with	6.0	μM	compared	to	IgG	F(ab’)2	alone.	This	Tm	change	is	7.58°C,	lower	than	both	CMH1	and	CMH2.	The	overall	shape	of	the	peak	is	similar	to	CMH2	with	F(ab’)2.	At	6.0	μM	the	Tm	is	56.97°C.	Concentrations	of	1.5	μM	and	0.75	μM	CMH3	have	similar	 fluorescence	 intensity	peaks	(4070	ΔFU)	with	Tm	of	58.88°C	and	58.74°C	respectively,	however,	0.75	μM	exhibits	a	possible	air	bubble	due	to	a	intensity	spike	at	60.59°C.	CMH3	at	0.38	μM	has	a	wider	and	flattened	peak	at	61.45°C	with	 lower	 intensity	of	3100	ΔFU.	The	curve	at	0.19	μM	mirrors	 the	 intensity	and	Tm	of	IgG	F(ab’)2	alone	(Tm	at	64.18°C).	The	concentrations	of	0.09	μM	and	0.05	μM	have	higher	Tm	than	that	of	IgG	F(ab’)2	alone.	
	Figure	125:	DSF	of	F(ab’)2	with	CMH3	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH3,	(−)	3.0	μM	CMH3,	(−)	1.5	μM	CMH3,	(−)	0.75	μM	CMH3.	B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH3,	(−)	0.19	μM	CMH3,	(−)	0.09	μM	CMH3,	(−)	0.05	μM	CMH3.		
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	 The	reduction	in	Tm	with	the	addition	of	6.0	μM	CMH4,	compared	to	the	F(ab’)2	control	 only	 is	 8.38°C,	 with	 the	 increase	 in	 fluorescence	 intensity	 seen	 in	 the	 other	chemically	modified	 heparins	with	 this	 immunoglobulin	 fragment.	 The	 concentrations	tested	can	be	grouped	into	two,	with	the	first	higher	intensity	peaks	belonging	to	CMH4	concentrations	of	6.0	–	0.38	μM,	with	intensity	at	these	concentrations	4500-5000	ΔFU.	The	0.19	μM	CMH4	concentration	along	with	0.09	μM	and	0.05	μM	belong	in	the	second	group	which	occur	≈	Tm	of	the	IgG	F(ab’)2	control.		
	 The	reduction	in	Tm	seen	with	6.0	μM	CMH5	addition	is	6.13°C,	with	the	Tm	at	this	 concentration	 at	 58.18°C	 with	 an	 increased	 intensity	 of	 3800	 ΔFU.	 With	 3.0	 μM	
Figure	126:	DSF	of	F(ab’)2	with	CMH4	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH4,	(−)	3.0	μM	CMH4,	(−)	1.5	μM	CMH4,	(−)	0.75	μM	CMH4.	
B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH4,	(−)	0.19	μM	CMH4,	(−)	0.09	μM	CMH4,	(−)	0.05	μM	CMH4.		
	Figure	127:	DSF	of	F(ab’)2	with	CMH5	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH5,	(−)	3.0	μM	CMH5,	(−)	1.5	μM	CMH5,	(−)	0.75	μM	CMH5.	B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH5,	(−)	0.19	μM	CMH5,	(−)	0.09	μM	CMH5,	(−)	0.05	μM	CMH5.		
	 219	
CMH5	the	Tm	with	IgG	F(ab’)2	reduces	to	57.71°C	with	a	higher	fluorescence	intensity.	The	CMH5	concentration	of	1.5	μM	has	a	similar	fluorescence	intensity	peak	as	6.0	μM	with	a	Tm	of	58.98°C,	with	the	intensity	falling	with	lowering	CMH5	concentration	but	the	peak	has	a	secondary	peak	at	62.22°C	which	is	mirrored	in	the	0.09	μM	and	0.05	μM	concentrations	 of	 CMH5	 with	 this	 immunoglobulin	 fragment.	 CMH5	 of	 0.05	 μM	 with	F(ab’)2	demonstrates	the	highest	melting	point	with	Tm	of	67.18	°C.		
	 The	Tm	shift	from	IgG	F(ab’)2	alone	to	protein	with	6.0	μM	is	4.13°C,	to	a	Tm	of	58.59°C.	The	intensity	of	the	6.0	μM	CMH6	with	IgG	F(ab’)2	peak	is	4000	ΔFU,	with	3.0	μM	and	1.5	μM	CMH6	peaks	with	this	Ig	having	the	same	peak	shape	and	fluorescence	
	Figure	128:	DSF	of	F(ab’)2	with	CMH6	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH6,	(−)	3.0	μM	CMH6,	(−)	1.5	μM	CMH6,	(−)	0.75	μM	CMH6.	B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH6,	(−)	0.19	μM	CMH6,	(−)	0.09	μM	CMH6,	(−)	0.05	μM	CMH6.		
	Figure	129:	DSF	with	F(ab’)2	and	CMH7	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH7,	(−)	3.0	μM	CMH7,	(−)	1.5	μM	CMH7,	(−)	0.75	μM	CMH7.	
B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH7,	(−)	0.19	μM	CMH7,	(−)	0.09	μM	CMH7,	(−)	0.05	μM	CMH7.		
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intensity.	The	Tm	of	3.0	μM	CMH6	is	58.34°C	and	at	1.5	μM	the	Tm	is	58.28°C.	The	peak	at	0.75	μM	is	more	broad	than	the	higher	concentrations,	with	Tm	of	60.52°C.		 Melting	temperature	of	IgG	F(ab’)2	decreases	to	56.83°C	with	the	addition	of	6.0	μM	CMH7;	a	reduction	in	Tm	of	6.07°C.	The	fluorescence	intensity	with	6.0	μM	CMH7	is	increased	from	2700	ΔFU	(F(ab’)2	control)	to	4300	ΔFU.	The	concentrations	3.0	μM,	1.5	μM,	 and	0.75	μM	CMH7	all	 have	higher	 intensity	peaks	 (3.0	μM	highest	 at	 5000	ΔFU)	than	6.0	μM.	CMH7	at	3.0	μM	has	a	Tm	of	56.84°C	and	a	 smaller	 sub-peak	at	70.46°C.	Concentrations	 of	 1.5	 μM	 and	 0.75	 μM	 CMH7	 have	 a	 Tm	 of	 56.99°C	 and	 57.44°C	respectively.	 At	 0.38	 μM	 CMH7,	 the	 intensity	 of	 the	 peak	 drops	 below	 that	 of	 6.0	 μM	CMH7	 to	 3800	 ΔFU,	with	 a	 Tm	 of	 58.61°C.	 The	 curve	 of	 0.09	 μM	 CMH7	with	 F(ab’)2	mirrors	the	shape	of	the	F(ab’)2	alone	peak	but	has	a	higher	Tm	of	63.69°C.		
	 Each	 concentration	 of	 CMH8	 tested	 has	≈	 Tm	 as	 IgG	 F(ab’)2	 alone	 (Tm	 of	62.50°C)	apart	from	1.5	μM	CMH8	which	has	a	Tm	at	60.37°C.	The	concentration	of	0.09	μM	CMH8	has	an	anomalous	spike	at	68.87°C	with	a	fluorescence	intensity	4370	ΔFU.		
	Figure	 130:	 DSF	 of	 F(ab’)2	 with	 CMH8	 in	 50	 mM	 sodium	 acetate	 buffer	 pH	 4.0	with	 3	 μM	human	IgG	F(ab’)2	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH8,	(−)	3.0	μM	CMH8,	(−)	1.5	μM	CMH8,	(−)	0.75	μM	CMH8.	B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH8,	(−)	0.19	μM	CMH8,	(−)	0.09	μM	CMH8,	(−)	0.05	μM	CMH8.		
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	 CMH9	with	IgG	F(ab’)2	is	the	most	complex	of	the	dataset.	A	reduction	in	Tm	of	9.97°C	 occurs	 on	 addition	 of	 6.0	 μM	 CMH9;	 the	 largest	 shift	 seen	 with	 this	 Ig.	 The	difference	in	fluorescence	intensity	between	these	two	peaks	is	an	increase	of	2100	ΔFU	with	 the	addition	of	CMH9	at	6.0	μM.	The	concentrations	of	3.0	μM	and	1.5	μM	CMH9	have	similar	Tm	to	6.0	μM	CMH9	at	52.64°C	and	52.13°C;	these	concentrations	of	CMH9	also	have	shoulder	peaks	at	Tm	of	67.78°C	and	68.99°C.	CMH9	at	0.38	μM	has	a	joined	peak	with	Tm	of	55.38°C	and	68.92	°C.	At	0.19	μM	CMH9	the	curve	 is	 flattened	across	30°C	to	80°C.	The	highest	point	of	this	curve	is	Tm	of	56.12°C	with	the	second	highest	region	with	 the	 Tm	 67.77°C,	 the	 same	 Tm	 as	 the	 spiked	 peak	 at	 0.38	 μM	 CMH9.	 The	CMH9	concentration	of	0.09	μM	has	a	Tm	of	65.76°C.	IgG	F(ab’)2	with	0.05	μM	CMH9	has	a	peak	which	mimics	the	shape	of	IgG	F(ab’)2	only,	with	Tm	of	64.66°C.	
	Figure	131:	DSF	of	F(ab’)2	with	CMH9	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	6.0	μM	CMH9,	(−)	3.0	μM	CMH9,	(−)	1.5	μM	CMH9,	(−)	0.75	μM	CMH9.	
B=	(−)	3	μM	IgG	F(ab’)2	region	with	(−)	0.38	μM	CMH9,	(−)	0.19	μM	CMH9,	(−)	0.09	μM	CMH9,	(−)	0.05	μM	CMH9.		
	Figure	132:	PCA	of	1st	derivative	DSF	data	of	F(ab’)2	with	CMH1	and	CMH8.	
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	 The	PCA	of	F(ab’)2	and	CMH	demonstrates	a	similar	relationship	as	Fab	with	the	modified	 heparin	 library.	 CMH1-7	 and	 CMH9	 follow	 the	 same	 distribution	 pattern	 in	both	PC1	and	PC2,	with	unsulphated	CMH8	demonstrating	limited	variability	in	PC1.		
6.2.8	Circular	dichroism	with	F(ab’)2	region	and	chemically	modified	heparins	
	 IgG	 F(ab’)2	 in	 far-UV	 circular	 dichroism,	 two	 regions	 of	 the	 spectrum	 will	 be	compared	 to	 identify	 differences	 in	 the	 secondary	 structure	 with	 the	 addition	 of	chemically	modified	 heparin;	 the	 peak	 at	 λ	 =	 209	 nm	 and	 the	 trough	 at	 λ	 =	 227	 nm.	CMH1	 shifts	 the	 spectra	 to	 a	 peak	 at	 λ	 =	 213	 nm	 and	 flattens	 the	 peak	 in	 the	 higher	wavelength	region	(Figure	133A).	Both	CMH2	and	CMH3	with	IgG	F(ab’)2	have	a	peak	at	λ	=	209	nm,	bit	with	CMH2	the	trough	is	at	λ	=	234	nm	(Figure	133B)	and	with	CMH3	this	 peak	 region	 is	 flattened	 (Figure	 133C).	 CMH4	 shifts	 the	 peak	 to	 the	 higher	wavelength	of	λ	=	213	nm	and	flattens	the	ellipticity	to	0	mdeg.		
	Figure	133:	Far-UV	CD	spectra,	of	F(ab’)2	with	CMH	1-4	with	50	mM	sodium	acetate	pH	4.0.	(−)	3	μM	IgG	F(ab’)2	region	with	A)	(−)	3	μM	CMH1,	B)	(−)	3	μM	CMH2,	C)	(−)	3	μM	CMH3	D)	(−)	3	μM	CMH4.		
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	 Both	CMH5	(Figure	134A)	and	CMH9	(Figure	134E)	retain	the	IgG	F(ab’)2	peak	at	λ	=	209	nm	but	with	CMH5,	the	trough	is	flattened	to	near	0,	and	with	CMH9,	this	trough	is	shifted	to	the	higher	wavelength	of	λ	=	231	nm.	Interestingly,	the	effect	of	CMH9	does	not	 display	 a	 large	 spectral	 change	 as	 seen	 in	 the	 other	 immunoglobulins	 tested.	Unsulphated	CMH8	causes	a	unique	spectral	shift	 to	a	 lower	wavelength	 from	λ	=	209	nm	to	λ	=	205	nm	(Figure	134D).		
6.2.9	F(ab’)2	stability	in	the	presence	of	low	molecular	weight	heparins		 F(ab’)2	 region	Tm	 is	 60.13°C	with	 an	 fluorescence	 intensity	 of	 2000	ΔFU,	with	fondaparinux	mimicking	the	same	shape	and	Tm	of	60.11°C.	The	other	LMWH	appear	in	the	same	region	in	two	groups.	UF	PMH	and	tinzaparin	have	Tm	of	53.80°C	and	53.84°C	
	Figure	134:	Far-UV	CD,	of	F(ab’)2	with	CMH	5-9	in	50	mM	sodium	acetate	pH	4.0.	(−)	3	μM	IgG	F(ab’)2	region	with	A)	(−)	3	μM	CMH5,	B)	(−)	3	μM	CMH6,	C)	(−)	3	μM	CMH7	D)	(−)	3	μM	CMH8,	
E)	(−)	3	μM	CMH9.		
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Dalteparin,	 enoxaparin,	 and	 reviparin	 have	 Tm	 of	 53.87°C,	 54.81°C	 and	 54.84°C.	 This	grouping	is	demonstrated	in	the	PCA	of	1st	derivative	DSF	data	(Figure	135).		
6.2.10	F(ab’)2	stability	in	the	presence	of	GAGs	and	heparin	controls		 As	shown	previously,	UF	PMH	reduces	the	Tm	of	F(ab’)2	by	6.65°C,	suggesting	a	reduction	 in	 structural	 stability	 of	 the	 immunoglobulin	 fragment	 (Figure	 136A).	 The	effects	of	the	compounds	tested	varies	with	F(ab’)2	compared	to	the	other	Ig	tested	so	far.	The	destabilisation	of	F(ab’)2	from	most	to	least	effect	 is	CMH1	>	DS	>	HS	>	CSC	>	CSA	>	Na2SO4	>	DS6	>	HA.			 The	Tm	of	DS	with	F(ab’)2	is	54.57°C	(Tm	Δ	5.98°C)	which	is	lower	that	that	of	HS	 but	 has	 a	 lower	 intensity	 peak	 compared	 to	 both	 CMH1	 and	HS	 at	 2550	 ΔFU	 and	more	 resembles	 the	 CSC	 peak.	 HS	 peak	 shape	 is	 more	 similar	 to	 CMH1	 in	 intensity	(36700	ΔFU)	but	the	Tm	is	higher	at	55.56°C	(Tm	Δ	4.99°C)	
		Figure	135:	PCA	of	1st	derivative	DSF	data	from	F(ab’)2	with	LMWH	and	UF	PMH.		
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The	 Tm	 of	 CSC	 is	 lower	 than	 that	 of	 CSA;	 55.82°C	 and	 57.45°C	 respectively.	 UA(2S)-GlcNS(6S)	 with	 F(ab’)2	 increases	 the	 Tm	 compared	 to	 F(ab’)2	 only	 by	 1.14°C	 up	 to	61.69°C.	The	addition	of	Na2SO4	doesn’t	modify	the	Tm	of	the	immunoglobulin	fragment,	but	the	fluorescence	intensity	of	the	curve	is	50	units	greater	than	F(ab’)2	alone	(2600	ΔFU).	 HA	 increases	 the	 Tm	 of	 F(ab’)2	 by	 2.69°C	 to	 63.24°C	 with	 no	 change	 in	 peak	intensity.		
	Figure	136:	DSF	of	F(ab’)2	with	GAGs	and	sulphate	controls	in	50	mM	sodium	acetate	buffer	pH	4.0.	(−)	3	μM	F(ab’)2	region	with	A)	(−)	6.0	μM	UF	PMH,	(−)	500	nM	sodium	sulphate,	B)	(−)	6.0	μM	DS6	(−)	12.0	μM	HS,	C)	(−)	6μM	CSA,	(−)	6.0	μM	CSC,	D)	(−)	6.0	μM	DS,	(−)	6.0	μM	HA.		
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6.2.10	F(ab’)2	stability	in	the	presence	of	size	defined	heparin	fractions		 .	 The	d.p.2,	 4	 and	6	 fragments	with	 F(ab’)2	have	higher	Tm	 that	 F(ab’)2	 alone,	with	the	Tm	from	highest	to	lowest	stability	as	d.p.4	>	d.p.6	>	d.p.2.	From	d.p.8	to	d.p.16	the	Tm	decreased	with	increasing	saccharide	length,	with	d.p.8	having	a	Tm	of	60.05°C	and	d.p.16	having	a	Tm	of	53.61°C,	the	lowest	Tm	in	this	data	and	most	similar	to	the	UF	PMH	with	F(ab’)2.	Heparin	fragments	of	d.p.18	and	d.p.20	have	the	Tm	of	54.61°C	and	54.17°C	respectively.	PCA	of	the	d.p.	fragments	with	F(ab’)2	suggests	similarity	in	the	1st	derivative	 DSF	 spectra	 of	 UF	 PMH,	 d.p.16	 and	 d.p.18,	with	 d.p.20	 and	 d.p.14	 grouped	separately.	
6.2.11	F(ab’)2	binds	heparin	in	Hi-trap	HPLC			 Heparin	affinity	chromatography	with	PBS	tested	at	different	pH	and	elution	with	2	M	 NaCl	 demonstrated	 IgG	 F(ab’)2	 bound	 to	 the	 heparin	 column	 at	 pH	 4.0	 and	 5.0,	shown	in	Figure	138.	Heparin	binding	affinity	 is	240	mM	in	pH	5.0	PBS,	and	at	pH	4.0	PBS	the	binding	affinity	suggests	a	stronger	interaction	at	799	mM	and	959	mM	NaCl.	As	with	 the	Fab/k	 region,	 at	 pH	4.0	PBS	 shows	elution	of	 two	populations	with	different	heparin	affinities.		
	Figure	 137:	 The	 PCA	 of	 1st	 derivative	 DSF	 data	 of	 F(ab’)2	 with	 PMH	 polymerization	 (D.P)	fragments	in	50	mM	sodium	acetate	buffer	pH	4.0.			
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The	Hi-Trap	affinity	binding	with	50	mM	sodium	acetate	at	pH	4.0,	as	with	Fab/k,	 the	resulting	binding	affinity	occurs	between	the	two	populations	eluted	in	pH	4.0	PBS;	814	mM	NaCl	(Figure	139).		
	Figure	138:	Human	IgG	F(ab’)2	fragment	in	heparin	HiTrap	affinity	HPLC	in	PBS	at	differing	pH	(4.0	–	7.4)	and	elution	with	2M	NaCl.	(−)	PBS	pH	4,	(−)	PBS	pH	5.0,	(−)	PBS	pH	6.0,	(−)	PBS	pH	7.0,	(−)	PBS	pH	7.4.		
	Figure	139:	Human	IgG	F(ab’)2	in	heparin	HiTrap	affinity	HPLC	in	50	mM	sodium	acetate	pH	4.0	with	2M	NaCl	elution.			
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6.3	Discussion		 The	 melting	 point,	 an	 equilibrium	 between	 folded	 and	 denatured	 protein	populations,	differs	by	3°C	for	Fab	and	F(ab’)2	fragments	of	IgG.	The	Fab	fragment	has	a	Tm	of	60°C,	whereas	the	much	larger,	diamer	F(ab’)2	has	a	Tm	of	63°C.	This	is	a	higher	Tm	than	that	of	whole	IgG	(53°C)	and	Fc	region	(45°C)	as	measured	in	DSF.	Tischenko	et	
al.	 (1982)	 established	 the	 Fc	 and	 Fab	 fragments	 of	 IgG	 are	 thermodynamically	independent	species,	even	when	separated	from	the	whole	immunoglobulin	(Tischenko,	Zavyalov,	 Medgyesi,	 Potekhin,	 &	 Privalov,	 1982).	 The	 average	 of	 the	 Tm	 from	 both	fragments	 (Fc	 and	Fab)	 is	 similar	 to	 the	Tm	 found	 for	 the	whole	 IgG	molecule	 in	 this	data,	 as	 shown	by	Tischenko	et	al.	 (1982)	 (idem).	The	marginally	 increased	Tm	of	 the	larger	immunoglobulin	fragment,	F(ab’)2	can	be	attributed	to	the	retention	of	the	hinge	region	and	two	disulphide	bonds	joining	the	CH2	domains.	Disulphide	bonds	are	present	in	 both	 the	 folded	 (native)	 and	 unfolded	 protein	 states,	 so	 do	 not	 require	 additional	energy	to	break	during	melting	(idem).	However	the	disulphide	bonds	contribute	to	the	decrease	 in	entropy	of	 the	denatured	state	 (Zavodszky	et	 al.,	 2001).	By	 increasing	 the	level	of	order	in	unfolded	protein	states,	more	energy	is	required	to	denature,	indicated	by	an	increase	in	Tm	(idem).				 Addition	 of	 the	 main	 disaccharide	 present	 in	 heparin,	 IdoA(2S)-GlcNS(6S)	(CMH1)	at	the	highest	concentration	tested	(6	μM)	caused	a	decrease	in	Tm	in	both	Fab	and	F(ab’)2	immunoglobulin	fractions;	Fab	experienced	a	drop	of	Tm	of	7.78°C,	whereas	F(ab’)2	reduced	by	8.93°C.	This	difference	may	be	attributed	to	the	increased	initial	Tm	experienced	 by	 F(ab’)2	 alone,	 denaturation	 with	 heparin	 resulting	 in	 the	 same	 final	unfolding.			 The	 library	 of	 9	 chemically	 modified	 heparins	 caused	 differing	 effects	 on	 the	stability	of	Fab	and	F(ab’)2.	CMH1	caused	a	reduction	 in	Tm	at	concentrations	greater	
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than	 0.19	 μM.	 At	 0.19	 μM,	 an	 intermediate	 state,	 demonstrated	 by	 a	 double	 peak,	showed	Tm	values	 both	 lower	 (55.30°C)	 and	higher	 (65.81°C)	 than	 that	 of	 Fab	 alone.	Increased	 Tm	 of	 Fab	 with	 concentrations	 of	 CMH1	 lower	 than	 0.19	 μM	 suggest	 a	stabilisation	effect	with	this	concentration	of	chemically	modified	heparin.			 This	 pattern	 of	 destabilisation	 at	 high	 concentrations	 tested,	 and	 a	 level	 of	immunoglobulin	 stabilisation	 at	 low	 concentrations	 is	mirrored	with	 other	 chemically	modified	heparins.	The	same	effect	 is	 seen	at	concentrations	 lower	 than	0.19	μM	with	CMH2,	CMH3,	and	CMH4.	With	CMH5	and	CMH6,	an	 intermediate,	double	peak	occurs	with	the	addition	of	0.38	μM	CMH,	with	lower	concentrations	of	this	chemically	modified	heparin	 increasing	 the	 Tm,	 suggesting	 an	 increase	 in	 immunoglobulin	 stability.	Desulphated	 CMH8	 caused	 an	 increase	 in	 Tm	 of	 Fab,	 suggesting	 a	 stabilisation	 and	increased	 resistance	 to	 thermal	degradation	at	 all	 concentrations	 tested.	Persulphated	CMH9	displayed	 the	greatest	 reduction	of	Tm	 in	 IgG	Fab.	Addition	of	6.0	μM	of	CMH9	caused	a	12.79°C	reduction	in	Tm;	the	highest	destabilisation	effect	with	Fab.	However,	a	 concentration	 of	 0.19	 μM	 displays	 an	 intermediate	 peak	with	 two	 Tm,	 55.55°C	 and	64.65°C.	Concentrations	below	0.19	μM	have	Fab	stabilisation	properties,	even	with	the	dramatic	effects	of	this	chemically	modified	heparin	at	higher	concentrations.			 F(ab’)2	 with	 the	 chemically	 modified	 heparin	 library	 displays	 a	 similar	 effect	with	 the	 0.19	 μM	 concentration.	 CMH1	 demonstrates	 an	 intermediate	 peak	 at	 this	concentration,	with	one	peak	at	57.1°C	and	the	other	at	69.08°C.	F(ab’)2	appears	better	able	to	resist	thermal	degradation	occuring	with	concentrations	of	CMH1	of	0.09	μM	and	0.05	 μM.	 This	 pattern	 of	 increasing	 F(ab’)2	 stability	with	 0.19	 μM	occurs	with	 CMH2,	CMH3,	CMH4	and	CMH6.	With	CMH5,	 this	 stabilising	of	F(ab’)2	occuring	at	 the	higher	concentration	of	0.38	μM	and	with	CMH7	stabilisation	occurs	at	the	lower	concentration	of	0.09	μM.		
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	 Unsulphated	CMH8	has	the	least	effect	on	F(ab’)2	at	all	concentrations	tested,	but	an	 anomalous	 peak	 occurs	 in	 the	 0.09	 μM	 experiment	 at	 Tm	 of	 68.87°C,	 which	 is	attributed	 to	 an	 air	 bubble.	As	 in	 the	Fab	 results,	 the	 effect	 of	 persulphated	CMH9	on	F(ab’)2	is	the	most	pronounced	of	the	chemically	modified	heparins	tested.	The	greatest	reduction	 in	Tm	of	F(ab’)2	 (9.97°C)	occurs	with	 the	addition	of	6.0	μM	CMH9.	A	wide	peak	structure,	with	two	discernable	peaks	occurs	with	0.38	μM	and	0.19	μM	CMH9,	one	peak	representing	a	less	stable	F(ab’)2	form,	one	peak	more	stable	than	F(ab’)2	alone.			 Four	 compounds	 (CMH1,	 CMH2,	 CMH3	 and	 CMH4)	 appear	 to	 affect	 the	 Tm	 of	both	Fab	and	F(ab’)2	to	a	similar	degree.	These	four	compounds	do	not	have	the	same	number	of	sulphate	moieties	per	disaccharide,	therefore	differing	charges.	This	may	be	attributed	to	being	no	discernable	structural	differences	caused	by	the	binding	of	these	four	 compounds	 to	 Fab	 or	 F(ab’)2,	 or	 that	 the	 structural	 changes	 associated	with	 the	binding	of	 these	compounds	may	be	different,	but	result	 is	 the	same	effect	on	thermal	stability,	 as	measured	 by	DSF.	 Far-UV	 circular	 dichroism	 allows	 for	 elucidation	 of	 the	secondary	 structure	 changes	 associated	 with	 the	 addition	 of	 these	 four	 chemically	modified	 heparins	with	 Fab	 and	F(ab’)2,	which	 result	 in	 the	 similar	 effect	 on	 thermal	stability.		 CMH5	does	not	 affect	 the	Tm	at	 high	 concentrations	more	predominantly	 than	the	other	library	members,	but	has	a	stabilising	effect	on	the	Tm	of	both	Fab	and	F(ab’)2	at	 a	 higher	 concentration	 (0.38	 μM).	 This	 could	 suggest	 a	 less	 potent	 destabilisation	effect	on	the	immunoglobulin,	and/or	a	more	potent	effect	 in	increasing	the	resistance	to	 thermal	 denaturation,	 with	 this	 concentration	 ratio	 of	 modified	 heparin	 to	immunoglobulin	fragment.		
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	 Unsulphated	CMH8	has	no	effect	on	the	stabilisation	of	Fab	and	F(ab’)2.	This	may	be	due	to	the	relatively	uncharged	nature	of	this	modified	heparin	resulting	in	little	or	no	charge	dependent	binding.			 Persulphated	heparin	 (CMH9)	produces	 the	greatest	 change	 in	Fab	and	F(ab’)2	thermal	stability.	The	increased	level	of	charge	or	the	arrangement	and	conformation	of	the	sulphated	functional	groups	associated	with	this	modified	heparin,	may	account	for	the	greatest	change	in	thermal	stability	of	both	immunoglobulin	fragments.			 Far-UV	CD	 of	 F(ab’)2	with	 persulphated	CMH9	 and	 unsulphated	 CMH8	did	 not	mimic	the	effects	of	the	most	and	least	expected	structural	change	as	seen	in	the	change	in	melt	profile	from	DSF.	CMH1,	CMH4	and	CMH7	modify	the	spectra	in	the	λ	=	209	nm	region	 in	a	 similar	way,	with	 the	peak	seen	 in	F(ab’)2	alone	 in	 the	λ	=	227	nm	region	absent	 with	 in	 the	 presence	 of	 these	 chemically	 modified	 heparins.	 CMH8	 causes	 a	different	spectral	shift	in	F(ab’)2	at	λ	=	209	nm,	shifting	this	peak	to	λ	=	205	nm	unlike	the	other	modified	heparins,	that	cause	a	peak	with	an	increased	wavelength.		 The	greatest	change	in	CD	spectra	with	Fab	was	seen	with	CMH2	and	CMH6.	No	change	 to	 the	CD	spectra	occurs	 in	 the	presence	of	unsulphated	CMH8,	unlike	F(ab’)2,	however,	 like	 F(ab’)2	 persulphated	 CMH9	 does	 not	 cause	 the	 greatest	 change	 in	secondary	structural	characteristics	as	demonstrated	by	CD.			 As	 with	 DSF,	 changes	 to	 the	 number	 and	 position	 of	 functional	 groups	 and	conformation	of	the	glycopolymer	linkage	regions	of	the	chemically	modified	heparins,	cause	changes	to	the	secondary	structure	of	the	Fab	and	F(ab’)2	immunoglobulins	in	CD.	The	magnitude	of	spectral	change	however,	does	not	represent	the	magnitude	of	change	in	 the	 disaccharide	 composition.	 The	 biological	 and	 pharmacological	 activities	 of	heparin	 and	 heparan	 sulphate	 have	 been	 attributed	 to	 a	 range	 of	 structural	 features,	from	high	levels	of	sequence	specificity	to	a	sole	dependence	on	high	negative	charge.		
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	 The	 synthetic	 pentsaccharide	 sequence,	 fondaparinux	 does	 not	 have	 a	destabilising	 effect	 on	 either	 Fab	or	 F(ab’)2,	 as	 expected	 for	 such	 a	 specific	 structural	formula	 and	 small	 molecular	 weight.	 Low	 molecular	 weight	 heparins	 dalteparin,	enoxaparin,	tinzaparin	and	reviparin	have	a	similar	effect	as	UF	PMH	and	reduce	the	Tm	of	both	Fab	and	F(ab’)2.			 The	saccharide	size	requirement	for	the	reduction	in	Tm,	as	shown	by	CMH1	for	Fab	is	d.p	20,	but	a	reduction	in	the	Tm	of	Fab	is	seen	with	a	d.p	16	heparin	saccharide.	In	F(ab’)2,	the	d.p	16	heparin	saccharide	demonstrates	a	reduction	in	Tm,	but	the	d.p	18	has	the	same	effect	as	full	length	heparin.			 Hi-trap	heparin	binding	HPLC	with	the	Fab	and	F(ab’)2	antibody	fragments	show	heparin	binding	at	the	acidic	pH	tested.	In	pH	5.0	Fab	bound	with	247	mM	NaCl	affinity	and	F(ab’)2	with	240	mM	NaCl	affinity.	At	pH	4.0,	 these	binding	affinities	 increased	to	755	mM	and	989	mM	NaCl	with	Fab	and	799	mM	and	959	mM	NaCl	with	F(ab’)2.	In	50	mM	sodium	acetate	pH	4.0,	heparin	binding	affinity	of	Fab	is	797	mM	NaCl,	and	F(ab’)2	is	814	mM	NaCl.		In	sodium	acetate	a	single	peak	is	eluted	at	pH	4.0,	whereas	at	pH	4.0	in	PBS	 the	 elution	 occurs	 over	 two	 peaks.	 The	 heparin	 affinity	 in	 sodium	 acetate	 occurs	between	the	two	quoted	peaks	present	in	pH	4.0	PBS	HPLC.			 The	 interaction	 between	 immunoglobulin	 fragment	 Fc	 region,	 whole	immunoglobulins	 and	 the	 antigen	 binding	 regions	 Fab	 and	 F(ab’)2	 and	 the	glycosaminoglycan	 heparin	 has	 been	 investigated.	 Fc	 bound	 BACE1	 cannot	 be	 used	under	acidic	conditions	to	demonstrate	heparin-BACE1	interactions	due	to	the	heparin-Fc	 interaction.	 The	 use	 of	 glycosaminoglycans	 in	 experiments	 with	 immunoglobulins	under	 acidic	 conditions	 requires	 further	 investigation	 to	 determine	 whether	 this	relationship	modifies	the	action	or	activity	of	the	immunoglobulin.	
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	 Studies	into	the	structural	changes	associated	with	heparin	binding	to	BACE1	will	be	made	using	native,	tag-free	BACE1	to	obtain	a	true	representation	of	the	BACE1-GAG	interaction.	This	 elucidation	will	 aid	 the	understanding	of	 this	 regulating	 relationship,	adding	knowledge	to	the	design	of	a	GAG	based	BACE1	inhibitor.			 Further	 to	 this	research,	 in	Chapter	8,	chemically	sulphated	GAG	analogues	will	be	screened	and	developed	for	BACE1	inhibition.	
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Chapter	7:	BACE1	structural	changes	induced	by	chemically	
modified	heparins	
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7.1	Introduction		 The	binding	and	 sequestration	of	 cations	 to	 the	 carboxylate,	N-	 and	O-sulphate	groups	of	heparin	and	HS	 is	 thought	 to	be	 the	evolutionary	 function	of	 these	 complex	polyanions	(Heidarieh	et	al.,	2013).	The	binding	of	cations	 to	heparin	 is	heterogenous,	with	both	high	and	low	affinity	binding	sites	present	across	the	heparin	polymer	(Landt,	Hortin,	Smith,	McClellan,	&	Scott,	1994).	Structural	studies	 indicate	 long-range	binding	interactions	 that	 occur	 at	 low	 pH	 between	 the	 carboxylate	 groups	 and	 sodium,	magnesium	and	calcium,	with	the	sodium	and	magnesium	binding	occurring	at	a	higher	pH	(Meneghetti	et	al.,	2015).			 The	 activity	 of	 heparin	 and	 HS	 can	 be	 dramatically	 varied	 in	 the	 presence	 of	physiological	 concentrations	 of	 cations	 (idem).	 Cations	 such	 as	 potassium	and	 sodium	both	 intra-	 and	 extracellularly,	 and	 levels	 of	 rarer	 cations	 such	 as	 copper,	 increased	during	tumourigenesis	and	angiogenesis	(idem).		
7.2	Results	
7.2.1	The	effect	of	chemically	modified	heparins	on	BACE1	thermal	stability		 The	melting	point	of	native,	tag-free	human	BACE1,	in	50	mM	sodium	acetate	pH	4.0	is	42.99	±	0.087°C.	As	expected	from	the	results	with	native	BACE1	and	heparin	in	Chapter	 3,	 The	 addition	 of	 CMH1	 at	 the	 highest	 GAG	 concentration	 tested	 (6.0	 μM)	reduced	 the	 native	 BACE1	 Tm	 by	 7°C	 to	 35.96°C	 (Figure	 140A).	 Decreasing	concentrations	of	CMH1	(3.0	μM,	1.5	μM	and	0.75	μM)	result	in	less	of	a	reduction	in	the	Tm	of	native	BACE1	to	near	the	protein	only	Tm,	at	41.96°C.	At	a	CMH1	concentration	of	0.38	μM,	the	Tm	of	native	BACE1	increases	dramatically,	 to	a	temperature	higher	than	the	 native	 protein	 alone,	 46.53°C	 (Figure	 140B).	 From	 this	 high	 Tm,	 the	 subsequent	reduction	in	the	concentration	of	CMH1	to	0.19	μM	and	0.09	μM	have	Tm	of	45.93°C	and	
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43.13°C	 respectivley.	 The	 lowest	 concentration	 of	 this	 chemically	 modified	 heparin	returning	the	native	BACE1	protein	back	to	approximately	the	native	Tm.		
	 The	 large	 Tm	 shift	 and	 associated	 higher	 than	 native	 Tm	 seen	 in	 CMH1	experiments	also	occurs	with	other	chemically	modified	heparins.	CMH2	drops	the	Tm	of	native	BACE1	at	the	highest	concentration	tested	(6.0	μM)	to	38.25°C,	but	not	as	significantly	as	CMH1	(Figure	140A).	Decreasing	concentrations	of	this	chemically	modified	heparin	gradually	increase	the	native	BACE1	Tm,	but	at	0.75	μM	CMH2	the	Tm	increases	to	a	melting	temperature	higher	than	the	native	BACE1	alone	(Figure	141A).	 At	 0.38	 μM	 and	 0.19	 μM	 CMH1,	 the	 Tm	 of	 native	 BACE1	 are	 higher	 than	
	Figure	141:	DSF	of	BACE1	with	CMH2	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH2,	(−)	3.0	μM	CMH2,	(−)	1.5	μM	CMH2,	(−)	0.75	μM	CMH2.	B=	(−)	3	μM	native	BACE1	with	 (−)	0.38	μM	CMH2,	 (−)	0.19	μM	CMH2,	(−)	0.09	μM	CMH2,	 (−)	0.05	μM	CMH2.		
			Figure	140:	DSF	of	BACE1	with	CMH1	in	50	mM	sodium	acetate	buffer	pH	4.0	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH1,	(−)	3.0	μM	CMH1,	(−)	1.5	μM	CMH1,	(−)	0.75	μM	CMH1.	B=	(−)	3	μM	native	BACE1	with	 (−)	0.38	μM	CMH1,	 (−)	0.19	μM	CMH1,	(−)	0.09	μM	CMH1,	 (−)	0.05	μM	CMH1.	
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BACE1	 alone,	 but	 are	 gradually	 reducing	 to	 reach	 approximately	 the	 same	 as	 native	BACE1	alone	with	0.09	μM	of	the	chemically	modified	heparin.			 2-Desulphated	CMH3	has	a	different	effect	on	native	BACE1,	when	compared	to	the	actions	of	CMH1	and	CMH2,	as	 the	higher	 concentrations	of	 this	modified	heparin	does	not	peturb	the	melting	temperature	of	native	BACE1	(43.07°C)	but	3.0	μM,	1.5	μM,	0.75	 μM	 (Figure	 142A)	 and	 0.38	 μM	 (Figure	 142B)	 increase	 the	 Tm	 up	 to	 a	 high	 of	46.09°C,	suggesting	a	stabilisation	effect.	The	two	lowest	concentrations	of	CMH3	have	Tm	similar	to	the	native	BACE1	control.		
	 CMH4	 at	 6.0	 μM	 reduces	 native	 BACE1	 Tm	 to	 38°C,	 with	 subsequent	 reduced	concentrations	increasing	the	Tm	of	the	protein,	until	0.75	μM	CMH4	which	has	a	Tm	of	44.98°C	(Figure	143A).	The	addition	of	0.38	μM	CMH4	increases	the	Tm	to	above	native	BACE1	melting	 (46.34°C),	 as	with	CMH1.	 Subsequently	 lower	 concentrations	of	CMH4	lead	to	a	reducing	Tm,	at	0.09	μM	this	Tm	is	43.43°C	(Figure	143B).		
	Figure	142:	DSF	of	BACE1	with	CMH3	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH3,	(−)	3.0	μM	CMH3,	(−)	1.5	μM	CMH3,	(−)	0.75	μM	CMH3.	B=	(−)	3	μM	native	BACE1	with	 (−)	0.38	μM	CMH3,	 (−)	0.19	μM	CMH3,	(−)	0.09	μM	CMH3,	 (−)	0.05	μM	CMH3.			
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	 CMH5	has	a	different	effect	on	the	Tm	of	native	BACE1	than	the	other	compounds	discussed	thus	far.	6.0	μM	has	a	Tm	of	44.28°C,	which	is	above	the	Tm	of	native	BACE1	alone	 (42.99	 ±	 0.087°C).	 This	 Tm	 increases	 further	 with	 the	 addition	 of	 lower	concentrations	of	CMH5	(3.0	μM	and	1.5	μM)	but	then	moves	to	gradually	decrease	from	the	maxima	Tm	of	 46.13°C,	 to	 temperatures	 similar	 to	 the	 Tm	of	 native	BACE1	 alone	(0.09	 μM	 Tm	 of	 42.71°C).	 This	 compound	 seems	 to	 stabilise	 native	 BACE1	 at	 most	concentrations	tested.				 At	 6.0	 μM	 6-desulphated,	 N-acetylated	 heparin	 (CMH6),	 the	 Tm	 of	 BACE1	 is	increased	 to	 45.46°C,	 with	 the	 Tm	 decreasing	with	 reducing	 concentrations	 of	 CMH6	(Figure	145A&B).	However	 at	 6.0	 μM	and	3.0	 μM	of	 CMH6	 the	 1st	 derivative	 curve	 in	
	Figure	144:	DSF	of	BACE1	with	CMH5	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH5,	(−)	3.0	μM	CMH5,	(−)	1.5	μM	CMH5,	(−)	0.75	μM	CMH5.	B=	(−)	3	μM	native	BACE1	with	 (−)	0.38	μM	CMH5,	 (−)	0.19	μM	CMH5,	(−)	0.09	μM	CMH5,	 (−)	0.05	μM	CMH5.	
	Figure	143:	DSF	of	BACE1	with	CMH4	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH4,	(−)	3.0	μM	CMH4,	(−)	1.5	μM	CMH4,	(−)	0.75	μM	CMH4.	B=	(−)	3	μM	native	BACE1	with	 (−)	0.38	μM	CMH4,	 (−)	0.19	μM	CMH4,	 (−)	0.09	μM	CMH4,	 (−)	0.05	μM	CMH4.		
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Figure	145A	demonstrates	a	broad	peak,	with	a	minor	peak	at	the	lower	temperature	of	38.10°C;	this	suggests	a	population	of	native	BACE1	is	more	susceptible	to	temperature	linked	 denaturation;	with	 some	 less	 stable	 than	 native	 BACE1	 and	 some	more	 stable.		The	Tm	of	BACE1	decreases	with	decreasing	concentrations	of	CMH6,	with	 the	 lowest	concentration	(0.09	μM)	producing	a	42.78°C	Tm	(Figure	145B).		
	 CMH7	 at	 6.0	 μM	 reduces	 the	 Tm	 of	 native	 BACE1	 by	 4.6°C,	 to	 38.38°C	 (Figure	146A).	 Both	 3.0	 μM	 and	 1.5	 μM	 have	 Tm	 values,	 which	 increase	 toward	 the	 native	BACE1	 only	 Tm.	 At	 0.75	 μM	 however,	 the	 Tm	 increases	 to	 44.53°C,	 with	 the	 first	derivative	melt	curve	showing	a	shoulder	curve,	with	a	flat	peak	region	occurring	at	the	lower	temperature	of	36.34°C	(Figure	146A).	The	Tm	with	the	lowest	concentration	of	
	Figure	145:	DSF	of	BACE1	with	CMH6	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH6,	(−)	3.0	μM	CMH6,	(−)	1.5	μM	CMH6,	(−)	0.75	μM	CMH6.	B=	(−)	3	μM	native	BACE1	with	 (−)	0.38	μM	CMH6,	 (−)	0.19	μM	CMH6,	(−)	0.09	μM	CMH6,	 (−)	0.05	μM	CMH6.	
		Figure	146:	DSF	of	BACE1	with	CMH7	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH7,	(−)	3.0	μM	CMH7,	(−)	1.5	μM	CMH7,	(−)	0.75	μM	CMH7.	B=	(−)	3	μM	native	BACE1	with	 (−)	0.38	μM	CMH7,	 (−)	0.19	μM	CMH7,	(−)	0.09	μM	CMH7,	 (−)	0.05	μM	CMH7.	
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CMH7	 tested	 (0.09	 μM)	 is	 still	 greater	 than	 the	 Tm	 of	 native	 BACE1	 alone	 (42.99	 ±	0.087°C),	suggesting	some	stability	increases	at	this	concentration.			 Unsulphated	 heparin,	 CMH8	 demonstrated	 a	maximum	 change	 in	 Tm	 of	 0.5°C.	with	the	addition	of	6.0	μM	shifting	the	Tm	of	native	BACE1	to	42.52°C	(Figure	147A).	Unsulphated	 heparin	 has	 the	 no	 effect	 on	 the	 Tm	 of	 native	 BACE1,	 displaying	 no	difference	across	the	modified	heparin	concentration	gradient	tested.		
	 Conversley,	the	greatest	change	in	Tm	displayed	occurs	with	the	addition	of	per-sulphated	 heparin	 (CMH9).	 The	 first	 derivative	 melt	 curve	 of	 concentrations	 greater	than	 0.38	 μM	 CMH9	 with	 native	 BACE1	 suggest	 the	 protein	 has	 undergone	 thermal	destabilisation	 temperatures	 lower	 than	 the	 limit	 of	 this	 experiment	 (<	 25.5°C).	With	concentrations	of	CMH9	0.38	μM	and	lower,	the	first	derivative	melt	curve	returns	with	Tm	of	36.87°C	at	this	concentration	(Figure	148C).	The	Tm	of	BACE1	then	increases	to	46.98°C,	with	0.19	μM	CMH9,	 an	 increase	 of	 10.11°C	 from	 the	Tm	at	 0.38	μM	 (Figure	145B).	 The	 final	 concentration	 tested,	 0.09	 μM,	 displays	 a	 reducing	 Tm	 but	 remains	higher	than	native	BACE1	at	45.43°C	(Figure	148B).		
	Figure	147:	DSF	 of	BACE1	with	CMH8	 in	 50	mM	 sodium	acetate	 buffer	 pH	4.0	A=	 (−)	3	 μM	native	BACE1	with	(−)	6.0	μM	CMH8,	(−)	3.0	μM	CMH8,	(−)	1.5	μM	CMH8,	(−)	0.75	μM	CMH8.	
B=	(−)	3	μM	native	BACE1	with	(−)	0.38	μM	CMH8,	(−)	0.19	μM	CMH8,	(−)	0.09	μM	CMH8,	(−)	0.05	μM	CMH8.	
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7.2.2	The	comparison	of	BACE1	thermal	stability	and	known	BACE1	inhibition	with	
the	addition	of	chemically	modified	heparins		 The	 research	 paper	 that	 initially	 identified	 chemically	 modified	 heparin	 as	potential	BACE1	regulating	compounds	worked	to	identify	a	modification	which	would	allow	for	simultaneous	BACE1	modulation	and	negated	anti-coagulant	activity	(Patey	et	al.,	2006).	Table	14	is	modified	from	the	Patey	et	al.,	2006	publication.		Table	 14:	 	 Experimental	 results	 from	 the	 BACE1	 FRET	 inhibition	 experiments	 by	 Patey	 et	 al.	(2006)	The	library	of	chemically	modified	heparin	compounds	was	assayed	for	BACE1	inhibition	with	the	half	maximal	inhibitory	concentration	(IC50).	
	
	Figure	148:	DSF	of	BACE1	with	CMH9	in	50	mM	sodium	acetate	buffer	pH	4.0.	A=	(−)	3	μM	native	BACE1	with	(−)	6.0	μM	CMH9	(−)	3.0	μM	CMH9	(−)	1.5	μM	CMH9	(−)	0.75	μM	CMH9.	B=	(−)	3	μM	native	BACE1	with	(−)	0.38	μM	CMH9	(−)	0.19	μM	CMH9	(−)	0.09	μM	CMH9	(−)	0.05	μM	CMH9	
C)	(−)	3	μM	native	BACE1	with,	(−)	0.75	μM	CMH9	(−)	0.38	μM	CMH9.	
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	 There	appears	no	correlation	between	FRET	BACE1	inhibiton	(data	from	Patey	et	
al.,	 2006)	 and	 structural	 stability	 defined	 by	 Tm	 change	 upon	 addition	 of	 6.0	 μM	 any	chemically	modified	heparin	(p=	0.3734).			 Patey	 et	 al.,	 2006	 found	 that	 replacement	 of	 N-sulphate	 with	 N-acetyl	 did	 not	greatly	reduce	 the	BACE1	 inhibitory	properties	of	 the	modified	heparin,	but	 improved	the	anti-coagulant	profile	of	the	compounds.	The	melting	point	data	show	interchanging	N-sulphate	and	N-acetyl	can	both	destabilise	BACE1,	shown	by	reduced	Tm	at	the	high	concentrations	 tested	 (6.0	 μM).	 The	 destabilising	 BACE1	 compounds	 are	 more	frequently	6-sulphated,	possibly	suggesting	a	role	for	this	modification	(Table	15).			 The	 average	 number	 of	 sulphates	 per	 disaccharide	 in	 the	 modified	 heparin	compounds	 that	 demonstrate	 a	 destabilisation	 effect	 on	 BACE1	 is	 2.4,	 whereas	 the	compounds	that	exhibit	a	stabilisation	effect	(CMH8,	CMH5	and	CMH6)	have	an	average	of	1	sulphate	per	disaccharide.		Table	15:	Chemically	modified	heparan	sulphate	configuration	at	positions	R1,	R2,	and	R3	alongside	the	Tm	of	BACE1	with	CMH	in	DSF.	Differential	scanning	fluorimetry	in	50	mM	sodium	acetate	buffer	pH	4.0	with	3	μM	native	BACE1.	Tm	of	native	BACE1	with	6.0	μM	of	each	heparin	type	recorded.		
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CMH3	 is	 quoted	 as	 having	 a	 BACE1	 inhibitory	 IC50	 of	 53	 ng/ml,	 the	 same	 as	 the	 per-sulphated	 heparin	 CMH9,	 however	 the	 DSF	 thermal	 stability	 data	 suggest	 these	 two	modified	 heparins	 have	 a	 different	 effect	 on	 the	 stability	 of	 BACE1	 during	 thermal	denaturation.	 CMH3	 improves	 BACE1	 thermal	 stability	 at	 some	 concentrations	 (most	efficiently	at	0.75	μM),	but	CMH9	causes	destabilisation	and	melting	under	the	25.5	°C	DSF	starting	temperature.			 The	Pearson	correlation	between	the	number	of	sulphates	per	disaccharide	and	the	Tm	with	6.0	μM	of	 chemically	modified	heparin;	 the	outcome	of	which	 suggests	 a	significant	correlation,	Pearson	correlation	coefficient	(n	=	9)	r	=	-0.81	(P	<	0.01	95	%	CI	-0.96	to	-0.30).	This	significance	suggests	rejection	of	the	null	hypothesis	that	there	is	no	causal	 link	 between	 the	 number	 of	 sulphates	 present	 on	 the	 disaccharide	 of	 the	chemically	modified	 heparin	 and	 the	 action	 of	 the	 aforementioned	 heparin	 in	 BACE1	destabilisation	as	measured	a	change	in	Tm	in	DSF.	A	relationship	therefore	may	exist	in	this	data	 to	 show	broadly,	 that	 the	 increasing	number	of	 sulphate	moieties	present	 in	the	 chemically	 modified	 heparin	 allows	 for	 increasing	 BACE1	 destabilisation	 and	reducing	Tm.			 If	 the	 persulphated	 heparin	 (CMH9	 is	 removed	 as	 a	 outlier,	 the	 correlation	coefficient	changes	to	r	=	-0.42	but	with	a	P	=	0.32	suggesting	a	relationship	cannot	be	shown	between	the	Tm	of	the	chemically	sulphated	heparin	 in	BACE1	melting	and	the	number	of	sulphate	moieties	present	on	the	heparin	disaccharide.	However,	the	number	of	sulphate	moieties	per	disaccharide	alone	is	not	an	accurate	predictor	of	the	effect	of	modified	heparin	on	the	thermal	stability	of	BACE1.			 The	PCA	of	BACE1	1st	derivative	DSF	data	with	the	chemically	modified	heparin	library	suggests	a	link	between	the	spread	of	principle	component	1	data	and	the	IC50	inhibitory	 concentration	 of	 the	 CMH.	 The	 more	 potent	 BACE1	 inhibiting	 CMH1	 and	
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CMH9	have	a	concentration	dependant	effect	on	the	1st	derivative	DSF	data,	with	these	variances	displayed	as	a	larger	range	PC1	dataset	(Figure	149).		
	Figure	149:	PCA	of	1st	derivative	DSF	data	of	BACE1	with	CMH1-8.	
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7.2.3	Far-UV	circular	dichroism	studies	of	BACE1	and	chemically	modified	heparins	
	 The	 CD	 spectra	 of	 BACE1	 alone	 is	 shown	 in	 the	 Figure	 151.	 The	 native	BACE1	enzyme	 in	50	mM	sodium	acetate	buffer	pH	4.0	has	a	 trough	at	 λ	=	220.5	nm	(Figure	151).	 This	 feature	 shifts	 to	 a	 higher	 λ	 =	 224.1	 nm	with	 CMH1	 and	 to	 λ	 =	 223.7	with	CMH8.			 Table	16	is	a	summation	of	the	spectral	changes	seen	at	the	λ	=	220	nm	region.	CMH8	 and	 the	 2-O-sulphated	 cousin,	 CMH6,	 have	 the	 same	 spectral	 features	 in	 this	region	with	the	ellipticity	of	-5.22	mdeg	at	λ	=	233.72	nm.	This	suggests	the	2-O-sulphate	
	Figure	151:	Far-UV	CD	of	human	BACE1	with	CMH1	and	CMH8	in	50	mM	sodium	acetate	pH	4.0,	(−)	3	μM	native	BACE1	with	(−)	CMH1	(−)	CMH8.	
	Figure	150:	PCA	of	1st	derivative	DSF	data	of	BACE1	with	CMH1	and	CMH9.		
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moiety	of	 the	chemically	modified	heparin	does	not	modify	 the	secondary	structure	of	native	BACE1	at	this	concentration.		
	 CMH2	and	the	more	heavily	sulphated	CMH9	also	have	a	similar	spectra	 in	this	region	with	the	ellipticity	maxima	at	λ	=	223.9	nm	(-4.6	mdeg).	This	may	mean	either	the	additional	 3-O-sulphates	 and	N-sulphates	 on	 persulphated	 heparin	 do	 not	 change	 the	secondary	 structure	 of	 BACE1	 when	 compared	 to	 CMH2,	 or	 the	 structural	 change	triggers,	on	average,	the	same	degree	of	secondary	structural	modification.			 CMH3	is	an	outlier	of	this	data,	with	this	chemically	modified	heparin	producing	an	ellipticity	maximum	(-1.14	mdeg)	at	λ	=	228.44.	The	shape	of	the	spectra	in	this	area	is	more	flat	when	compared	to	the	other	modified	heparins	(Figure	152).			
	Figure	152:	Far-UV	CD	of	human	BACE1	with	CMH	in	50	mM	sodium	acetate	pH	4.0	(−)	BACE1	with	(−)	CMH1,	(−)	CMH2,	(−)	CMH3,	(−)	CMH4,	(−)	CMH5,	(−)	CMH6,	(−)	CMH7,	(−)	CMH8,	(−)	CMH9.		
Table	16:	Far-UV	CD	of	BACE1	with	CMH	in	50	mM	sodium	acetate	pH	4.0.			
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	 No	 simple	 correlation	 between	 number	 of	 sulphates	 per	 disaccharide	 and	perturbation	 of	 the	 CD	 spectra	 in	 this	 area	 is	 apparent,	 with	 both	 low	 and	 highly	sulphated	modifications	present	across	this	spectral	region	(Figure	152).		
7.2.4	 The	 effect	 of	 cation	 form	 on	 the	 ability	 of	 heparin	 to	 perturb	 the	 thermal	
stability	of	BACE1	
	 The	aim	of	these	experiments	was	to	determine	whether	the	type	of	cation	paired	to	highly	electronegative	heparin	would	modify	the	structure	or	functional	properties	of	the	molecule	 sufficiently	when	bound	 to	BACE1	 to	 change	 the	melting	 temperature	of	this	 protein.	To	 this	 end,	 a	 range	of	 valancies,	 atomic	 sizes,	 and	 a	polyatomic	 ion	was	employed.			 BACE1	alone	in	DSF	data	posesses	a	Tm	of	42.99	±	0.087°C.	Unmodified	sodium	heparin	supplied	from	Celsus	Laboratories	with	BACE1	in	DSF	reduced	the	melting	point	by	 8.2°C	 to	 34.7°C	 (Table	 17).	 Using	 the	 same	 Celsus	 heparin	 source	 and	 batch,	 the	cations	were	exchanged	to	sodium,	which	reduced	the	magnitude	of	Tm	shift	seen	with	
Table	17:	DSF	Tm	of	BACE1	with	a	library	of	defined	cation	forms	of	heparin	in	50	mM	sodium	acetate	buffer	pH	4.0	with	3.0	μM	native	BACE1	and	6.0	μM	heparin.		
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the	unmodified	heparin	and	BACE1.	Sodium	and	potassium	cation	forms	gave	the	same	Tm	when	added	to	BACE1	with	a	Tm	of	38.8°C,	a	Tm	shift	of	4.1°C.			 Using	a	correlation	matrix,	strong	correlation	(Pearson	correlation	r	=	-0.69	(P	<	0.01	95%	CI	-0.90	to	-0.23,	n	=	13)	was	identified	between	the	Tm	of	BACE1	with	cation	heparin	 in	 the	 DSF	 termal	 stability	 assay	 and	 the	 atomic	 radius	 of	 the	 cation	 used.	Valency	did	not	show	a	correlation	to	Tm.		
		 Heparin	preparations	for	pharmaceutical	use	are	supplied	in	sodium,	potassium,	lithium,	and	ammonium	forms.	In	this	data,	the	sodium	and	potassium	forms	of	heparin	perturb	the	melting	temperature	to	a	greater	degree	(38.8°C)	than	ammonium	(41.2°C)	and	lithium	(42.1°C).		The	unmodified	sodium	Celsus	heparin	shifts	the	Tm	of	BACE1	to	34.7°C,	which	is	closer	to	the	result	seen	with	chemically	modified	CMH1	seen	in	section	7.2.1	 (35.96°C).	 The	 method	 for	 production	 of	 the	 cation	 heparins	 therefore	 could	
	Figure	153:	PCA	of	1st	derivative	DSF	of	BACE1	with	defined	cation	 forms	of	heparin	 in	50	mM	sodium	acetate	buffer	pH	4.0.	
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modify	the	action	of	these	compounds	in	DSF	as	the	two	sodium	heparins	differ	in	effect	of	Tm	by	4.1°C	(Table	17).			 PCA	of	 the	 thermal	denaturation	curves	 from	DSF	of	human	BACE1	with	cation	forms	of	heparin	at	a	single	screening	concentration	is	shown	in	Figure	153.	Potassium	and	sodium	form	of	heparin	are	grouped	together	with	a	similar	principle	component	1	(PC1)	 and	 the	 same	PC2.	Magnesium,	 calcium	and	 copper	 PMH	exhibit	 the	 same	PC1,	and	differing	PC2.	Zinc	and	silver	PMH	have	 the	same	PC1	and	PC2	values,	 suggesting	these	cation	forms	have	the	same	effect	on	thermal	denaturation	BACE1	in	DSF.	The	two	iron	oxidation	states	tested	demonstrate	the	smallest	effect	on	BACE1,	migrating	in	the	same	 group	 as	 BACE1	 control.	 Interestingly,	 the	 cation	 forms	which	 demonstrate	 the	lowest	thermal	destabilisation	of	BACE1	in	DSF	(Figure	153)	are	the	closest	in	the	PC2	to	the	BACE1	control	in	PCA.	The	forms	of	heparin	with	the	greatest	effect	on	Tm,	sodium,	potassium	and	barium	are	the	furthest	from	the	BACE1	control	in	PC2.		
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7.3	Discussion		 Grouping	 the	 effects	 of	 the	 chemically	 modified	 heparin	 library	 allows	identification	of	four	main	effects	on	native	BACE1	in	50	mM	sodium	acetate	pH	4.0,	in	DSF.	Using	the	first	derivative	melt	curve,	the	Tm	of	each	BACE1:modified	heparin	ratio	was	determined.			 The	 first	 group,	 the	 destabilisers,	 act	 at	 the	 high	 concentrations	 tested	 (≥	 0.75	μM),	to	destabilise	the	structure	of	native	BACE1	as	shown	in	a	reduction	in	Tm.	At	low	concentrations	(≤	0.38	μM),	these	chemically	modified	heparins	have	the	opposite	effect,	stabilising	 the	 native	 BACE1	 and	 increasing	 the	 Tm.	 6.0	 μM	 CMH1	 destabilises	 native	BACE1	 to	 reduce	 the	 Tm	 from	 42.99°C	 to	 35.96°C.	 This	 maximum	 thermal	destabilisation	 reduces	with	 decreasing	 CMH1	 concentration,	 at	 0.38	 μM	 the	 effect	 is	reversed,	with	a	more	stable	Tm	of	46.53°C.	Concentrations	lower	than	this	reduce	the	Tm	to	close	to	the	native	BACE1	Tm.	CMH2	follows	a	similar	pattern,	with	the	Tm	shift	with	 6.0	 μM	 is	 38.27°C	 and	 the	 stabilisation	 effect	 occurring	 at	 0.75	 μM	 CMH2,	suggesting	a	less	potent	destabiliser	than	CMH1.	CMH4	reduces	the	Tm	to	38.00°C	with	6.0	μM	with	0.75	μM	causing	a	stabilisation	(44.98°C),	but	with	0.38	μM	causing	a	more	stable	comformation	with	Tm	of	46.34°C.	CMH7	has	an	effect	on	BACE1	most	similar	to	CMH2	with	0.75	μM	CMH7	causing	a	wide	Tm	peak	with	two	Tm	values,	one	at	a	lower	Tm	of	37.56°C	the	other	at	44.53°C,	suggesting	an	intermediate	with	two	populations	of	BACE1.			 The	second	group,	 the	stabilisers,	act	 to	 improve	 the	 thermal	stability	of	native	BACE1	 in	 DSF.	 CMH3	 at	 the	 highest	 concentration	 tested	 (6.0	 μM)	 does	 not	 have	 a	stabilising	 effect,	 but	 at	 lower	 concentrations,	 the	 Tm	 of	 native	 BACE1	 increases	 to	 a	maximum	of	46.09°C.	CMH5	has	a	similar	effect,	with	the	high	Tm	of	46.13	°C	caused	by	1.5	 μM	 of	 CMH3.	 CMH6	 has	 a	 stabilising	 effect	 at	 all	 concentrations	 tested,	 with	 the	
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highest	 Tm	 of	 45.46°C.	 The	 high	 concentration	 peaks	 have	 a	 peak	 shape	 in	 the	 38°C	region	however,	suggesting	a	population	of	BACE1	with	a	lower	melting	point.			 The	 third	 group	 of	 one,	 CMH8,	 has	 a	minimal	 effect	 on	 the	 thermal	 stability	 of	native	 BACE1,	 with	 no	 concentration	 dependence.	 This	 lack	 of	 concentration	dependence	 suggests	 this	 chemically	modified	 heparin	may	 not	 bind	 to	 native	BACE1	under	these	conditions.	The	work	done	by	Patey	et	al.	 (2006)	described	the	activity	of	this	unsulphated	heparin	derivative	as	‘almost	abolished’	(Patey	et	al.,	2006);	this	would	align	with	the	thermal	stability	data	shown	here.				 The	fourth	group	of	one,	CMH9	caused	the	most	dramatic	change	in	the	thermal	stability	of	native	BACE1,	with	high	concentrations	 tested	of	6.0	μM	to	1.5	μM	causing	the	 absence	 of	 a	 melt	 curve.	 This	 indicates	 native	 BACE1	 denatured	 at	 room	temperature	prior	 to	 the	 initial	 25.5°C	 starting	 experimental	 temperature.	At	0.19	μM	and	0.09	μM,	CMH9	still	retains	the	ability	to	stabilise	BACE1	causing	an	increase	in	Tm	to	a	maximum	of	46.98°C.	The	 inhibitory	activity	of	persulphated	heparin	 is	described	by	Patey	et	al.	(2006)	(Patey	et	al.,	2006)	and	demonstrates	activity	similar	to	CMH3	but	these	 two	compounds	have	very	different	effects	 in	on	 the	 thermal	stability	of	BACE1.	This	 suggests	 that	 the	 heparin-BACE1	 binding	 interaction	 is	 different	 for	 these	 two	compounds,	but	the	effect	the	compounds	have	on	the	activity	of	the	enzyme	is	similar.		 Klaver	 et	 al.	 2010	 suggests	 a	 relationship	 between	 heparin	 concentration,	 the	binding	 between	 BACE1	 to	 heparin,	 and	 the	 activity	 of	 BACE1	 (Klaver	 et	 al.,	 2010).	Heparin	 high	 affinity	 binding,	 occurring	 at	 low	heparin	 concentrations	 allows	 enzyme	activation,	whereas	low	affinity	binding	occurring	at	high	heparin	concentrations	causes	BACE1	enzyme	inhibition	(idem).	This	suggests	a	balance	to	regulate	the	activity	of	the	enzyme	 through	 variable	 binding	 roles	 for	 heparin	 (idem).	 	 Here,	 the	 chemically	modified	heparins	 that	 act	 to	 stabilise	BACE1	at	 low	concentrations;	 this	may	 suggest	
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binding	with	high	affinity	at	 low	concentrations.	Chemically	modified	heparins	that	act	to	destabilize	at	high	PMH	concentrations,	may	be	binding	with	low	affinity.	The	BACE1	inhibitory	activity	of	the	chemically	modified	heparins	identified	in	the	work	by	Patey	et	
al.	(2006)	does	not	directly	align	with	the	changes	seen	in	the	Tm	and	therefore	stability	of	BACE1	in	these	DSF	experiments.	However,	the	action	of	unsulphated	CMH8	suggests	some	crossover	between	the	activity	and	structural	studies.			 Future	repetition	of	the	DSF	thermal	stability	experiments	with	CMH	with	BACE1	including	 the	APP	peptide	will	demonstrate	 if	 the	destabilisation	changes	occur	and	 if	the	activity	of	BACE1	is	modified.		 Far-UV	 CD	 identifies	 changes	 to	 the	 secondary	 structure	 of	 BACE1	 at	physiological	pH	 (4.0)	with	 the	 addition	of	heparin	 and	 chemically	modified	heparins.	The	peak	at	λ	=	220	nm	in	native	BACE1	alone	demonstrated	the	greatest	change	with	the	 addition	 of	 CMH3,	which	 does	 not	 follow	 the	 trend	 spectral	 shape,	 also	 causing	 a	decrease	in	ellipticity	at	this	wavelength,	as	seen	by	other	chemically	modified	heparins.			 CMH8	 and	 CMH6	 display	 the	 same	 spectral	 features	 at	 the	 λ	 =	 223	 nm	 peak	suggesting	the	2-O-sulphate	on	this	disaccharide	repeat	unit	does	not	cause	a	change	in	the	glycosaminoglycan	chain	able	 to	generate	a	secondary	structural	change	 to	BACE1	upon	 binding.	 Instead,	 CMH7	 and	 CMH5	 display	 a	 1.6	 nm	 peak	 difference,	 suggesting	some	 aspect	 of	 the	 2-O-sulphate	 addition	 to	 this	 heparin	 form	 causes	 some	 BACE1	structural	modification.			 In	 the	 analysis	 of	 the	 CD	 spectra	 using	 the	 BeStSel	 analysis	 software,	 the	proportion	 of	 secondary	 structure	 elements	 of	 BACE1	 remains	 consistant	 with	 the	addition	of	 the	 chemically	modified	heparin	 library.	The	 changes	 to	BACE1	 secondary	structure	occurred	through	the	reduction	in	antiparallel	(right-twisted)	β-sheet	present	in	the	protein,	becoming	disordered.	Considering	per-sulphated	heparin	an	outlier,	 the	
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next	most	potent	Tm	reducing	chemically	modified	heparin	is	CMH1,	which	also	causes	the	greatest	loss	of	ordered	antiparallel	(right-twisted)	β-sheet	in	BACE1.	This	suggests	a	 possible	 causal	 relationship	 between	 the	 reduced	 β-sheet,	 the	 increase	 in	 BACE1	structural	 disorder	 and	 the	 resulting	 decrease	 in	 thermal	 stability	 seen	 in	 DSF	 in	 the	presence	 of	 a	 polymer	 of	 the	most	 common	 disaccharide	 in	 heparin,	 the	most	 potent	inhibitor	of	the	BACE1	enzyme	(Scholefield	et	al.,	2003),	IdoA(2S)-GlcNS(6S).				 However,	across	the	whole	chemically	modified	heparin	library	the	relationship	between	 the	 proportion	 of	 BACE1	 antiparallel	 (right-twisted)	 β-sheet	 loss	 due	 to	chemically	modified	 heparin	 and	 the	melting	 point	 of	 BACE1	with	 the	 same	modified	heparin	shows	no	correlation	(Pearson	correlation	coefficient	(n	=	9)	r	=	-0.16	(P	>	0.01	95	%	CI	-0.74	to	-0.57)).		 The	 sodium	 form	of	Celsus	PMH	used	as	 received,	 caused	a	 reduction	 in	Tm	of	native	 BACE1	 double	 that	 of	 the	 sodium	 cation	 form	 of	 PMH	 created	 for	 these	experiments.	 The	 process	 in	 which	 the	 specific	 cation	 forms	 are	 made	 could	 have	modified	 a	 property	 of	 the	 PMH,	 thereby	 changing	 the	 binding	 capabilities	 or	destabilisation	 effect	 of	 the	 treated	 PMH	 form.	 Conversley,	 unmodified	 Celsus	 PMH	could	 contain	 an	 assortment	of	 cations	 that	 give	 rise	 to	 an	 effect	 greater	 than	 for	 any	single	 homogeneous	 cation	 change.	 Removal	 and	 replacement	 of	 this	 ‘Celsus	 type’	positively	 charged	 mixture	 and	 replacement	 with	 pure	 sodium	 cations	 reduces	 the	destabilisation	effect	of	PMH.	At	 low	pH,	Na+,	Ca2+,	and	Mg2+	 interact	with	heparin	in	a	delocalized	way,	 in	anionic	sites	across	the	molecule,	at	neutral	pH	Ca2+	binds	forming	chelate	bonds	in	specific	regions	of	the	heparin	polymer;	no	preferred	binding	site	was	detected	for	Na+	and	Mg2+	(Karpukhin,	Feofanova,	Nikolaeva,	Mamontov,	&	Dobrynina,	2006).	Calcium	binding	at	neutral	pH	alters	the	proportion	of	conformation	states,	from	60:40	ratio	of	1C4:2S0,	to	80:20,	stiffening	the	molecule	(idem).	
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	 Potassium	 ions	 had	 the	 same	 effect	 as	 replacement	 with	 known	 sodium	 ions,	demonstrating	the	same	level	of	destabilisation	of	BACE1	to	a	Tm	of	38.8°C.	The	other	1+	valency	cations,	lithium	and	silver	have	a	less	pronounced	effect	on	PMH	destabilisation	of	BACE1.	Some	cation	forms	negate	the	 large	destabilising	effect	seen	with	full-length	heparin,	and	the	effects	seen	with	cation	forms	such	as	sodium	and	potassium	heparin.	Iron	(II)	and	magnesium	forms	halt	the	Tm	reduction	and	BACE1	thermal	destabilisation	seen	 with	 the	 addition	 of	 PMH.	 This	 suggests	 a	 structural	 change	 to	 the	 heparin	molecule,	such	as	the	stiffening	seen	with	calcium	binding,	which	either	halts	binding	to	BACE1,	or	binds	without	modification	to	the	structure	of	BACE1	thereby	not	altering	the	Tm	 in	 DSF.	 Experiments	 to	 determine	 if	 there	 is	 binding	 and	 consequently	 a	concentration	dependant	effect	to	this	interaction	would	shed	light	on	this	question.			 Zinc,	 silver	 and	 iron	 (III)	 all	 demonstrate	 small	 stabilising	 effects	 on	 BACE1	melting.	The	increase	in	BACE1	Tm	in	the	presence	of	these	cation	heparins	is	<1°C	over	the	Tm	of	BACE1	alone	(42.99	±	0.087°C),	so	the	significance	of	this	increase	in	stability	is	undetermined.			 The	 substitution	 pattern	 and	 cation	 form	 of	 the	 heparin/HS	 disaccharide	constituents	of	 the	glycopolymer	are	known	to	have	subtle	and	complex	effects	on	the	conformation	 of	 the	 iduronate	 ring	 (Ferro	 et	 al.,	 1986)	 and	 the	 glycosidic	 linkage	geometries	(Yates	et	al.,	2000).	Here,	these	changes	have	demonstrated	a	differing	effect	on	the	thermal	stability	and	secondary	structure	of	the	target	protein,	BACE1.				
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Chapter	8:	Investigating	glycosaminoglycan	structural	
mimetics	as	potential	inhibitors	of	BACE1	
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8.1	Introduction	
8.1.1	The	requirement	for	heparin	and	HS	mimetics			 Heparan	 sulphate	 and	 its	 highly	 sulphated	 analogue	 heparin	 can	 interact	 with	proteins	 or	 peptides	 utilising	 a	 chain	 specific	 binding	 fragment,	 or	 in	 a	 charge-dependant,	 monosaccharide	 non-specific	 manner	 (Krylov,	 Ustyuzhanina,	 &	 Nifantiev,	2011).	 Specific	 chain	 structural	 requirements	 include	 the	 pentasaccharide	 binding	sequence	 in	 the	 AT	 interaction	 and	 fibroblast	 growth	 factor	 FGF-FGFR	 binding	interactions,	 requiring	 a	minimum	 trisaccharide	 fragment	 (idem).	 Conversley,	 charge-based,	 non-specific	 binding	occurs	 through	 the	 spatial	 organisation	of	 charged	 groups	creating	 favourable	binding	pockets	or	regions	within	the	polysaccharide	3D	structure	and	usually	occurs	over	a	greater	area	than	that	of	chain-specific	binding	(idem).			 The	 diverse	 variety	 of	 physiological	 and	 pathological	 actions	 in	which	 heparin	and	HS	are	involved,	places	substantial	restraints	on	the	use	of	these	drugs,	with	effects	of	 heparin	 administration	 including	 haemorrhagia	 and	 thrombocytopenia	 (Gollub	 &	Ulin,	1962).	The	anticoagulant	activity	of	heparin	and	heparin-derived	polysaccharides	precludes	their	therapeutic	application	as	anti-inflammatory,	anti-tumour	and	anti-viral	agents.	Identification	of	specific	sequence	requirements	(akin	to	the	AT	interaction)	may	negate	 the	 anticoagulant	 efficacy	 through	 more	 targeted	 pharmacology,	 and	 lead	 to	alternative	 treatments	 for	 disease	 targets	 (Geerts	 et	 al.,	 2008).	 Due	 to	 the	 complex	nature	 of	 heparin	 and	HS	 electrostatic	 binding	 interactions,	 this	may	 not	 be	 possible,	rather,	 the	selection	of	heparin/HS	mimetics	 that	have	mitigated	anti-coagulant	action	with	minimum	saccharide	size,	no	off-target	effects	and	a	defined	structure,	would	offer	a	 attractive	 alternative	 to	 polysaccharides	 such	 as	 heparin.	 Due	 to	 the	 difficulty	 in	obtaining	pure	GAGs	 from	animal	extractions,	 the	unavoidable	contamination	risk	and	
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high	financial	burden	of	using	animal	derived	tissue,	chemical	synthesis	of	HS/heparin	mimicking	 GAG	 saccharides	 has	 been	 investigated	 (Schworer	 et	 al.,	 2013)	 (Miura,	Fukuda,	Seto,	&	Hoshino,	2016).			 Another	method	for	the	identification	of	heparin	mimetics	is	the	isolation	of	GAG	mimicking	compounds	from	plant	and	animal	sources,	which	can	be	chemically	modified	using	routine	and	scalable	chemistry,	to	produce	active	heparin	mimetics.	This	method	may	be	more	feasible	than	full	synthesis	as	the	high	availability	of	the	starting	material	and	good	yield	would	allow	for	scalable	production.	The	source	of	starting	material	can	also	 be	 highly	 tractable	 ensuring	 high	 purity	 and	 low	 risk.	 The	 cost	 of	 chemical	modification	would	be	low	when	compared	with	full	synthesis	of	GAG	based	saccharides,	due	 to	 the	 equipment,	 reagents,	 environment,	 and	 synthetic	 steps	 required	 for	 the	production,	with	each	step	reducing	the	final	product	yield.	Heparin	mimetics	have	been	demonstrated	 to	 have	 activity	 in	 many	 biochemical	 interactions	 commonly	 involving	heparin	or	HS,	some	of	which	are	discussed	below.		
8.1.2	Examples	of	heparin	mimetics		 The	attachment	and	entry	of	Flavivirus	 to	host	cells	occurs	through	endogenous	GAG	binding	(Baba,	Snoeck,	Pauwels,	&	Declercq,	1988).	Heparin	mimetics	can	compete	for	these	viral	high-affinity	GAG	binding	regions	through	competitive	inhibition,	halting	the	infectivity	of	the	invading	virus	(idem).	Dengue	fever	infection	of	Vero	cells	(in	vitro)	can	be	inhibited	by	the	heparin	analogue	suramin	(Chen	et	al.,	1997)	as	well	as	with	a	series	 of	 polyanionic	 compounds	 that	 probed	 requirements	 for	 molecular	 size	 and	sulphation	levels	(Marks	et	al.,	2001).	Sulphated	polysaccharides κ/ι/ν	carrageenan	G3d	and	 the	 D/L-galactan	 hybrid	 C2S-3	 derived	 from	 red	 seaweeds	 Gymnogongrus	
griffithsiae	and	Cryptonemia	crenulata,	showed	50%	inhibition	against	dengue	serotype	2	 (1	 μg/ml)	 (Talarico	 et	 al.,	 2005).	 Activity	was	 seen	 against	 serotype	 1	 in	 hepatoma	
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HepG2	cells,	foreskin	fibroblast	cells	and	Vero	cells,	but	showed	no	activity	in	mosquito	C6/36	HT	cells	(Aedes	albopictus),	suggesting	a	differing	route	of	cell	entry	(idem).		 Galactomannans	 isolated	 from	 Mimosa	 scabrella	 and	 Leucaena	 leucocephala	seeds	were	 chemically	 sulphated	 by	 Ono	 et	 al.	 (2003)	 and	 tested	 as	 anti-viral	 agents	against	 dengue	 and	 yellow	 fever	 virus	 (Ono	 et	 al.,	 2003).	 When	 testing	 against	intraperitoneal	 yellow	 fever	 infections	 of	 young	 mice,	 with	 a	 dose	 of	 49	 mg/kg,	 the	galactomannan	 from	 M.	 scabrella	 showed	 an	 87.7%	 protection	 against	 death	 while	galactomannan	 from	 L.	 leucocephala	 gave	 96.5%	 protection	 (idem).	 Inoculation	simultaneously	with	yellow	fever	virus	(37.5	LD50)	afforded	even	more	protection	with	93.3%	and	100%	resistance	respectively	(idem).			 Many	 sulphated	 polysaccharides	 have	 been	 demonstrated	 to	 inhibit	 the	 viral	invasion	of	human	 immunodeficiency	virus	 (HIV)	 including	 carrageenans	 (Nakashima,	Kido,	et	al.,	1987),	heparin	(T.	Ito	&	Tsumoto,	2013),	dextran	sulphate	((1-6)-α-glucan)	(Nakashima,	 Yoshida,	 et	 al.,	 1987),	 fucoidan	 (Baba,	 Snoeck,	 et	 al.,	 1988),	 pentosan	polysulphate	 (Baba,	 Nakajima,	 et	 al.,	 1988),	 polysulphated	 polyxylan	 	 (Biesert	 et	 al.,	1988)	 and	mannan	 sulphate	 (M.	 Ito	 et	 al.,	 1989)	 in	 vitro,	 however	 the	 anti-coagulant	capabilities	of	these	compounds	were	a	barrier	to	their	therapeutic	use	in	HIV.			 Semi-synthetic	 sulphated	 polysaccharides	 with	 attenuated	 anti-coagulant	capabilities	 such	as	 lentinan	sulphate	 (branched	 (1-3)-β-glucan)	 (Yoshida	et	al.,	1988)	and	 curdlan	 sulphate	 ((1-3)-β-glucan)	 have	 been	 shown	 to	 retain	 potent	 anti-viral	(Kaneko	et	al.,	1990)	and	anti-parasite	action	(Kyriacou	et	al.,	2007).			 Sulphated	 glycosides	 derived	 from	 kelp	 (Laminaria	 spp.)	were	 synthesised	 by	Katsuraya	et	al.	(1999)	from	tetraose,	pentaose	and	hexaose	saccharides	and	tested	for	the	effects	seen	with	changing	alkyl	chain	length	and	number	of	glucose	residues	as	anti-HIV	agents	 (Katsuraya,	Nakashima,	Yamamoto,	&	Uryu,	1999).	The	anti-HIV	activity	of	
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both	 the	 dodecyl	 laminara-pentaosides	 and	 hexaosides	 increased	 with	 increasing	sulphate	level	with	the	fully	sulphated	pentaoside	showing	highest	activity	(idem).			 Infection	of	the	Anopheles	mosquito	by	Plasmodium	spp.	occurs	post	blood	meal	when	 the	 parasite	 ookinete	 invades	 midgut	 epithelial	 cells	 through	 micronemal	proteins,	with	the	essential	involvement	of	CS	on	the	luminal	surface	and	HS	on	the	basal	surface	(Sinnis	et	al.,	2007).	Knockdown	of	essential	CS	and	HS	biosynthetic	enzymes	in	the	mosquito	vector	showed	 limited	 infection	by	plasmodium	 spp.	 illustrating	CSA	and	chondroitin	sulphate	E	(CSE)	are	essential	for	some	micronemal	invasion	(F.	W.	Li	et	al.,	2004).	Mathias	et	al.	(2013)	designed	small	CS	mimics	capable	of	competitive	inhibition,	blocking	 the	 ookinete-GAG	 interactions	 required	 through	 PfWARP	 (von	 Willebrand	factor	 A	 domain-related	 protein)	 and	 PfCTRP	 (circumsporozoite	 protein	 and	thrombospondin-related	 anonymous	 protein-related	 protein)	 binding	 for	 entry	 into	mosquito	 microneme	 (Mathias	 et	 al.,	 2013).	 The	 synthetic	 polysulfonated	 polymer	blocked	oocyst	development	by	up	to	99%	(P	<	0.0001)	in	P.	falciparum	and	P.	berghei	infected	 mosquitos	 (idem).	 The	 CS	 mimicking	 compound	 was	 found	 to	 bind	 the	 GAG	binding	 PfCTRP	 blocking	 the	 transmission	 to	 the	mosquito	 and	 therefore	 ookinete	 to	oocyst	parasite	progression	(idem).			 Most	GFs	and	cytokines	 involved	 in	cellular	growth	and	repair	are	 found	 in	 the	extracellular	 matrix	 and	 stored	 via	 specific	 interactions	 with	 GAGs	 (Tillman,	 Ullm,	 &	Madihally,	2006).	The	use	of	GAG	mimetics	such	as	fucoidan,	pentosan	polysulphate	and	dextran	sulphate	 in	wound	healing	have	been	demonstrated	 to	stimulate	 tissue	repair	similarly	 to	 endogenous	 GAGs,	with	 others	 improving	 on	 the	 efficacy	 seen	with	 these	native	GAGs	(Ikeda	et	al.,	2011).	These	GAG	mimetics	act	 to	replace	endogenous	GAGs	degraded	by	matrix	endoglycosidases,	improving	the	tissue	scaffold	and	potentiating	the	effects	 of	 heparin-binding	 GF	 (Rouet	 et	 al.,	 2006),	 heparin	 binding	 proteins	 such	 as	
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thrombin,	and	chemokines	RANTES	(Regulated	on	Activation,	Normal	T	Expressed	and	Secreted/CCL5)	(Sutton	et	al.,	2007)	and	SDF1	(stromal	cell-derived	factor-1)	(Friand	et	al.,	2009).	Ikeda	et	al.	(2011)	determined	topical	application	of	a	heparin	mimetic	d.p.12	oligosaccharide	 named	 HM4120,	 promoted	 the	 healing	 of	 skin	 ulcers	 as	 well	 as	 the	polymeric	control	material	but	had	preferable	attenuated	effects	in	coagulation	(Ikeda	et	al.,	2011).		Garcia-Filipe	et	al.	(2007)	also	identified	a	heparan	sulphate	mimetic	dubbed	RGTA	 OTR4120	 synthesised	 from	 T40	 dextran,	 as	 a	 potent	 post-burn,	 tissue	regenerating	treatment	(Garcia-Filipe	et	al.,	2007).		 Interferon-γ	(IFN-γ)	along	with	a	number	of	cytokines	and	GF,	 interact	with	HS	with	high	affinity	(IFN-γ	=	10-9	M),	acting	as	a	molecular	sink,	providing	increased	local	concentrations	of	the	cytokines	and	GFs	(Lortat-Jacob,	Turnbull,	&	Grimaud,	1995).	HS	moderates	 IFN-γ	C-terminal	proteolytic	cleavage	 through	binding	proximity,	providing	an	increase	or	decrease	in	biological	activity	of	this	cytokine	(idem).	Other	GAGs	tested	such	 as	 CS	 and	DS	 do	 not	 bind	 IFN-γ	 suggesting	 a	more	 specific	 binding	 requirement	than	a	polyanionic	nature	(idem).	The	IFN-γ	binding	domain	of	HS	was	identified	as	two	small	N-sulphated	hexa-	to	octa-	saccharides	flanking	a	N-acetylated	region,	rich	in	GlcA	residues	 of	 approximately	 7	 kDa	 in	 length	 (idem).	 Synthetic	 production	 of	 this	 region	may	permit	modulation	of	IFN-γ	levels	useful	for	immune	stabilisation.			 The	 complex	 growth	 factor	 family	 of	 FGFs	 and	 FGFRs	 are	 involved	with	many	processes	 in	 growth	 and	 development,	 and	 require	 HS	 to	 create	 binding	 complexes	between	ligand	and	receptor	in	order	for	signalling	to	occur	(Ornitz,	2000).	HS	synthesis	alters	 over	 the	 course	 of	 development	 and	 the	 substitution	 along	 the	 polysaccharide	chain	 is	also	both	tissue	and	cell	dependent	 (Allen	&	Rapraeger,	2003).	Changes	 to	HS	therefore,	may	regulate	morphogen	signalling	and	effect	the	growth	and	development	of	an	organism	(idem).	In	HS-FGF	complex	binding,	polysaccharide	sequence	specificity	is	
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absent,	but	there	is	a	degree	of	structural	requirement	for	FGF	complex	signalling	(Rudd	et	 al.,	 2010).	 Charge	 density	 alone	 does	 not	 account	 for	 the	 HS/FGF/FGFR	 signalling	capabilities	 as	 shown	 by	 Yates	 et	 al.	 2004	 (Yates	 et	 al.,	 2004).	 Rudd	 et	 al.	 (2010)	hypothesised	that	an	effective	FGF/FGFR	binding	complex	required	a	polysaccharide	not	with	 a	 specific	 primary	 sequence,	 but	 rather	 with	 conformation	 and	 charge	characteristics	 specific	 for	 the	 binding	 complex	 activation	 (Rudd	 et	 al.,	 2010).	 This	research	proposed	any	polysaccharide	could	have	the	potential	to	fulfil	the	FGF	complex	requirements	 irrespective	of	 the	primary	chain	sequence,	as	 factors	such	as	hydration	and	 pH	 affect	 the	 molecular	 structure	 (idem).	 In	 addition	 to	 9	 modified	 heparin	polysaccharides	 (Yates	 et	 al.,	 2000;	 Yates	 et	 al.,	 1996),	 39	 alternative	 chemically	sulphated	 polysaccharides,	 including	 tylose,	 gums	 such	 as	 xanthan	 gum,	 pectin,	 ι-carrageenan	and	glycogen	were	 tested	 for	 the	ability	 to	promote	FGF/FGFR	signalling	using	differential	scanning	fluorimetry	(DSF),	synchrotron	radiation	circular	dichrosim	(SRCD)	and	a	BaF	signalling	assay	(Rudd	et	al.,	2010).	The	stability	and	signalling	ability	of	FGF-1	was	reached	by	chemically	sulphated	xanthan	gum	and	ι-carrageenan	(idem).	FGF2	was	 stabilised	 and	active	with	 chemically	 sulphated	 tylose	 and	 locust	bean	gum	with	 lower	 levels	 of	 activity	 seen	 with	 the	 other	 sulphated	 polysaccharides,	 through	differences	 between	 FGF1	 and	 FGF2	 structural	 and	 charge	 requirements	 (idem).	Chemical	 sulphation	 is	 one	 of	 the	 most	 exploited	 approaches	 to	 heparin	 mimetic	production	(Papy-Garcia	2005).	
8.1.3	Experimental	aims		 The	aim	of	this	study	is	to	identify	and	quantify	a	small	group	of	polysaccharide	heparin	 analogues	with	 potent	 BACE1	 inhibition	 activity	 and	 attenuated	 action	 in	 the	coagulation	cascade,	to	take	forward	for	future	therapeutic	development.		
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8.1.4	Composition	of	the	polysaccharide	scouting	library		 The	examples	of	non-heparin	GAG	analogues	acting	as	mimetics	for	heparin	or	HS	in	 biological	 systems	 lends	 support	 to	 the	 thesis	 that	 these	 more	 easily	 accessible,	cheaper	and	safer	polysaccharides	can	be	investigated	with	potential	in	all	heparin/HS	biological	systems,	including	as	modulators	of	the	heparin/HS	binding	aspartyl	protease	BACE1.	 The	 creation	 of	 a	 chemically	 sulphated	 polysaccharide	 library	 of	 heparin	mimetics	 employed	 as	 a	 screening	 resource	 has	 enabled	 identification	 of	 hit	 BACE1	inhibitors,	 with	 potential	 for	 future	 combinatorial	 chemistry	 to	 produce	 an	 effective	BACE1	inhibitor.		 The	 members	 of	 this	 polysaccharide	 library	 were	 selected	 based	 on	 criteria	including	 cost,	 tractability,	 scalability,	 purity,	 required	 purification,	 and	 composition.	Table	18	is	a	summary	of	the	compounds	selected.	The	qualitative	yield	upon	chemical	sulphation	 is	 included	 to	 identify	 potential	 hits	 alongside	 brief	 information	 on	 the	compound	composition.		
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	 Table	18:	GAG	mimetic	 library	composed	of	tractable,	 scalable	and	economically	selected	polysaccharide	members.	
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	Table	18	continued.	
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8.1.5	Background	of	methods	used	
8.1.5.1	Fluorescent	resonant	energy	transfer	(FRET)		 Förster	 coupling	 is	 the	 transfer	 of	 energy	 from	 one	 atom	 to	 a	 closely	 linked	second	 atom	 through	 the	 transfer	 of	 a	 virtual	 photon	 (exhibiting	 the	 same	characteristics	of	photon	transfer	but	only	acting	for	a	 limited	time)	in	a	non-radiative	manner	when	maintaining	proximity	(Forster,	1959).	The	Förster	radius	is	the	distance	through	which	half	the	emission	energy	is	transferred	to	the	acceptor		(3-6	nm),	but	the	transfer	can	occur	over	 larger	distances	of	up	 to	10	nm	with	a	weaker	effect	 (Sekar	&	Periasamy,	 2003).	 Förster	 coupling	 is	 used	 experimentally	 to	 examine	 if	 two	chromophores	 are	 close	 to	 each	 other	 and	 has	 been	 described	 as	 a	 ‘molecular	 ruler’	(Stryer,	1978).		 Förster	 (fluorescence)	 resonance	 energy	 transfer	 (FRET)	 utilises	 the	 energy	transfer	between	a	donor	and	acceptor,	with	the	donor	or	the	donor	and	acceptor	being	light	sensitive	molecules	(Clegg,	2009).	Bound	to	a	peptide,	receptor	or	other	target,	the	donor	and	acceptor	identify	real-time	changes	to	the	proximity	of	these	two	molecules.	Figure	154	illustrates	this	interaction.		
Figure	 154:	 Schematic	 of	 fluorescence	 resonance	 energy	 transfer	 reaction	 with	BACE1	cleaving	APPSW	FRET	peptide,	excitation	at	λex=	320	nm.	Inhibition	of	BACE1	halts	APPSW	cleavage,	therefore	quenching	the	emission	at	λem=	405	nm.	
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	 FRET	allows	for	the	real	time	analysis	of	biological	interactions	at	a	distance	far	beyond	 that	 of	 the	 diffraction	 limit	 for	 optical	 microscopy	 (Clegg,	 2009).	 The	 donor	fluorescence	lifetime	is	extended	due	to	the	method	of	energy	transfer	and	deactivation,	leading	 to	 slower	 photobleaching	 kinetics	 (idem).	 If	 both	 the	 donor	 and	 acceptor	molecules	are	light	sensitive,	the	fluorescence	of	the	acceptor	can	be	directly	measured,	allowing	a	real-time	and	direct	measurement	of	the	proximity	of	the	fluorophores;	this	is	called	sensitised	emission	(idem).			 The	 decoupling	 of	 donor	 or	 acceptor	 molecule	 from	 the	 peptide,	 ligand	 or	receptor	 can	 lead	 to	 a	 false	 positive	 assay	 result.	 This	 is	more	 important	 in	 complex	systems	such	receptor	studies	and	microscopy	than	 in	a	 three	constituent	biochemical	assay,	where	controls	can	account	for	any	unpredicted	changes	in	fluorescence.			 The	FRET	method	to	screen	for	BACE1	inhibitors	was	modified	from	Yokosawa	et	
al.,	(1983)	using	Swedish	mutation	APP	fragment	(SEVNLDAEFRK	replacing	KM,	lysine	methionine	 for	 NL	 asparagine	 leucine)	 bound	 to	 the	 donor	 molecule	 7-amino-4-methylcoumarin	 (MCA)	 on	 the	 N-terminus	 and	 acceptor	 molecule	 2,4-dinitrophenol	(DNP)	on	the	C-terminus	(Yokosawa,	 Ito,	Murata,	&	 Ishii,	1983).	This	MCA-APPSW-DNP	substrate	 is	cleaved	by	BACE1	to	 form	a	MCA-containing	fragment	that	excites	at	λex	=	320	 nm	 fluoresces	 at	 λem	 =	 405	 nm.	 Inhibition	 of	 BACE1	 diminishes	 the	 fluorescence	seen	at	λem	=	405	nm.	Proteolytic	cleavage	of	the	APPSW	by	BACE1	between	asparagine	and	 leucine	 residues	 releases	 the	 fluorophores,	 energy	 quenching	 of	 DNP	 no	 longer	occurs,	allowing	the	excitation	and	emission	of	MCA.	Scholefield	et	al.	(2003)	employed	this	 FRET	 assay	 to	 identify	 heparin	 as	 a	 physiological	 regulator	 of	 BACE1	 and	 other	work	further	utilised	the	method	for	identifying	the	structural	requirements	for	BACE1	modulation	and	improving	the	hit	heparin	derivatives	(Patey	et	al.,	2006;	Scholefield	et	al.,	2003)	(Patey	et	al.,	2006)	(Beckman	et	al.,	2006)	(Patey	et	al.,	2008).	
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8.1.5.2.	Coagulation	assays			 The	 action	 of	 each	 semi-synthetic	 sulphated	 polysaccharide	 in	 the	 intrinsic	pathway	 was	 determined	 through	 the	 activated	 partial	 thromboplastin	 time	 (aPTT)	assay,	which	assesses	the	contact	activation	or	intrinsic	pathway	and	the	factors	XII,	XI,	IX	 and	 the	 common	pathway	 factors	 X	 and	 II,	 forming	 a	 clot	 upon	 activation	 of	 fibrin	(factor	I).			 The	prothrombin	time	(PT)	assay	was	used	to	identify	sulphated	polysaccharides	that	perturb	the	activation	of	the	tissue	factor	(trauma)	pathway,	or	extrinsic	pathway	that	 utilises	 factor	 VII,	 and	 common	 pathway	 factors	 X	 and	 II,	 forming	 a	 clot	 upon	activation	of	fibrin.			 The	aPTT	and	PT	results	are	presented	as	half	maximal	effective	 concentration	(EC50)	 as	 a	 maximum	 clotting	 time	 cut	 off	 of	 120	 seconds	 was	 used.	 Unfractionated	heparin	inhibits	the	activation	of	factor	X,	thrombin	(factor	II),	factors	VIII,	IX,	XI	and	XII	directly	or	 through	 the	specific	 interaction	with	serpin	 inhibitor,	antithrombin.	LMWH	interact	 more	 specifically	 with	 factor	 X	 to	 minimise	 the	 off	 target	 effects	 seen	 with	unfractionated	heparin	such	as	heparin	induced	thrombocytopenia	(HIT).			 Sulphated	 polysaccharide	 candidates	 demonstrating	 intrinsic	 pathway	 results	100	times	less	active	than	PMH	may	be	considered	a	possible	hit	as	the	anti-coagulant	capacity	 of	 these	 hits	 will	 be	 negated	 and	 therefore	 limit	 the	 off-target	 effects	 as	potential	therapeutics.			 Clinical	 data	 suggest	measurement	 of	 aPTT	does	 not	 adequately	 correlate	with	blood	 heparin	 levels	 or	 patients	 anti-thrombotic	 activity	 (Baker,	 Adelman,	 Smith,	 &	Osborn,	 1997).	 Baker	 and	 colleagues	 suggest	 the	 differences	 in	 the	 heparin	requirements	 for	 each	patient,	 alongside	 the	pharmacokinetic	 and	pharmacodynamics	variations	 in	 heparin	 dosing,	 leads	 to	 the	 aPTT	 being	 an	 unreliable	 test	 method	 for	
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assessing	 patient	 heparin	 therapy	 (idem),	 however	 the	 assay	 will	 demonstrate	interaction	with	other	factors	not	just	AT,	factor	IIa	and	factor	Xa.	This	work	found	there	was	 no	 causal	 relationship	 between	 aPTT	 results	 and	 more	 specific	 screening	 to	determine	the	anti-factor	Xa	activity	of	the	heparin	from	a	blood	sample,	in	a	significant	number	of	cases	(idem).	The	aPTT	and	PT	assays	screen	compound	activity	through	the	coagulation	 pathway,	 using	 human	 serum,	 allowing	 for	 indications	 of	 anti-coagulation	effect.	Specific	anticoagulation	factor	screening	provides	a	more	accurate	picture	of	the	effects	 of	 the	 hit	 compound.	 The	 aPTT	 therapeutic	 range	 corresponding	 to	 a	 heparin	concentration	that	gives	0.35	to	0.7	anti-factor	Xa	heparin	units	per	millilitre	has	been	suggested	to	be	a	more	reliable	metric	for	heparin	monitoring	(Hirsh	&	Raschke,	2004).			 The	interaction	between	heparin	and	antithrombin	during	inhibition	of	factor	Xa	occurs	through	a	specific	pentasaccharide	sequence	(Vanboeckel	&	Petitou,	1993).	The	more	non-specific	binding	of	heparin	 saccharides	>18	mer	 in	 length	 is	 required	when	acting	as	a	scaffold	for	AT/thrombin	(factor	IIa)	interactions,	leading	to	the	inhibition	of	factor	 II	 (Olson,	Halvorson,	&	Bjork,	 1991).	Almost	 all	 heparin	 chains	 are	 of	 sufficient	length	(>18	mer)	to	mediate	the	AT/factor	IIa	interaction	leading	to	the	equal	action	of	UF	 heparin	 in	 factor	 IIa	 inhibition	 and	 the	more	 specific	 sequence	 requirement	 anti-factor	Xa,	with	a	ratio	of	1:1	factor	IIa	to	factor	Xa	inhibition	(Bates	&	Weitz,	2005).		
8.1.5.3	Level	of	sulphation		 In	 order	 to	 quantify	 the	 level	 of	 sulphation	 for	 each	 chemically	 modified	 hit	polysaccharide,	 a	 biochemical	 colorimetric	 assay	 was	 employed,	 with	 calibration	obtained	with	 dextran	 sulphate	 due	 to	 its	 independently	 ascertained	 sulphation	 level.	The	level	of	sulphate,	and	therefore	the	charge	of	the	polysaccharide	is	important	when	designing	therapeutics,	as	the	least	charged	molecules	are	less	likely	to	interact	strongly	with	the	myriad	of	other	possible	binding	targets	within	the	body.		
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	 The	assay	employed	was	modified	for	a	multiwall	format	from	the	work	by	Terho	and	 Hartiala	 in	 1971	 and	 utilises	 the	 reduction	 of	 barium	 chloride	 by	 the	 liberated	sulphate	ion,	which	in	turn	results	in	the	colour	change	of	the	reporter	dye,	rhodizonic	acid	to	a	rhodizonate	anion	(Terho	&	Hartiala,	1971).	
8.1.5.4	Determining	Molecular	weight			 Size	 exclusion	 chromatography	 (SEC)	 separates	 molecules	 on	 the	 basis	 of	hydrodynamic	volume;	the	effective	hydrated	radius	 in	solution,	or	Stokes	radius.	This	radius	 depends	 on	 the	 molecular	 shape	 and	 the	 arrangement	 of	 water	 molecules	surrounding	 the	molecule.	The	 result	 of	 these	 factors	when	moving	 through	a	viscous	liquid	causes	drag.		
𝑅! =  𝑘!𝑇6𝜋𝜂𝐷	Where	 RH	 is	 the	 hydrodynamic	 volume,	 kB	 is	 the	 Boltzmann	 constant,	 T	 is	 the	temperature,	η	is	the	liquid	viscosity	and	D	is	the	diffusion	constant.	The	 diffusion	 constant	 (D)	 is	 effected	 by	 the	 mobility	 constant	 (μ)	 and	 the	 electrical	charge	(q).	
𝐷 = µ𝑘!𝑇𝑞 	The	mobility	constant	takes	 into	account	the	 ionic	charge	of	 the	molecule	(ze)	and	the	drag	through	the	mobile	phase	(f).	 µ =  𝑧𝑒𝑓 	Solutes	of	RH	larger	than	the	column	matrix	pores	are	too	large	to	penetrate	the	beads,	therefore	 pass	 through	 the	 mobile	 phase	 of	 the	 column	 only,	 and	 are	 eluted	 first.	Molecules	with	a	RH	less	than	the	matrix	pore	size	pass	through	the	bead	pores,	and	are	therefore	eluted	at	 a	 later	 time;	 fractionating	 the	 sample	by	molecular	 size.	The	HPLC	
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profile	 demonstrated	 the	 size	 distribution	 of	 the	molecules	within	 the	 sample,	 and	 is	defined	as	the	molecular	weight	distribution	of	the	sample.		Gel	 permeation	 chromatography	 utilises	 samples	 with	 known	 molecular	 weight	 to	calibrate	 each	 column,	 to	 allow	 for	 calculation	 of	 unknown	 sample	 weight	 average	molecular	 weight	 (Mw),	 number	 average	 molecular	 weight	 (Mn)	 and	 polydispersity	index	(PDI).	PDI	of	a	polymer	is	the	distribution	of	molecular	mass	and	is	calculated	by:	
𝑃𝐷𝐼 = 𝑀!𝑀! 	
8.1.5.5	1H	Nuclear	magnetic	resonance	spectroscopy	
	 Proton	nuclear	magnetic	 resonance	 spectroscopy	 (1H-NMR)	occurs	 through	 the	absorption	and	resonant	frequency	of	the	proton	in	the	sample,	relative	to	the	strength	of	the	magnetic	field	acting	on	the	sample	(Bloembergen,	Purcell,	&	Pound,	1947).	The	spin	 of	 the	 protons	 align	 either	 with	 (α	 orientation)	 or	 opposing	 (β	 orientation)	 the	magnetic	 field	 (idem).	 Electromagnetic	 energy	 is	 used	 to	 switch	 orientation	 of	 more	protons	into	the	β	orientation	(idem).	Upon	cessation	of	energy	input,	the	nuclei	 ‘relax’	back	into	the	lower	energy	α	orientation,	causing	a	fluctuating	local	magnetic	field;	this	is	the	resonance	of	the	proton	and	is	displayed	as	a	NMR	peak	(idem).			 The	 number	 of	 peaks	 indicates	 the	 number	 of	 different	 protons	 present	 in	 the	molecule,	with	the	integral	of	each	peak	indicating	the	number	of	protons	experiencing	the	 same	 environments,	 allowing	 deduction	 of	 the	 chemical	 structure	 of	 organic	molecules	(idem).	Splitting	of	the	peaks	indicates	the	near	environment	to	each	proton	in	 the	 molecule,	 with	 neighboring	 hydrogen	 atoms	 affecting	 the	 split	 (idem).	 The	electronic	 environment	 the	 proton	 experiences	 in	 the	 molecule	 alters	 the	 resonance	within	the	applied	magnetic	field,	therefore	indicating	the	amount	shielding	the	proton	experiences	through	electronegativity	(idem).			
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	 1H-NMR	was	 utilised	 in	 this	work	 to	 identify	 changes	 to	 proton	 environments	upon	chemical	sulphation	of	the	hit	polysaccharides.		
8.1.5.6	Fourier	transform	infra-red	spectroscopy		 Fourier	 transform	 infrared	 spectroscopy	 (FTIR)	 involves	 the	 absorption	 or	transmittance	of	infrared	radiation	through	a	sample	(B.C.Smith,	2011).	Intra-molecular	bonds	absorb	IR	radiation	at	different	frequencies,	depending	on	the	functional	groups	present	 (idem).	 Bonds	 absorb	 light	 of	 different	 wavelengths	 depending	 on	 the	environment,	 including	 the	 atoms	 present,	 their	 conformation	 and	 the	 local	environment	 functional	 groups	 (idem).	 These	 environmental	 influences	 modify	 bond	vibrations	including	stretching,	rocking,	scissoring,	wagging	and	twisting,	which	change	the	frequency	of	the	radiation	being	absorbed,	therefore	shifting	the	resulting	IR	peaks	(idem).				 The	interferogram	of	a	sample	is	collected	through	the	use	of	a	broadband	light	source	 that	 is	 modulated	 through	 interference	 to	 produce	 a	 spectrum	 with	 each	wavelength	of	light	periodically	blocked,	until	a	full	spectrum	has	been	measured	(idem).	Fast	 fourier	transform	of	the	 interferogram	gives	 light	absorbtion	or	transmittance	for	each	wavelength	(idem).	FTIR	was	employed	to	identify	changes	to	the	structure	of	hit	polysaccharides	when	they	have	been	chemically	sulphated.		
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8.2	Results	
8.2.1	 Fluorescent	 resonance	 energy	 transfer	 (FRET)	 for	 the	 screening	 of	 BACE1	
inhibitors		 An	 initial	 test	of	FRET	activity	using	previously	assayed	heparins,	 to	determine	the	 reproducibility	 and	 comparability	 to	 published	 literature	 was	 done	 to	 ensure	validity	of	this	technique	and	assess	the	assay	post	method	transfer.		
	 Bovine	lung	heparin	(BLH)	and	porcine	mucosal	heparin	(PMH)	were	assayed	in	triplicate.	 Figure	 155	 demonstrates	 the	 dose-response	 curves	 obtained	 once	 both	 no	enzyme	 control	 and	 full	 reaction	 control	 were	 taken	 into	 account,	 with	 the	 resulting	fluorescence	 represented	 as	 a	 percentage	 of	 BACE1	 inhibition.	 The	 inhibition	 activity	seen	by	Scholefield	et	al.	(2003)	with	BLH	gave	an	IC50	of	1-2 μg/ml	in	the	FRET	BACE1	inhibition	assay,	with	PMH	IC50	of	5	μg/ml	(Scholefield	et	al.,	2003).	Later,	Patey	et	al.	(2006)	noted	a	 significantly	 reduced	 IC50,	with	PMH	 IC50	 of	 28.0	ng/ml,	 however	BLH	was	not	tested	(Patey	et	al.,	2008).	Neither	publication	noted	a	promotive	effect	at	lower	concentrations	of	heparin	 (<	1	μg/ml),	but	 this	effect	was	noted	 in	 the	Beckman	et	al.	(2006)	publication,	with	inhibitory	concentrations	of	heparin	>10	μg/ml	and	promotive	
	Figure	 155:	 Dose	 response	 curve	 of	 BACE1	 FRET	 utilised	 to	 determine	 the	 affect	 of	 human	BACE1	 (FLAG-tag)	 detecting	 the	 cleavage	 of	 FRET	 peptide	 derived	 from	 the	 APPSW	 (Mca-SEVNLDAEFRK(Dnp)RR-NH2	Fluorogenic	Peptide	Substrate)	 λex=	 320	nm	λem=	 	405	nm,	 in	 50	mM	sodium	acetate	pH	4.0,	over	1.5	hours.	A)	BLH	IC50	=	2.554	μg/ml	R2=	0.9303	and	B)	PMH	IC50=	2.943	μg/ml	R2=	0.8949	
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concentrations	<1	μg/ml	in	rBACE1	(Beckman	et	al.,	2006).	The	results	in	Figure	155A	demonstrate	 BLH	 in	 BACE1	 FRET	 had	 an	 IC50	of	 2.554	 μg/ml	 (R2=	 0.9303)	with	 12.5	μg/ml	 and	 above	 giving	 ≈	 100%	 inhibition	 of	 BACE1	 processing	 of	 the	 APPSW	 FRET	peptide,	relative	to	the	no	enzyme	control.	The	control	containing	no	enzyme	was	used	as	 a	 100%	 inhibition	 control	 to	 allow	 for	 the	 native	 fluorescence	 levels	 of	 the	 FRET	peptide.	BLH	at	3.13	μg/ml	showed	a	54%	inhibition	of	BACE1,	with	concentrations	of	BLH	 lower	 than	 this	 (1.56	μg/ml	and	 lower)	demonstrating	 the	ability	 to	 improve	 the	fluorescence	 signal	 beyond	 levels	 seen	 in	 the	 full	 reaction	 control.	 BLH	 at	 1.56	 μg/ml	exhibits	 a	 130%	 increase	 in	 fluorescence	 over	 the	 uninhibited	 FRET	 fluorescence.	 At	0.78	μg/ml,	0.39	μg/ml	and	0.20	μg/ml	the	level	of	fluorescence	promotion	is	≈	150%,	with	this	level	reducing	to	62%	at	0.097	μg/ml.			 Figure	155B	shows	the	comparable	FRET	dose	response	of	PMH	yielding	an	IC50	of	3.045	μg/ml	(R2=	0.9303)	with	concentrations	over	12	μg/ml	exhibiting	inhibition	of	FRET	 peptide	 cleavage	 of	 ≈	 100%.	 PMH	 at	 4.1	 μg/ml	 yields	 65%	 inhibition	 and	concentrations	lower	than	this	show	some	stimulating	activities	but	this	action	is	not	as	pronounced	as	BLH.			 The	 data	 show	 BLH	 and	 PMH	 have	 similar	 potency	 as	 BACE1	 inhibitors	 as	evidenced	 by	 their	 IC50	 values,	 but	 as	 described	 by	 Beckman	 et	 al.,	 (2006)	 at	 lower	concentrations,	in	this	data	<	1.4	μg/ml	in	PMH	and	<	1.56	μg/ml	in	BLH,	heparin	acts	to	promote	 the	 fluorescence	 as	measured	at	 λem=	405nm.	The	 reasons	 for	 this	 increased	fluorescence	were	investigated	to	determine	whether	the	effect	was	due	to	actual	BACE1	inhibition	 or	 an	 effect	 of	 fluorophore	 uncoupling,	 energy	 donation	 or	 alike.	 Heparins	were	assayed	with	APPSW	FRET	peptide	alone	to	detect	any	increase	in	fluorescence	due	to	MCA/DNP	uncoupling	or	energy	donation	but	no	change	fluorescence	above	baseline	was	 seen	 (data	not	 shown)	 leading	 to	 the	 conclusion	BLH	and	 to	 a	 lesser	 extent	PMH	
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can,	at	lower	concentrations	(<	1.4	μg/ml),	stimulate	the	activity	of	this	BACE1	in	an	in	
vitro	FRET	cleavage	assay.			 Even	 though	BLH	 is	 the	more	potent	BACE1	 inhibitor	when	compared	 to	PMH,	BLH	is	currently	more	difficult	and	expensive	to	obtain.	This	 form	is	not	utilised	aas	a	pharmaceutic	due	to	concerns	with	prion	contaminants.	With	the	availability	of	PMH	at	the	 required	 quantities	 for	 comparison	 throughout	 the	 following	 investigations,	 this	heparin	source	will	be	utilised	in	the	following	experiments.	
8.2.2	FRET	screening	of	semi-synthetic	chemically	sulphated	polysaccharide	library		 A	 library	of	39	polysaccharides	 from	various	different	 sources	were	 chemically	sulphated	using	adaptation	 to	 the	method	of	Yoshida	et	 al.	 (Yoshida	et	 al.,	 1988).	The	resulting	 library	was	screened	using	FRET	 for	BACE1	 inhibitory	activity	at	1	μg/ml	 to	ensure	 screening	 ruled	 out	 polysaccharides	 with	 the	 ability	 to	 stimulate	 BACE1	 in	 a	similar	way	 to	 BLH/PMH.	 Screening	 occurred	with	 BACE1	 alongside	 control	 readings	including	 sulphated	 polysaccharide	 and	 FRET	 substrate	 alone,	 to	 ensure	 no	fluorophore:substrate	 decoupling.	 The	 results	 in	 Figure	 133	 show	 the	 percentage	inhibition	 of	 BACE1	 by	 each	 chemically	 sulphated	 polysaccharide	 in	 the	 library,	alongside	 the	 known	 BACE1	 inhibitor	 OM99-2	 (100	 nM)	 and	 PMH	 (1	 μg/ml)	 for	reference.			 Both	 sulphated	 gum	 arabic	 and	 per-sulphated ι-carrageenan	 exhibited	 the	strongest	capacity	for	BACE1	inhibition	with	over	100%	inhibition	of	fluorescence.	The	reduction	in	fluorescence	was	assayed	without	BACE1	enzyme	to	determine	the	effect	of	sulphated	 polysaccharide	 alone	 to	 ensure	 the	 test	 polysaccharides	 did	 not	 directly	quench	fluorescence	at	λem=	405nm	or	decouple	the	fluorophors.	Gum	arabic	derivative	arabic	 acid	 is	 a	 purified	 polysaccharide	 but	 exhibits	 lower	 but	 still	 significant	 BACE1	inhibitory	activity	 (76.5%).	This	may	be	explained	by	 the	molecular	 complexity	of	 the	
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gum	including	other	polysaccharides	that	further	improve	its	inhibitory	activity	beyond	the	 action	 of	 the	 more	 pure	 arabic	 acid.	 Both	 gum	 arabic	 and	 ι-carrageenan	 are	comprised	 of	 galactopyranosyl	 residues,	 in	 the	 case	 of	 ι-carrageenan,	 these	 take	 the	form	 of	 a	 repeating	 disaccharide	 of	 (1-3)	 linked	 α-D-galactose	 and	 (1-4)	 linked	 β-D-galactose	and	in	arabic	acid	this	(1-3)	linked	β-D-galactose	chain	is	branched	with	(1-3)	β-D-galactose	chains	linked	(1-6)	to	the	main	chain.	All	carrageenans	contain	the	same	strictly	alternating	disaccharide	sequence	with	the	α-linked	galactose	occurring	as	a	3,6-anhydro	unit	and	the	β-linked	sugar	occurring	as	the	3-sulphate.	The	ability	of	the	three	carrageenans	 tested	 to	 inhibit	 BACE1	 are	 different,	 with	 ι-carrageenan	 the	 best	carrageenan	 inhibitor,	 with	 λ-carrageenan	 inhibition	 by	 62%	 and	 κ-carrageenan	 by	47%.	The	differences	between	the	carrageenan	structures	 include	modifications	to	the	native	 sulphation	 level	 and	 the	 presence	 of	 the	 3,6-anhydro	 unit	 replacing	 the	 α-D-galactose	as	shown	in	Figure	156.		
	 Sulphated	 gum	 mastic,	 ethyl	 cellulose	 and	 agarose	 demonstrated	 BACE1	inhibition	of	98.5%,	94.2%	and	91.4%	respectively.	Other	cellulose	derivatives	did	not	
Figure	 156:	 Haworth	 projections	 of	 the	 ι,	 λ	 and	 κ	 carrageenans	 displaying	 the	 differences	 in	structure.		
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show	 similar	 efficacy,	with	 tylose	 the	most	 active	 at	 47.37%	 and	 then	 carboxymethyl	cellulose	 (21.79%),	 hypromellose	 (3.97%)	 and	 (hydroxypropyl)methyl	 cellulose	 (-15.39%).	 (Hydroxypropyl)methyl	cellulose	caused	 increased	 fluorescence	measured	at	λem=	405	nm	by	15%	above	the	non-inhibited	control.	Locust	bean	gum	and	paramylon	produced	 increased	 fluorescence	 as	 calculated	 as	 normalised	 percentage	 inhibition	(NPI),	 with	 sulphated	 locust	 bean	 gum	 giving	 a	 12.36%	 fluorescence	 increase	 and	sulphated	 paramylon	 displaying	 the	 highest	 promotive	 effect	 at	 41.59%.	 These	sulphated	 compounds	 did	 not	 increase	 the	 fluorescence	 in	 the	 no-enzyme	 controls,	suggesting	they	act	to	promote	BACE1	activity	beyond	in	vitro	100%	activity.	
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	Figure	 157:	 Dose	 response	 curve	 of	 BACE1	 FRET	utilised	 to	 determine	 the	 affect	 of	 human	BACE1	 (FLAG-tag)	 detecting	 the	 cleavage	 of	 FRET	 peptide	 derived	 from	 the	 APPSW	 (Mca-SEVNLDAEFRK(Dnp)RR-NH2	Fluorogenic	Peptide	Substrate)	λex=	320	nm	λem=		405	nm,	in	50	mM	 sodium	 acetate	 pH	 4.0,	 over	 1.5	 hours.	 Initial	 screen	 of	 chemically	 sulphated	polysaccharide	library	at	1	μg/ml	in	FRET	with	BACE1	and	APPSW	FRET	peptide	(n=3).	Known	BACE1	inhibitor	OM99-2	was	assayed	at	100	nM	and	PMH	(1	μg/ml)	included	for	reference.		
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	 Sulphated	 levan	 and	 gellan	 gum	 inhibited	 BACE1	 by	 84.3%	 and	 83.5%	respectively.	 Glycogen	 type	 II	 (74.71%)	 inhibited	BACE1	 to	 a	 similar	 degree	 of	 arabic	acid	 (76.51%),	but	 the	standard	deviation	shows	disparity	between	 the	 two	screening	well	 results,	 suggesting	 an	 error	 that	 could	 have	 originated	 in	 pipetting	 or	 alike.	Glycogen	 type	 II	will	 be	 taken	 as	 a	 hit	 compound	 for	 further	 testing	 to	determine	 the	activity	to	a	more	precise	degree.			 Sulphated	 compounds	 that	 showed	 negligible	 efficacy	 in	 BACE1	 inhibition	 as	determined	by	FRET	include	hypromellose	(3.97%),	starch	(2.46%)	and	styrax	(0.86%).	Starch	contains	80-80%	amylopectin	which	is	composed	of	branched	D-glucose	α-D-(1-4)	 linkaged	 and	 α-D-(1-6)	 linkaged	 at	 branch	 points	 and	 gives	 a	 negligable	 BACE1	inhibition	of	3.97%,	whereas	 the	structurally	 related	glycogen	 type	 II	 contains	a	more	highly	branched	and	compact	amylopectin	structure	inhibits	by	74.71%.		
8.2.3	Coagulation	screening	of	chemically	sulphated	polysaccharide	library		 The	 screening	 of	 the	 sulphated	 polysaccharide	 candidate	 library	 for	 their	perturbation	 of	 the	 extrinsic	 and	 intrinsic	 coagulation	 pathway	 was	 carried	 out	 to	identify	 unfavourable	 anti-coagulant	 activity,	 potentially	 mimicking	 the	 action	 of	heparin	and	its	low	molecular	weight	counterparts	in	coagulation.		
8.2.3.1	Activated	partial	thromboplastin	time			 The	 activated	 partial	 thromboplastin	 time	 (aPTT)	 assay	 was	 used	 to	 identify	compounds	 that	 have	 unfavourable	 activity	 in	 the	 contact	 activation	 (intrinsic)	coagulation	pathway.			 The	PMH	 is	more	 active	 in	 the	 intrinsic	 aPTT	 assay,	 leading	 to	 a	 reduced	EC50.	This	 is	 due	 to	 the	 multiple	 points	 for	 inhibition	 by	 heparin	 alongside	 the	 common	
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pathway	 factors,	 whereas	 heparin	 can	 only	 effect	 ATIII	 binding	 to	 factor	 VII	 in	 the	extrinsic	pathway	so	the	inhibitory	effect	is	reduced.		
Table	 19:	 Activated	 partial	 thromboplastin	 (aPTT)	 of	 chemically	 sulphated	 polysaccharides	 using	 50	 μl	Seimens	Pathromtin	SL	reagent,	50	μl	normal	human	citrated	plasma,	25	μl	test	sample	and	25	μl	50	mM	calcium	 chloride,	 maximum	 time	 for	 clot	 formation	 120	 seconds.	 Half	 maximal	 effective	 concentration	(EC50)	of	 sulphated	 library	screening	 including	R2	and	PMH	control.	EC50	is	quoted	as	 x	 fold	higher	than	PMH.	
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	 Candidates	 showing	 intrinsic	pathway	 results	 greater	 than	10	 fold	 that	of	PMH	may	 be	 considered	 a	 possible	 hit	 as	 the	 anti-coagulant	 capacity	 of	 these	 hits	 will	 be	negated	and	therefore	 limit	 the	off-target	effects	as	potential	 therapeutics	as	shown	in	Table	19.			 All	 tested	 sulphated	 compounds	 exhibit	 an	 attenuated	 anticoagulant	 capacity	suggesting	 no	 compound	 mimics	 the	 precise	 polyanionic	 sulphated	 arrangement	required	 for	 anti-thrombin	 binding	 or	 direct	 serpin	 interactions	 of	 the	 intrinsic	 and	common	 pathway.	 Sulphated	 gellan	 gum	 shows	 the	 highest	 potency	 of	 the	 library	compounds	at	inhibiting	clotting	in	the	contact	activation	pathway	(aPTT	assay),	with	an	EC50	of	2.18	μg/ml,	a	nearly	8	fold	lower	activity	as	compared	to	PMH	EC50	of	0.27	μg/ml.	Gum	mastic,	 agarose,	pullulan	and	psyllium	seed	gum	also	have	EC50	values	within	10	fold	of	PMH.			 κ	and	λ	carrageenan	have	similar	potency	in	the	aPTT	assay	with	EC50	of	3.28	and	4.12	 μg/ml	 respectively.	 ι-carrageenan	 has	 an	 EC50	approximately	 double	 the	 related	carrageenans,	at	7.55	μg/ml.	Tara	gum	and	gum	ghatti	have	similar	activities,	with	EC50	of	14.35	and	15.88	μg/ml	respectively.	A	similar	relationship	is	seen	between	the	gums	accroides	 and	 gum	arabic	with	 EC50	of	 22.87	 and	23.20	 μg/ml	 respectively.	 Sulphated	pectin	 and	 its	 esterified	 cousin	 potassium	 pectate	 have	 similar	 activities	 in	 which	potassium	pectate	is	the	more	potent	with	EC50	of	23.97	μg/ml	and	pectin	30.26	μg/ml.	These	 related	 compounds	 however	 are	 100	 fold	 less	 potent	 than	 PMH.	 Sulphated	compounds	with	higher	EC50	than	pectin	will	be	considered	to	have	no	remarkable	anti-coagulant	capabilities.		 The	 main	 constituent	 of	 starch,	 amylopectin,	 has	 similar	 potency	 as	 the	 more	branched	 amylopectin	 cousin,	 glycogen	 type	 II,	 with	 starch	 500	 fold	 less	 potent	 than	PMH	at	inhibiting	the	contact	activation	pathway,	and	glycogen	780	fold	less	potent.		
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	 Progressing	 to	 alginic	 acid	 and	 sodium	 alginate,	 these	 structurally	 related	compounds	have	similar	potency	at	235.3	and	323.9	μg/ml	EC50.	The	related	compound	propylene	glycol	alginate	displays	approximately	40	times	higher	activity	in	aPTT	(EC50	of	6.28	μg/ml).			 Fructose	 polymers,	 sulphated	 inulin	 and	 levan	 have	 similar	 influence	 in	 aPTT,	with	 inulin	 EC50	 of	 1151	 μg/ml	 and	 levan	 EC50	 of	 1671	 μg/ml.	 Similarly,	 related	compounds	 (hydroxypropyl)methyl	 cellulose	 and	 hypromellose,	 differing	 in	 their	quantity	of	hydroxypropyl	constituent,	show	no	anti-coagulant	activity.			 Locust	bean	gum	returns	an	 interrupted	 result	 for	 the	R2	value	due	 to	Prism	6	software	 working	 to	 a	 maximal	 number	 of	 iterations	 to	 analyse	 for	 non-linear	regression.	If	the	software	cannot	reach	a	result	within	a	dozen	iterations,	a	interrupted	result	is	returned	in	order	to	not	consume	processing	power.		
8.2.3.2	Prothrombin	time		 Sulphated	 agarose	 is	 the	 most	 potent	 anti-coagulant	 screened	 in	 the	 PT	 assay	measuring	the	perturbation	of	the	extrinsic	with	a	8.1	fold	reduced	EC50	from	PMH,	with	PMH	EC50	of	5.19	μg/ml	and	agarose	EC50	of	42.10	μg/ml.	Sulphated	agarose	is	similarly	8	fold	reduced	in	the	aPTT	assay	relative	to	PMH.			 Levan	has	an	EC50	of	42.65	μg/ml	in	PT,	which	is	8.2	fold	less	potent	than	PMH	at	perturbing	clotting	through	tha	extrinsic	pathway,	but	relative	to	its	effects	in	the	aPTT	assay,	where	this	compound	shows	limited	effects	(EC50	of	1671	μg/ml);	6000	fold	less	potent	than	PMH.	Sulphated	welan	and	inulin	are	structurally	related	fructose	polymers,	but	 their	 activities	 in	 the	 PT	 assay	 are	 distinctive	 as	 compared	 to	 the	 similarity	 in	potency	seen	in	the	aPTT	assay.		
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Table	 20:	 Prothrombin	 time	 (PT)	 of	 chemically	 sulphated	 polysaccharides	 using	 50	 μl	 Seimens	Thromborel	S	reagent,	50	μl	normal	human	citrated	plasma,	50	μl	test	sample,	maximum	time	for	clot	formation	 120	 seconds.	 Half	 maximal	 effective	 concentration	 (EC50)	 of	 sulphated	 library	 screening	including	R2	and	PMH	control.	EC50	is	quoted	as	x	fold	higher	than	PMH.	
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	 Welan	occupies	 similar	anticoagulant	activities	 in	both	 the	PT	and	aPTT	assays	with	8.3	fold	attenuated	action	in	the	extrinsic	pathway,	and	10.2	fold	attenuation	in	the	aPTT	assay.	A	group	of	gums	occupy	a	similar	potency	in	the	PT	assay	between	44	and	46	 fold	 reduced	 anti-coagulant	 activity.	 These	 compounds	 include	 sulphated	 tara,	tamarind,	guar,	gellan,	mastic	and	ghatti	gums	with	decreasing	action	in	the	PT.			 Sulphated	xanthan	gum	and	sodium	alginate	have	the	same	EC50	of	105.4	μg/ml	in	 the	 PT	 assay;	 with	 a	 20	 fold	 reduced	 potency	 than	 PMH.	 After	 which	 the	 next	compounds	 are	 another	 group	 of	 gums	 with	 85	 to	 90	 fold	 attenuated	 PT	 activity	including	 gum	 accroides,	 karaya	 gum,	 locust	 bean	 gum	 and	 gum	 arabic.	 Compounds	occupying	the	 least	potent	anti-coagulant	positions	 in	 the	PT	assay	correspondingly	 in	the	aPTT	are	hypromellose,	inulin	and	paramylon.			 The	carrageenans	tested,	 ι,	κ	and	λ	show	similar	activity	in	the	PT	assay,	with	κ	carrageenan	 the	 most	 potent	 anti-coagulant	 with	 an	 EC50	 of	 44.07	 μg/ml,	 with	 λ	carrageenan	EC50	of	47.05	μg/ml	and	 finally	 ι	 carrageenan	EC50	of	50.95	μg/ml,	 varing	from	8.48	to	9.81	fold	less	activity	than	PMH.			 Cellulose	 based	 sulphated	 compounds	 are	 also	 spread	 through	 the	 compounds	tested,	 with	 varying	 EC50	 values.	 The	 most	 potent	 anticoagulant	 of	 the	 cellulose	compounds	 tested	 is	 ethyl	 cellulose	 with	 an	 EC50	 of	 47.51	 μg/ml.	(Hydroxypropyl)methyl	 cellulose	 and	 tylose	 (MH300)	 have	 very	 similar	 EC50	of	 490.3	μg/ml	 and	 491.9	 μg/ml	 respectively.	 The	 potency	 of	 hypromellose	 in	 the	 PT	 assay	 is	further	reduced	with	an	EC50	of	1545	μg/ml	 followed	by	carboxymethyl	cellulose	with	an	EC50	of	2697	μg/ml	(500	fold	less	activity	than	PMH).			 Structurally	 related	 alginate	 compounds,	 alginic	 acid	 propylene	 glycol	 alginate	and	 sodium	 alginate	 show	 no	 related	 activity	 in	 the	 PT	 assay,	 with	 anti-coagulant	potency	ranging	from	EC50	of	42.19	μg/ml	in	propylene	glycol	anginate,	to	105.4	μg/ml	
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in	 sodium	alginate	 and	of	 472.1	μg/ml	 in	 alginic	 acid	 (8.12,	 20.38	 and	94.36	 fold	 less	than	PMH	respectively).		
8.2.4	Sulphated	library:	hit	selection		 A	strategy	for	hit	selection	of	the	library	of	chemically	sulphated	polysaccharides	from	 various	 sources	was	 chosen	 to	 identify	 compounds	 for	 further	 experimentation.	Screening	anti-coagulant	activity	versus	the	highly	active	anti-coagulant	unfractionated	PMH.	This	metric	 allows	 selection	of	 compounds	with	 attenuated	potency	 in	 intrinsic,	extrinsic	 and	 common	 coagulation	 pathways	 to	 ensure	 a	 primary	 requirement	 for	limiting	off	 target	effects	of	 these	complex	anionic	polysaccharides.	The	anti-coagulant	activity	 of	 the	 sulphated	 library	 of	 polysaccharides	was	 combined	 into	 a	 ‘coagulation	factor’	determined	by	multiplying	the	EC50	values	in	μg/ml	of	aPTT	and	PT	assays.	The	following	hit	selection	criteria:	1-	 Inhibition	 of	 BACE1	 in	 FRET	 assay	 at	 one	 concentration	 (1	 μg/ml)	 demonstrating	greater	than	50%	BACE1	inhibition.		2-	 Screening	 anti-coagulant	 activity	 versus	 the	 highly	 active	 anti-coagulant	unfractionated	PMH.	The	selection	of	compounds	based	on	this	anti-coagulation	metric	required	hit	to	have	activity	100	fold	less	than	that	of	unfractionated	PMH	to	limit	off-target	effects.		3-	The	yield	of	 the	chemical	 sulphation	method	 is	 required	 to	be	greater	 than	40%	as	shown	 in	 table	 4	 (greater	 than	 +),	 which	 will	 allow	 for	 an	 economically	 viable	 and	scalable	product.			 Table	 21	 identifies	 the	 6	 top	 compounds	 identified	 from	 the	 initial	 screening	following	 assessment	 derived	 from	 the	 above-mentioned	metrics.	 The	 hit	 compounds	are	 gum	 arabic,	 ι-carrageenan,	 glycogen	 type	 II,	 levan,	 λ-carrageenan,	 gum	 ghatti	 and	
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guar.	Five	other	sulphated	compounds	passed	the	metrics	outlined	above,	apart	from	the	yield	 requirements.	 These	 include	 tara	 gum,	 ethyl	 cellulose,	 propylene	 glycol	 alginate,	welan,	 and	 arabic	 acid.	 However,	 these	 compounds	 could	 be	 listed	 in	 phase	 2	investigations	 if	 no	 hits	 can	 be	 brought	 forward	 after	 further	 analysis	with	 a	 view	 to	improving	the	yield	of	the	sulphation	reaction.		Table	21:	Hit	selection	Table	to	demonstrate	sulphated	polysaccharide	library	members	in	two	required	 metrics,	 %	 inhibition	 of	 BACE1	 in	 FRET	 required	 50%	 inhibition,	 and	 coagulation	factor	(aPTT	(μg/ml)	*PT	(μg/ml))	required	100	fold	less	potent	anti-coagulant	activity	relative	to	unfractionated	PMH.		
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	 Interestingly,	ι	-carrageenan,	λ-carrageenan	and	gum	arabic	contain	1-3	linked	D-galactopyranose	residues,	differing	as	 the	carrageenans	are	α-1-3	rather	 than	the	gum	arabic	 being	 β-1-3	 and	 the	 carrageenans	 include	 alternating	 1-4	 linked	 β-D-galactose	residues.	 Gum	 arabic	 contains	 side	 chains	 limited	 to	 2	 -	 5	 residues	 in	 length	 and	 is	constructed	with	α-L-arabinofuranosyl,	α-L-rhamnopyranosyl,	β-D-glucuronopyranosyl	and	 4-O-methyl-β-D-glucuronopyranosyl	 units.	 The	 carrageenans	 have	 differing	sulphate	patterns,	with	λ-carrageenan	containing	the	α-linked	unit	2-6	disulphated	and	the	 β-linked	 unit	 2	 sulphated,	 and	 ι-carrageenan	 containing	 an	 α-linked	 galactose	occurring	 as	 a	3,6-anhydro-2-sulphate	unit	 and	 the	β-linked	 sugar	occurring	 as	 the	3-sulphate	unit.			 Guar	has	a	main	chain	of	(1-4)-linked	β-D-mannopyranosyl	units	with	single	α-D-galactopyranosyl	units	linked	(1-6)	on	average	to	every	second	main	chain	unit,	whereas	gum	ghatti	has	backbone	chain	of	(1-6)-linked	β-D-galactopyranosyl	units	with	some	(1-4)-D-glucopyranosyluronic	acid	units,	some	joining	(1-2)-D-mannopyranosyl	units,	and	some	L-arabinofuranose	units.		
8.2.5	BACE1	FRET	hit	dose	response	The	seven	hit	compounds	were	tested	for	their	potency	in	BACE1	FRET	inhibition	using	a	dose	response	assay.	The	results	of	which	are	found	in	Figure	158	and	Table	22.				 The	most	potent	inhibitor	of	the	tested	hit	compounds	was	sulphated	levan	with	an	 IC50	of	 0.822	 μg/ml	 (R2	 0.9893)	 which	 is	 ~3	 times	more	 potent	 than	 that	 of	 BLH	(2.554	μg/ml)	in	the	FRET	BACE1	inhibition	experiment.	At	lower	concentrations,	each	sulphated	carbohydrate	promoted	the	activity	of	BACE1	in	the	FRET	assay,	apart	 from	sulphated	gum	ghatti,	which	at	the	lowest	concentration	tested	(10	ng/ml)	still	showed	BACE1	 inhibition	 of	 ~20%	 (Figure	 19).	 Sulphated	 gum	 arabic,	 λ-carrageenan	 and	 ι–
	 287	
carrageenan	 all	 exhibit	 more	 potent	 BACE1	 activity	 than	 BLH	 and	 PMH,	 with	 IC50	of	1.034	μg/ml,	1.194	μg/ml	and	1.481	μg/ml	respectively.	Guar	and	glycogen	type	II	have	similar	IC50	values	of	9.904	μg/ml	and	10.030	μg/ml	respectively,	which	are	~3.5	times	less	potent	than	heparin,	but	as	selected	concurrently	with	their	anti-coagulant	potency,	are	more	favourable	BACE1	inhibitors	than	both	BLH	and	PMH.		
	 In	addition	to	testing	the	seven	sulphated	hit	compounds,	the	unmodified	parent	compounds	were	tested	to	assess	for	BACE1	inhibition	activity.	Unmodified	gum	ghatti	and	guar	would	not	solubilise	at	the	required	concentration	so	were	not	included	in	this	screening.		The	Figure	159	illustrates	the	percentage	inhibition	of	BACE1	in	FRET	assay.	
	Figure	 158:	 Dose	 response	 curve	 of	 BACE1	 FRET	 utilised	 to	 determine	 the	 affect	 of	 human	BACE1	 (FLAG-tag)	 detecting	 the	 cleavage	 of	 FRET	 peptide	 derived	 from	 the	 APPSW	 (Mca-SEVNLDAEFRK(Dnp)RR-NH2	Fluorogenic	Peptide	Substrate)	λex=	 320	nm	λem=	 	405	nm,	 in	 50	mM	sodium	acetate	pH	4.0,	over	1.5	hours.	Chemically	sulphated	(−)	glycogen,	(−)	guar,	(−)	gum	arabic,	(−)	levan,	(−)	ι-carrageenan,	(−)	λ-carrageenan,	(−)	gum	ghatti.	
Table	22:	Dose	response	curve	of	BACE1	FRET	utilised	to	determine	the	affect	of	human	BACE1	(FLAG-tag)	 detecting	 the	 cleavage	 of	 FRET	 peptide	 derived	 from	 the	 APPSW	 (Mca-SEVNLDAEFRK(Dnp)RR-NH2	Fluorogenic	Peptide	Substrate)	 λex=	 320	nm	λem=	 	405	nm,	 in	 50	mM	 sodium	 acetate	 pH	 4.0,	 over	 1.5	 hours.	 Half	 maximal	 inhibitory	 concentration	 (IC50)	 of	BACE1	in	the	FRET	assay.			
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	 The	BACE1	inhibition	of	chemically	sulphated	guar	and	glycogen	type	II	is	lower	at	1	μg/ml	in	the	FRET	dose	response	experiments	(Figure	158)	than	in	the	initial	one	concentration	 screen	 (Figure	 157).	 This	 disparity	 could	 be	 due	 to	 the	 polydisperse	nature	 of	 the	 polysaccharides,	 with	 one	 sample	 containing	 a	 mixture	 of	 more	 potent	inhibitory	polysaccharide.			 PMH	at	1.0	μg/ml	inhibits	~100%	of	BACE1,	with	this	effect	mirrored	in	both	ι-	and	λ-	carrageenans	tested.	These	saccharides	have	native	levels	of	sulphation,	and	this	may	be	the	reason	the	unmodified	compounds	maintain	BACE1	inhibition	activity	akin	to	PMH	when	tested	in	FRET	experiments	(Figure	159).	Unmodified	glycogen	type	II	and	levan	gave	 similar	 results	with	16%	and	12%	promotion	of	BACE1	 respectively	while	unmodified	 gum	 arabic	 promoted	 BACE1	 action	 in	 the	 FRET	 by	 71%,	 suggesting	 that	chemical	 sulphation	 dramatically	 changes	 the	 activity	 of	 this	 compound	 upon	interaction	with	BACE1.		
	Figure	159:	BACE1	FRET	utilised	to	determine	the	affect	of	human	BACE1	(FLAG-tag)	detecting	the	 cleavage	 of	 FRET	 peptide	 derived	 from	 the	 APPSW	 (Mca-SEVNLDAEFRK(Dnp)RR-NH2	Fluorogenic	Peptide	Substrate)	λex=	320	nm	λem=		405	nm,	in	50	mM	sodium	acetate	pH	4.0,	over	1.5	hours.	Original,	unmodified	compounds	tested	at	1.0	μg/ml.		
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	 Further	investigations	into	the	effectiveness	of	unmodified	ι-	and	λ-	carrageenans	were	 completed	 to	analyse	 the	potency	of	BACE1	 inhibition.	Figure	160	demonstrates	that	while	for	λ-carrageenan	a	dose	response	curve	was	obtained	with	an	IC50	of	2.347	μg/ml,	no	similar	dose	response	curve	could	be	obtained	through	Prism	6	software.		 The	position	of	data	points,	when	comparing	both	carrageenans,	show	similarity	but	 Prism	 6	 software	 has	 been	 unable	 to	 plot	 a	 curve	 to	 the	 non-linear	 regression	analysis	 for	 ι-carrageenan.	With	 the	 position	 of	 the	 data	 points	 being	 similar	 in	 both	instances	however,	an	IC50	of	~2.5	μg/ml	could	be	extrapolated.		
8.2.6	Anti-factor	Xa	and	IIa	activity		 PMH	 and	 the	 hit	 sulphated	 compounds	 were	 tested	 in	 colorimetric	 assays	 to	determine	 their	effectiveness	at	 inhibiting	 factor	Xa	and	 factor	 IIa	 (thrombin)	 through	the	binding	and	promotion	of	anti-thrombin.	Unfractionated	PMH	reported	an	IC50	of	13	ng/ml	 (R2	 0.9778)	 in	 the	 anti-factor	 Xa	 assay,	 and	 19	 ng/ml	 (R2	 0.9837)	 in	 the	 anti-factor	IIa,	representing	similarly	1:1	ratio	in	activity	in	anti-factor	IIa	to	anti-factor	Xa.		
	Figure	160:	Dose	response	curve	of	unmodified	compounds,	BACE1	FRET	utilised	to	determine	the	affect	of	human	BACE1	(FLAG-tag)	detecting	the	cleavage	of	FRET	peptide	derived	from	the	APPSW	(Mca-SEVNLDAEFRK(Dnp)RR-NH2	Fluorogenic	Peptide	Substrate)	λex=	320	nm	λem=		405	nm,	 in	50	mM	sodium	acetate	pH	4.0,	over	1.5	hours.	A)	 ι-carrageenan,	no	dose	response	B)	λ-carrageenan	IC50=	2.347	μg/ml.	
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In	 the	 anti-factor	 Xa	 assay,	 the	most	 potent	 inhibitor	 after	 PMH	was	 sulphated	 levan,	with	 an	 IC50	 of	 790	 ng/ml	 (R2	 =	 0.9615),	 ~60	 fold	 less	 than	 PMH	 (Table	 23).	 Both		sulphated	λ-carrageenan	and	guar	had	similar	potency,	with	 IC50	of	1.100	μg/ml	(R2	=	0.9354)	 and	 IC50	 of	 1.170	 μg/ml	 (R2	 =	 0.9513),	 85	 and	 90	 times	 less	 activity	 to	 anti-factor	 Xa	 than	 PMH	 respectively.	 As	 a	 specific	 pentasaccharide	 structural	 sequence	 is	required	 for	 the	 binding	 to	 anti-thrombin	 and	 subsequent	 inhibition	 of	 factor-Xa,	 the	sulphated	structure	of	levan	and	possibly	λ-carrageenan	and	guar	may	include	correctly	orientated	 functional	groups	 to	mimic	 the	pentasaccharide	 including	 the	 required	and	rare	 3-0-sulphate,	 or	 the	 chemically	 sulphated	 polysaccharides	 include	 sequence	 or	structural	features	which	promote	in	a	different	way,	but	achieve	similar	results	in	this	
in	vitro	colorimetric	assay.		
	Figure	 161:	 Dose	 response	 of	 chemically	 sulphated	 ι-carrageenan	 in	 anti-factor	 Xa	 inhibition	assay.	 Promotive	 action	 of	 ι-carrageenan	 measured	 through	 anti-thrombin	 binding	 and	subsequent	inhibition	of	the	serpin	factor	X	activation.	Colour	change	measured	at	λabs=	405	nm,	with	inhibition	leading	to	an	increase	in	absorbance	at	this	wavelength.			
Table	 23:	 Results	 of	 colorimetric	 assays	 for	 anti-factor	 Xa	 and	 anti-factor	 IIa	 activity	 of	unfractionated	PMH	along	with	 the	chemically	sulphated	hit	polysaccharides.	Results	 reported	as	IC50	values	indicating	inhibition	to	half	maximal	enzymatic	activity	and	R2	values.		
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	 Chemically	sulphated	polysaccharides	gum	ghatti,	gum	arabic,	and	glycogen	type	II	have	the	most	favourable	anti-factor	Xa	profiles,	with	each	reporting	an	IC50	>500	fold	that	of	PMH.	Gum	arabic	(IC50	of	29.7	μg/ml)	correlation	coefficient	is	significantly	lower	suggesting	the	IC50	determined	from	this	experimental	set	is	not	as	representative	of	the	raw	data,	when	compared	to	the	other	polysaccharides	tested.	ι-carrageenan	shows	no	dose	response	relationship	and	no	anti-factor	Xa	activity	(Figure	161).		 The	anti-factor	IIa	action	of	PMH	and	hit	polysaccharides	is	also	shown	in	Table	23.	 In	 this	 activity	 assay,	 ι-carrageenan	 is	 a	more	 potent	 activator	 of	 AT	 than	 that	 of	unfractionated	 PMH,	 with	 IC50	 of	 8.0	 ng/ml	 (R2	 0.9980)	 and	 19.0	 ng/ml	 (R2	 0.9837)	respectively.	This	high	 level	 of	 activity	 is	 entirely	different	 from	 the	 same	 compounds	action	 in	 AT/factor	 Xa	 interactions	 suggesting	 no	 specific	 sequence	 simulating	 the	heparin	pentasaccharide,	but	the	saccharide	size	required	to	mimic	the	>18	saccharides	required	for	the	less	specific	AT/thrombin	promotion.				 λ-carrageenan	has	approximately	4	times	less	activity	than	PMH	in	the	anti-factor	II	 assay,	 with	 IC50	 of	 75.0	 ng/ml	 (R2	 0.9895),	 followed	 by	 levan	 with	 ~18	 times	 less	activity	than	PMH.	The	three	chemically	sulphated	polysaccharides	that	show	>300	fold	reduced	 activity	with	 anti-thrombin	 in	 factor	 II	 activation	 are	 gum	 ghatti,	 gum	 arabic	and	glycogen	type	II,	with	IC50	of	7.0	μg/ml,	10.6	μg/ml	and	100.9	μg/ml	respectively.			 With	 ι-carrageenan	 displaying	 higher	 activity	 in	 the	 anti-factor	 IIa	 assay	 than	PMH,	 this	 polysaccharide	 is	 not	 favourable	 even	 considering	 its	 complete	 inactivity	 in	the	anti-factor	Xa	assay.	The	three	hit	compounds	displaying	favourable	characteristics	from	 these	 specific	 serpin	 activation	 assays	 are	 gum	 ghatti,	 gum	 arabic	 and	 glycogen	type	II.		
	 292	
	 There	is	no	significant	correlation	(Pearson	correlation	coefficient)	between	the	actions	of	sulphated	hit	polysaccharides	in	factor	Xa	and	factor	IIa	experiments	and	the	Mw	or	degree	of	sulphation	of	these	compounds	(data	not	shown).		
8.2.7	Sulphate	level	determination	
	 A	 modified	 version	 of	 the	 assay	 by	 Terho	 and	 Hartiala	 (1971)	 was	 used	 for	sulphate	 level	 determination.	 Barium	 chloride	 and	 rhodizonic	 acid	 calorimetric	 assay	was	 used	 to	 determine	 the	 level	 of	 sulphation	 for	 each	 compound.	 Dextran	 sulphate	contains	approximately	17%	sulphur,	which	equates	to	2.3	sulphate	groups	per	glycosyl	residue,	with	the	molecular	weight	calculated	as	438.04	Da.	Calibration	of	the	assay	by	dextran	 sulphate	 allowed	 deduction	 of	 moles	 of	 sulphate	 per	 microgram	 of	 material.	Unfractionated	PMH	has	2.3	to	3.0	nmoles	of	sulphate	per	microgram	of	PMH	(Table	24)	and	was	 used	 as	 a	 control	 as	 the	 average	 sulphate	 level	 has	 been	 determined	 as	 2.3	sulphates	 per	 disaccharide	 (Sarrazin	 et	 al.,	 2011)	 or	 2.7	 sulphate	 groups	 per	disaccharide	(Toida	et	al.,	1997).			 Glycogen	 type	 II	 is	 the	most	 sulphated	of	 the	hit	 compounds,	with	between	6.6	and	 8.0	 nmoles	 of	 sulphate	 groups	 per	microgram	 of	 polysaccharide	 (Table	 24).	 The	
Table	 24:	Sulphate	 level	determination	completed	with	hydrolysed	 sulphated	compound,	 λabs=	520	nm	reading.	Calibration	with	dextran	sulphate,	the	sulphate	 levels	of	7	hit	polysaccharides	and	PMH,	in	nmoles	of	sulphate	per	μg	of	compound.			
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most	 variation	 in	 sulphate	 level	 estimates	 comes	 from	 gum	 ghatti,	 which	 contains	between	 4.6	 and	 6.5	 nmoles	 of	 sulphate	 per	microgram	of	 polysaccharide	 (Table	 24).	The	 range	 is	 quoted	 due	 to	 the	 linear	 range	 of	 the	 assay	 giving	multiple	 absorbance	readings	applicable	for	conversion	into	moles/μg.	The	sulphation	level	of	levan	crosses	into	the	broad	range	determined	for	gum	ghatti,	with	levels	estimated	between	4.5	and	4.7	 nmoles/μg	 giving	 a	 more	 specific	 value	 when	 compared	 with	 the	 range	 of	 1.9	nmoles/μg	in	gum	ghatti	(Table	24).		 Chemically	sulphated	ι-carrageenan	is	more	highly	sulphated	than	λ-carrageenan	with	both	carrageenans	spanning	the	sulphate	range	of	PMH.	ι-carrageenan	has	between	2.8	and	3.4	nmoles	of	sulphate	per	microgram	of	polysaccharide,	whereas	λ-carrageenan	has	the	lower	number	of	2.1	to	3.2	nmoles/μg.	λ-carrageenan	has	a	wider	sulphate	range	than	 that	of	heparin,	 but	 spans	 the	whole	 sulphate	 level	 range	of	unfractionated	PMH	measured	in	this	assay	(Table	24).		 Gum	 arabic	 has	 a	 reduced	 level	 of	 sulphation	 compared	with	 PMH,	with	 levels	between	 1.7	 and	 2.3	 nmoles	 per	 microgram	 of	 polysaccharide.	 Chemically	 sulphated	guar	has	sulphate	levels	of	0.45	nmoles	per	microgram,	which	is	the	lowest	sulphation	level	of	the	hit	compounds	tested	(Table	24).		
8.2.8	Molecular	weight	determination				 Gel	 permeation	 chromatography	 using	 two	 1.6	 x	 70	 cm	 columns	 packed	 with	different	 media,	 sephacryl	 S100	 and	 S500	 matrix,	 was	 used	 with	 isocratic	 250	 mM	ammonium	chloride	to	separate	a	range	of	molecular	weights	from	1	×	103	Da	to	2	×	107	Da.	Molecular	weight	markers	were	used	 to	 calibrate	 the	 system,	before	 sulphated	hit	compounds	were	 tested.	 Number	 average	molecular	weight	 (Mn)	 is	 a	measure	 of	 the	mean	molecular	weight	of	the	molecules	in	the	polysaccharide,	expressed	as	the	sum	of	
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weights	molecules	 divided	by	 the	number	 (n)	 of	molecules	 in	 the	 sample.	 The	weight	average	molecular	 weight	 accounts	 for	 larger	molecules	 containing	more	 of	 the	 total	mass	compared	to	smaller	molecules	of	the	polysaccharide,	therefore	the	Mw	is	always	larger	 than	 Mn.	 Polydispersity	 index	 (PDI)	 is	 a	 measure	 of	 the	 spread	 of	 molecular	weights	in	the	sample	illustrating	the	heterogeneity	of	polymer	molecular	weights.	The	gel	permeation	chromatography	(GPC)	peak	was	analysed	to	calculate	the	above	values,	disregarding	the	zero	intensity	regions.		Number	average	molecular	weight	was	calculated	as	follows:	Normalised	intensity	I	=	Intensity	–	minimum	intensity	Elution	time	at	intensity	I:	ET	(min)=	(time	(s)/sampling	rate	(Hz))/60	Elution	volume	EV	(ml)=	ET/flow	rate	(ml/min)	Fraction	of	column	volume	FCV	(ml)=	EV/total	column	volume	(ml)	Mass	at	intensity	I-	Input	FCV	into	line	equation	from	SEC	calibration	(example	as	follows)	𝑥 = 10^(− 85.821×𝐹𝐶𝑉! + 191.93×𝐹𝐶𝑉! − 147.61×𝐹𝐶𝑉 + 42.862)	Mn=	(Σ	x)/	(Σ	I)	To	calculate	Mw:	Weight	fraction	W=	(x	I)/(Σ	x	I)	Total	mass	at	time	point	WM	=	W	x	Mw=	Σ	(W	x)	To	calculate	PDI:	PDI	=	Mw/	(Σ	x	I)	
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The	example	SEC	HPLC	 spectrum	 in	Figure	162	has	been	annotated	 to	 show	Mn,	Mw,	and	peak	molecular	weight	(Mp).		
	 Table	 25	 demonstrates	 the	 chemically	 sulphated	 compound	 with	 the	 largest	molecular	weight	is	gum	arabic	(4.5	x	1013	Da),	followed	by	λ-carrageenan	(1.25	x	1013	Da).	 These	 compounds	 also	 have	 the	 largest	 polydispersity	 index	 of	 the	 hit	 library	tested,	as	expected	with	glycopolymers	of	this	size.	The	larger	the	molecular	weight	of	the	polymer,	the	more	possibilities	for	different	size	glycopolymer	chains	due	to	random	chain	 depolmerisation.	 ι-carrageenan	 and	 glycogen	 type	 II	 have	 similar	 molecular	weights	of	7900	Da	and	8100	Da	respectively,	but	glycogen	type	II	chains	demonstrate	a	larger	 size	 range	 (PDI	 =	 2.1).	 Average	 molecular	 weight	 of	 tinzaparin	 is	 6500	 Da,	therefore	 ι-carrageenan	 is	 most	 representative	 of	 these	 pharmaceutically	 important	LMWH.			 Chemically	 sulphated	 gum	 ghatti	 has	 a	 larger	 polydispersity	 than	 chemically	sulphated	guar,	but	a	molecular	weight	104	lower	than	this	hit	compound.	Whether	the	PDI	of	gum	ghatti	is	large	for	the	molecular	weight	of	this	glycopolymer,	or	the	PDI	for	guar	is	low	for	this	larger	Mw	is	unknown.	However,	the	large	PDI	of	gum	ghatti	suggests	
	
	Figure	 162:	 Schematic	 of	 a	 GPC	 chromatogram	 annotated	 to	 demonstrate	 Mw,	 Mn,	 and	 Mp	values	of	a	single	peak	elution.	 	
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fractionation,	 without	 further	 depolmerisation,	 of	 this	 chemically	 sulphated	 hit	compound	could	yield	lower	molecular	weight	glycopolymer,	preferential	in	therapeutic	development,	for	a	BACE1	inhibitor.		
8.2.9	Spectroscopic	analysis	of	sulphation		 Structural	 analysis	 with	 H+	 nuclear	 magnetic	 resonance	 (NMR)	 and	 Fourier	transform	 infra-red	 spectroscopy	 (FTIR)	 was	 employed	 to	 detect	 changes	 of	 the	molecular	structure	from	the	original	source	material	upon	chemical	sulphation.			 Introduction	or	increase	of	the	absorption	bands	related	to	levels	of	sulphate	in	FTIR	 have	 been	 identified	 near	 1250	 cm-1,	 representing	 asymmetrical	 S=0	 stretching	vibration	and	near	820	cm-1	for	symmetrical	stretching	of	the	C-O-S	in	the	C-O-SO3	group	(J.	K.	Yan,	Wang,	Ma,	&	Wu,	2013).	The	associated	reduction	of	absorption	bands	at	2940	cm-1	and	1020	cm-1	relating	to	the	C-H	and	C-O-H	respectively,	are	reduced	due	to	the	increasing	addition	of	sulphate	moieties	(J.	K.	Yan	et	al.,	2013).	
Table	 25:	 GPC	 results	 of	 hit	 sulphated	 polysaccharides,	 Cecil	 HPLC	 system	 and	 two	 C16/70	columns,	with	sephacryl	S100	and	S500	media.	Isocratic	250	mM	ammonium	chloride	was	used	to	separate	at	0.5	ml/min	with	a	sampling	rate	of	2.63	Hz	using	Analogue	devices	AD	7194	data	collection	software	on	a	Cecil	CE1200	wavelength	monitor	at	λabs=	210	nm,	with	a	 run	 time	of	9.38	hours.			
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	 Figure	 163	 shows	 the	 FTIR	 spectra	 of	 glycogen	 type	 II,	 comparing	 absorption	bands	between	unmodified	material	and	chemically	sulphated	compound.	In	sulphated	
	Figure	164:	FTIR	spectra	of	levan	and	chemically	sulphated	levan.	Thermo	Scientific	Nicolet	iS5	Spectrometer,	analysed	with	OMNIC	series	software.	Spectra	from	550	cm-1	–	4000	cm-1.	Average	of	 five	 independent	 measurements	 with	 128	 scans	 at	 a	 resolution	 of	 2	 cm-1.	 (−)	 Chemically	sulphated	levan,	(−)	unmodified	levan.	
	Figure	163:	FTIR	spectra	of	glycogen	 type	 II	and	chemically	 sulphated	glycogen	 type	 II.	Thermo	Scientific	Nicolet	iS5	Spectrometer,	analysed	with	OMNIC	series	software.	Spectra	from	550	cm-1	–	4000	cm-1.	Average	of	five	independent	measurements	with	128	scans	at	a	resolution	of	2	cm-1.	(−)	Chemically	sulphated	glycogen,	(−)	unmodified	glycogen.		
	 298	
glycogen,	 a	 strong	 absorption	 peak	 around	 1250	 cm-1	 appears	 alongside	 a	 smaller	increase	in	intensity	near	820	cm-1	suggesting	an	increase	in	S=O	asymmetrical	stretch	(1250	cm-1)	and	C-O-S	symmetrical	stretching	(820	cm-1).	Concurrent	reduction	 in	 the	peak	 intensity	 near	 1020	 cm-1	 illustrates	 reduction	 in	 the	 C-O-H	 intensity	 and	 a	 less	defined,	 flatter	 region	near	2940	cm-1	may	 imply	a	decrease	 in	C-H.	A	peak	 shift	 from	unmodified	 glycogen	 at	 3300	 cm-1	 to	 3450	 cm-1	 seen	 in	 sulphated	 glycogen	 is	 also	observed	and	could	be	due	to	a	change	in	R-O-H.	Non-hydrogen	bonded	hydroxyl	groups	absorb	 strongly	 between	 3700-3584	 cm-1,	 with	 intermolecular	 hydrogen	 bonding	occurring	at	lower	3550-3200	cm-1,	at	the	expense	of	the	free	hydroxyl	peak.		
	 Similar	spectral	changes	are	seen	in	levan	as	shown	in	Figure	164.	With	a	more	pronounced	 reduction	 in	 peak	 intensities	 near	 2940	 cm-1	 and	 820	 cm-1.	 The	 FTIR	spectra	of	levan	contains	a	more	pronounced	change	in	peak	wavenumber	and	intensity	
	Figure	165:	FTIR	spectra	of	guar	and	chemically	sulphated	guar.	Thermo	Scientific	Nicolet	iS5	Spectrometer,	analysed	with	OMNIC	series	software.	Spectra	from	550	cm-1	–	4000	cm-1.	Average	of	five	independent	measurements	with	128	scans	at	a	resolution	of	2	cm-1.	(−)	Chemically	sulphated	guar,	(−)	unmodified	guar.	
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between	3300	cm-1	to	3500	cm-1,	however	the	intensity	 is	greater	 in	unmodified	levan	and	reduced	dramatically	in	sulphated	levan.			 Sulphated	guar	has	a	peak	at	around	1250	cm-1	when	compared	 to	unmodified	guar,	 but	does	not	 exhibit	 a	 similar	 change	 in	peak	 structure	around	820	 cm-1	(Figure	165).	 	Near	810	 cm-1	 and	890	cm-1,	 both	 the	 sulphated	and	unmodified	guar	have	 the	similar	peak	shapes,	which	Li	et	al.	(2005)	attribute	to	the	two	carbohydrate	moieties	of	α-D-galactopyranosyl	 and	 β-D-mannopyranosyl	 units	 respectively	 (Li,	 He,	 Chen,	 &	 Ni,	2005).	The	hydrolysis	of	guar	during	the	acidic	environment	of	the	sulphation	reaction	did	not	change	the	frequencies	 in	the	FTIR	spectra	and	showed	no	selectivity	between	the	pyranose	units,	according	to	Li	and	colleagues	(idem).			
	Figure	 166:	 FTIR	 spectra	 of	 ι-carrageenan,	 and	 chemically	 sulphated	 ι-carrageenan.	 Thermo	Scientific	Nicolet	iS5	Spectrometer,	analysed	with	OMNIC	series	software.	Spectra	from	550	cm-1	–	4000	cm-1.	Average	of	five	independent	measurements	with	128	scans	at	a	resolution	of	2	cm-1.	(−)	Chemically	sulphated	ι-carrageenan,	(−)	unmodified	ι-carrageenan.	
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	 The	carrageenans	tested	have	native	sulphation,	shown	in	Figures	166	and	167	are	 very	 similar	 in	 structure	 between	 chemically	modified	 and	 native	 compound.	 The	intensity	 of	 peaks	 around	 1250	 cm-1	 and	 820	 cm-1	 is	 increased	 in	 both	 chemically	sulphated	carrageenans,	but	little	else	of	the	spectra	is	changed.		
	Figure	 167:	 FTIR	 spectra	 of	 λ-carrageenan	 and	 chemically	 sulphated	 λ-carrageenan.	 Thermo	Scientific	Nicolet	iS5	Spectrometer,	analysed	with	OMNIC	series	software.	Spectra	from	550	cm-1	–	4000	cm-1.	Average	of	five	independent	measurements	with	128	scans	at	a	resolution	of	2	cm-1.	(−)	Chemically	sulphated	λ-carrageenan,	(−)	unmodified	λ-carrageenan.		
	Figure	168:	FTIR	spectra	of	gum	ghatti	and	chemically	sulphated	gum	ghatti.	Thermo	Scientific	Nicolet	 iS5	Spectrometer,	analysed	with	OMNIC	series	 software.	Spectra	 from	550	cm-1	–	4000	cm-1.	 Average	 of	 five	 independent	measurements	with	 128	 scans	 at	 a	 resolution	 of	2	cm-1.	 (−)	Chemically	sulphated	gum	ghatti,	(−)	unmodified	gum	ghatti.		
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	 The	 FTIR	 spectra	 of	 gum	 ghatti	 and	 chemically	 sulphated	 gum	 ghatti	 show	differences	at	659	cm-1,	1080	cm-1,	1730	cm-1,	and	1920	cm-1	(Figure	168).	These	peaks	appear	 with	 the	 chemical	 sulphation	 of	 the	 glycopolymer.	 The	 peak	 at	 1510	 cm-1	 in	unsulphated	 gum	 ghatti	 is	 shifted	 to	 a	 lower	wavenumber	 (1440	 cm-1)	with	 chemical	sulphation,	suggesting	the	bond	seen	here	is	still	present	but	has	been	modified	with	the	sulphation	process.		
	 A	similar	result	is	seen	in	the	H+	NMR	spectra	of	gum	arabic,	with	both	sulphated	and	 unsulphated	 compound	 showing	 little	 discernable	 difference	 in	 structure	 (Figure	169A),	 aside	 from	 the	 appearance	 of	 a	 peak	 at	 3	 p.p.m	 in	 chemically	 sulphated	 gum	arabic.		 The	 spectra	 of	 glycogen	 type	 II	 is	 more	 complex	 post-sulphation,	 with	 the	number	and	intensity	increasing	between	3	and	6	p.p.m.	Introduction	of	a	defined	peak	at	3	p.p.m	 is	 similar	 to	 that	of	gum	arabic	and	 is	also	seen	 in	 the	spectra	of	sulphated	levan.	A	wide	and	undefined	peak	increases	from	unmodified	glycogen	between	3	and	4	p.p.m,	to	between	3	and	4.5	p.p.m,	before	the	defined	water	peak.	The	loss	of	the	single	post-water	peak	in	unmodified	glycogen	is	replaced	with	a	peak	around	5.1	p.p.m,	with	other	peaks	visible	to	6	p.p.m	as	seen	in	Figure	169B.		
	Figure	169:	1H	NMR	spectra	(400	MHz)	of	(−)	chemically	sulphated	and	(−)	unmodified	(A)	gum	arabic	(B)	glycogen	type	II.		
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	 Aside	 from	 the	peak	 seen	 at	 3	p.p.m	 in	 the	 sulphated	 levan,	 structural	 changes	from	the	unmodified	compound	are	seen	between	3.6	and	4.5	p.p.m.	Smaller	peaks	seen	clustered	in	unmodified	levan	in	this	range	resolve	into	a	defined	peak	at	approximately	4.2	p.p.m.	A	less	defined	and	a	lower	intensity	peak	is	seen	at	at	3.7	p.p.m	(Figure	170A).	Levan,	along	with	gum	arabic	and	guar	share	a	peak	at	5	p.p.m.	The	5	p.p.m	peak	in	guar	is	 present	 in	 both	 the	 unmodified	 and	 chemically	 sulphated	 compound	 to	 a	 similar	degree	 of	 relative	 intensity.	 The	NMR	 spectra	 for	 guar	mirrors	 the	 FTIR	 spectra,	with	minimal	changes	seen	upon	chemical	sulphation.		
	Figure	170:	1H	NMR	spectra	(400	MHz)	of	(−)	chemically	sulphated	and	(−)	unmodified	(A)	levan	(B)	guar.		
	Figure	171:	1H	NMR	spectra	(400	MHz)	of	(−)	chemically	sulphated	and	(−)	unmodified	(A)	λ	carrageenan	(B)	ι	carrageenan.	
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	 λ	 carrageenan	 spectra	 changes	 with	 chemical	 sulphation	 are	 shown	 in	 peak	changes	at	2.8	and	5.2	p.p.m,	with	the	appearance	of	peaks,	peak	loss	is	seen	at	3.2,	3.4	and	5.0	p.p.m.	In	ι	carrageenan,	less	structural	change	is	seen	with	chemical	sulphation,	small	peaks	seen	between	4.0-4.3	p.p.m	the	only	apparent	change	(Figure	147).		
8.2.10:	 Interaction	studies:	Circular	dichroism	(CD)	analysis	of	hit	 compounds	with	
BACE1		 The	 evidence	of	 specific	 structural	 changes	 in	BACE1	due	 to	 the	binding	of	 the	chemically	 sulphated	 hit	 compounds	 was	 analysed	 with	 the	 known	 BACE1	 binding	control	PMH,	 shown	 in	Chapter	7.	 Each	hit	 compound	 tested	 changes	 the	 structure	of	BACE1,	when	 compared	 to	BACE1	 alone,	 and	 each	 has	 a	 similar	 effect	 to	 the	 changes	seen	between	BACE1	and	PMH.			 The	far-UV	CD	spectra	of	BACE1	including	UF	PMH	causes	a	change	in	the	angle	of	polarisation	 leading	 to	an	 increased	amplitude	 into	 the	negative	 range	between	λ	=	200	and	λ	=	250	nm,	with	a	trough	at	approximately	λ	=	215	nm	that	could	be	attributed	to	increased	β-sheet	formation.		
Table	26:	Far	UV-CD	peak	maxima	to	identify	β-sheet	structure	of	native	BACE1.	Reaction	buffer	50	mM	sodium	acetate	pH	4.0,	data	captured	by	Spectral	Manager	and	processed	with	Prism	7	data	analysis	software.			
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	 A	similar	 increase	 in	ellipticity	 is	displayed	upon	addition	of	each	hit	sulphated	GAG	 analogue.	 Addition	 of	 the	 carbohydrate	 leads	 to	 an	 increased	 negative	 signal	between	λ	=	215	and	λ	=	225	nm.	Hit	compounds	also	demonstrate	spectral	changes	in	the	region	lower	than	λ	=	200	nm.			 Peak	wavelength	position	alters	upon	addition	of	the	hit	compounds	(Table	26).	As	 the	 peak	 amplitude	 in	 the	 negative	 region	 of	 the	 CD	 spectrum	 increases	 in	wavelength,	 the	CD	 intensity	has	exhibits	an	 inverse	 trend.	The	amplitude	of	 the	peak	reduces	as	the	peak	maxima	shifts	toward	a	higher	wavelength.			 High	tension	(HT)	voltage	increases	in	each	sample	tested	at	wavelengths	lower	than	 200	 nm	 suggesting	 a	 increase	 in	 detector	 saturation	 possibly	 due	 to	 the	 high	concentration	of	BACE1	used	in	these	experiments.	The	theoretical	cut	off	for	HT	voltage	affecting	the	spectra	is	>	500	V:	no	compound	tested	increases	over	400	V.		
8.2.11	 Interaction	 studies:	 differential	 scanning	 fluorimetry	 (DSF)	 analysis	 of	 hit	
compounds	with	BACE1	
8.2.11.1	Differential	scanning	fluorimetry	with	porcine	mucosal	heparin		 Figure	 172	 is	 the	 thermal	 denaturation	 of	 native	 BACE1	 with	 differing	concentrations	 of	 UF	 PMH,	 displayed	 as	 the	 first	 derivative	 of	 the	 data,	 averages	smoothed	 across	 12	 neighbours.	 Quantities	 of	 heparin	 above	 12.5	 μg/ml	 shift	 the	stability	 of	 BACE1	 to	 an	 unstable	 configuration	 with	 a	 reduced	 Tm,	 while	 heparin	concentrations	below	this	increase	the	Tm	of	BACE1	suggesting	a	stabilising	effect.	This	change	is	more	effectively	illustrated	in	Figure	172,	where	the	Tm	values	are	displayed	relative	 to	 their	 stability	 of	 BACE1,	 including	 the	 standard	 deviation	 across	 three	readings	 to	 show	 accuracy	 and	 reproducibility.	 The	 change	 in	 Tm	 occurring	 between	12.5	 μg/ml	 and	 6.25	 μg/ml	 UF	 PMH	 is	 5.3	 °C	 and	 spans	 the	 Tm	 of	 BACE1	 alone,	
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suggesting	 a	 shift	 between	 these	 PMH	 concentrations	 from	more	 unstable,	 to	 a	more	stable	configuration.	The	lowest	concentration	of	PMH	tested	affords	the	stability	most	like	that	of	BACE1	alone,	taking	standard	deviation	of	the	readings	into	account,	could	be	considered	the	same	Tm.		
	 At	100	μg/ml	UF	PMH	into	a	solution	containing	3.0	μM	of	native	BACE1,	the	Tm	of	 BACE1	 becomes	 more	 unstable,	 from	 43.06	 °C	 ±	 0.19	 °C	 to	 a	 destabilised	 Tm	 of	35.53	°C	±	0.41	°C	(Figures	172	and	173).		
	 Analysing	the	relationship	between	PMH	and	BACE1	in	DSF	studies	alongside	the	initial	 experiments	 into	 the	 activity	 relationship	 between	 PMH	 and	 BACE1	 seen	 in	
	Figure	172:	1st	derivative	DSF	of	BACE1	with	UF	PMH	in	50	mM	sodium	acetate	buffer	with	3	μM	native	human	BACE1.	A=	(−)	3	μM	native	BACE1	with	(−)	100	μg/ml	UF	PMH,	(−)	50	μg/ml	UF	PMH,	 (−)	 25	μg/ml	UF	PMH	(−)	12.5	μg/ml	UF	PMH	B=	 (−)	3	 μM	native	BACE1	with	 (−)	6.25	μg/ml	UF	PMH	(−)	3.125	μg/ml	UF	PMH	(−)	1.56	μg/ml	UF	PMH.	
	Figure	 173:	 Change	 in	Tm	of	 native	BACE1	with	 UF	 PMH	 relative	 to	 native	BACE1	 (alone)	 as	expressed	in	DSF	from	the	results	in	Figure	172	including	the	standard	deviation	of	n=3	repeats.	Zero	value	equates	to	BACE1	alone,	no	PMH	added.	
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section	3.2.1,	 there	 is	a	relationship	between	the	stability	of	BACE1	with	PMH	and	the	activity	of	the	enzyme	in	FRET.	When	comparing	the	relative	ratios	of	enzyme	and	PMH	ligand,	to	negate	the	differences	in	required	concentrations,	the	highest	concentration	of	PMH	in	DSF	(100	μg/ml)	exhibits	inhibition	in	the	BACE1	FRET	assay.	The	smallest	shift	in	Tm	seen	with	12.5	μg/ml	of	PMH	in	DSF	in	the	equivalent	FRET	assay	shows	the	least	change	from	the	control	in	the	BACE1	activity.	When	BACE1	is	most	unstable	with	PMH,	PMH	is	most	inhibitory	in	FRET,	and	when	PMH	has	the	least	effect	on	BACE1	activity	it	is	the	most	similar	in	stability	to	unchallenged	BACE1.			 A	simple	relationship	between	stability	and	effect	on	activity	is	not	clear	as	PMH	activities	as	a	BACE1	promotor	do	not	align	with	the	region	of	more	stable	than	normal	Tm,	 therefore	 a	 Pearson	 correlation	 test	 will	 be	 conducted	 to	 determine	 whether	 a	correlation	is	present	and	to	what	significance.		
	 PMH	has	a	concentration	dependant	effect	on	BACE1	in	DSF	and	this	range	was	utilised	 in	 further	 experiments	 to	 screen	 the	 hit	 sulphated	 analogue	 compounds.	 The	
	Figure	174:	Combined	results	from	DSF	and	FRET,	showing	Tm	and	activity	of	BACE1	with	PMH	presented	 as	 a	 ratio	 of	 BACE:PMH	 to	 allow	 for	 comparison	 between	 assays.	 Grid	 line	 on	 LHS	showing	native	BACE1	activity	with	no	PMH	and	on	RHS	the	melting	point	of	native	BACE1	with	no	PMH.	(43.06	°C).		
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unknown	molarity	of	 the	hit	 compounds	 and	 the	unidentified	binding	 ratio	of	 protein	and	compound	prompted	the	use	of	the	same	w/v	ratios	as	PMH	(μg/ml)	(Uniewicz	et	al.,	2010).	
8.2.11.2	Differential	scanning	fluorimetry	with	hit	sulphated	compounds		 The	 hit	 sulphated	 carbohydrates	 were	 screened	 in	 differential	 scanning	fluorimetry	 to	 identify	 the	 effects	 on	 BACE1	 denaturation.	 Each	 compound	 changed	BACE1	Tm	in	a	concentration	dependent	manner	 to	differing	degrees.	Table	27	shows	the	changing	Tm	with	the	addition	of	the	hit	compounds	and	PMH,	and	includes	the	Tm	of	BACE1	alone	in	each	experiment.			
	 Both	 gum	 ghatti	 and	 ι carrageenan	 at	 100,	 50	 and	 25	 μg/ml	 show	 no	 first	derivative	peak	 structure	within	 the	 tested	 temperature	 range	of	 25	 °C	 to	 99	 °C.	 This	slow	reduction	in	fluorescence	from	between	52-61	kFU	to	45-47	kFU	over	the	25	°C	to	99	 °C	 cycle	 may	 suggest	 BACE1	 has	 denatured	 at	 room	 temperature	 and	 is	 further	aggregating	over	the	experimental	course,	excluding	the	Sypro	dye.	This	is	shown	in	ι-carrageenan	in	DSF	with	BACE1	in	Figure	175.		
Table	27:	Melting	temperatures	of	BACE1	in	DSF	with	differing	concentrations	of	hit	compounds	and	PMH	for	comparison.	Differential	scanning	fluorimetry	in	50	mM	sodium	acetate	buffer	pH	4.0	with	3	μM	native	BACE1.	StepOnePlus	PCR	machine,	temperature	ramping	25.5	°C	-	99	°C,	0.5	°C	 increments,	 every	 30	 seconds,	with	 30	second	plate	 read	 time.	 Sypro	Orange	 reporter	 dye.	Read	with	TAMRA	filter	λexc=	546	nm	λem=	579	nm		
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 ι	Carrageenan	at	12.5	μg/ml	reduces	the	Tm	of	BACE1	to	34.43°C;	approximately	1°C	lower	than	100	μg/ml	PMH	in	the	same	experiment.	The	Tm	increases	with	reducing	
ι carrageenan	 concentration,	 with	 6.25	 μg/ml	 Tm	 of	 37.99°C,	 and	 subsequent	 lower	concentrations	 tested	 giving	 Tm	 of	 BACE1	 higher	 than	 BACE1	 alone,	 implying	 a	stabilising	effect	similar	to	that	seen	with	PMH	at	6.25	and	3.125	μg/ml	(Table	27).			
		 Addition	 of	 gum	 ghatti	 at	 12.5	 μg/ml	 gives	 a	 Tm	 peak	 with	 BACE1	 at	 a	temperature	 higher	 than	 that	 of	 BACE1	 alone,	 suggesting	 this	 ratio	 of	 gum	 ghatti	 to	
	Figure	176:	1st	derivative	DSF	of	BACE1	with	gum	ghatti	in	50	mM	sodium	acetate	buffer	pH	4.0	with	3	μM	native	BACE1.	A=	(−)	3	μM	native	BACE1	with	(−)	100	μg/ml	gum	ghatti,	(−)	50	μg/ml	gum	ghatti,	(−)	25	μg/ml	gum	ghatti	(−)	12.5	μg/ml	gum	ghatti	B=	(−)	3	μM	native	BACE1	with	(−)	6.25	μg/ml	gum	ghatti	(−)	3.125	μg/ml	gum	ghatti	(−)	1.56	μg/ml	gum	ghatti.		
	Figure	175:	1st	derivative	DSF	of	BACE1	with	ι-carrageenan	in	50	mM	sodium	acetate	buffer	pH	4.0	 with	 3	 μM	 native	 human	 BACE1	 A=	 (−)	 3	 μM	 native	 BACE1	 with	 (−)	 100	 μg/ml	 ι	carrageenan,	 (−)	 50	 μg/ml	 ι-carrageenan,	 (−)	 25	 μg/ml	 ι-carrageenan	 (−)	 12.5	 μg/ml	 ι-carrageenan	B=	(−)	3	μM	native	BACE1	with	(−)	6.25	μg/ml	ι-carrageenan	(−)	3.125	μg/ml	ι-carrageenan	(−)	1.56	μg/ml	ι-carrageenan.	
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BACE1	stabilises	the	enzyme	structure	(Figure	176).	At	double	the	concentration	of	gum	ghatti	(25	μg/ml),	BACE1	shows	no	melt	curve	as	mentioned	above	(Figure	176).	 	The	higher	 Tm	 seen	 may	 suggest	 a	 stabilising	 effect,	 which	 is	 gradually	 lessened	 upon	titration	of	gum	ghatti	to	the	lowest	concentration	tested	of	1.56	μg/ml,	which	a	similar	Tm	of	BACE1	alone	(Table	27).			 The	melting	curve	of	λ	carrageenan	has	a	similar	structure	to	ι carrageenan	and	gum	 ghatti	 at	 100,	 50	 and	 25	 μg/ml	 sulphated	 compound,	 but	 below	 30°C	 there	 is	greater	 change	 in	 the	 spectra	 (Figure	 177),	 suggesting	 the	 room	 temperature	denaturation	 prior	 to	 the	 experimental	 ramping	 was	 occurring	 prior	 to	 the	 first	fluorescence	reading	at	25.5°C.	The	curve	flattening	post	30°C	suggests	aggregation	and	exclusion	of	Sypro	dye	(Figure	153).		
		 With	12.5	and	6.3	μg/ml	of	λ	carrageenan,	BACE1	has	an	unstable	structure	with	the	 Tm	 shifting	 from	 the	 native	 form	 at	 42.5°C	 to	 33.36°C	 and	 37.99°C	 respectively.	Concentrations	of	λ	carrageenan	lower	than	this	have	an	increased	Tm	exhibiting	some	stabilising	capabilities	(Table	27).		
	Figure	177:	1st	derivative	DSF	of	λ	carrageenan	in	50	mM	sodium	acetate	buffer	pH	4.0	with	3	μM	native	 BACE1.	A=	 (−)	 3	 μM	 native	 BACE1	with	 (−)	 100	 μg/ml	 λ	 carrageenan,	 (−)	 50	 μg/ml	 λ	carrageenan,	 (−)	 25	 μg/ml	 λ	 carrageenan	 (−)	 12.5	 μg/ml	 λ	 carrageenan	 B=	 (−)	 3	 μM	 native	BACE1	 with	 (−)	 6.25	 μg/ml	 λ	 carrageenan	 (−)	 3.125	 μg/ml	 λ	 carrageenan	 (−)	 1.56	 μg/ml	 λ	carrageenan.		
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	 Chemically	 sulphated	glycogen	 type	 II	and	guar	both	have	similar	effects	 in	 the	DSF	 experiments	 with	 BACE1.	 Guar	 increases	 BACE1	 Tm	 at	 100,	 50	 and	 25	 μg/ml	concentrations,	at	12.5	μg/ml	and	6.25	μg/ml	the	Tm	shifts	to	within	the	expected	Tm	of	BACE1	alone	suggesting	 the	presence	of	guar	at	 these	 concentration	has	no	 structural	effect	 on	 the	 enzyme.	 Concentrations	 of	 guar	 below	 this	 have	 a	 negligible	 stabilising	effect	 when	 compared	 to	 the	 unchallenged	 BACE1	 (Table	 27).	 Chemically	 sulphated	Glycogen	type	II	stabilises	BACE1	at	12.5	μg/ml	(Tm	44.59°C	±	0.14°C)	and	to	a	 lesser	extent	 at	 6.25	 μg/ml	 (Tm	 43.85°C	 ±	 0.09°C),	 but	 this	 effect	 is	 absent	 at	 the	 lower	concentrations	tested	(Table	27).		 The	 hit	 compounds	 chemically	 sulphated	 levan	 and	 gum	 arabic	 have	 similar	effects	 to	 PMH	 in	 BACE1	 DSF;	 both	 compounds	 destabilise	 BACE1	 at	 high	concentrations.	 Between	 12.5	 μg/ml	 and	 6.3	 μg/ml	 the	 Tm	 changes	 from	 39.71°C	 ±	0.43°C	to	45.02°C		±	0.55°C,	a	difference	of	5.3°C,	a	greater	change	than	PMH	at	the	same	v/w	 concentration	 (Figure	 178).	 Sulphated	 levan	 shows	 a	 similar	 trend	 at	 these	concentrations,	 with	 the	 difference	 between	 the	 destabilising	 12.5	 μg/ml	 to	 the	stabilising	6.25	μg/ml	7.6°C	(Table	27).		
	Figure	178:	1st	derivative	DSF	data	of	BACE1	with	gum	arabic	in	50	mM	sodium	acetate	buffer	pH	4.0	with	3	μM	native	BACE1.	A=	(−)	3	μM	native	BACE1	with	(−)	100	μg/ml	gum	arabic,	(−)	50	μg/ml	gum	arabic,	 (−)	25	μg/ml	gum	arabic	(−)	12.5	μg/ml	gum	arabic	B=	(−)	3	μM	native	BACE1	with	(−)	6.25	μg/ml	gum	arabic	(−)	3.125	μg/ml	gum	arabic	(−)	1.56	μg/ml	gum	arabic.		
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	 The	trends	associated	with	DSF	have	revealed	groupings	according	to	the	effects	of	the	hit	chemically	sulphated	compounds	on	BACE1	in	the	thermal	stability	assay	DSF.	One	group	consists	of	guar	and	glycogen	type	II,	which	show	the	least	effect	on	BACE1	at	all	concentrations	tested,	another	group	comprising	of	ι carrageenan	and	λ	carrageenan	have	 a	 significant	 effect	 on	 BACE1	 structure	 at	 the	 higher	 concentrations	 tested,	 and	offer	a	measure	of	stability	at	the	lower	concentrations.	A	group	containing	gum	arabic	and	 levan	mimic	 the	 trend	seen	when	PMH	is	used	 in	 the	same	w/v	concentrations	 in	the	 DSF	 experiments.	 The	 last	 group	 comprises	 of	 gum	 ghatti,	 which	 has	 a	 similarly	destabilising	effect	on	BACE1	at	 the	higher	concentrations	 tested	as	 the	carrageenans,	but	 subsequent	 concentrations	 tested	 lend	 an	 immediate	 stabilising	 effect	 to	 BACE1	with	12.5	μg/ml	giving	a	3.5°C	improvement	in	stability.		
8.2.12	Correlation	anaysis			 Correlation	 analysis	 was	 performed	 to	 identify	 any	 relationship	 between	 the	activity	 of	 chemically	 sulphated	 hit	 compound	 in	 BACE1	 inhibition	 in	 FRET	 and	structural	 and	 activity	 characteristics	 of	 the	hit	 compounds.	 This	was	done	using	 a	 2-tailed	Pearson	 correlation	 coefficient	 analysis	 (95%	confidence	 interval)	with	Prism	6	software.	 Data	 were	 compared	 to	 the	 BACE1	 IC50	 to	 ascertain	 relationships	 between	experimental	 results.	The	 following	Table	28	 shows	 the	 correlation	 coefficient	 (r)	 and	significance.		 This	 data	 show	 there	 is	 no	 significant	 correlation	 between	 sulphated	 hit	compound	Mw,	Mn,	PDI,	anti-factor	Xa	activity,	anti-factor	IIa	activity,	sulphate	level	and	shift	 in	 CD	peak	maxima.	However	 there	 is	 significant	 correlation	 (P	 <	 0.05)	 between	BACE1	inhibition	in	FRET	and	the	effect	of	100	μg/ml	of	hit	sulphated	compound	on	the	Tm	 of	 BACE1	 as	 measured	 in	 DSF.	 The	 +0.8645	 correlation	 in	 this	 relationship	 may	
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show	 reduced	 potency	 in	 BACE1	 inhibition	 is	 linked	 to	 a	 higher	 Tm	 and	 a	 more	stabilising	effect	in	DSF,	with	a	more	potent	BACE1	inhibitor	having	a	more	destabilising	effect	on	BACE1	in	DSF.		
	 No	 correlation	 between	 BACE1	 inhibition	 and	 Mw	 of	 hit	 sulphated	 compound	rules	out	the	simple	relationship	between	number	of	molecules	and	activity.	The	smaller	Mw	hit	compounds	such	as	ι-carrageenan	and	glycogen	type	II	have	no	correlation	with	high	potency	in	BACE1	inhibition	due	to	the	increased	molarity	only.		
Table	 28:	 Pearson	 correlation	 matrix	 between	 the	 BACE1	 FRET	 IC50	 concentrations	 of	 the	chemically	sulphated	heparin	mimetics	and	the	Mw,	Mn,	PDI,	anti-factor	Xa	activity,	anti-factor	IIa	 activity,	 sulphate	 level,	 change	 in	 CD	 λ	 from	 220	 nm,	 and	 perturbation	 of	 Tm.	 Significant	correlation	 identified	 between	 the	 FRET	 IC50	 results	 and	 DSF	 change	 in	 Tm	 of	 the	 modified	compound	library.		
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8.3	Discussion	
8.3.1	Heparin	activity	with	BACE1			 BACE1	was	inhibited	by	PMH	and	BLH,	with	BLH	a	more	effective	inhibitor	(IC50	2.554	μg/ml,	R2	=	0.9303)	 than	PMH	(IC50	2.943	μg/ml,	R2	=	0.8949).	Scholefield	et	al.	(2003)	 concluded	 the	 inhibition	 of	 BACE1	with	 BLH	 had	 an	 IC50	of	 1-2 μg/ml	with	 a	maximum	inhibition	level	of	50-60%,	however	this	research	saw	inhibition	with	BLH	at	100%	 (Scholefield	 et	 al.,	 2003).	 PMH	was	 a	 similarly	 slightly	 less	 potent	 inhibitor	 of	BACE1,	but	also	displayed	BACE1	inhibition	levels	up	to	100%.	BLH	at	12.5	μg/ml	gave	100%	 inhibition,	 with	 levels	 of	 PMH	 greater	 than	 12.5	 μg/ml	 exhibiting	 the	 same	potency	for	complete	BACE1	inhibition.		 At	 concentrations	 of	 BLH	 lower	 than	 1.56	 μg/ml,	 the	 fluorescence	 of	 FRET	substrate	 exceeded	 that	 of	 the	 standard	 uninhibited	 reaction,	 suggesting	 some	promotion	 activity.	At	 concentrations	 of	 PMH	 lower	 than	4.1	μg/ml	 this	 promotion	of	fluorescence	 was	 also	 seen.	 More	 promotion	 activity	 was	 seen	 in	 BLH,	 with	 130%	increased	fluorescence	with	1.56	μg/ml	BLH.	PMH	had	less	of	a	promotionary	effect,	as	at	4.1	μg/ml	the	increased	fluorescence	is	54%	over	the	uninhibited	control.		 No	 change	 in	 fluorescence	 was	 seen	 with	 the	 substrate	 and	 heparin	 alone,	suggesting	 no	 heparin	 induced	 decoupling	 of	 the	 FRET	 pair,	 or	 changes	 to	 the	 FRET	action	with	the	additional	ligand.	This	suggests	the	increase	in	fluorescence	is	an	effect	of	 heparin	 on	 the	 BACE1	 enzyme	 directly	 linked	 to	 the	 activity	 in	 cleaving	 the	 FRET	peptide.			 Beckman	et	al.	(2006)	surmised	this	dual	modulatory	effect	may	be	caused	by	the	existence	of	a	large	potential	GAG	binding	region	present	on	the	BACE1	surface,	which	is	located	near	the	pro-domain	and	loop	regions	(Beckman	et	al.,	2006).	The	ability	of	pro-
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BACE1	 to	 be	 inhibited	 by	 low	 concentrations	 of	 heparin	 is	 thought	 to	 be	 due	 to	 the	positively	charged	GAG	binding	region,	which	can	conceivably	bind	heparin	chains	in	a	variety	 of	 different	 conformations,	 some	 at	 high	 affinity	 and	 some	with	 lower	 affinity	(idem).	 The	 concentration	 of	 the	 heparin	 in	 solution,	 therefore,	 effects	 which	 affinity	binding	can	occur,	with	high	concentrations	of	heparin	allowing	for	both	high	and	 low	affinity	 binding	 and	 low	 concentrations	 experiencing	 high	 affinity	 binding	 only.	 The	difference	in	GAG	orientation	within	this	region	may	act	to	modulate	BACE1	activity.			 Klaver	et	al.	(2010)	show	pro	BACE1	is	strongly	activated	by	low	concentrations	of	 heparin	 due	 to	 the	 increase	 in	 positively	 charged	 binding	 sites	 on	 the	 pro	 domain	(Klaver	et	al.,	2010).	This	may	suggest	the	BACE1	used	in	these	experiments	was	rich	in	pro-BACE1	and	therefore	experienced	activation	at	the	lower	concentrations	of	heparin	tested.	 The	 level	 of	 stimulation	 of	 BACE1	 activity	was	 shown	 to	 be	 dependant	 on	 the	overall	 structure	 and	 charge	 of	 heparin,	 with	 more	 highly	 sulphated	 heparin	 having	more	of	a	stimulating	effect	on	BACE1	cleavage	of	the	FRET	peptide	(Klaver	et	al.,	2010).	BLH	is	more	highly	sulphated	than	PMH	suggesting	a	reason	for	the	increased	activity	of	this	heparin	source	over	the	PMH.			 The	source	of	FLAG-BACE1	used	in	these	FRET	experiments	may	include	a	higher	level	 of	 pro-BACE1	 than	 Scholefield	 et	 al.	 (2003)	 using	 HEK293T	 expressed	 as	 an	 Fc	fusion	protein,	possibly	explaining	why	their	results	do	not	exhibit	any	heparin	induced	activation	of	BACE1.	Sucessive	work	by	Patey	et	al.	(2006)	used	C-terminal	FLAG	tagged	BACE1	from	HEK293	from	Sigma;	no	mention	of	BACE1	promotion	is	mentioned	in	this	or	 subsequent	work	 (Patey	 et	 al.,	 2006,	 2008).	 Post-assay	 transfer,	 the	 FRET	 assay	 is	calibrated	with	outcomes	expected	from	published	data.		
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8.3.2	Sulphated	compound	library	screening			 A	 total	 of	 39	 chemically	 sulphated	 polysaccharides	 were	 screened	 in	 the	calibrated	BACE1	FRET	activity	assay,	with	seven	compounds	identified	exhibiting	over	80%	 inhibition	 of	 BACE1	 when	 tested	 at	 1	 μg/ml	 and	 acceptable	 yield.	 These	compounds	 were	 chemically	 sulphated	 gum	 arabic,	 levan,	 ethyl	 cellulose,	 agarose, ι	carrageenan,	 gum	 mastic	 and	 gellan	 gum,	 the	 most	 potent	 of	 which	 are	 chemically	sulphated	 gum	 arabic	 and	 ι	 carrageenan.	 Compounds	 which	 display	 between	 60	 and	80%	 BACE1	 inhibition	 at	 1	 μg/ml	 are	 chemically	 sulphated	 glycogen	 type	 II,	 λ	carrageenan,	propylene	glycol	alginate,	arabic	acid	and	welan.	Compounds	which	exhibit	BACE1	 FRET	 inhibition	 of	 between	 50	 and	 60%	 are	 chemically	 sulphated	 gum	 ghatti,	guar,	 tara	 gum	 and	 pullulan.	 Chemically	 sulphated	 members	 of	 the	 polysaccharide	library	that	show	little	to	no	effect	in	BACE1	FRET		(<5%	inhibition)	are	hypromellose,	starch	 and	 styrax.	 In	 a	 similar	 way	 to	 BLH	 and	 PMH	 tested	 previously,	 activators	 of	BACE1	were	 identified	 among	 the	 chemically	 sulphated	 library,	 including	 locust	 bean	gum,	(hydroxypropyl)methyl	cellulose	and	paramylon.			 Fluorescence	 level	 assays	 were	 completed	 with	 each	 compound	 to	 show	 no	polysaccharide:FRET	 substrate	 interactions	 to	 artificially	 supress	 or	 improve	 the	fluorescence	reading.			 The	 activated	 partial	 thromboplasin	 time	 (aPTT)	 measures	 the	 intrinsic	 and	common	 pathways	 of	 coagulation.	 This	 assay	 has	 many	 coagulation	 factors	 involved,	when	 compared	 to	 the	 simpler	 extrinsic	 pathway.	 This	 complexity	 engenders	 more	binding	sites	for	the	interaction	with	ATIII	and	heparin,	therefore	lower	concentrations	of	 heparin	have	 a	 greater	 effect	 in	 aPTT.	This	 is	 demonstrated	by	 the	 reduced	EC50	of	PMH	 in	 this	 assay	 (0.274	 μg/ml).	 aPTT	 experiments	 demonstrated	 all	 sulphated	polysaccharide	 library	 members	 were	 five	 fold	 or	 more	 less	 active	 than	 PMH.	
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Compounds	that	are	within	10	fold	the	activity	of	PMH	are	chemically	sulphated	gellan	gum,	gum	mastic,	agarose,	pullulan	and	psyllium	seed	gum.	Compounds	within	20	fold	of	the	 activity	 of	 PMH	 in	 aPTT	 are	 chemically	 sulphated	 welan,	 arabic	 acid,	 amylose,	 κ	carrageenan,	λ	carrageenan	and	ethyl	cellulose.			 The	 prothrombin	 time	 (PT)	 assay	 measures	 the	 time	 for	 clotting	 through	 the	extrinsic	 and	 common	 pathways	 initially	 stimulated	 by	 the	 production	 of	 tissue	 fluid	from	 damaged	 cells.	 The	 EC50	 control	 of	 PMH	 in	 the	 PT	 assay	 was	 5.196	 μg/ml;	 no	chemically	 sulphated	 polysaccharides	 achieved	 within	 5	 fold	 the	 activity	 of	 heparin,	however	19	polysaccharides	displayed	EC50	within	10	fold	of	heparin	activity.		 Chemically	 sulphated	 agarose	 has	 anticoagulant	 activity	 within	 10	 fold	 the	activity	of	PMH	(PT		EC50	of	42.1	μg/ml,	APTT	EC50	of	2.344	μg/ml).	The	anti-coagulant	activity	of	chemically	sulphated	agarose	has	been	published	by	Matsuhiro	et	al.	(2014)	with	data	suggesting	similar	results	at	low	concentrations	of	polysaccharide	(Matsuhiro,	Barahona,	 Encinas,	 Mansilla,	 &	 Ortiz,	 2014).	 Matsuhiro	 et	 al.	 (2014)	 employed	 a	 SO3	pyridine-complex	method	of	sulphation	differing	from	the	method	stated	above	by	the	use	of	formamide	and	sulfur	trioxide	pyridine	complex	(Vogl,	Paper,	&	Franz,	2000)	as	opposed	 to	 the	 chlorosulphonic	 acid	 method	 (Matsuhiro	 et	 al.,	 2014).	 Agarose	 was	sulphated	 at	 positions	 C-6	 of	 the	 β-galactopyranosyl	 residue	 and	 C-2	 of	 the	 α-3,6-anhydrogalactopyranosyl	residue	and	partially	sulfated	at	position	C-2	of	the	β	residue	(idem).	The	similarity	in	anti-coagulation	activity	of	chemically	sulphated	agarose	from	Matsuhiro	et	al.	(2014)	and	this	data	could	indicate	a	similar	pattern	of	polysaccharide	sulphation.			 Chemically	 sulphated	 levan	exhibited	much	higher	 activity	 in	 the	PT	assay	 (8.2	fold	of	PMH),	than	the	aPTT	assay	(6000	fold	less	than	PMH)	when	compared	to	PMH,	
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which	may	 suggest	 a	more	 specific	 interaction	 between	 particular	 coagulation	 factors	and	this	polysaccharide.				 Chemically	sulphated	welan	displays	similar	activities	 in	both	PT	and	aPTT	(PT	8.3	 fold	 APTT	 10.2	 fold),	 which	 may	 suggest	 a	 non-specific	 interaction	 across	 all	coagulation	factors,	or	a	more	specific	role	in	the	common	pathway	to	both	aPTT	and	PT	coagulation.			 The	identification	of	lead	compounds	from	the	BACE1	FRET	activity	assay	(>50%	inhibition)	 and	 attenuated	 effects	 in	 the	 coagulation	 assays	 are	 chemically	 sulphated	gum	arabic,	ι	carrageenan,	glycogen	type	II,	levan,	λ	carrageenan,	gum	ghatti,	guar	gum,	tara	 gum,	 ethyl	 cellulose,	 propylene	 glycol	 alginate	 and	 arabic	 acid.	 Reasonable	requirement	 for	 the	 yield	 of	 sulphated	 polysaccharide	 to	 be	 over	 40%	 after	 chemical	sulphation	identifies	a	lead	compound	library	including	7	polysaccharides:	gum	arabic, ι	carrageenan,	λ	carrageenan,	glycogen	type	II,	levan,	gum	ghatti	and	guar	gum.			 Sulphated	glycosaminoglycans	have	been	evidenced	to	act	as	heparin/HS	mimics	in	many	instances.	The	7	lead	compounds	have	been	investigated	to	varying	degrees	in	other	 research	 as	 heparin/HS	mimetics	 as	 outlined	 below.	 Some	 of	 this	 research	 has	included	 toxicity	 screening	 of	 library	members,	 adding	 favourable	 evidence	 to	 the	 hit	compound	as	a	potential	therapeutic.		 Heparin	and	HS	are	structural	analogues	of	C.	trachomatis	LGV	biovar	attachment	ligand	used	to	attach	and	enter	epithelium	at	mucosal	surfaces	(Stephens	et	al.,	2000).	Heparin	 and	 HS	 can	 completely	 inhibit	 the	 cell	 invasion	 by	 C.	 trachomatis.	 (idem).	 In	HELA229	cells,	arabic	gum	and	sulphated	glycogen	can	inhibit	the	binding	and	epithelial	invasion	by	C.	trachomatis	 and	was	attributed	 to	both	 the	 charge	and	 structure	of	 the	polysaccharides	(Petronio	et	al.,	1997).	The	similar	activity	of	carrageenans	was	shown	in	ME180	human	cervical	cell	line	(Zaretzky,	Pearcepratt,	&	Phillips,	1995).	
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	 Glycogen	type	II	can	inhibit	rubella	virus	multiplication	by	20%	with	no	toxicity	reported	at	1	mg/ml;	the	method	of	virus	replication	is	thought	to	be	blocking	of	viral	invasion	(Mastromarino	et	al.,	1997).		 Carrageenans	are	extensively	 shown	 in	 the	 literature	 to	 inhibit	 viral	 adherence	and	invasion.	This	viral	inhibition	activity	occurs	in	dengue	virus	(Talarico	et	al.,	2005),	HIV	(Pirrone,	Wigdahl,	&	Krebs,	2011),	Herpes	(Carlucci	1997),	mumps	virus,	influenza	B	 (Gerber,	 Dutcher,	 Adams,	 &	 Sherman,	 1958),	 and	 murine	 CMV	 (Hamasuna,	 Eizuru,	Shishime,	&	Minamishima,	1993).			 The	anti-herpes	activity	of	carrageenans	is	directly	related	to	the	amount	of	a-D-galactose	 2,6-disulphate	 residues	 present	 in	 the	 polysaccharide	 chain,	 suggesting	 a	degree	of	structural	specificity	for	the	polysaccharide	to	inhibit	invasion	(Carlucci	et	al.,	1997).	 No	 toxicity	 was	 seen	 in	 the λ	 carrageenans	 and	 the	 partially	 cyclized	 υ/ν	carrageenan	derived	from	red	seaweed	Gigartina	skottsbergii	(idem).		 Heparin	 and	 HS	 bind	 lipopolysaccharide	 receptor	 protein	 on	 murine	lymphocytes;	this	action	is	mimicked	by	λ	carrageenan	along	with	other	polysaccharides	(Dziarski	&	Gupta,	1994).			 Sulphated	 levan	 from	 Halomonas	 smyrnensis	 has	 anti-coagulant	 activity	 in	intrinsic	 pathway	 like	 heparin	 (Erginer	 2016).	 The	 action	 in	 coagulation	 of	 levan	 is	shown	 to	 proceed	 by	 thrombin	 inhibition,	 with	 decreasing	 factor	 Xa	 activity	 with	increasing	concentration.	Sulphated	levan	was	a	better	inhibitor	of	factor	X	than	heparin	(Erginer	2016).	This	potent	anti-coaguation	activity	was	not	seen	in	this	work,	however	the	source	of	levan	is	different	(Zymomonas	mobilis),	resulting	in	levan	of	differing	chain	length	and	could	be	the	cause	for	the	dissimilarity.			 Chemically	 sulphated	 guar	 gum	 from	 Cyamopsis	 tetragonolobus	 has	 a	 1,4-β-linked-D-mannopyranosyl	main	chain	with	α-D-galactopyranosyl	units	attached	by	(1	-
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6)	 linkages	 (Li	 et	 al.,	 2005).	 Unsulphated	 guar	 gum	 had	 no	 activity	 in	 the	 intrinsic	pathway	of	coagulation,	but	a	3.4	x	104	Da	(DS	of	0.85)	fraction	of	sulphated	guar	had	the	high	anticoagulant	activity	in	the	aPTT	assay	(idem).			 Sulphated	 polysaccharides	 and	 unmodified	 carrageenans	 have	 activity	 in	 other	heparin/HS	mimicking	processes.	However,	 the	 lead	 compounds	 show	 little	 structural	similarity	 within	 the	 group,	 suggesting	 the	 screening	 has	 not	 identified	 an	 easily	identifiable	 structural	 requirement	 for	 BACE	 inhibition	 while	 limiting	 the	anticoagulation	effects	of	these	compounds.	
8.3.3	Lead	compound	analysis		 The	IC50	of	the	lead	compound	library	splits	the	polysaccharides	into	a	group	of	5	chemically	 sulphated	 polysaccharides	 including	 levan,	 gum	 ghatti,	 gum	 arabic,	 λ-carrageenan,	and	 ι-carrageenan	with	IC50	range	of	0.8-1.5	μg/ml,	exceeding	the	BACE1	inhibition	 activity	 seen	 with	 full	 length	 PMH	 and	 BLH.	 The	 second	 group	 has	approximately	10	fold	less	activity	and	contains	chemically	sulphated	guar	and	glycogen	type	II	with	IC50	of	9.9-10	μg/ml.			 The	 two	 carrageenans	 selected	 differ	 as	 λ	 carrageenan	 has	 an	 alpha	 linked	 2,6	disulphated	subunit	and	β-linked	2-sulphated	subunit	(3	sulphates	per	disaccharide).	 ι	carrageenan	 has	 alpha	 linked	 3,6	 anhydro-2-sulphated	 unit	 and	 β	 linked	 3-sulphated	subunit	 (2	 sulphates	 per	 disaccharide)	 (Knutsen,	Myslabodski,	 Larsen,	&	Usov,	 1994),	however	 in	chemically	sulphated	carrageenan	this	discrete	sulphate	structure	may	not	be	 present	 as	 every	 available	 position	 on	 the	 disaccharide	may	 be	 sulphated.	 ι	 and	 κ	carrageenan	 can	 self	 assemble	 into	 helical	 structures	 in	 solution,	while	 λ	 carrageenan	does	 not	 form	 a	 helical	 structure	 (idem).	 The	 similarities	 in	 activity	 of	 ι	 and	 λ	
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carrageenans	in	BACE-1	FRET	indicate	these	structural	differences	do	not	differentially	affect	these	compounds	in	inhibition	screening.		 The	 inhibition	 activity	 of	 the	 carrageenans	 follows	 the	 native	 (unmodified)	sulphate	 level	 of	 the	 disaccharides,	 with	 λ	 carrageenan	 the	 most	 active	 carrageenan	BACE1	 inhibitior	 (3	 sulphates	 per	 disaccharide),	 ι	 carrageenan	 second	most	 active	 (2	sulphates	 per	 disaccharide)	 and	 κ	 carrageenan	 the	 least	 active	 carrageenan	 tested	 (1	sulphate	 per	 disaccharide).	 However,	 chemical	 sulphation	 of	 these	 compounds	increasing	 the	 number	 of	 sulphates	 per	 disaccharide	will	 have	 subsequently	modified	this	DS	number,	with	the	sulphate	level	of	chemically	sulphated	ι	carrageenan	(2.8	–	3.4	nmoles	sulphate/μg	compound)	higher	than	that	of	chemically	sulphated	λ	carrageenan	(2.1	–	3.2	nmoles	sulphate/μg	compound).			 Gum	ghatti	and	gum	arabic	are	both	constructed	of	β-D	galactopyranosyl	units,	differentially	linked,	with	gum	ghatti	1-6	linked	and	gum	arabic	1-3	linked.	Gum	arabic	includes	 1-2	 D-mannopyranosyl	 units	 in	 the	 core	 structure.	 Both	 compounds	 have	 a	branched	 structure.	 Gum	 ghatti	 has	 a	 complex	 array	 of	 branching	 neutral	 sugar	 units	including	 galactopyranose,	 arabinofuranose	 and	 arabinopyranose	 units	 (Deshmukh,	Setty,	 Badiger,	 &	 Muralikrishna,	 2012).	 Gum	 arabic	 side	 chains	 are	 1-6	 linked	 to	 the	main	chain	and	consist	of	1-3	β-D	galactopyranosyl	units,	averaging	2-5	units	long.	This	structure	 is	 further	modified	with	 neutral	 sugars	 arabinofuranosyl,	 rhamnopyranosyl,	glucuronopyranosyl	 and	 4-O-methyl-β-D-glucuronopyranosyl	 units.	 Chemically	sulphated	gum	ghatti	(IC50	0.871	μg/ml)	is	marginally	more	potent	BACE1	inhibitor	than	gum	arabic	(IC50	1.034	μg/ml).			 Levan	 is	composed	of	β-(2,6)	 linked	D-fructo-furanosyl	core	with	β-(2,1)	 linked	D-fructo-furanosyl	 branches	 with	 a	 D-glucosyl	 residue	 at	 the	 end	 of	 the	 chain	 (R.	Srikanth	 et	 al.,	 2015).	 Chemically	 sulphated	 levan	 has	 the	most	 favourable	 IC50	 in	 the	
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FRET	BACE1	inhibition	experiment	(IC50	0.822	μg/ml).	Levan	is	the	only	hit	compound	utilising	 a	 furan	 disaccharide	 repeat	 unit,	 with	 gum	 ghatti	 and	 gum	 arabic	 also	containing	a	 furan	but	not	as	 the	staple	repeat	unit	of	 the	saccharide.	The	presence	of	this	chemically	 sulphated	 furan	could	be	 involved	with	 the	 increased	potency	of	 these	three	compounds	in	comparison	to	the	pyran-based	other	hit	polysaccharides.			 Chemically	sulphated	guar	(IC50	9.904	μg/ml)	and	type	 II	glycogen	(IC50	10.030	μg/ml)	are	hit	compounds	that	give	BACE1	FRET	IC50	results	 ten-fold	 less	potent	 than	the	 other	 identified	 hit	 polysaccharides.	 Guar	 gum	 is	 constructed	 of	 β-D-mannopyranosyl	 residues	with	 1-6	 linked	 branches	 of	 alpha-D-galactopyranosyl	 units	on	 average	 every	 2	 core	 units	 (Wang,	 Zhao,	Wang,	 Yao,	 &	 Zhang,	 2012).	 Glycogen	 is	constructed	of	α	1,4	linked	glucose	with	α	1-6	glucose	branching.		 Unmodified	 (native)	 carrageenans	have	activity	 in	BACE	FRET	 inhibition,	while	naturally	 unsulphated	 parent	 compounds	 such	 as	 levan	 show	 levels	 of	 BACE1	promotion,	 suggesting	 a	 possible	 charge	 requirement	 for	 inhibitory	 activity.	 λ	carrageenan	for	example	has	IC50	of	1.194	μg/ml	when	chemically	sulphated,	and	an	IC50	of	2.347	μg/ml	when	unmodified.	The	chemical	sulphation	has	modified	the	compound	to	 increase	 the	 anti-BACE1	 activity.	 This	 could	 be	 caused	 by	 the	 increase	 in	 sulphate	levels	 in	 the	 compound,	 or	 the	 depolymerisation	 of	 the	 compound	 caused	 by	 the	vigorous	 sulphation	 reaction.	Unmodified	 glycogen,	 gum	arabic	 and	 guar	 promote	 the	activity	of	BACE1	at	1	μg/ml,	by	up	 to	65%	in	 the	case	of	gum	arabic.	Gum	ghatti	and	guar	are	insoluble	at	1	mg/ml	when	unmodified	so	cannot	be	tested	for	BACE1	activity.		 Hit	 compound	sulphated	 levan	had	 the	most	potent	action	 in	 the	antithrombin:	factor	Xa	interaction	(60	fold	less	than	PMH).	Erginera	et	al.	(2016)	showed	chemically	sulphated	 levan	 from	 Halomonas	 smyrnensis	 displayed	 activity	 through	 the	 intrinsic	pathway	of	coagulation,	similar	to	the	action	of	heparin	(Erginer	et	al.,	2016).	Sulphated	
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levan	from	H.	smyrnensis	was	found	to	be	a	poor	inhibitor	of	the	extrinsic	pathway,	like	heparin.	In	the	investigation	by	Erginera	et	al.,	all	sulphated	levans	tested	were	shown	to	bind	to	the	pentasaccharide	binding	site	of	antithrombin	(Arg	47,	Lys	114,	Lys	125	and	Arg	129),	mimicking	 the	heparin	 interaction	(idem).	Some	sulphated	 levan	derivatives	also	bind	factor	II	(thrombin)	via	direct	inhibition	(Hsd	57,	Asp	102	and	Ser	195),	unlike	heparin,	with	the	most	sulphated	levan	(Fruf	1S-β(2-6)-Fruf	1S)	also	bound	in	a	similar	way	to	heparin	at	Exosite	II	(Arg	93,	Lys	126,	Lys	236	and	Lys	240)	(idem).	Chemically	sulphated	levan	from	Zymomonas	mobilis	appears	to	retain	the	pentasaccharide	binding	capabilities	 associated	with	Erinera	et	al.	 2016	and	exhibited	 less	potent	 anti-factor	 II	activity	 (approximately	 40	 fold	 less	 potent	 than	 PMH)	 suggesting	 this	 compound	 is	different	in	structure,	Mw	and/or	DS	than	the	(Fruf	1S-β(2-6)-Fruf	1S)9	from	Erginera	et	al	(2016)	(Muro,	Rodriguez,	Abate,	&	Sineriz,	2000).			 The	anticoagulation	activity	of	 the	carrageenans	 is	 thought	to	act	 through	more	than	one	mechanism,	with	direct	and	indirect	inhibition	of	thrombin	and	the	activation	of	AT	and	heparin	co-factor	II	(Pereira,	Mulloy,	&	Mourao,	1999).	Some	fucans	have	been	demonstrated	to	have	anti-factor	Xa	activity	(Church,	Meade,	Treanor,	&	Whinna,	1989),	whereas	others	do	not	(Colliec	et	al.,	1991).	The	action	of	fucoidan	on	heparin	cofactor	II	and	 AT	 occurs	 in	 most	 cases,	 with	 action	 on	 thrombin,	 factor	 X	 and	 factor	 II	 more	variable	 (Pereira	et	al.,	1999).	Factors	 that	have	been	demonstrated	 to	affect	 the	anti-coagulation	activity	of	carrageenans	include	core	composition,	molecular	weight,	degree	of	 sulphation	 and	 sulphate	 position	 (Jiao,	 Yu,	 Zhang,	 &	 Ewart,	 2011).	 High	 fucose,	sulphate	 level	 (Nishino	 &	 Nagumo,	 1992)	 and	 higher	 molecular	 weight	 carrageenans	displayed	greater	anti-coagulant	activity	(Nishino,	Aizu,	&	Nagumo,	1991).			 ι	carrageenan	has	been	determined	to	have	higher	average	sulphate	level	(2.8-3.4	nmoles	sulphate/ug	compound),	and	significantly	smaller	Mw	(7.9	kDa)	and	PDI	(1.08)	
	 323	
than	 λ	 carrageenan	 (2.1	 -3.2	 nmoles	 sulphate/ug	 compound).	 λ	 carrageenan	 is	marginally	 active	 in	 anti-factor	 Xa	 (approximately	 64	 fold	 less	 potent	 than	 PMH),	 but	shows	potency	in	anti-factor	II	assay	with	approximatley	9	fold	less	potency	than	PMH.	ι	carrageenan	has	no	dose	dependent	effect	in	anti-factor	Xa,	but	is	more	potent	than	PMH	in	 anti-factor	 II	 experiments.	 This	 could	 be	 due	 to	 a	 direct	 effect	 on	 factor	 IIa,	 or	 a	improved	 ATIII:factor	 IIa	 interaction,	 not	 beneficial	 for	 factor	 Xa	 dependent	 anti-coagulation.	Chemically	sulphated	ι	carrageenan	and	glycogen	share	the	same	order	of	magnitude	 molecular	 weight,	 but	 have	 opposing	 effects	 in	 anti-factor	 Xa	 (no	 dose	response	vs	IC50	730	μg/ml	respectivley)	and	anti-factor	IIa	(most	potent	anti-factor	IIa	vs	 least	 potent	 respectively)	 suggesting	molecular	 weight	 alone	 does	 not	 account	 for	anti-coagulant	success.			 Chemically	 sulphated	 gum	 ghatti,	 gum	 arabic	 and	 glycogen	 type	 II	 have	favourable	 attenuated	 anti-factor	 Xa	 and	 factor-IIa	 activities;	 there	 is	 no	 correlation	between	compound	size	(Mw)	and	degree	of	sulphation.			 There	 is	 no	 correlation	 between	 the	 activity	 of	 the	 hit	 chemically	 sulphated	compounds	 in	BACE1	inhibition	and	anti-factor	Xa	activity	(P	=	0.18)	or	anti-factor	 IIa	activity	(P	=	0.12)	as	shown	from	a	two-tailed	Pearson	correlation	coefficient	analysis.	This	suggests	some	selectivity	or	differing	requirements	rather	than	an	‘active	molecule’	versus	 an	 ‘inactive	 molecule’.	 A	 strong	 correlation	 between	 these	 anti-coagulation	results	 and	 BACE1	 inhibitor	 results	 would	 add	 more	 complexity	 to	 the	 search	 for	 a	specifically	targeting	BACE1	inhibitor	with	no	off-target	activity.		 The	degree	of	sulphation	of	the	hit	compounds	does	not	account	for	the	potency	in	 FRET	 BACE1	 inhibition.	 Chemically	 sulphated	 glycogen	 has	 the	 highest	 measured	level	of	sulphate	(6.6-8.0	nmoles/ug	compound)	but	is	12	times	less	potent	than	the	best	BACE1	inhibitor,	Levan.		
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	 Chemically	 sulphated	 levan	 and	 gum	 ghatti	 are	 the	 most	 potent	 of	 the	 hit	compounds	 in	 the	BACE1	FRET	assay,	and	share	a	similar	degree	of	 sulphation	 (levan	4.5-4.7	nmoles/ug	compound	and	gum	ghatti	4.6-6.5	nmoles/ug	compound).	Gum	ghatti	more	 broad	 sulphate	 range	 may	 be	 due	 to	 the	 wider	 PDI	 demonstrating	 greater	variation	in	Mw	of	molecules	of	the	compound.			 The	 larger	 PDI	 of	 gum	 ghatti	 and	 wider	 range	 estimated	 for	 the	 degree	 of	sulphation	may	lead	to	a	reduction	in	active	molecules	capable	of	BACE1	inhibition;	size	fractionation	 to	 purify	 the	 chemically	 sulphated	 gum	 ghatti	may	 yield	 a	 fraction	with	high	levels	of	BACE1	potency,	a	more	specific	DS,	and	lower	molecular	weight,	which	is	more	suitable	for	advancement.			 Structure	 of	 native	 λ	 carrageenan	 may	 protect	 the	 compound	 from	depolyerisation	 effects	 caused	 by	 the	 strongly	 acidic	 and	 increased	 temperatures	associated	with	the	sulphation	reaction.	λ	carrageenan	retains	a	high	molecular	weight	and	 a	 wide	 range	 of	 PDI,	 whereas	 ι	 carrageenan	 has	 a	 considerable	 lower	molecular	weight	and	the	smallest	range	of	PDI	of	the	hit	compounds	tested.	The	native	forms	of	both	these	carrageenans	have	similar	molecular	weights	and	PDI	due	to	the	similarities	in	origin	and	method	of	extraction.		 FTIR	 spectra	 show	 little	 change	 upon	 chemical	 sulphation	 to	 the	 natively	sulphated	 ι	and	λ	carrageenans	and	to	guar	gum.	This	 is	corroborated	by	 the	sulphate	level	 determination	 data,	 which	 identifies	 chemically	 sulphated	 guar	 to	 have	 a	 low	sulphate	 level	 of	 0.45	 nmoles	 sulphate/μg	 compound.	 The	 carrageenan	 FTIR	 spectra	show	little	change	as	 these	compounds	have	native	sulphation.	 ι	carrageenan	sulphate	peaks	 in	 FTIR	 have	 a	 lower	%	 transmittance,	 suggesting	 more	 ‘bonds’	 and	 therefore	molecules	at	this	wavenumber.	Lower	transmittance	and	therefore	higher	absorbance	at	
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1250	cm-1	and	820	cm-1	suggest	chemical	sulphation	has	added	to	the	sulphate	peaks	at	these	wavenumbers.			 Appearance	 of	 sulphate	 peaks	 and	 the	 reduction	 of	 C-H	 and	 C-O-H	 peaks	 in	chemically	 sulphated	 glycogen,	 levan,	 guar	 and	 gum	 ghatti	 illustrates	 the	 chemical	modification	of	additional	sulphate	and	quantifies	the	results	of	the	barium	chloride	and	rhodizonic	acid	calorimetric	assay	to	determine	sulphate	levels.			 It	may	be	 that	FTIR	 is	not	high	resolution	enough	 to	 identify	 sulphate	position,	rather	 acting	 as	 a	 basic	 detector	 of	 modified	 compound,	 caused	 by	 the	 sulphation	reaction	and	resulting	structural	changes.			 Structural	 changes	 as	 a	 result	 of	 chemical	 sulphation	 are	mirrored	 in	 H+	 NMR	spectroscopy.	With	 chemical	 sulphation	 largely	 leading	 to	more	 complex	 spectra	with	the	appearance	of	novel	peaks.	The	number,	chemical	shift	and	intensity	of	the	peaks	are	indicative	of	 large	structural	change	from	the	parent	material,	 including	an	increase	 in	peak	 number	 and	 intensity	 at	 the	 high	 chemical	 shift	 region.	 This	 suggests	 more	 H	deshielding	 in	the	molecule	due	to	the	addition	of	electronegative	sulphate	groups.	An	average	chemical	shift	reduction	(main	broad	peak	shifting	left)	suggests	the	addition	of	electronegative	functional	groups	due	to	sulphation.		 The	greatest	change	seen	in	H+	NMR	is	with	chemical	sulphation	of	glycogen	type	II,	which	was	determined	to	have	the	highest	sulphate	level	of	the	hit	compounds	in	the	colourmetric	assay.			 Gum	 arabic,	 with	 the	 quanitified	 sulphate	 level	 of	 1.7-2.3	 nmoles	 sulphate/μg	compound	exhibits	much	less	structural	change	upon	chemical	sulphation	than	glycogen	in	1H	NMR.		
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	 Peaks	in	the	1H	NMR	of	levan	upon	chemical	sulphation	are	reduced,	with	peaks	appearing	at	between	3.6	and	4.5	ppm,	with	a	new	defined	peak	at	4.2	ppm	and	5	ppm;	both	with	higher	intensity.	This	suggests	the	deshielding	of	H+	due	to	sulphate	additions.	Sulphated	levan	sulphate	levels	are	4.5-4.7	nmoles/μg,	whereas	guar	sulphate	levels	are	10	 fold	 lower	 at	 0.45	 nmoles	 sulphate/μg	 compound.	 The	 H+	 NMR	 spectra	 of	 these	chemically	sulphated	compounds	mirrors	 this,	with	sizeable	changes	 in	sulphate	 levan	spectra,	and	minimal	changes	to	chemical	shift,	and	peak	intensity	in	sulphated	guar.	A	small	peak	at	5.5	ppm	in	sulphated	guar,	from	a	more	shielded	5.3	ppm	is	the	only	clear	indication	of	additional	sulphate	integration.			 The	average	chemical	shift	moves	downfield	in	both	carrageenans	upon	chemical	sulphation,	but	the	clear	peak	at	5.2-5.5	ppm	is	reduced	in	λ	carrageenan	and	the	same	as	the	parent	compound	in	ι	carrageenan.			 More	 variation	 in	 peak	 location	 and	 intensity	 is	 seen	 in	 λ	 carrageenan	 than	 ι	carrageenan;	this	may	be	due	to	the	large	molecular	weight	spread	PDI	(164.97)	in	this	polymer,	with	molecular	polydispersity	leading	to	increased	spectral	complexity.			 Far	UV	 circular	 dichroism	experiments	with	PMH	and	hit	 chemically	 sulphated	compounds	 with	 BACE1	 in	 50	 mM	 sodium	 acetate	 buffer	 at	 pH	 4.0,	 show	 secondary	structure	changes	with	the	addition	of	each	polysaccharide.	The	buffer	conditions	were	chosen	to	mirror	the	activity	effects	seen	in	the	BACE1	FRET	activity	assay.	The	addition	of	PMH	at	 the	same	molar	ratio	as	the	BACE1	FRET	experiments	causes	a	peak	at	218	nm	(-12	mdeg),	which	is	not	evident	with	BACE1	alone	and	could	be	representative	of	the	 increase	of	β	sheet	motif	 in	BACE1.	This	additional	β	sheet	structure	could	modify	the	structure	of	BACE1	active	site	or	flap	region	leading	to	enzymic	inhibition.			 The	change	 in	 the	angle	of	 light	polarisation	due	 to	BACE1	secondary	structure	modification	 is	mirrored	with	the	addition	of	each	chemically	sulphated	hit	compound	
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suggesting	a	similar	mode	of	interaction	between	sulphated	polysaccharide	and	BACE1.	Levan	 causes	 the	 greatest	 change	 in	 absorbance,	with	 glycogen	 displaying	 the	 second	highest	absorbance.			 Differential	 scanning	 fluorimetry	of	BACE1	with	PMH	 illustrates	destabilisation	of	 BACE1	with	 the	 addition	 of	 concentrations	 of	 PMH	 greater	 than	 12.5	 μg/ml	 and	 a	more	 stable	 configuration	with	 a	 greater	melting	 point	 at	 concentrations	 of	 PMH	 less	than	12.5	μg/ml.	This	data	may	suggest	the	presence	of	high	concentrations	of	PMH	bind	in	low	affinity	sites	or	both	high	and	low	affinity	sites	causing	inhibition	of	proteolysis	as	suggested	by	Beckman	et	al.,	2006	(Beckman	et	al.,	2006).	The	lower	concentrations	of	PMH	binding	only	to	high	affinity	sites	on	BACE1	could	cause	alternate	conformational	modifications	 which	 increase	 enzyme	 stability	 and	 therefore	 the	 promote	 BACE1	proteolysis	of	the	APP	ligand	(idem).			 The	 highest	 concentrations	 of	 hit	 polysaccharides	 λ	 carrageenan	 and	 ι	carrageenan	 tested	 in	 DSF	 have	 a	 more	 pronounced	 effect	 than	 that	 of	 PMH,	 which	indicates	 potein	 denaturation	 at	 room	 temperature	 or	 in	 the	 first	 10	 °C	 of	experimentation.	 Glycogen	 type	 II	 and	 guar	 both	 show	Tm	 increases	with	 the	 highest	polysaccharide	 concentrations	 tested,	 suggesting	 a	 stabilising	 effect	mirroring	 activity	and	CD	structural	data	previously	described.	Levan	and	gum	arabic	show	a	similar	effect	as	the	same	concentrations	of	PMH	in	DSF,	possibly	indicating	similar	binding	regions	or	pattern.	Gum	ghatti	 follows	a	similar	denaturation	pattern	as	the	carrageenans	at	high	concentrations	but	at	12.5	μg/ml,	this	sulphated	polysaccharide	lends	stabilising	activity	to	BACE1,	increasing	the	Tm.	This	concentration	may	indicate	a	‘sweet	spot’	of	number	of	binding	interaction	in	low	affinity	regions,	leading	to	a	very	stable	form	of	BACE1.			 Pearson	correlation	analysis	of	BACE1	activity	in	the	FRET	inhibition	experiment	with	each	chemically	sulphated	polysaccharide	was	analysed	againist	 the	other	results	
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inclusing	 molecular	 weight	 of	 sulphated	 polysaccharide,	 coagulation	 effects,	 sulphate	level	and	perturbation	of	CD	spectra.	The	correlation	between	BACE1	inhibition	activity	in	 the	 FRET	 and	 perturbation	 of	 BACE1	 melting	 point	 as	 measured	 in	 the	 DSF	experiment	 was	 P	 <	 0.05.	 This	 suggests	 a	 link	 between	 the	 binding	 of	 the	 sulphated	polysaccharides	in	low	and	high	affinity	sites,	depending	on	the	concentration,	modifies	BACE1	 structure	 to	 effect	 the	 action	 of	 BACE1	 proteolysis	 of	 APP.	 The	 correlation	analysis	 of	 the	 CD,	 measuring	 the	 secondary	 structure	 changes	 associated	 with	sulphated	 polysaccharide	 binding,	 does	 not	 show	 the	 same	 relationship,	 possibly	indicating	a	more	subtle	structural	change	than	this	far	UV	CD	experiment	has	realised.			 The	 conformation	 change	 associated	 with	 binding	 of	 these	 sulphated	polysaccharides	 could	 be	 further	 investigated	 using	 other	 techniques	 such	 as	 more	specialised	NMR	to	determine	changes	in	rotational	correlation	time,	small	angle	x-ray	(SAXS)	or	neutron	scattering	(SANS)	experiments	(Seeliger	&	de	Groot,	2010).			 The	 aim	 of	 this	 investigation	 was	 to	 identify	 sulphated	 polysaccharide	compounds	with	 analogous	 activity	 to	 PMH	 in	 the	 inhibition	 of	 BACE1,	 while	 lacking	other	 PMH	 characteristics	 such	 as	 anti-coagulant	 activity,	 high	 charge	 and	 molecular	weight.			 Chemically	 sulphated	 levan	 is	 the	best	BACE1	 inhibitor	 identified,	has	58	 times	lower	 factor	 X	 activity	 and	 17	 times	 lower	 factor	 II	 activity.	 The	 factor	 X	 activity	 of	sulphated	 levan	 however,	 is	 the	 highest	 of	 the	 7	 hit	 compounds	 identified	 in	 this	research,	 therefore	 is	 not	 the	 most	 ideal	 candidate	 when	 looking	 only	 at	 this	performance	metric.	Sulphate	determination	results	suggest	this	polysaccharide	is	more	highly	sulphated	than	PMH,	but	has	a	relatively	low	molecular	weight	when	compared	to	the	 other	 polysaccharides	 tested.	 The	 far	 UV	 CD	 spectra	 show	 BACE1	 secondary	structural	change	associated	with	saccharide	binding	 is	similar	to	that	of	PMH	binding	
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and	melting	point	when	challenged	with	100	μg/ml	sulphated	levan	the	most	similar	to	the	effects	of	PMH	(34.5	°C	with	PMH	melting	point	of	35.5	°C).			 Chemically	 sulphated	 gum	 ghatti	 also	 has	 a	 BACE1	 activity	 in	 the	 nanogram	range,	without	detrimental	anti-coagulant	activity.	The	estimated	range	of	sulphate	level	for	 this	polysaccharide	 is	 the	widest	of	 the	hit	 compounds	 tested,	which	may	 indicate	varying	 degrees	 of	 sulphation	 of	 the	 saccharide	 chains.	 The	 molecular	 weight	 is	significantly	greater	than	levan,	with	a	wider	dispersibility	 index,	suggesting	the	range	of	sulphate	detected	could	be	due	to	a	wider	range	of	molecular	size.	Structural	changes	associated	with	 the	binding	of	 chemically	 sulphated	gum	ghatti	differ	 in	DSF,	with	 the	thermal	stability	suggesting	a	denaturation	effect	with	the	highest	concentrations	tested.	CD	 data	 shows	 structurally	 similar	 changes	 to	 PMH	 but	 absorbance	 reduced.	 This	 hit	compound	has	desireable	characteristics	for	further	analysis	including	depolymerisation	and	 size	 fractionation	 to	 isolate	 active	 fragments	 with	 lower	 molecular	 weight	 and	sulphation	 level,	 and	 investigation	 into	 the	 structural	 effects	 associated	 with	 BACE1	binding.			 Chemically	sulphated	gum	arabic	has	low	microgram	activity	in	BACE1	inhibition	and	favourable	anti-coagulation	activity,	alied	with	one	of	the	lowest	charge	sulphation	levels.	 However,	 this	 compound	 has	 been	 identified	 as	 having	 the	 highest	 molecular	weight	 of	 all	 hit	 compounds	 tested,	 with	 the	 greatest	 PDI	 ranges.	 Further	 work	 to	depolymerise,	separate	and	characterise	the	resulting	fractions	may	allow	for	isolation	of	a	more	size	and	charge	specific	fraction,	possibly	emphasising	a	more	potent	BACE1	inhibitior.	 Structural	 analysis	of	 this	polysaccharide	 suggests	 similar	 action	as	PMH	 in	DSF	 experiments	with	 CD	 results	 giving	 a	 similar	 structural	 change	 but	with	 reduced	absorbance.		
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	 Chemically	sulphated	carrageenan	hit	compounds,	λ	and	 ι,	have	 low	microgram	BACE1	 inhibition	 values,	 but	 are	 potent	 anti-factor	 II	 inhibitors.	 The	 anti-thrombin	(factor	 II)	activity	of	 chemically	 sulphated	 ι	 carrageenan	 is	greater	 than	PMH,	but	 this	chemically	 sulphated	 polysaccharide	 does	 not	 show	 a	 concentration	 dependant	interaction	with	factor	X.	This	suggests	 ι	carrageenan	may	alternatively	be	a	candidate	for	 further	 investigations	as	a	direct	thrombin	inhibitor,	 if	other	off-target	 interactions	are	attenuated.			 Chemically	 sulphated	 guar	 and	 glycogen	 type	 II	 have	 similar	 BACE1	 inhibition	potency	and	have	produced	a	similar	DSF	thermal	stability	profile.	These	two	candidates	however,	do	not	have	similar	anti-coagulant	profiles,	molecular	weight	characteristics	or	sulphate	levels.	The	similarity	in	their	BACE1	activity	and	melt	profile	therefore,	 is	not	due	to	similarities	in	the	molecular	structure,	size	or	charge.	Chemically	sulphated	guar	gum	 is	 the	 candidate	 with	 the	 lowest	 charge,	 while	 glycogen	 II	 has	 both	 the	 highest	sulphation	levels	and	the	most	attenuated	factor	II	and	X	activity.				 Chemically	sulphated	levan	and	gum	ghatti	are	the	two	candidate	hits	to	progress	to	 structural	 analysis,	 production	 refinement,	 BACE1	 binding	 characterisation,	combinatorial	chemistry,	scalability	and	tractability	studies.	Chemically	sulphated	gum	arabic	 has	 a	 favourable	 BACE1	 inhibiton	 profile,	 but	 retains	 a	 large	molecular	weight	and	PDI.	Production	refinement,	depolymerisation,	fractionation,	fraction	re-testing	and	characterisation	of	the	active	fractions	are	the	next	step	for	this	hit	compound.		
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Chapter	9:	Discussion	and	future	direction	
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	 This	study	has	established	the	heparin	binding	activity	of	an	antibody,	at	acid	pH.	The	three	main	antibody	fragments	Fc,	Fab,	and	F(ab’)2	demonstrated	heparin	binding	between	 pH	 4.0	 and	 5.0.	 To	 ensure	 the	 presence	 of	 heparin	 binding	 region/s	 of	immunoglobulins,	 whole	 immunoglobulins	 were	 selected,	 and	 also	 demonstrated	heparin	 binding	 at	 these	 pH.	 Antibodies	 raised	 to	 a	 range	 of	 antigen	were	 utilised	 to	ensure	the	traditional	antibody-antigen	binding	was	not	occurring,	masking	the	studied	heparin-antibody	interaction.			 The	demonstration	of	heparin	binding	on	both	 the	Fc	region,	 consisting	of	only	heavy	chain	immunoglobulin	domains,	and	the	Fab/F(ab’)2	regions,	constructed	of	both	heavy	and	light	chain	domains,	suggests	a	feature	common	to	all	of	these	domain	regions	being	the	cause	of	heparin	affinity.	Also,	the	cross	species	nature	(human	and	mouse	Ig	used)	suggests	a	feature	present	in	both	species	immunoglobulin.		 No	 heparin	 binding	 was	 seen	 at	 pH	 >	 5.0,	 suggesting	 the	 acidic	 nature	 of	 the	buffer	system	created	the	binding	capacity.	This	could	occur	through	the	protonation	of	positively	 charged	 residues,	 creating	 a	 de	 novo	 heparin	 binding	 site/s	 on	 the	immunoglobulin.	Also,	 relatively	neutral	 immunoglobulin	pI	 (IgG	≈	7.4	and	 IgM	≈	6.5)	suggests	 a	 level	 of	 unfolding	 possible	 at	 this	 pH.	 However,	 the	 antibodies	 do	 not	demonstrate	 denaturation	 at	 this	 pH,	 as	 demonstrated	 by	 differential	 scanning	flurometry	 and	 far-UV	 CD	 experiments.	 This	 may	 suggest	 the	 initial	 stages	 of	 intra-immunoglobulin	domain	unfolding,	which	would	occur	on	each	antibody	and	fragment	tested.	This	 initial	unfolding	could	expose	or	create	a	de	novo	heparin-binding	region,	not	accessible	or	constructed	at	physiological	pH.		 The	use	of	 structurally	defined	heparins	 to	 initially	 screen	 the	 immunoglobulin	binding	 requirements	 isolated	 no	 disaccharide	 specific	 structural	 requirements	 (i.e	preference	 for	 2-O-desulphated	 or	 6-O-desulphated	 heparin),	 but	 did	 suggests	 a	
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preference	 for	 macroscopic	 structural	 trends,	 for	 example,	 completely	 desulphated	CMH8	had	a	 reduced	effect	on	 the	 structural	 changes	associated	with	heparin	binding	(demonstrated	by	UF	PMH).		 The	chemically	modified	heparin	used	in	these	studies	was	screened	for	binding	activity	 in	 the	 structural	 stability	 assay,	 differential	 scanning	 fluorimetry,	 to	 detect	 a	shift	 in	 thermal	denaturation	due	 to	 ligand	binding,	 and	 in	 far-UV	CD	 spectroscopy	 to	determine	secondary	structural	changes	associated	with	binding.	To	 improve	on	these	methods,	 surface	 plasmon	 resonance	 (Liedberg,	 Nylander,	 &	 Lundstrom,	 1983)	 will	quantify	 the	 strength	of	 binding	 to	 each	 form	of	 chemically	modified	heparin.	Also,	 to	screen	 a	 larger,	 more	 specifically	 structured	 heparin	 library,	 a	 glycan	 microarray	(Heimburg-Molinaro,	Song,	Smith,	&	Cummings,	2011;	Otto	et	al.,	2011)	could	be	used	to	isolate	specific	structural	residues	required	for	binding,	if	they	exist.			 To	 identify	 the	 protein	 sites	 of	 heparin	 binding,	 site-directed	 mutagenesis	(Flavell,	Sabo,	Bandle,	&	Weissmann,	1974;	Ho,	Hunt,	Horton,	Pullen,	&	Pease,	1989)	of	the	heparin	binding	site	could	be	used.	This	method	would	insert	point	mutation	in	the	gene	sequence,	that	when	expressed,	may	alter	or	remove	the	heparin	binding	site.	This	level	 of	 specific	 residue	 mutation	 allows	 for	 the	 determination	 of	 both	 the	 antibody	region	 for	 heparin	 binding,	 and	 also	 the	 arrangement	 of	 amino	 acids,	 critical	 for	 the	binding.	 This	 method	 commonly	 allows	 elucidation	 into	 the	 type	 of	 binding	 and	sequence	specific	requirements	for	the	interaction.			 Later,	CRISPR/Cas	technology	(Cong	et	al.,	2013;	Jinek	et	al.,	2012)	could	modify	the	heparin	binding	regions	 in	vivo,	 to	determine	any	phenotype	alterations.	However,	as	the	heparin-immunoglobulin	interaction	occurs	under	acidic	conditions	 in	vitro,	 this	may	not	result	in	a	modified	phenotype.	
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	 The	 investigation	 into	 biochemical	 tags	 and	 the	 influence	 these	 peptide	sequences	 can	 have	 on	 the	 structure	 of	 BACE1	 was	 investigated.	 The	 branch	 of	therapeutic	 discovery	 based	 on	 the	 ability	 of	 heparin	 to	 inhibit	 BACE1	 requires	 the	screening	 of	 highly	 polyanionic	 glycosaminoglycans.	 These	 molecules	 are	 unlike	conventional	 small	 molecular	 inhibitors	 selected	 by	 pharmaceutical	 companies	 for	scouting	 libraries	 in	 both	molecular	weight	 and	 charge.	Glycosaminoglycans	 are	more	likely	 to	 interact	 with	 charged	 amino	 acids	 and	 with	 regions	 of	 positive	 charge	 in	 a	protein,	 having	 concequences	 for	 the	 type	 of	 biochemical	 tag	 suitable	 for	 this	 BACE1	inhibitor	screening.	This	work	found	the	FLAG-BACE1	is	most	similar	to	the	structure	of	native,	untagged	BACE1.	This	is	not	unexpected,	as	the	molecular	weight	of	this	tag	is	the	smallest	of	the	three	tested,	but	the	charge	of	the	additional	DYKDDDDK	motif	seems	to	have	 a	 negligable	 effect	 on	 BACE1	 secondary	 structure	 and	 thermal	 stability.	 Native	BACE1	 is	 still	 the	 gold	 standard	 choice	 for	 all	 BACE1	 studies,	 however,	 the	 additional	cost	 of	 this	 form	 of	 protein	 requires	 a	 suitable	 proxy	 and	 therefore	 FLAG-BACE1	 is	recommended.			 Unfractionated	 heparin	 inhibition	 of	 BACE1	 was	 assessed	 in	 a	 fluorescent	resonant	 energy	 transfer	 (FRET)	 assay	 to	determine	 the	 activity	 of	UF	BLH	and	PMH.	Currently	available	 literature	 is	 conflicted	with	 regards	 to	 the	action	of	heparin.	 Some	groups	identify	heparin	solely	as	a	BACE1	inhibitor	(Patey	et	al.,	2006,	2008;	Scholefield	et	 al.,	 2003),	while	 others	have	determined	both	 inhibitory	 and	promotionary	 activity	(Beckman	et	al.,	2006;	Klaver	et	al.,	2010).	This	work	identified	both	heparin	inhibition	and	 activation	 of	 BACE1,	 with	 high	 concentrations	 of	 PMH/BLH	 >	 12.5	 μg/ml	demonstrating	BACE1	 inhibition	 of	 100	%,	while	 concentrations	 <	 1.56	 μg/ml	 of	 BLH	and	<4.1	μg/ml	of	PMH	displaying	potent	stimulation	of	BACE1	APP	proteolysis.		
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	 This	existence	of	two	forms	of	heparin	binding	regions,	one	with	high	affinity,	one	with	low	affinity	for	heparin	could	explain	the	modulatory	effect	of	heparin	in	vitro.	High	concentrations	of	heparin	bind	both	the	high	and	low	affinity	regions	on	BACE1	causing	inhibiton	of	activity.	Low	concentrations	of	heparin	bind	only	the	high	affinity	regions,	preferentially;	therefore	stimulation	of	BACE1	activity	occurs.			 This	dual	action	may	be	a	result	of	 the	non-physiologic	system	used	to	monitor	BACE1	action	 in	vitro,	as	the	concentrations	of	heparan	sulphate	 in	vivo	are	unlikely	to	reach	these	proportions.	However,	the	intricacies	of	this	interaction	cannot	be	measured	in	 this	FRET	assay.	Molecular	elucidation	of	 the	BACE1-	heparin/HS	 interaction	would	be	 required	 to	ascertain	 the	exact	mechanism	 for	 this	 interplay.	X-ray	 crystallography	could	establish	the	structure	of	heparin	bound	BACE1.	The	presence	of	multiple	heparin	chains	bound	 in	different	 regions,	or	a	 single	 region	populated	by	one	or	more	chains	could	be	determined.			 The	 39	member	 chemically	 sulphated	 polysaccharide	 library	was	 screened	 for	BACE1	 inhibiton	 and	 anti-coagulant	 activity,	 to	 identify	 selected	 polysaccharides	 for	further	analysis.	More	specific	anti-coagulant	activity	was	assessed	through	anti-factor	Xa	 and	 IIa	 activity,	 the	 glycopolymer	 size	 was	 determined	 with	 SEC	 GPC,	 molecular	charge	 to	 identify	 sulphate	 levels	 was	 completed,	 structural	 studies	 with	 BACE1	was	completed	using	far-UV	CD,	DSF,	NMR,	and	FTIR.	FRET	using	FLAG-BACE1	was	done	to	determine	the	hit	compound	IC50	and	this	data	was	processed	to	correlate	activity	to	the	other	assayed	metrics.			 The	 reduction	 in	 Tm	 seen	 with	 the	 binding	 of	 GAGs	 to	 BACE1	 occurs	 at	 high	concentrations	 of	 all	 the	 GAG	 and	GAG	 analogues	 tested.	 The	 Tm	 reduction	 from	DSF	correlated	with	the	FRET	IC50	in	the	hit	sulphated	compound	library.	This	suggests	DSF	
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to	measure	 the	 Tm	 perturbation	may	 offer	 an	 alternative	 to	 the	 expensive	 and	 time-consuming	FRET	experiments,	to	isolate	hit	compounds	for	BACE1	inhibition.		 From	 the	 7	 chemically	 sulphated	 hit	 compounds	 forming	 the	 ‘hit’	 library,	chemically	sulphated	levan	and	gum	ghatti	have	been	determined	as	the	two	compounds	to	 take	 forward	 to	 the	 next	 stage	 of	 inhibitor	 studies.	 Depolymerisation	 and	fractionation	 of	 these	 two	 chemically	 sulphated	 glycopolymers	 would	 yield	 a	 new	library	of	lower	molecular	weight	compounds.	Further	BACE1	activity	experiments	will	identify	 the	 active	 fractions	 of	 the	 two	 primary	 hit	 compounds.	 Structural	characterisation	 will	 be	 possible	 on	 the	 smaller	 glycopolymers,	 with	 possible	combinatorial	chemistry	potential	in	the	future.		
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Appendix	
11.1	Native	BACE1	amino	acid	sequence		The	amino	acid	sequence	of	native	recombinant	BACE1	is	as	follows:	tqhgirlplrsglggaplglrlpretdeepeepgrrgsfvemvdnlrgksgqgyyvemtvgsppqtlnilvdtgssnfavgaaphpflhryyqrqlsstyrdlrkgvyvpytqgkwegelgtdlvsiphgpnvtvraniaaitesdkffingsnwegilglayaeiarpddslepffdslvkqthvpnlfslqlcgagfplnqsevlasvggsmiiggidhslytgslwytpirrewyyeviivrveingqdlkmdckeynydksivdsgttnlrlpkkvfeaavksikaasstekfpdgfwlgeqlvcwqagttpwnifpvislylmgevtnqsfritilpqqylrpvedvatsqddcykfaisqsstgtvmgavimegfyvvfdrarkrigfavsachvhdefrtaavegpfvtldmedcgynipqtdestlmt-ddddk	
